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Abstract 
‘The capability approach is a broad, normative framework for the evaluation of well-
being’(p.94)[1], which has attracted growing interest in health and health economics research.  
A broader measure of well-being may more accurately capture the effects of some 
interventions, than traditional health-related quality of life measures.  The ICECAP-A and 
ICECAP-O are two measures of a person’s well-being, with a theoretical grounding in the 
capability approach, designed for use in health and social care research. 
This thesis reports qualitative and quantitative investigations into the validity and 
responsiveness of the ICECAP measures.  A methodological review of existing validation 
studies was completed.  Seventeen semi-structured interviews with health research 
professionals were carried out and an iterative, constant comparative, thematic analysis was 
completed to assess the content validity of the ICECAP-A.  The construct validity and 
responsiveness of the measures were assessed using two randomised controlled trials: the 
BEEP trial (ISRCTN 93634563) and the Past BP trial (ISRCTN 29062286). 
Qualitative and quantitative results provide positive indications of validity.  The qualitative 
work showed that research professionals viewed the ICECAP-A as a relevant and feasible 
measure for use in health research.  The quantitative results confirmed the majority of a priori 
hypotheses in the validity analyses, while longitudinal data provided evidence that the 
measures are responsive to self-reported changes in health status.   
In conclusion, this thesis reports the first assessment of validity in a randomised controlled 
trial setting and the first analysis of responsiveness.  While further testing of the ICECAP 
measures is required, results indicate that the measures are appropriate for use in health 
research.  
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Introduction 
The measurement of quality of life is of importance in randomised controlled trials and in 
health economic evaluations occurring alongside these trials.  Quality of life measurement has 
been dominated by a focus on health-related quality of life, with only a minority of existing 
measures focusing on the broader aspects of quality of life.  The capability approach is a 
theoretical basis upon which a broader measurement of quality of life can be based.  Efforts to 
apply the capability approach to quality of life measurement in the area of health research 
have been undertaken in recent years.  The question of whether capability based measures 
accurately capture the construct which they are designed to measure (capability) is of utmost 
importance in the design, testing and use of these measures.  This thesis explores the validity 
and responsiveness of two capability based quality of life measures being used in health 
research: the ICECAP-O and ICECAP-A measures. 
Chapter one describes the evolution in normative health economics from welfarism to 
capability.  It begins by describing the key tenets of welfarism and provides a description of 
the limitations of this approach.  The description of approaches that have gone beyond 
welfarism begins with extra-welfarism.  The theoretical basis of this approach is provided and 
its practical implementation is described.  Finally the theoretical basis of the capability 
approach is described. 
Chapter two has two parts.  Firstly the randomised control trial is described and the current 
norms of quality of life measurement in trials are considered.  The use of preference based 
measures, often used in health economic analysis, is covered in detail.  Attempts to 
“operationalise” the capability approach are examined, with a particular focus on the ICECAP 
capability measures.  The second part of chapter two provides a methodological review of 
studies which have sought to validate the ICECAP measures or provide validity information 
through their research.  The current evidence base is documented and areas for future research 
are described. 
Chapter three introduces the theory of psychometric testing.  Psychometrics is an area in 
which the underlying theory has undergone considerable change in the last 60 years.  The 
field is still evolving.  The section will describe the evolution of psychometrics from criterion 
based testing to the more scientific approach of construct validation.  The importance of 
validating the content of the descriptive system of the measure independent from the scores 
generated is discussed.  Finally, the challenges of validating a capability measure in a 
randomised controlled trial are discussed. 
Chapters four and six describe the qualitative and quantitative methods employed in this 
thesis, respectively.  Chapter four describes the recruitment and interviewing of informants 
and the process of transcribing and analysing the data.  The comparative direct approach is a 
novel method of assessing content validity.  This was developed based on experiences of this 
qualitative work and is described in detail.  Chapter six describes the process for recruiting 
trials to participate in this work as well as the data provided by the two trials which were used 
in the final analysis.  The methods and statistical analyses used for both the validity and 
responsiveness analysis are described. 
Chapter five presents the results of the qualitative analysis.  How informants defined quality 
of life is examined in detail and the informants’ opinions of the content of the ICECAP-A 
measure are described.  The comparative direct approach is used to draw comparison between 
these.  Finally, a conceptual model of how quality of life measures are selected for use in 
randomised controlled trials, which was an emergent theme from this work, is discussed.   
Chapter seven presents the results of the construct validity analysis. Results from the PastBP 
and BEEP trials are presented separately.  A number of different comparator measures are 
used.  A priori hypotheses presented in chapter six are tested using suitable statistical 
analyses.  Factor analysis is used to assess the relationship between items of the ICECAP 
measures and EQ-5D-3L.      
The results of the responsiveness analysis are provided in Chapter eight.  The results of the 
ICECAP-O analysis using data from the PastBP trial are presented first, followed by the 
results of the ICECAP-A analysis using the BEEP data.  Contained within this chapter are 
descriptions of the choice of anchors and the creation of anchor groups.  Numerous anchor 
analyses are provided for each measure.  
The discussion is presented in Chapter 9.  The primary contributions of the work and its 
strengths and weakness are discussed.  The findings of both the qualitative and quantitative 
research are discussed through the use of broad themes of research.  Directions for future 
research are proposed.  
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CHAPTER 1. WELFARISM, EXTRA-WELFARISM 
AND THE CAPABILITY APPROACH 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Note on chapter: Small sections of this chapter have been submitted to the University of 
Birmingham as part of an essay towards an MSc in Health Economics and Health Policy.  In 
line with University of Birmingham regulations, where appropriate, this essay has been 
referenced to indicate the use of previously submitted material.     
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1.1. Chapter Introduction 
A primary challenge of health care financing and management is the allocation of scarce 
resources between many needs and wants [2–5].  Health care policy makers, responsible for 
priority setting, are faced with ever increasing numbers of treatments, ever increasing costs 
and constantly changing rates and loci of illness.  Economists and health economists have 
sought to assist policy makers through applying the discipline of economics to health policy.  
Positive economics seeks to explain ‘the effects of an event on objectively measureable 
economic variables’(p.1)[6], while normative economics seeks to inform decisions about how 
resources should be allocated through economic evaluations of costs and benefits [6].   
Within the field of normative economics, a spread of ideas has resulted in differing 
approaches and competing schools of thought to the challenge of resource allocation in health 
[5].  These different approaches are not clear cut and well defined.  Rather, the evolution from 
welfarism towards extra-welfarism and the capability approach has resulted in a blurring of 
the boundaries between the three main approaches to health resource allocation, with common 
themes running through all [7].   
This spread of ideas and evolution of theory has led to differences in the methods through 
which each approach measures outcomes and what outcomes are measured.  Therefore, along 
with this evolution of theory, there has been a change in the outcome measures used to inform 
normative decisions in health care.  
This chapter provides an introduction to the different philosophies of normative economic 
evaluation and resource allocation in health.  It sequentially defines welfarism and extra-
welfarism and describes the methods through which each approach measures outcomes.   
Critiques of each approach are presented, with a focus on the justification and reasoning for 
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the development of the capability approach.  The main tenets of Amartya Sen’s capability 
approach are described along with a discussion of the challenges of “operationalising” the 
approach.   
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1.2. The Welfarist approach 
The following section describes neo-classical welfare economics [8].  The evolution of the 
utility principle is discussed and its consequentialist and individual nature is critiqued.  The 
requirement for maximisation of an outcome, through the Pareto Criterion, is presented.  This 
section concludes by detailing the limited nature of welfare economics as an evaluative tool 
and draws on Brouwer’s [9] ‘seeds’ of extra-welfarism, in order to demonstrate the value of a 
different framework.       
1.2.1. Theoretical basis of welfarism 
‘Welfare economics is the framework within which the normative significance of economic 
events is evaluated’(p.1)[10].  It attempts to assess the consequences and value of an event for 
economic arrangements.  In health this framework can be used for the economic evaluation of 
treatments and technologies.  While the ultimate goal of welfare economics (that of using the 
instruments of economics for the improvement of human life [11]) has not changed, the 
framework within which this should be done has been under constant evolution.  The classical 
interpretation, proposed in Arthur Pigou’s landmark text The Economics of Welfare [11], takes 
welfare to be an interpersonally comparable commodity that can be summed across 
individuals, allowing a sum maximum to be reached.  However, as a result of convincing 
critiques by authors such as Lionel Robbins [12] and others, which highlight the impossibility 
of making objective interpersonal comparisons of welfare, a neo-classical form of welfare 
economics has emerged.  This school of thought has, for now, secured welfare economics in 
‘the informational basis of ordinal and interpersonally non-comparable welfare’(p.3)[13].   
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1.2.1.1. Utility in welfare economics 
The attitude within economics towards utility has always been ambiguous and the meaning of 
utility has changed over time [14].  The current characterisation, although widely accepted in 
welfare economics, is still the focus of debate and empirical research.  The implications of 
these different meanings are important, and the careless use of this term can cause confusion.   
The original interpretation, which was proposed by Jeremy Bentham, forwarded utility as a 
measure of pleasure.  Bentham [15,16] suggested that utility referred to the “sovereign 
masters” of pleasure and pain, that ultimately determine our actions.  This hedonistic 
interpretation of utility has been termed experienced utility [17].  Edgeworth [16,18] extended 
this interpretation with the suggestion of an imaginary measurement instrument: the 
‘hedonimeter’.  Similar to a barometer, this instrument would measure positive or negative 
pleasure at any moment, and plot experienced utility as a function of time [19], thereby 
allowing the quantification of pleasure over a given period.  The idea that utility was 
measurable on a cardinal scale was a key concept of early interpretations and allowed for 
interpersonal comparisons of utility.    
This interpretation was, however, largely rejected by economists at the start of the twentieth 
century [20].  Pareto [21] stated that the cardinal measurement of utility was not required, 
while Robbins [12] argued that cardinal utility was not a measurable concept.  This difficulty 
with interpersonal comparisons is aptly summed up by Hicks [22]:  
 ‘You cannot take a temperature when you have to use, not one thermometer, but an 
immense number of different thermometers, working on different principles, and with 
no necessary correlation between their registrations’(p.699).   
The measurement of observable choices was preferred on the basis that individuals act as 
rational agents and will choose the option that yields most utility.  This step simplified the 
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measurement of utility by requiring solely the observation and the ordinal ranking of an 
individual’s choices, and not the measurement of pleasure or pain, that results from that 
choice.  This interpretation of utility is therefore one of human wants, intuitively defined by 
Irving Fisher as “wantability” [23].  This decision utility gives a representation of an 
individual’s preference ordering over goods bundles or states of the world [9]. 
It is self-evident that if individuals are able to accurately want that which they will in turn 
enjoy, known as affective forecasting [19], then experienced and decision utility will yield the 
same outcome [24].  However, if individuals are not able to make accurate decisions about 
future utility, then a clear divergence in the two concepts can be seen.  Empirical research 
suggests that this may be the case.  Sieff et al. [25] found lower levels of distress in patients 
who had just received a positive HIV test result than was expected by the same patients before 
the test result was received.  Redelmeier & Kahneman [26] found that patients 
“misremembered” their self-reported level of pain during a colonoscopy procedure, when 
asked about it after surgery.  Furthermore, it is persuasively suggested that the ex-ante 
concept of decision utilities is affected by individual’s attitudes, with a focus on transitions, 
while the ex-post concept of experienced utility is focused on experiences and states 
[19,20,24].  For example: the ex-ante attitude to being diagnosed with HIV might be one of 
horror, while the ex-post reality of living with HIV in the 21
st
 Century is, for most, that of a 
manageable, chronic disease.  Empirical findings and theoretical propositions such as these 
have led some [19,20] to re-evaluate the potential for the use of experienced utility on the 
basis that decision utility may lead to the systematic over or under estimation of utility.  
While this research is both of interest and importance, it is at an early stage.  In line with the 
majority of modern welfare economics writings, in the remainder of this text the term ‘utility’ 
will refer to decision utility.           
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1.2.1.2. Consequentialism in welfare economics 
Consequentialism is a key foundation of welfare economics [8].  As a theoretical proposition 
it stipulates that only utility derived from the outcome of behaviours, such as the consumption 
of goods or the utilisation of services, is relevant [8,9].  The process by which these outcomes 
are arrived at is not relevant.  To illustrate this point, consider two treatments that return a 
patient to full health.  In Treatment A, due to poor levels of information provision and 
unhelpful staff attitudes, the patient undergoes an unsatisfactory and uninformed treatment 
experience, before full health is returned; while during Treatment B no such problems occur.  
Consequentialism dictates that these two treatments are judged to be equal, based on the 
assumption that both treatments return the patient to full health, and therefore yield the same 
utility.  Simply put: the end, and not the means, is of importance [27]. 
The primary critique of consequentialism, and the use solely of outcome utility, is contained 
implicitly within the proposition of process utility.  Mooney [27] noted that being treated with 
respect and deference, and maintaining dignity is of concern to patients during the healing 
process.  Furthermore, if a treatment or process reduces the concern or worry a patient 
experiences then this may be of value, independent of the outcome of treatment.  This may be 
particularly true in areas such as palliative and end-of-life care.  
Empirical research, within both general economics and health economics, has sought to 
determine whether process utility is of importance to the individual.  Birch et al. [28] found 
significant differences in process utility between patients who received aggressive and 
conservative follow-up treatment after mildly abnormal cervical smears.  Benz and Stutzer 
[29] found workers gained utility from not only the level of pay they received (outcome 
utility), but also from the way pay is determined through worker/employer consultations 
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(process utility).  Further research by Hahn [30], Frey et al. [31] and Tsuchiya [32] has yielded 
similar findings.  Therefore, the exclusive focus on outcome utility may fail to capture large 
portions of the “effect” a treatment has upon an individual. 
1.2.1.3. Individual Sovereignty 
The idea of individual sovereignty maintains that the individual is the best judge of their 
utility or welfare [5,33].  In welfare economics the individual is characterised as an 
autonomous being, who is rational and has exogenous preferences [34].  It is presumed that 
the individual has the ability to compare and order alternatives, based on some value of 
welfare or utility [33].  Through this preference ordering the individual will act to competently 
maximise their utility through the choices they make [35].  Through this reasoning the 
individual is maintained as the best judge of the choices required to maximise their utility.  
For example: when buying a car a consumer will make choices between comfort and style, 
and speed and reliability.  While the salesman can advise, only the individual will know what 
best satisfies their needs and wants within their budget constraints [5]. Implicitly this rejects 
the idea of paternalism and the role of a proxy decision maker [35].   It is also of interest to 
note that the focus of neo-classical welfare economics is not on the individual, but rather on 
the choices that individuals make.  This has led some to criticise the welfare economic 
perception of the individual as reductionist and restricted, and not adequately representative of 
the complexity of the human psyche [34].    
1.2.1.4. The Pareto principle 
To determine whether a social situation is better or worse than alternatives, an assessment 
must be based on a defined set of criteria, or value judgements [36].  The values and criteria 
used will determine whether a situation is judged as optimal or not.  Welfare economists have 
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widely used the Pareto principle.  This says that ‘if state A is ranked higher than state B for 
one person, and all other persons rank A at least as high as B, then A should be ranked higher 
than B in the social ordering’(pp.2/3)[10].  There is judged to be an improvement in social 
welfare if one person is made better off (moved from state B to A) without anyone else being 
made worse off (moved from A to B) [4] and under these circumstances change is desirable. 
The Pareto principle is considered a weak value judgement [36] for two reasons.  Firstly, on 
the basis that many other value judgements could incorporate it without having it violate their 
premise and almost any other value judgement of social welfare is likely to violate the basis 
of the Pareto principle.  Ng [36] gives the example of a judgement that makes some people 
significantly better off, while others are made insignificantly worse off.  It is impossible for 
the Pareto principle, in its strongest form, to incorporate such a judgement.  Secondly, neo-
classical welfare economists suggest that it is intuitively acceptable to most people.  This is a 
contention disputed by many economists on the basis that when it is emphasised that a change 
can only happen under Pareto conditions, most people would voice concern. 
An economic or social situation is said to be Pareto optimal when ‘every individual is as well 
off as he can be made, subject to the condition that no reorganisation permitted shall make 
any individual worse off’(p.701)[22].  Under this condition there is production efficiency (more 
of one good cannot be produced without producing less of another) and exchange efficiency 
(commodities cannot be reallocated without making some worse off) [10].  There can be many 
different distributions of social wealth in which welfare can be considered optimal under this 
criterion and it is impossible to compare Pareto optimal conditions.  Pareto non-comparability 
also exists in situations where one state is preferred by some, while another state is preferred 
by others.  Therefore, policies which do not offer a uniform/unidirectional increase in social 
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welfare, but rather redistribute wealth, are Pareto non-comparable.  This constitutes a major 
weakness of this approach. 
1.2.1.4.1. Compensation principle  
The issue of Pareto non-comparability was addressed by the proposition of the hypothetical 
compensation test [22,37].  This stated that it was not necessary for the economist to 
demonstrate that nobody suffered from a policy, rather it is sufficient ‘to show that even if all 
those who suffer as a result are fully compensated for their loss, the rest of the community 
will still be better off than before’(p.550)[37].  As its name suggests this compensation doesn’t 
need to be paid in practice, rather it needs to be demonstrated that it could be paid in 
principle.  In doing this Kaldor has separated efficiency issues from equity issues, by 
delimiting the scope of the economist to efficiency and the responsibility of the politician to 
distribution and equity [38].  Therefore, it does not, as has been suggested, consider 
distribution and equity to be irrelevant, but considers it not to be the responsibility of the 
economist. 
This is a stronger value judgement than that contained within a strict interpretation of the 
Pareto principle.  It operates with the understanding that compensation may not be paid in 
practice and that some may suffer as a result of a policy.  It is unclear, when considering 
sectors such as education and health, how and in what form compensation may hypothetically 
be paid.  Furthermore, it does not allow for the Pareto principle to rank options that are 
considered Pareto optimal. 
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1.2.2. Welfarist approach in practice 
Effort has been made to “operationalise” welfare economics in health as well as in other fields 
of research.  In health this has taken the form of the cost-benefit analysis. 
1.2.2.1. Cost-Benefit Analysis  
Cost-benefit analysis offers a theoretically sound form of economic evaluation, underpinned 
by the theory of welfare economics [39].  Through the identification of all the effects of an 
intervention or treatment, and the measurement of these effects in a common metric, cost-
benefit analysis allows summative benefits to be compared with summative costs [40].  To 
facilitate this comparison this common metric is usually money [41].  The attachment of 
monetary values to the cost and benefits of a programme, allows the assessment of whether 
that programme provides a net benefit to society [39].  In practice, the use of cost-benefit 
analysis in healthcare has had many practical, conceptual and ethical problems, largely 
associated with the valuing of benefits in monetary terms [42],  in the years since it was first 
forwarded as an idea [40] and applied in practice [43].  An examination of two approaches to 
monetary valuation of benefits is the best way to highlight the strengths and weaknesses of 
this concept.  A description of the methodology by which one of these approaches, the 
willingness to pay approach, elicits values is included  
1.2.2.1.1. Human capital approach 
The human capital approach uses market wage rates to place monetary weights on gains in 
healthy time resulting from an intervention or programme [42].  In doing so it assumes that 
the value of a period of life is equal to the wage that person receives during it.  Therefore, the 
worth of a programme can be valued by the future income that would have been foregone due 
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to ill health [39].  This approach implicitly assumes that the more a person earns the more 
their health is worth. This values are then discounted back to yield an accurate present value.   
1.2.2.1.3. Willingness to Pay 
Willingness-to-pay can be determined by observing individuals or asking individuals for their 
preferences.  In the case of observed preference, an individual’s behaviour allows the 
determination of the value placed on benefits [39].  However, in health care there are a limited 
number of opportunities to observe this behaviour due to the rare occurrence of illness and the 
limited presence of markets in the health care system.  Therefore, stated preference techniques 
are often used, whereby people are asked to indicate their preference in monetary terms [39].  
Willingness to pay is the primary stated preference technique used in health economics. 
The willingness to pay technique elicits the monetary values people attach to healthcare 
outcomes.  The theoretical premise is that the maximum amount an individual states that they 
are willing to pay (or sacrifice), is an indication of the utility they will gain from that 
treatment.  When considering their willingness to pay, an individual will consider all the 
attributes of the intervention that is important to them, and not just those designated as 
important by a third party [42].  Therefore, from the perspective of consumer sovereignty, 
WTP might be considered a superior measurement process [44].  Theoretically it allows 
individuals to consider the effects on people other than themselves and, if given enough 
information about the programme, individuals could potentially consider efficiency and equity 
aspects.  There are a number of methods by which willingness to pay can be estimated. 
Conjoint analysis and contingent valuation  are most frequently used [45].   
During the process of contingent valuation participants are initially given information on the 
hypothetical programme and (possibly) the nature of the illness [46].  They are then required 
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to indicate their willingness to pay by way of one of three methods.  These may either take the 
form of a response to an open ended question, participation in a form of bidding game 
(whereby the binary yes/no response to the previous question determines the next value 
considered), or a hypothetical referendum where the participant is presented with one price 
for a treatment and they indicate that they either will or will not pay that fee [47]. 
Conjoint analysis also, normally, requires the presentation of introductory information.  
Participants are then presented with competing choices described by key attributes, where the 
levels of the attributes are different in each choice [46].  The process would be repeated 
numerous times with the levels of the attribute varied.  This approach differs from contingent 
valuation in that it does not require the individual to state their willingness to pay, but rather 
to choose between two alternatives. 
1.2.2.2. Cost benefit summary  
Cost benefit analysis theoretically offers a potential method of economic evaluation in 
healthcare, which would allow for the maintenance of consumer sovereignty and has the 
scope to measure all aspects of health care important to the individual.  However, the use of 
the sole metric of money means that other forms of evaluation have taken precedence over 
this technique. 
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1.2.3. Welfarism critique 
Strong critiques have been levelled against the suitability of welfarism as the basis for 
resource allocation.  Welfarism has been critiqued directly as having five primary 
weaknesses: the incompatibility of the Pareto principle with “real world” situations; the 
incompetence of the health care consumer; the limiting nature of utility as the basis for 
evaluation; adaptation; and the monetary valuation of benefit. 
1.2.3.1. Pareto principle paralysis 
The Paretian welfarist position, that welfare increases when a person, or group of people, are 
made better with no other person, or group of people, being made worse off, is of little help in 
allocation decisions [4].  The primary reason for this is that the overwhelming majority of 
allocation decisions involve winners and losers [7] and the Pareto principle makes no 
allowance for this.  In health care allocation, a treatment that benefits one group will often be 
funded at the cost of others.  Use of the Pareto principle in resource allocation can result in 
policy paralysis and no decision being taken despite the self-evident need for action.   This 
policy paralysis resulting from the Pareto principle can subsequently leave a situation, which 
most reasonable people would find sub-optimal, unchanged.  ‘A state can be Pareto optimal 
with some people in extreme misery and others rolling in luxury, so long as the miserable 
cannot be made better off without cutting into the luxury of the rich’(p.32)[48].  Furthermore, 
the compensation principle, is difficult to apply in health, as even theoretically it is difficult to 
see how “winners” can compensate “losers” with a supplement of “health” or some other 
utility enhancing attribute [49]. 
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1.2.3.2. The incompetent consumer 
The presupposition that the consumer will rationally act to maximise their welfare relies on 
the assumption of consumer competence [3].  It assumes that the consumer knows all options, 
understands all options and makes informed and accurate decisions as to which is the best 
option.  However, in health, a lay person is rarely competent enough to decide upon the most 
efficacious path of treatment.  The patient is often not best placed to maximise their utility (or 
health) and this decision will normally be deferred, to varying degrees, to an agent, in this 
case a doctor [3,50].  This transferral of competence runs counter to the individualistic nature 
of welfarism, which cannot consider such expert opinion [5].    
1.2.3.3. The utility principle 
The consequentialist nature of welfarism holds that only the utility gained from the health 
resulting from a treatment is relevant.  Subsequently welfarism ignores other rich information 
sources [51] and filters out all non-utility information [52].  Amartya Sen, who is one of the 
most ardent critics of utility as an evaluative space, questions whether desire fulfilment and 
being happy is all there is to life [53].  Critics of utility argue that information such as a 
positive healing experience, ability to undergo treatment that is in line with a person’s moral 
or religious values, or being treated with deference while in care cannot be captured by using 
utility as the metric of value.  Sen has argued that the evaluative space of utility is too thin to 
form an account of whether a situation offers a social good [54].   
In an extension to this line of critique Sen contests that there is a duality in the ethical 
conception of a person, which utility fails to capture.  This is covered in greater detail later in 
this chapter, but in brief: a person will have well-being goals which they wish to follow and 
agency goals which they may wish to achieve, with agency referring to goals, commitments 
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or values that can, but do not necessarily, include well-being.  Agency goals can both conflict 
and complement one’s well-being. Under Sen’s interpretation of utility, welfarism is not able 
to capture both well-being and agency, and with this inability, information of real importance 
is lost.  
In his final strand of critique, Sen somewhat switches the focus to the question “equality of 
what?” [55].  Sen notes that every enduring social theory has demanded equality in some 
space [53].  Over time, theories and social arrangements have proposed equality in the form of 
liberties [56] and primary goods [57], as well as in many other areas.  Utilitarianism seeks 
equality in the evaluative space of utility: everyone’s utility gains hold the same weight, and a 
utility loss is acceptable to no one.  But, demanding equality in one space, can lead to or 
justify inequality in another [55].  Therefore Sen argues that the question “equality of what?” 
is of utmost importance [53].  Sen rejects utility as the appropriate evaluative space on the 
basis that seeking equality of utility, especially in conjunction with the Pareto principle, can 
cause unacceptable inequality in another space [53]. 
1.2.3.4. Adaptation and outcome assessment 
The potential for people to adapt to their situation or surrounding is considered a further 
limitation to using utility as an outcome metric [53]. In everyday life, adaptation is a part of 
the human psyche that prevents individuals from becoming transfixed on details and gives 
them the ability to react appropriately to future events.  However, in outcome assessment it 
may result in inappropriate measurement, which can be compounded by using utility as an 
outcome metric. 
‘A person, who has had a life of misfortune, with very little opportunities, and rather 
little hope, may be more easily reconciled to deprivations than others reared in more 
fortunate and affluent circumstances.  The metric of happiness may therefore distort 
the extent of deprivation, in a specific and biased way’(p.45) [58] 
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Sen [55] argues convincingly that in the case of poverty the metric of individual desire 
fulfilment, used by welfare economists, may not adequately measure a person’s deprivation.  
His assertion that there are those who have accepted the hardship that exists in their lives, and 
tapered their expectations so, is illustrated in his editorial for the BMJ [59].  Sen observed 
higher reported morbidity in an affluent Indian state, which had higher life expectancy, than 
in the deprived state of Bihar, with lower life expectancy. Sen cites, among other things the 
people of Bihar’s ‘very low perception of illness’(p.861) as a reason for this disparity in reported 
morbidity. 
Work in health and disability has shown similar differences.  Seminal works by Sackett and 
Torrance [60] and Brickman et al. [61] showed, respectively, that there were considerable 
differences in how dialysis patients and the general public valued health-related quality of life 
for those requiring dialysis and that paraplegics were only marginally less happy than non-
paraplegic controls.  Oswald  [62] has recently presented longitudinal evidence that the degree 
of adaptation of ‘life satisfaction’ is in the order of 30% to 50% in those who suffered “quite 
serious” levels of impairment. 
1.2.3.5. Monetary valuation  
The application of the welfarist approach to resource allocation through the cost-benefit 
analysis model has a number of weaknesses and limitations.  Firstly, the human capital 
approach raises ethical questions: should the worth of an individual’s health be valued solely 
by their financial activity?  Does an unemployed person’s health have no value? Furthermore, 
practical limitations are also present.  Wage rates only accurately represent productivity when 
certain labour market conditions are met [39] and any imperfections within the labour market, 
of which there are normally many, will give inaccurate quantifications of productivity.  If the 
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lost employee can be quickly replaced from a pool of suitably skilled people, the productivity 
loss may be limited to a “frictional cost” of recruitment and training [42].  Lastly, and possibly 
most damning, is a criticism which comes from within welfare economic theory: this 
approach is not based on individuals’ preferences or valuation of health gains. 
Willingness to pay is inevitably a function of ability to pay(p.211)[63], leading to equity 
concerns [42].  A further concern surrounds whether asking people to value health gains in 
monetary terms could invite methodological problems.  Individuals may find it unacceptable, 
or incomprehensible, to be asked to decide how much they would be willing to pay for health 
care, or how much they are willing to accept for continued poor health or death.  This may 
lead to protest bids, whereby the respondent gives a value that indicates an objection to the 
question, i.e. an impossibly high figure, or a zero bid [42].   
1.2.4. Welfarism critique summary 
The critical appraisal of the welfarist approach has led many to believe that it is poorly fitted 
to resource allocation, especially in health [4,64].  This critique has been on both practical and 
theoretical grounds.  While some have maintained the ability of welfarism to assist in resource 
allocation [65], the majority accept that a different approach is needed [4,7,48,66].  This led to 
the development of extra-welfarism.       
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1.3. The Extra-Welfarist Approach 
This section describes the main motivation for the development of the extra-welfarist 
approach.  The primary differences between extra-welfarism and welfarism are described and 
the ways in which it has been put into practice are examined.  The section concludes with a 
summary of the critiques levelled at the extra-welfarist approach, which often focus on its 
practical application. 
1.3.1. The seeds of extra-welfarism 
Brouwer et al. [9] have identified a number of ‘seeds’ that led to the rejection of welfarism 
and the acceptance of the need for a different model of resource allocation in health.  
Brouwer’s “seeds” are non-direct critiques of welfarism.   
The first seed is the concept of the “merit good”.  Some goods are too meritorious to be left 
open to the will of market mechanisms, and should be subsidised, in some form, by the state 
[5,67].  The concept of a ‘merit good’ can be understood as a good which has a greater value 
to society than is reflected in its market price, due often to the externalities that the good 
produces [67].  If provision was left to market forces they would be under provided, so 
normally they are subsidised by the state.  Education and health care are routinely considered 
as merit goods, as is transport infrastructure such as roads.   
A second seed was the assertion of a specific, rather than general, desire for equality.  Tobin 
[68] proposed that people consider that the allocation of some goods and services should be 
based on egalitarian principles, while for other goods this desire is absent.  For example; 
people may accept a situation where some people do and some people don’t have access to 
Perrier, but not a situation where some don’t have access to basic, clean drinking water.  
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Similar suppositions are found in John Rawls’s [57] ‘basic goods’ theory and Walzer’s [69] 
spheres of justice premise.   
Thirdly, great weight was added through Sen’s offer of functionings and capabilities as more 
appropriate metrics for the measurement of wellbeing [30,48,53,70,71].  The capability 
approach has found traction as an idea in policy areas outside of poverty and human 
development, where it was initially proposed.  A fuller description of this approach, which 
contains a strong critique of welfarism, is provided in a later section of this chapter.    
The fourth seed, and possibly the most damning criticism of the welfarist approach from a 
practical health provision perspective, is the continued rejection of welfarist policies in health 
by governments.  In the UK, the 1944 white paper titled ‘A National Health Service’ and in 
the US, the Social Security Act of 1965, showed the rejection of strict welfarist policies [9].  
The majority of governments are focused on ensuring a basic level of healthcare for all 
citizens.  An understanding of trades offs, where some lose and some win, is essential for 
ensuring this provision.  Furthermore, provision of health is not left solely to the individual 
and there is an acceptance that decision makers can be a good addition to health resource 
allocation [72]. 
Extra-welfarism was developed throughout the 1970’s and 1980’s in response to critiques 
similar to the one presented above [5,72,73].  Coast et al. [4] detail extra-welfarism’s large 
theoretical departure from standard neo-classical welfarism:    
 ‘extra-welfarism is defined as transcending traditional welfare by supplementing these 
welfares with other ‘non-goods characteristics’ of individuals such as health state, 
freedom of choice and even quality of relationships between individuals’(p.1192). 
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1.3.2. Theoretical basis of extra-welfarism  
The meaning of extra-welfarism has caused considerable confusion and consternation since its 
beginnings [33,74].  Culyer’s extra-welfarism [73] draws heavily on Sen’s [70,75,76] theory 
of functioning and capability to enrich the evaluative space, by permitting outcomes other 
than utility and allowing these to be elicited from people other than affected individuals [5,9].   
It has been both defined as surpassing traditional welfare economics [73] and criticised for 
adding little content to already existing theories [77].  This confusion has been so chronic and 
persistent that as recently as 2008, Brouwer, Culyer and colleagues [7] have further tried to 
clearly delimit extra-welfarism, through a clear statement of ways in which it diverges from 
the welfarist approach.  Brouwer et al. [9] assert that the extra welfarist approach differs from 
welfarism in four ways.  Firstly, it ‘permits the use of outcomes other than utility’(p.330)[7] in 
the analysis of the welfare of the individual.  Secondly, it does not constrain the sources of 
valuation solely to affected individuals.  Thirdly, it allows outcomes to be weighted by 
principles other than preferences.  Finally, it departs from the Pareto principle in allowing 
interpersonal comparisons in the evaluative space.   
1.3.2.1. Beyond utility 
The inability of the welfarist approach to admit non-utility information has been a focal point 
for criticisms of welfarism.  Sen [78] proposed information on the basic capabilities of an 
individual as an example of non-utility information that is important and relevant to the 
assessment of a person’s welfare and asserts that people have needs that are independent of 
their utility.   
Extra-welfarism relaxes the assumptions of welfare economics [77] by rejecting the sole focus 
on utility-based interpretations of welfare [79].  In doing this it allows information other than 
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utility to be included in the assessment of welfare.  This information can include the process 
of care and, importantly, health.  In extra-welfarism health is not valued for the utility it 
produces, rather for its own sake, on the basis that health is the principal outcome of health 
care [64].  In admitting other sources of information, the extra-welfarist is not rejecting utility 
information, rather recognising that utility is one of many sources of information [7].  Nor are 
the preferences of the public necessarily superseded.  Preference measurement can be applied 
to non-utility information, such as health gains or capability improvements [80].  This 
movement beyond utility has allowed the claim that, as a theoretical model, extra-welfarism 
offers more breadth than neo-classical economics [7,75,80]. 
1.3.2.2. Accepting paternalism  
Extra-welfarism departs, in two ways, from viewing affected individuals as the only relevant 
source of evaluation.  Firstly, it recognises the role of a decision maker in defining the 
evaluative space [7].  This requires the selection of what should be, and what should not be, 
considered relevant by a policy or decision maker.  Sen [81] claims that this is not an 
embarrassment for extra-welfarism; a claim which is reaffirmed when we consider that 
Sugden and Williams had previously proposed such an approach, under the welfarism 
umbrella [72].  Secondly, extra-welfarism permits “stakeholders”, other than the affected 
individuals to be regarded as appropriate sources of information.  Therefore family members, 
doctors, health managers and citizens’ juries can all be considered legitimate sources of 
information.  
1.3.2.3. Weighting of outcomes 
Support has been found for the distribution of health outcomes by some method other than 
sum maximisation [82], such as distributed in favour of the young [83], in favour of lower 
23 | P a g e  
 
socio-demographic levels [84,85] or in favour of those who have the lowest levels of existing 
health [86].  While there is no consensus among extra-welfarists on if, and on what terms, 
health should be distributed, the extra-welfarist model would theoretically allow for such 
prioritisation.  Outcome measures could be used to inform such judgements.  Outcome gains 
for those below a defined level could be given greater weights than those above that level.  
Culyer  [74] notes that it is possible to fully integrate these weights into cost-effectiveness 
analysis, allowing both efficiency and equity to inform health policy and resource allocations.   
1.3.2.4. Interpersonal comparisons 
Interpersonal comparisons are the corner stone of the extra-welfarist approach  to decision 
making [7].  The use of health measures allows individuals to be compared on some measure 
of health.  This can facilitate comparison between patients with different conditions and 
funding decisions between two or more very different treatments.  Therefore, the policy 
paralysis, which occurs from the inability of the Pareto Criterion to incorporate interpersonal 
comparisons, is avoided.   
1.3.3. Extra-welfarism in practice 
1.3.3.1. Cost-effectiveness analysis 
Cost-effectiveness analysis offers a method by which both the costs and the consequences of 
treatments can be measured within the theoretical boundaries laid down by the extra-welfarist 
approach [87].  Cost-effectiveness analysis quantifies the benefit of a treatment through a 
natural single unit, such as lives saved, cases detected or life years gained [88].  A number of 
outcome measures or endpoints are suitable for use, with the outcome expressed in cost per 
unit of effect [87].  Under cost-effectiveness analysis, intermediate endpoints, such as blood 
pressure as an indicator of stroke risk, and final endpoints, such as cardiovascular related 
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death, or all-cause mortality, can be used.  Although intermediate outcomes may be 
acceptable, ideally a link between intermediate and final outcome should be clearly 
demonstrated [87].  Patient completed quality of life measures are a frequently used outcome 
measure in cost-effectiveness analysis.  A summary of these measures is provided in chapter 
two.   
1.3.3.2. Cost-utility analysis    
Cost utility analysis is the most frequently used form of economic analysis for decisions 
involving health care resource allocation [89].  Here utility refers to the preferences of groups 
of individuals for a health outcome.  This method allows health outcomes to be ‘valued 
according to their desirability’(p139)[89].  Therefore, while cost-utility analysis is often 
considered as a subgroup of cost-effectiveness analysis, it has clear and important 
distinctions, not least that it recognises the importance of considering public preferences [90]. 
The methods by which these preferences are elicited vary, but focus around four main 
processes for drawing out preferences: the visual analogue scale, standard gamble, time trade-
off and the discrete choice experiment.  The visual analogue scale is a simple approach 
whereby subjects are asked to rank their preferences in order of most to least preferred and 
then to place the outcomes on a scale so that the distances between placements correspond to 
the difference in preferences [89].  If options were only marginally preferred then spacing 
would be small, whereas clear preferences would see larger spacing.  In the standard gamble 
approach the subject is offered two options.  In option one the subject stays in a chronic state 
for life; option two there are two possible outcomes, with probabilities attached: outcome one 
the person is returned to full health and lives for as set number  of years (probability y) and 
option two the subject dies immediately (1-probability y) [89].  The probabilities are varied, 
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systematically, until the participants are indifferent between the two options.  Third, in the 
time trade-off approach the subject is offered two options [89,91].  Option one is to live in the 
diseased state for a given period of time.  Option two is to live in a healthy state for a period 
of time less than Option one.  The time is varied until the subject is indifferent.  Finally, a 
discrete choice experiment is a survey method based on choices of attributes [92,93].  The 
participant is presented a number of different hypothetical states.  In each scenario the 
participant is asked to choice between two or more options which vary on important attributes 
or characteristics [92–94].     
These processes through which preferences are elicited are time consuming and too 
cumbersome for use in the majority of research settings, where efficiency and speed of data 
collection is required.  In response to this limitation, pre-scored, patient-completed, health-
related quality of life measures are routinely used.  In this situation, weightings for the 
responses to a health-related quality of life measure are elicited through one of the methods 
described above and “attached” to the measure.  The response to the quality of life measure 
can then be scored, using the weighted responses, to give an output that recognises patient or 
the general public’s preferences.  These quality of life measures are considered in greater 
detail in chapter 2. 
1.3.3.3. The quality adjusted life year 
The quality-adjusted life-year (QALY) was introduced in 1968 [95] and furthered by 
Weinstein et al. [96] and others [97].  The QALY defines health as value weighted time 
accumulated over a given time horizon [98].  The QALY represents a common unit of 
effectiveness that can be used across economic evaluation in different clinical areas [90].  
Using the QALY, a year of life is adjusted for the life quality during that year and reduced 
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down to a single value [97].  A score of 1 indicates that someone is living in perfect health for 
one year.  A score lower than 1 suggests that a person is either living in a degree of poor 
health for that year or they have lived for less than a year.  A treatment or programme can 
increase QALYs by either increasing the quality of life during a period of time, or extending 
the period of time a person lives for.  The QALY concept dictates that quality weighting is 
preference-based, anchored at death and measured on an interval scale [89].  The QALY 
incorporates both the quantity of life (mortality) and the quality of life (morbidity) into one 
measure.  The QALY seeks to incorporate preferences through use of the cost-utility approach 
to obtain the weighting of the measurement.   
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1.3.4. Extra-welfarism critique 
The critiques levelled against extra-welfarism have been focused on the practical application 
of the approach rather than the theoretical proposition.  In practice, extra-welfarism’s 
complexity and breadth is not retained and a more limited departure from welfarism is 
realised [5].  Three main limitations are noted: the limitation of the evaluative space, the 
limitation of the evaluative scope and the commitment to maximisation. 
1.3.4.1. The limitation of the evaluative space 
Theoretically, extra-welfarism expands the evaluative space by allowing outcomes other than 
utility to be used in evaluation [7].  In practice the expansion of the evaluative space in extra-
welfarism is more limited, with  utility replaced with health as the sole outcome measure [77].  
Therefore, rather than permitting other outcomes, extra-welfarism has changed the exclusive 
focus from utility to health.  Furthermore, while the health of patients is viewed by many as 
highly relevant to the evaluation of health technologies and treatments, it could be perceived 
as a narrower evaluative space than that of utility [4,49].  
The adoption by extra-welfarists of health as the sole outcome measure, may be considered 
especially limiting in some life situations and for some fields of medicine [99].  For those who 
are in the end stage of life or living with a chronic disease, health may not be the only, or even 
the most important, outcome of their treatment.  Furthermore, for medical specialties such as 
geriatrics, or in situations where social and medical considerations overlap, such as in social 
care or public health, use of health as the only measure of worth for the treatment being 
provided is unlikely to capture the effect of a treatment accurately . 
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1.3.4.2. The limitation of evaluative scope 
Along with the limitation of the evaluative space, a less discussed limitation is in the 
evaluative scope of the approach: the people considered relevant.  Cost-effectiveness analysis 
has maintained a focus on patients, on the assumption that the patient population will receive 
any health gains provided.  This assumption excludes the potential that close relatives and 
informal carers may benefit from health and non-health gains in the quality of life as the 
health of the person they care for improves [100].  Currently very few economic evaluations 
go beyond the patient; however discussion is taking place about the appropriate scope of 
extra-welfarist analysis [101,102].  Furthermore, evidence exists that this limitation of the 
scope may lead decision makers to reach different decisions on the cost-effectiveness of an 
intervention than would be reached if the broader impacts of an intervention were considered 
[102].   
1.3.4.3. The commitment to maximisation 
The practical expression of extra-welfarism has maintained the importance of maximisation as 
a measure of good, with the maximisation of health replacing utility [103].  Coast [4] states 
that this is not linked to any theoretical basis, rather it has been asserted by early decision 
makers and reported in early academic works [96,103].  Potentially, this occurred as it is a 
position which is acceptable or traditional within economics and can be viewed as a weak 
value judgement. 
This commitment to maximisation has been further criticised for being against the wishes of 
the majority of the public, who would like to see a more egalitarian distribution of health 
benefit and gain.  Dolan et al’s [82] review of the literature predating 2001, showed under a 
number of circumstances, that the public favoured a distribution of wealth by some criteria 
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other than maximisation of population health.  A large body of literature has been published 
since 2001 which has showed that the public may want to prioritise the young over the old 
[104,104] and the severely sick over those who are less sick [86,105], while there is some 
indication that the public wants to consider whether the illness was self-inflicted in the 
decision making process [106].  Taken as a whole, the literature suggests that under some 
circumstance the public do not support maximisation of health.  
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1.4. The capability approach 
This section will describe the theoretical underpinnings of the capability approach.  Many of 
the previous sections of this chapter (notably sections: 1.2.3. Welfarism critique, 1.3.1. The 
seeds of extra-welfarism, 1.3.2. Theoretical basis of extra-welfarism and 1.3.4. Extra-
welfarism critique) are important in understanding the capability approach and should be 
considered in conjunction with the following section.  The section concludes with a summary 
of the challenges of “operationalising” – putting into a health-research-useable form – the 
capability approach.  A full summary of current efforts to operationalise the approach and an 
in-depth description of the ICECAP-O and ICECAP-A measures are provided in Chapter 2.   
1.4.1. Theoretical basis of Capability 
‘The capability approach is a broad, normative framework for the evaluation and assessment 
of individual well-being’(p.94)[1].    Proposed by Amartya Sen and developed by Sen, 
Nussbaum [107] and others, the approach offers a substantial diversion from welfairsm and 
the practical expression of extra-welfarist approaches.  Generous credit is given by Sen to 
theorists, economists and philosophers, ranging from Aristotle to Adam Smith to John Rawls, 
who preceded him and influenced and shaped his thinking [55].  The capability approach 
proposes a rich and broad evaluative space on which judgements should be based [53,54].  
The capability approach has been considered for use in health research and health service 
evaluation because of both the limitations with the current methods of assessment and the 
increasing recognition that health interventions often result in outcomes other than health. 
1.4.1.1. Functioning and capability 
The central feature of Sen's capability approach is to advocate the evaluation of situations 
based on the extent to which a person is able to function [66].  Sen [53,75] states that the 
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ability to achieve valuable functionings, consisting of “beings” and “doings”, determines a 
person’s well-being.  Sen defines actual achievement as “functioning” (e.g. living without 
illness).  A person’s achieved state of well-being can be assessed through a functioning 
vector, which is a measure of a person’s functionings [53,54].  Sen defines freedom to achieve 
as “capability” (e.g. the option to live without illness).  When assessing well-being Sen 
advocates going further than measuring a person’s achieved functionings.  He says that 
measuring the functionings which a person has the ability to achieve (their capability) offers a 
fuller assessment of quality of life [53,70,75].  A person’s capability set can be thought of as a 
set of vectors of functionings from which a person can choose.   
The benefits of measuring capability rather than functioning can be described using a slightly 
altered version of Sen’s well-known fasting example [70].  Consider two people, Person A 
and Person B, who both require an operation and consequently a blood transfusion.  Person A 
is not able to have the operation because there is no blood available in her country or 
geographical area.  Person B is not able to have the operation because of an objection 
(religious or otherwise) to receiving blood, despite plenty of blood being available in his 
country.  In assessing these individual’s functionings one would conclude that they are the 
same: neither had the operation.  However, by assessing these individual’s capability they are 
shown to be very different: Person B, in an objective sense is able to have the operation, 
whereas Person A does not have that choice.  Sen states that there is ‘at least no informational 
loss in seeing well-being assessment in terms of capabilities, rather than directly in terms of 
achieved...functioning’(p.39) [70].  
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1.4.1.2. The relationship between a good and an individual 
A motivation for measuring well-being in terms of functionings and capabilities is Sen’s 
assessment of the relationship between financial wealth, physical goods and an individual.  
Being well off is not one and the same as being well [52].  Well-being is influenced by a 
person’s income, but a person’s income does not determine a person’s well-being.  Personal 
characteristics ensure that while there is a causal relationship between money and well-being, 
this relationship is not complete.  For example, a person with severe mental or physical 
disability will require greater wealth and will need to possess more goods to be able to live in 
the same quality of life as a non-disabled individual [52]. 
Sen makes the distinction between four different aspects of the relationship between a good 
and an individual, by using the example of a bicycle [108,109].  The good is the bike; the 
characteristics are the qualities of the bike (e.g. movement); the utility is the pleasure gained 
from owning the bike; and the functioning is an individual’s use of the bike (riding) [108].  
The personal characteristics of an individual will determine both the utility gained from the 
bike and the functionings achieved: a competent and enthusiastic cyclist would gain more 
from the good than an individual who cannot cycle. 
The variations in personal characteristics lead to variations in the conversion of good, 
resources and wealth into both utility and functionings.  Therefore, resources do not have an 
intrinsic value, rather their value is in the opportunities they provide [54].  The capability 
approach sets out to value these opportunities directly, and in doing so accounts for the 
significant effects that the conversion of goods and resources can have. 
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1.4.1.3. The distinction between agency and well-being 
As noted earlier, the capability approach advocates a richer and broader evaluative space than 
traditional welfarist and extra welfarist approaches.  The capability approach identifies two 
distinctions, which form four subcategories within the evaluative space.  The first, discussed 
above, is between capability and functioning.  The second distinction is between “well-being 
goals” and “agency goals” [70].   
Well-being goals are basic goals that relate directly to the well-being of that person.  These 
may include living without severe illness, living under shelter and having acceptable nutrition 
[70,110].  Agency goals are normally more complex goals that an individual has reason or 
motivation to seek [70].  These goals can be ambitions such as to live by a certain set of 
standards or morals, or career ambitions.  Agency goals may be linked to, or may themselves 
be well-being goals [53]: a person may enjoy keeping themselves healthy and free of disease 
by eating well and taking regular exercise.  The pleasure gained from this is greater than 
simply the basic achievement of a minimum standard of life: it has greater agency to the 
individual.  However, agency goals may also be goals that are different to, and have a 
deleterious effect upon, well-being [53].  For example, a person may be highly career focused 
and work long, stressful days in order to achieve the promotion or position they value.  This 
work may take its toll upon their health, and therefore they are achieving their agency goal at 
some cost to their well-being.   
These two distinctions, between capability and functioning and between well-being and 
agency, result in four sub-categories in the evaluative space: well-being achievement 
(functioning); agency achievement (functioning), well-being freedom (capability) and agency 
freedom (capability) [70]. 
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1.4.1.4. Basic versus complex capabilities 
Sen [70] makes a further, two level distinction between basic capability, ‘the ability to satisfy 
certain crucially important functionings up to certain minimally adequate levels’(p.41), and 
more complex capabilities, which is closely related to well-being and agency.  Sen [53,76] 
states poverty can be viewed as a failure of basic capabilities, such as the ability to be disease 
free and have basic nutrition, to reach acceptable levels.  In such circumstances, a focus on 
basic capabilities and functionings may allow us ‘to go a fairly long distance’(p.44)[53] in terms 
of analysis.  However, in situations where these basic capabilities are taken for granted, such 
as in many developed countries, then a broader range of more socially orientated capabilities 
may be needed to judge a person’s well-being and agency [76].  In the analysis of health and 
social care interventions in a developed country, a broader range of capabilities would likely 
be required.   
1.4.2. Operationalising the capability approach 
The capability approach has a number of notable differences from other, competing, 
normative theories.  The approach is not a list of commodities or personal traits and Sen has 
purposively left it incomplete to allow for plurality in the evaluative space [110].  This makes 
capability a complex theory.  Sugden [54] has questioned the extent to which the theory is 
operational: ‘given the rich array of functionings that Sen takes to be relevant, given the 
extent of disagreement among reasonable people about the nature of a good life, and given the 
unresolved problem of how to value sets, it is natural to ask how far Sen’s framework is 
operational’(p.1953).  In some ways Sen has compounded this challenge by stating that ‘if an 
underlying idea has an essential ambiguity, a precise formulation of that idea must try to 
capture that ambiguity rather than hide or eliminate it’(pp.33-34) [70].   
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A number of proposals have been given regarding how to operationalise the approach.  
Robeyns [111] describes a continuum of ways in which the capability theory could be made 
operational.  At one end of the continuum is structured, methodological driven research where 
a reductive statistical technique is used upon a rich data set to identify important functionings 
and capabilities.  At the other end is an approach based on theoretical underpinnings. 
Nussbaum’s list of “central human capabilities” is the most well-known example at the 
theoretical end of the spectrum.  Nussbaum proposes ten capabilities (life; bodily health; 
bodily integrity; senses; emotions; practical reason; affiliation; other species; play; and 
control) which she holds all humans to be morally entitled to [107].  Critiques of this list have 
stated that the list lacks legitimacy and consensus.  Nussbuam states that the list is formed at 
the abstract level and should be translated into implementation at the local level [111], but 
many of the ten capabilities on the list might be considered irrelevant to many research 
settings, or it might be considered unreasonable to expect a medical intervention to alter some 
of the capabilities listed.  
Sen has not proposed a list of capabilities and has indicated that in different contexts different 
capabilities are likely to be important [4].  In line with this thinking Robeyns proposed a 
“check and balance” procedure by which capabilities should be selected by researchers and 
policy makers.  This procedure is: explicit formulations, where the list is described, discussed 
and defended; methodological justification, whereby the method of formulation is discussed 
and defended; different levels of generalisability, whereby the lists are generated at stages 
ranging from ideal theory to practical implementation; and exhaustion, where checks are 
completed to ensure no important capability is left out.  
36 | P a g e  
 
Despite the challenges, the capability approach has been recognised as providing a theoretical 
framework through which disability can be described [112] and assessed [110].  It has been 
cited as a way through which the effects of public health interventions, which may reach 
outside of a purely health domain, can be accurately assessed for health economic evaluation 
[113].  Furthermore, the potential for the approach to provide a richer evaluative space for 
economic evaluation in health per se and to challenge some of the value judgements which 
currently exist in health economic evaluation has been noted [4,66]. 
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1.5. Conclusion 
In this chapter the central tenets of welfarism, extra-welfarism and the capability approach are 
introduced.  The theoretical evolution from welfarism towards and extra-welfarist approach 
has been described and the limitations of both approaches are discussed.  Welfarism critiques 
have remained largely theoretical and have focused on the potential results of using Utility as 
the evaluative space in conjunction with the Pareto Principle; while for extra-welfarism 
critiques have been centred on the truncation of the scope of the approach when put into 
practice in health.     
The capability approach may provide a solution to many of the limitations of the welfarist and 
extra-welfarist approaches.  It offers a broader evaluative space than health or utility, which 
may provide a fuller conceptualisation of the value of a given situation.  This approach is the 
focus of this thesis, which seeks to extend recent work that has developed two new patient 
reported outcome measures for use within a health and social care setting: the ICECAP-A 
[114–116] and ICECAP-O [109,117,118] measures.   
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CHAPTER 2. QUALITY OF LIFE AND CAPABILITY 
MEASUREMENT IN RANDOMISED CONTROLLED 
TRIALS 
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2.1. Chapter introduction 
Chapter 1 provided a description of how, theoretically, the capability approach diverged from 
welfarist and extra-welfarist approaches.  The practical application of the capability approach 
will likely differ from established methods for measuring quality of life in health research.  
Attempts to put this theory into practice in a health research setting are at an early stage.  In 
order to provide an indication of how the capability approach may extend current methods for 
assessing quality of life, a summary of the types of quality of life measures used in health 
research, the purposes of use and how measures “fit” into extra-welfarist theory is provided in 
this chapter.  A description of efforts to operationalize the capability approach in a research 
setting is provided with reference to the OCAP and OxCAP measures, the ASCOT measures 
and the ICECAP capability measures.  The development and valuation of the ICECAP 
measures are discussed in detail.  A methodological review of studies assessing the validity of 
the ICECAP measures concludes the chapter.  First, however, this chapter starts with a 
summary of a modern trial.  Randomised controlled trials are considered a gold standard 
research technique [119].  Health economic analysis is frequently conducted alongside trials 
[120] and quality of life measures are increasingly being utilised as outcomes in trials 
[121,122] [119].  If the ICECAP measures are to be used routinely in health research, they will 
be used in trials.  Two randomised controlled trials are also the vehicle through which this 
thesis has assessed the validity of the ICECAP measures.  A summary is provided through 
discussion of the characteristics of the modern trial methodology: randomisation, blinding and 
comparison.   
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2.2. The randomised controlled trial 
A central feature of modern medicine is the use of the randomised controlled trial in 
evaluating the effectiveness of medical procedures and interventions [123].  A rigorously 
planned and properly executed ‘prospective study comparing the effect and value of 
intervention(s) against a control’(p.2) is a powerful investigative tool, which is considered a 
gold standard experimental technique [119].   Modern trial methodology is a complex 
discipline that is focused around three basic characteristics: randomisation, blinding and 
comparison [123].   
2.2.1. Characteristics of a randomised controlled trial 
2.2.1.1. Randomisation 
Randomisation, the process by which a patient entering a trial has a pre-defined chance of 
being allocated to the treatment or control group, is a key feature of the modern randomised 
controlled trial [124].  It has three main methodological advantages.  The deliberate 
introduction of an element of chance into the assignment of treatments reduces the possibility 
for bias in the allocation of treatments [125,126].  It helps produce groups that are similar both 
by factors that will be measured by the trial, such as health status, age and ethnicity, and 
factors that are unobserved, such as undiagnosed disease.  The production of groups that are 
similar means that they are also statistically comparable [126].   Finally, it safeguards the 
validity of statistical tests [124].  For example, use of the chi-squared and t-test can be 
justified on the basis of randomisation alone.  If, however, the sample is not random a number 
of other considerations, such as the distribution of responses need to be considered [126]. 
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The process of randomisation can be very simple, such as the toss of a coin or the use of a 
random number generator[127].  While such unrestricted randomisation is an acceptable 
approach, other methods of randomisation do have practical advantages for a trial.  Block 
randomisation, where participants are randomised in groups, can reduce the risk of serious 
imbalance due to chance [125,128–130].  Stratified randomisation, whereby participant 
characteristics are considered in order to ensure groups that are comparable by some 
prognostic or risk factor, can be useful in small studies where a potential imbalance is likely 
[127].  Whatever the process of randomisation chosen, the randomisation schedule should be 
concealed from both the researchers and participants of the trial, to ensure the study are 
“blinded”. 
2.2.1.2. Blinding 
The purpose of blinding, or the concealment of the treatment allocation, is to ‘prevent the 
identification of the treatments until all such opportunities for bias have passed’(p.1914)[125].  
There are a number of forms of bias that can occur when the treatment allocation is not 
concealed [131]: response bias is when participants respond according to how they think they 
are expected to (e.g. intervention group should improve); attrition bias is the increased 
dropout amongst patients who know they are not receiving the intervention treatment; and 
outcome or observer bias is the potential of assessors to preferentially assess patients who 
they know are receiving the intervention.  Furthermore, blinding removes the potential for a 
placebo effect or the psychological impact of patients knowing that they are or are not 
receiving the intervention. 
A double blind trial is a study where neither the participant nor the researchers (both those 
collecting and analysing data) know the treatment allocation [125].  A double blind study 
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design is considered the “gold standard” in trials.  While methodologically superior, double 
blind studies can be very difficult in practice, especially in trials where researchers are 
delivering different treatments or interventions.  A single blind study is a study where only the 
investigator knows the allocation and an unblinded, or open label, study is a situation where 
both the researcher and the participant know the allocation [119].  The risk for bias in this last 
situation is high; however, in some situations, such as surgical trials, this is the only practical 
option [132]. 
2.2.1.3. Comparison 
The comparator treatment is an important methodological and ethical consideration.  If an 
established “best” therapy exists the control group in a trial would usually be expected to have 
this treatment administered.  In situations where the best therapy is not widely available, 
either for cost reasons, lack of clinical ability (often in the case of surgical interventions) or 
organisational capacity, then placebo controls may be considered.  Use of a placebo control 
when a best therapy exists is considered ethically questionable [119].   
A trial which has the objective to show that the new intervention or therapy is more effective 
than the control is termed a superiority trial [125,133].  However, not all trials are superiority 
trials.  Non-inferiority trials have the objective of a comparison with the control, to see if the 
intervention treatment is not clinically inferior to the control [125,134].  This comparison may 
be needed if the new treatment is thought to be cheaper than the existing treatment, or to 
induce fewer side-effects. 
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2.3. Measurement of outcomes for cost-effectiveness 
analysis alongside clinical trials 
Cost-effectiveness analyses express value in cost per unit of effect, with the measure of effect 
being chosen to suit the purpose of the intervention under consideration [88].  For example, a 
screening programme may assess cost per disease detected, while a curative intervention may 
assess cost per disease cured.  Early cost-effectiveness assessments used a number of different 
measures of effect [89]: reduction in mmHg of blood pressure in a cost-effectiveness study of 
treatment of hypertension [135]; cases of deep-vein thrombosis detected in a cost-
effectiveness analysis of a screening programme [136]; or episode-free days in the clinical 
area of asthma [137].   
Use of such clinical or “natural” outcome measures have some limitations.  They make 
comparison between cost-effectiveness interventions in different areas very difficult.  
Furthermore, trade-offs cannot be made explicitly [89].  Consequently quality of life 
instruments have become an increasingly important way of assessing the efficacy of an 
intervention or treatment in a randomised controlled trial [119].  They are used both as 
outcomes in health economic analysis alongside the trial and as primary and secondary 
measures independent of health economic analysis.   
The development of quality of life measures can be traced back to attempts to extend 
assessment beyond clinical outcomes, such as the presence or absence of disease or disease 
markers [138].  One of the earliest efforts, the Karnofsky Performance Scale, was conceived 
in 1947 as a one item measure, which asks patients to rate their health on a 0 to 100 scale 
[139].  This was later followed by more detailed, multi-item assessments of health status, such 
as the Sickness Impact Profile [140] and the Nottingham Health Profile [141].  Later 
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measures, such as the EuroQoL five dimension (EQ-5D) [142,143], Short Form (36) Health 
Survey (SF-36) [144] and European Organisation for Research and Treatment of Cancer 
quality of life questionnaire (EORTC QLQ-C30) [145], while maintaining a focus on health, 
have included assessment of social, psychological or emotional functioning. 
2.3.1. Types of health-related quality of life measures 
The health-related quality of life measures currently used in health research can be 
categorised as: generic, illness specific, aspect specific and patient specific. 
2.3.1.1. Generic health-related quality of life measures 
Generic measures can be used in studies of different illnesses and differing patients.  Many of 
these measures may be applicable for use within the general population.  Two frequently used 
examples are the EQ-5D and SF-36.   
The EQ-5D is a brief measure which assesses the quality of life attributes of mobility, self-
care, usual activities, pain/discomfort and anxiety/depression [142,143].  Two versions now 
exist with the earlier version offering three response categories (EQ-5D-3L) and the later five 
(EQ-5D-5L) [146–148].  From these questions a single index score can be calculated. 
The SF-36 is a longer questionnaire than the EQ-5D-3L and addresses eight health attributes: 
physical functioning, physical role, bodily pain, general health, vitality, social functioning, 
emotional role and mental health [144].  A score for each attribute is provided by a scale.  
From these scales, two summary scores of physical health and mental health can be 
calculated.   
45 | P a g e  
 
2.3.1.2. Illness specific health-related quality of life measures 
An example of an illness specific questionnaire is the EORTC QLQ-C30 cancer specific 
questionnaire [145].  The measure was designed for use across a range of cancers.  This 30 
item questionnaire assesses physical, cognitive, emotional and social functioning, broad 
symptoms, such as fatigue and pain, and specific symptoms, such as dyspnoea and diarrhoea.  
In addition to the core QLQ-C30, the EORTC group also offer a number of additional 
modules that recognise that different cancers have different morbidities and different 
treatments have different side-effects [149]. 
2.3.1.3. Aspect specific health-related quality of life measures 
Aspect specific questionnaires are used to assess the effect of a disease or treatment on an 
aspect of quality of life that a researcher wants to explore in more detail [138].  An example of 
such a measure is the Hospital Anxiety and Depression Scale (HADS).  The HADS is a 14 
question measure that has been used across a wide variety of clinical conditions [150].  It 
assesses both anxiety and depression, and produces subscales for each.  Scores over a cut off 
are indicative of anxiety disorder or depression. 
2.3.1.4. Patient specific health-related quality of life measures 
A small number of measures have been developed based on the characteristics of the patients.  
For example the PedsQL is a short generic, standardised instrument which is appropriate for 
use with children and adolescents and their parents [151].  The Geriatric Depression Scale is 
an aspect specific measure appropriate for use with elderly patients as a measure of their 
psychological health [152]. 
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2.3.2. Health-related quality of life measures and extra-welfarism 
The majority of quality of life measures used in health and clinical research still focus on 
health functioning [138].  In a number of cases, measures that were designed as health status 
measures are frequently referred to as quality of life measures in the literature and an 
assumption is often made that if a person’s health is poor, then quality of life must be reduced 
[138].  Health is used as an indicator of quality of life.  Therefore, the majority of instruments 
used can, and are, most accurately described as health-related quality of life measures. 
Cost-effectiveness analysis seeks to quantify the benefit of a treatment through a single unit of 
effect [88].  This unit may be life years, or cardiac events.  It may also be scores from patient-
reported health-related quality of life measures.  The outcome measures discussed above are a 
selection of measures which “fit” within the theoretical boundaries of cost-effectiveness 
analysis: they offer quantification of benefit through the score which they provide.  The 
measures also “fit” within the practical application of extra-welfarism seen in the literature, 
which has sought to focus on health and health functioning.  
Cost-utility analysis differs from cost-effectiveness analysis in requiring health outcomes to 
be valued according to the utility they provide.  This measurement of value, or preferences, 
allows the formation of the QALY, or some variant, such as the DALY [89].  The three most 
widely used techniques, which were discussed in section 1.3.3.2. Cost-utility analysis (Time 
Trade Off, Standard Gamble and Visual Analogue Scale (VAS)), are all time-consuming 
methods of eliciting preferences.  Pre-scored measures have become a popular method for 
“bypassing” these time-consuming measurements each time an economic analysis is 
conducted [89].    
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2.3.2.1. Utility measures 
Three commonly used health-related quality of life measures with preference scores attached 
are the EQ-5D-3L [142,143], the Short Form 6 Dimension (SF-6D) [153,154] and the Health 
Utilities Index (HUI) [155,156].  The EQ-5D-3L, the descriptive system for which is 
described above, had the preferences for its scoring system estimated using the TTO approach 
[157].  The SF-6D, developed in 2002 by Brazier et al is based on the longer SF-36 measure 
[153].  It defines health-related quality of life as including physical functioning, role 
limitations, social functioning, pain, mental health, and vitality and preference weights were 
derived using standard gamble methodology [153].  The HUI classifies health-related quality 
of life under 8 headings: vision, hearing, speech, ambulation, dexterity, emotion, cognition 
and pain [155].  The weights for the measure were estimated using standard gamble methods 
[155,156]. 
While these measures have some differences, both in what they define health-related quality 
of life to be and the way they calculated the pre-scored preference weights, they all have an 
important methodological similarity: the index score is a summary of the value of the health 
state and not just a description of the health state.  As an example of this distinction, take a 
hip replacement operation.  Preference based measures don’t just assess whether the hip 
replacement resulted in increased mobility, but also the value which people get from this 
increased mobility.  This allows comparisons with other interventions on the basis of 
population preferences and the calculation of QALYs.  
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2.4. Measuring capability 
A primary critique of the extra-welfarist approach is that in practice, the broad evaluative 
space is significantly limited by a focus on health [7].  Many health and social care 
interventions may provide benefits other than health [4,66].  For example, a social care 
intervention to enable elderly people to live in their home may have little impact on the self-
reported health of people, but a considerable impact on their independence and enjoyment.  
Equally a patient who is on an end of life care pathway may value quality time spent with 
relatives over feelings of good health and vitality.  The majority of current health-related 
quality of life measures fail to assess such outcomes, or such outcomes constitute only a small 
weight in the overall score.  In cases where the benefits of a treatment or an intervention are 
not captured by the measures used, then intervention may be undervalued.  This has led some 
to advance the measurement of capability as providing a richer evaluative space.   
A small number of measures of capability have been developed, generally focusing on the use 
of questionnaires to assess capability.  The process of development of these questionnaires 
has been varied and attempts occur at different positions along the continuum described by 
Robeyns et al [111], discussed in Chapter 1.  Differences also exist in the influence that the 
capability approach had on these measures.  Some measures were designed with the explicit 
intent from the outset of measuring capability.  Other measures “adopted” the capability 
approach as a framework for interpreting findings during the methodological process of 
developing a measure. 
This section considers three efforts which have relevance and potential for use in a health or 
social research setting: the OCAP and OxCAP measures; the ASCOT measure; and the 
ICECAP measures.  Other measurement instruments have been developed, or are in the 
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process of development, but at the time of writing these are the most advanced and complete 
measurement instruments.   
2.4.1. OCAP and OxCAP measures 
The OCAP and later the OxCAP instruments are a group of measure which are developed 
from the theoretical work of Martha Nussbaum.  The development of the OCAP is therefore 
placed at the theoretical underpinnings end of Robeyns [111] continuum1.  Anand et al [158] 
developed a survey which assessed Nussbaum’s ten central capabilities using questions asked 
in the British Household Panel Survey (BHPS), which is a large 5000 house survey designed 
to be representative of the British population.  This measure was then administered to 1048 
UK residents in 2005 [159].  The focus of this research was to assess to what extent the 
attributes included in the OCAP are predictors or covariates of subjective well-being (life 
satisfaction).  Anand et al [159] found roughly a third of the attributes in the OCAP to be 
predictive of subjective well-being.  
Anand notes that using questions which are already in use, such as the ones included in the 
BHPS is a strength of such an approach [159].  However, this method also has its weaknesses.  
The use of questions not designed for the purpose of assessing capability may reduce the 
effectiveness of this measure.  In this case, as Anand notes [159], for many of the capabilities 
being assessed, capability is being inferred from an item which assesses functioning. 
Lorgelly et al [113] sought to refine the OCAP developed by Anand and collegues into a 
measure appropriate for evaluating public health interventions.  Using a mixed methods 
approach, Lorgelly et al [113] reduced the number of items through a reductive process based 
on the factor loadings from factor analyses and the correlational associations between items.  
                                                 
1
 Robeyns continuum is described in Chapter 1 and defines capability measure development as being either 
theoretically or methodologically driven. 
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18 items remained across Nussbaum’s ten capabilities.  Each question in the OCAP-18 holds 
equal weight and all responses are coded on a 0 to 1 scale.  Consequently, as some of 
Nussbaum’s central capabilities are assessed by more than one question, the OCAP-18 does 
give extra weight to some of Nussbaum’s capabilities [113].  This equal weighting may 
represent a weakness in the measure, especially when using it for resource allocation 
decisions. 
The most recent development in this research area is the development of the OxCAP-MH by 
Simon et al [160] through refining the original OCAP for use in a mental health context.  
Through a process of qualitative discussions with experts, including psychiatrists and 
psychologists, and pilot work with mental health service users, a 16 item questionnaire was 
formed.  Scores range from 16 to 80, with the intention that having a minimum score different 
from 0 reflects an ethical standpoint ‘that life has its own intrinsic capability value’(p.8)[160].  
An initial validity assessment has been completed, with correlations found with the EQ-5D-
3L [160]. 
2.4.2. ASCOT 
The Adult Social Care Outcomes Tool Kit (ASCOT) began life as the Older People’s Utility 
Scale (OPUS) [161].  The OPUS was designed to accurately reflect the utility of social care 
interventions.  Developed through qualitative work with professionals in the field of social 
care, five domains were identified as key outcomes of social care: safety, food and nutrition, 
social participation, personal care, and involvement and control over daily life [161].  Further 
analysis indicated that the most important of these domains to people receiving social care 
interventions was personal care.  Four further attributes were added in 2005 to make ASCOT 
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a 9 item questionnaire:  activities and occupation, home cleanliness and comfort, anxiety, and 
dignity and respect [162]. 
The ASCOT measure seeks to go beyond standard measures of self-reported health and 
health-related quality of life [163].  Firstly, it recognises that assisting people with disability 
means going beyond basic functioning, such as sanitation and feeding [163].  It seeks to assess 
concepts of well-being such as social contact and community status.  In recognising this 
requirement a clear parallel can be drawn with the distinction between well-being and agency 
defined in the capability approach.  Furthermore, the ASCOT measure seeks to assess the 
impact that a social care intervention has upon whether a functioning is achievable for a 
person.  To do this it makes the distinction between functioning that a person is able to 
achieve on their own and functioning that they can achieve with the help of the social care 
intervention.  To do this the ASCOT questionnaire assesses whether “my home is as clean and 
comfortable as I want” rather than “I can clean my home”.    
While the developers of the ASCOT measure make clear reference to the capability approach, 
the measure appears to be focused on assessing achieved functioning rather than capabilities.    
The phrasing of the questions starts with “I have”, 2I get” and “I feel” which appear to assess 
functioning.  This tension between the measure and the capability approach is understandable 
as the theory appears to have been adopted relatively late in the development process, rather 
than the measure being built on the theory. The capability approach had a greater impact on 
the later stages of the measure development than the earlier stages.  Therefore, the 
development of this measure can be seen at the methodologically driven research end of the 
Robeyns  continuum [111]. 
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2.4.3. The ICECAP capability measures 
The ICECAP-O and ICECAP-A measures are two broad, self-completed well-being 
measures.  Both measures are conceptually linked to Sen’s capability approach by defining 
well-being as the ability to achieve important functionings [164].  They are designed for use in 
economic evaluation of health and social care.  As shown in Figure 1, the number of research 
projects and randomised controlled trials registered to use the ICECAP-A or ICECAP-O 
measures has increased year-on-year. 
Figure 1: The number of research studies registering to use the ICECAP-A or ICECAP-
O measure by year  
 
*Numbers taken from the ICECAP registered users database held at the University of Birmingham 
2.4.3.1. ICECAP-O 
The development of the ICECAP-O started in 2006, with the work of Grewal et al [109] to 
identify quality of life attributes of older people for use in a new index measure.  A focus of 
this paper was to go beyond the traditional means through which health economists and 
researchers have measured quality of life.  It was noted by authors that health status, or some 
limited non-health variables such as material wealth, were often used as proxies for measuring 
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quality of life [109].  Efforts were made to identify quality of life attributes, rather than health 
and other attributes that potentially have an effect upon quality of life. 
Grewal et al [109] completed 40 in-depth, informant led interviews with members of the 
British public.  Purposive sampling was used to ensure a range of informants with different 
socio-demographic characteristics were included in the sample.  Appropriate qualitative 
techniques were used to enable informants to fully describe attributes of quality of life, and a 
thematic framework was used to analyse data.  Authors found six broad factors that influence 
quality of life: activities/doing something; home and surroundings; family and other 
relationships; standard of health; standard of living/wealth; and religion/faith/spirituality 
(p1895)[109].  Through these factors the authors identified five attributes which covered the 
important values from the six factors.  These attributes were overarching themes which 
related to one or more of the factors.  For example, feelings of value and self-worth (defined 
below as “role”) were derived through informant’s relationships and the activities they were 
able to do.  These five attributes are: 
 Attachment which ‘incorporates feelings of love, friendship, affection and 
companionship, sources of which appear to include partners, family, friends, and 
pets’(p1897) [109]. 
 Role which ‘incorporates the idea of having a purpose that is valued, either by the 
individual and/or others’(p1897) [109]. 
 Enjoyment that ‘pulls together notions of pleasure and joy, and a sense of satisfaction, 
sources of which include personal and communal activities’(p1897) [109]. 
 Security which ‘incorporates ideas of feeling safe and secure, not having to worry and 
not feeling vulnerable’(p1897) [109]. 
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 Control that ‘involves being independent and able to make one’s own decisions’(p1897) 
[109]. 
Authors noted that the ability to function was a ‘major theme emerging from the 
findings’(p1899)[109], specifically when informants discussed poor quality of life.  Informants 
discussed poor health, or poor health of a partner, as factors which reduced their ability to 
achieve the factors and attributes discussed above.  The main theoretical work that Grewal et 
al [109] used to interpret the findings was Sen’s capability approach [70].  The major theme of 
ability to function, which emerged from the research, shows noteworthy similarities to Sen’s 
focus on the importance of what a person is able to do, rather than what they actually do.  
Furthermore, the finding that health is not simply an end in itself, and that people may value 
factors other than health, sits neatly with Sen’s distinction between well-being and agency. 
The five attributes of Attachment, Role, Enjoyment, Security and Control were used by Coast 
and colleagues [100,118] in the development of the ICECAP-O instrument.  The conceptual 
terms were refined into a classification system that would hold meaning for the general 
population of 65 and over.  For example, the term “role” was rephrased to “doing things that 
make me feel valued”.  This was done through semi-structured interviews with 19 informants.  
Iterative techniques were used to refine and test language for both the attributes themselves 
and the response levels for each attribute.  The result of this development process was five 
attribute items, each with four response levels (see Appendix 1). 
The terminology of the ICECAP-O measures was designed to fit with the capability approach.  
Questions were prefixed with “I can” and “I am able” and are designed to assess people’s 
ability to function rather than their actual functioning.  Coast et al [118] note that while the 
capability approach is incorporated into the measure, the measure is also highly influenced by 
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health economic norms of assessing health through people’s perceptions, therefore not 
offering an objective assessment of capabilities.  The authors note ‘that “pure” capabilities 
researchers would refer to this instrument as an index of “perceived capability”’(p.881)[118].  
Coast et al [118] completed the valuation of the ICECAP-O measure using a type of discrete 
choice experiment, the best-worst scaling method.  This is a scenario-based procedure 
whereby respondents are asked to choose the best and worst scenarios from a selection of 
methods [165].  From these choices values for the capability sets were derived [118].  This 
valuation considered attributes from full capability to no capability and did not make any 
assumptions about where death fell on this scale [118].  Having no control was associated 
with the lowest level of value for an attribute.  Differences were seen in the value that 
participants placed on each level of each attribute.  Changes between levels at the top of the 
item were of less value to respondents than changes between levels at the bottom of the 
measure.  For example, the difference between “no” and “a little” Attachment was 
considerable and larger than the difference for other items.  The difference between “all” and 
“a lot” of Security was larger than the differences between the top two levels on other items.     
2.4.3.2. ICECAP-A 
The development and valuation of a capability measure for the whole of the adult population 
began with work by Al-Janabi et al [115] to identify and refine the attributes for the ICECAP-
A instrument.  This two stage work first involved 36 semi-structured interviews with a 
purposively selected sample of the general population.  The focus of this first stage of work 
was to identify what was important to people’s lives.  The analysis identified a similar, but not 
identical, list of five attributes: Stability, Attachment, Autonomy, Achievement and 
Enjoyment.  ‘Attachment, Autonomy and Enjoyment are almost identical, albeit with some 
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adjustment in wording, to three attributes in the ICECAP-O measure’(p173)[115].    The 
Stability item has similarities with the Security item in the ICECAP-O, but with a greater 
focus on the present [115].  It refers to a desire for continuity in life and is affected by a broad 
range of factors including health, employment status and fear of crime [115].  The 
Achievement item shows similarities to Role, but goes beyond it in scope.  It refers to the 
ability of an individual to move forward in life, achieve goals and is associated with success at 
work, having a family and owning things [115]. 
The second stage of this work was to establish the appropriate terminology to be used in the 
instrument [115].  Based on 18 semi-structured interviews the terms Stability, Attachment and 
Autonomy were judged to be unsuitable for inclusion, and the terminology was changed: 
Stability became “settled and secure”; Attachment became “love, friendship and support”; and 
Autonomy became “independence”[115].   The Achievement item was supplemented with 
“progress” and Enjoyment was supplemented with “pleasure”, to increase understanding 
[115].  As with the ICECAP-O, questions were prefixed with “I can” and “I am able” in order 
to assess capability rather than achieved functioning.  For the final version of the ICECAP-A 
see Appendix 2. 
The best-worst scaling method was used to estimate capability values [166].  413 individuals 
were sampled through a random sampling method stratified by geographic area of the UK and 
socio-economic deprivation [166].  The results indicated that people held strong preferences 
for Stability and Attachment attributes, with Autonomy being the next most important item.  
As a result, Attachment and Stability each account for 22% of the weight in the estimated 
tariff score, with other items accounting for roughly 18% weight each [166].  As with the 
ICECAP-O, there were differences in the values that participants placed on the levels of each 
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item.  Again, this results in the situation where change at the top of the measure (between the 
top two levels of an item) is valued less than changes at the lower end of the measure. 
2.4.4. Capability measures and public policy in the UK 
In 2013 the National Institute for Health and Care Excellence (NICE) was given responsibility 
for developing guidance and standards for social care in England [167].  NICE discharges this 
responsibility in co-operation with the Social Care Institute for Excellence (SCIE), which 
leads the NICE Collaborating Centre for Social Care (NCCSC) [168].   Both NICE and SCIE 
have indicated that when measuring the effectiveness of social care interventions a flexible 
approach is needed which reflects ‘the nature of effects delivered by different social care 
interventions or programmes’ [169].  Both organisations have recognised the need for the use 
of broad preference based measures, with the ICECAP measures and the ASCOT measure 
highlighted as appropriate for use [169,170].  SCIE has noted that both the ASCOT and 
ICECAP measures are ‘relatively new and validity and reliability are still being tested’[170].  
While, the psychometric properties of these measures are being determined NICE and SCIE 
are currently encouraging the use of the ASCOT and ICECAP measures in tandem to 
understand how they complement each other. 
2.4.5. Thesis and the ICECAP-O and ICECAP-A 
This thesis seeks to assess the validity and responsiveness of the ICECAP-O and ICECAP-A 
capability measures in a trial setting.  The ICECAP-SCM is an additional measure from the 
“ICECAP family” designed for use with patients at the end of life.  It is a supportive care 
measure, which is not designed for use as a quality of life measure and therefore not 
considered in this thesis.  There are differences between the ICECAP-A and ICECAP-O in the 
attributes which are assessed.  Where the same attribute is assessed in both measures, there 
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are differences in the wording of the items.   Validity results that are found in one measure 
cannot blindly be applied to the other.  Therefore, in the methodological review and the 
primary research in this thesis the results pertaining to the ICECAP-A and ICECAP-O are 
clearly demarcated.  In the discussion this distinction is somewhat relaxed, with references to 
“ICECAP measures” where appropriate.  However, when a discussion point refers only to one 
measure this is clearly stated.    
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2.5. A methodological review of the psychometric 
properties of the ICECAP measures 
2.5.1 Aim of review  
The aim of this review was three-fold.  The first aim was to identify, compile and document 
the body of research providing information on the validity of the ICECAP-O and ICECAP-A 
measures.  A small body of validation research has quickly developed since the development 
of the ICECAP-O measure in 2008.  Identification of this existing research is useful in 
informing future directions for research.  The second aim was to synthesise this research to 
assess the psychometric properties of the ICECAP-A and ICECAP-O measures.  The 
ICECAP measures are two relatively new measures and validation work is at an early stage.  
Therefore, it was anticipated that in many circumstances it would not be possible to form firm 
conclusions on validity from the evidence found.  In these circumstances an effort was made 
to fully describe the results.  A third aim was to inform the development of evidence-based 
hypotheses which were used in the validation analyses presented in Chapter 7 of this thesis.  
As described in Chapter 3, the formation of evidence-based hypotheses is an important step in 
a rigorous and scientific approach to validation.  The hypotheses formed are reported in the 
methods chapter rather than here. 
2.5.2. Review methodology 
The review methodology was specified and documented in advance of the systematic review.   
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2.5.2.1. PICOS criteria 
The PICOS (Population, Intervention, Comparators, Outcomes, Study Design) criteria, from 
the Centre for Reviews and Dissemination, University of York, are a useful way of framing 
the question which a review seeks to answer [171] and allowing clear communication of the 
research that is to be included in a review.  The PICOS criteria for this review were formed 
with the knowledge that a small body of literature existed.  The population, interventions and 
outcomes that were eligible for inclusion in the review were kept deliberately broad.  Had a 
greater body of literature existed the review could have focused on validity in select 
populations or circumstances, such as with patients or in randomised controlled trials, but this 
was not possible. 
2.5.2.1.1. Population 
This review did not exclude any studies based on the characteristics of the population used.  
General population and patient populations were included.   
2.5.2.1.2. Interventions 
This review included interventional and non-interventional primary research. 
2.5.2.1.3. Comparators 
Comparators normally refer to the control treatment used in a comparative study such as a 
randomised controlled trial.  In the context of validity research, it should be considered as 
referring to constructs or anchors against which a measure is validated.  No study will be 
excluded on the basis of the comparators used.   
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2.5.2.1.4. Outcome 
Any outcome which provided information on the psychometric properties of either the 
ICECAP-A or ICECAP-O was included.  The majority of outcomes are presented as 
descriptive statistics, correlation analysis, univariate statistics such as chi-squared or 
ANOVAs or multi-variate statistics such as regression models.  
2.5.2.1.5. Study design 
Qualitative and quantitative study designs were included in the review.   
2.5.2.2. Review search strategy 
The main search strategy was completed in July, 2013 and was updated in November, 2013.   
A 3 stage search strategy was employed: 
1. A keyword/MeSH term search used the OVID search facility.  The OVID search 
facility provides an online platform through which scientific research can be 
systematically accessed.   An initial scoping search was used to identify appropriate 
search terms.  Based on the results of this scoping search the terms “ICECAP*” and 
“Quality of life” and the terms “ICECAP*” and “capabilit*” were searched on all 
databases available through the OVID search facility (these included Embase and 
Medline).  Placing a “*” after the words expanded the terms so that a broader range of 
words or terms were searched.   
2. A comprehensive key person search was completed via e-mail correspondence.  The 
database of registered ICECAP users held at the Health Economics Unit, the 
University of Birmingham and a list of those attending the 2011 ICECAP workshop 
were used to identify people who had potentially assessed the psychometric properties 
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of the measure.  All individuals providing an email address were contacted and asked 
two questions: 1) had they completed any validation work on the ICECAP measures; 
and 2) were they aware of anyone who had (see Appendix 3). 
3. A forward/backward citation search was completed on all articles included from steps 
1 and 2 of the search strategy.  The forward search was completed on OVID, while the 
backward search was completed via a manual inspection of the article reference lists. 
2.5.2.3. Article screening 
A two-step article screening process was employed: 
1. Title and abstract screen.  All articles identified had their titles and abstracts screened 
for relevance.  In the case of uninformative titles and abstracts not allowing 
understanding of content, the article was forwarded into the full text review.  A second 
assessor check was completed on all identified references. 
2. Full text review.  A full text review of articles was completed to check for relevance.   
2.5.2.4. Inclusion and exclusion criteria 
Inclusion criteria were kept deliberately broad to allow identification of all relevant studies in 
this relatively new and under researched area.  Articles were selected for inclusion if they met 
the following criterion: 
 The study provided empirical data on the psychometric properties of the ICECAP-O 
or ICECAP-A measure.   
Articles were excluded from the review if they met one or more of the following criteria: 
 The study presented theoretical debate, without empirical data. 
 The article was not written in the English language. 
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2.5.3. Search results 
The keyword/MeSH term searched identified 56 references of potential relevance to the 
review.  The database of registered ICECAP measure users and the list of attendees at the 
2011 ICECAP workshop identified 59 “key people” with an e-mail address.  E-mails were 
sent to all these people.  Responses were received from 36 people, with the majority stating 
they did not know of any relevant papers.  Seven potentially useful references were identified 
through these key persons.  The forward/backward citation search identified 12 citations.  Of 
the 75 identified articles 59 were excluded after the title/abstract screen.  3 were excluded 
after the full text review, leaving 13 articles for inclusion in the review.  Results are reported 
in line with PRISMA guidelines.  
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Figure 2: Methodological review citation identification, inclusion and exclusion 
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2.5.3.1. Study characteristics of articles included in review 
Thirteen studies [114,116,117,172,173,173–182] providing information on the psychometric 
properties of the ICECAP measures were identified and included in the review.  Table 1 
provides a summary of the study characteristics, while Appendix 4 provides an in-depth look 
at the characteristics of each study.   
Eleven studies provided information on the ICECAP-O measure [117,172–180,182], while 
two provided information on the ICECAP-A measure [116,181].  The predominance of papers 
referring to the ICECAP-O is likely due to the greater length of time for which this measure 
has been in use compared to the ICECAP-A.  The majority of the studies were small to 
medium sized quantitative works, with two qualitative studies identified.  General population 
and patient samples were used.  Studies collected data on a number of comparator measures; 
the most common of these was the EQ-5D-3L, administered in the majority of studies.  Socio-
demographic, disability and well-being data were also frequently collected.  The 13 articles 
identified were produced by four research groups: Coast and colleagues, based at the 
University of Birmingham, UK; Ratcliffe and colleagues, the University of Adelaide and 
Flinders University, Australia; Makai and colleagues, Erasmus University and Davis and 
colleagues, the University of British Columbia 
The majority of studies were cross-sectional studies, using data from one time point.  The 
characteristics of the samples used in the studies differed (see Appendix 4).   The 
predominance of studies assessing the validity of the ICECAP-O means that (appropriately) 
the studies have used elderly populations.  The majority of studies have sampled more female 
participants than male. Studies have used both the general public and patients as participants.  
Those studies which used patient populations held some similarities.  Patients were generally 
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non-hospitalised patients: either rehabilitation patients or falls prevention patients.  The only 
study to use hospitalised patients was Makai et al [172].  The average health state of 
participants in these studies, judged by mean scores on the EQ-5D-3L, varied from good to 
very poor.   
Studies used a number of statistical approaches: descriptive statistics, multiple bivariate tests 
and multivariate tests.  Some studies used the UK ICECAP-O measure or/and algorithm in 
non-UK populations.  The studies by Davis [173,174] used the same data set of patients 
visiting a falls prevention clinic.  The same population of post-acute hospital rehabilitation 
patients was used in studies by Ratcliffe [176], Couzner [175] and Couzner [178].  
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Table 1: Characteristics of research articles included in review 
Characteristic Number of studies 
ICECAP version  
 ICECAP-O 11 
 ICECAP-A 2 
Study type  
 Quantitative 11 
 Qualitative 2 
Size of study sample (of quantitative studies n=11)  
 Small (<200) 3 
 Medium (200-500) 5 
 Large (>500) 3 
General population or patients*  
 General population 6 
 Patients 8 
Country  
 Australia 4 
 Canada 2 
 Netherlands 2 
 United Kingdom 5 
Comparators used**  
 EQ-5D-3L 10 
 Physical functioning measure (not EQ-5D-3L) 3 
 Mental health measures 2 
 Measures of well-being, happiness or life-satisfaction 4 
 Socio-demographic characteristics  5 
Research group  
 Coast and colleagues (Birmingham and Bristol) 5 
 Davis and colleagues (British Columbia) 2 
 Makai and colleagues (Erasmus) 2 
 Ratcliffe and colleagues (Adelaide and Flinders) 4 
* One study used patients and general population; **Multiple studies used multiple comparators. 
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2.5.4. ICECAP-O results 
2.5.4.1. ICECAP-O completion rates 
Completion rates for the ICECAP-O measure were assessed by Davis et al [173]; Makai et al 
[172]; Coast et al [117]; Couzner et al [175]; Flynn et al [177]; Makai et al [180]and varied 
between 92% and 98%.  No conclusion of how the completion method (self-completed or 
administered) or setting (clinical or home) affects the results could be made from this small 
number of studies. 
Qualitative think aloud work by Horwood et al [182] showed that informants completing the 
measure showed a low level of struggle and minimal difficulties.  20 participants completed 
the measure while concurrently verbalising their thoughts.  Results showed that, of the 100 
items completed (i.e. 5 items completed by 20 informants), informants struggled on 7% of 
these.  The majority of problems were caused by informants struggling with comprehension 
of the item.  
2.5.4.2. Response distribution 
The distribution of responses on the ICECAP-O tariff score or ICECAP-O individual items 
was assessed by a number of the articles identified.    Two studies assessed the distribution of 
ICECAP tariff scores (Flynn et al [177]; Davis et al [173]).  Both studies showed a clustering 
of values above 0.8, with a very small number of responses under 0.6.  Coast et al [117], 
Makai et al [180], Ratcliffe et al [176], Couzner et al [178], Ratcliffe et al [179] and Couzner et 
al [175] assessed the spread of responses across levels of each item of the ICECAP measures, 
discussed in relation to each attribute below.   
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2.5.4.2.1. Attachment response distribution 
Studies showed similar response distributions for the Attachment item.  Between 55% and 
60% of respondents categorised themselves as having full capability and sequentially lower 
percentages for the lower levels (see Figure 3).  The study by Makai and colleagues was an 
exception to this pattern, with a higher percentage of patients recently discharged from 
hospital categorising themselves in the second level of capability.  Authors indicate that this 
difference may be due to worse mobility in their population than other study populations and 
general populations [180]. 
Figure 3: Response distribution for Attachment item in research articles included in 
review 
 
*patient values, **general population values 
2.5.4.2.2. Security response distribution 
In comparison to the Attachment item, a lower percentage of respondents categorised 
themselves as having full capability for the Security item and a greater variability in responses 
was found (see Figure 4).  Reponses were more evenly split between the top two levels.  
Between 1% and 15% of respondents categorised themselves as having no capability on this 
item.  A different response pattern can be seen in Makai et al’s study, which showed a higher 
percentage of respondents reported full capability for Security.  Authors hypothesise that this 
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difference may be due to cultural differences in the Dutch population.  This is the second 
study to report high values for the ICECAP-O Security item in the Dutch population, with 
Makai et al [172] reporting high values in this item (this was not reported in these figures as 
the value was not expressed as a percentage of respondents answering each level, rather an 
unweighted mean and median score).   
Figure 4: Response distribution for Security item in research articles included in review 
 
*Patient values, **general population values 
2.5.4.2.3. Role response distribution 
The most frequent response for the Role item was level 3, with percentages varying between 
34 and 55% (see Figure 5).  The percentage of respondents categorising themselves as having 
full capability varied around 20% to 25%, with exceptions from Couzner et al’s 2013 study 
general population values and Ratcliffe et al’s 2013 study which found close to 40% with full 
capability. 
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Figure 5: Response distribution for Role item in research articles included in review 
 
*patient values, **general population values 
2.5.4.2.4. Enjoyment response distribution 
The response pattern to the Enjoyment item showed a (somewhat) even distribution of 
responses between the top three capability levels (see Figure 6).  A small number of 
respondents categorised themselves as having no capability. 
Figure 6: Response distribution for Enjoyment item in research articles included in 
review 
 
*patient values, ** general population values 
2.5.4.2.5. Control response distribution 
Notable variability exists in the response distributions of the Control items.  A division is 
apparent between studies: three studies found that below 20% categorised themselves as 
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having full-capability and four studies found that roughly 40% categorised themselves as 
having full capability (see Figure 7).  Most of the studies which found the percentage of 
participants in full capability approaching or over 40% were using general population samples 
and data were collected in a non-medical setting.  All other studies used patient populations. 
Figure 7: Response distribution for the Control item in research articles included in 
review 
 
*patient values, **general population values 
2.5.4.3. ICECAP-O measure and socio-demography  
A number of socio-demographic variables were used in studies identified.  There was little 
uniformity in the comparators used and the reporting methods, which limits the ability of a 
methodological review to synthesise results [183].  Three topics were identified where 
multiple studies had reported the same (or very similar) outcomes and it was possible to 
synthesise these in a narrative review.  A detailed review of socio-demographic variables, as 
well as other variables used in studies, is presented in Table 2. 
2.5.4.3.1. Gender 
No study hypothesised or found any association between the gender of participants and the 
ICECAP-O tariff score or scores on individual items. 
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2.5.4.3.2. Age 
Studies that provided hypotheses expected increasing age to be associated with decreasing 
ICECAP-O score.  Mixed results for the association between ICECAP-O scores and age were 
found.  Makai et al [180] and Flynn et al [177] found associations between the age of the 
participant and the ICECAP-O tariff score, with younger individuals having higher capability.  
Coast et al [117] showed associations between age and the items of Role, Enjoyment and 
Control.  These studies contrast with studies by Ratcliffe et al [176] and Couzner et al [175] 
which found no association between the age and ICECAP-O items and Couzner et al [175] 
which found no association with the overall ICECAP-O score.  
2.5.4.3.3. Relationships and living with partner 
Studies hypothesised that higher ICECAP-O capability scores would be expected in those 
living with a partner or in a relationship.  The ICECAP-O items of Attachment [117,175] and 
Role [117] were associated with a person’s relationship or marital status, with those in 
relationships reporting more capability.  Flynn et al [177] found living alone to be associated 
with ICECAP-O tariff scores, with those living independently having lower scores.
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Table 2: Summary of primary hypotheses, findings and conclusions from research articles referring to ICECAP-O included in 
review  
 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Coast 
(2008) 
Socio-demographic 
Weak evidence that age would be associated 
with Role and Control, but not with other items.  
Sex would not be associated with any item. 
 
General well-being 
Assessment of general well-being would be 
associated with a number of items. 
Contact with others 
Strong evidence that Attachment and weaker 
evidence that Security, Enjoyment and Role 
would be associated with contact with others. 
 
Health 
Assessments of health would show associations 
with Control, Role and Enjoyment, weaker 
evidence of associations with Security and no 
association with Attachment. 
Social support 
Strong evidence of associations between 
measures of social support and Security, Role, 
Enjoyment and Control. 
Socio-demographic 
Strong evidence of associations between age and 
Control and Role, and weak evidence of 
association with Enjoyment.  No relationships 
between sex and any item. 
General well-being 
Evidence of general well-being associated with 
items. 
Contact with others 
Marital status was associated with items as 
anticipated.  Contact with others unexpectedly 
showed weak or no association with Attachment 
or Security. 
Health 
Strong evidence of association of health with all 
items.  Mental health most strongly associated 
with Attachment and Enjoyment; physical health 
with Role, Enjoyment and Control. 
Social support 
Receipt of informal care highly associated with 
Enjoyment, Control, Role and Security. 
 
In general relationships that were anticipated a 
priori were found.  This indicates that the 
ICECAP-O measure is measuring what it is 
designed to measure. 
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Couzner 
(2012) 
Health 
Anticipated that Control, Enjoyment and Role 
would be associated with health status measured 
by the EQ-5D-3L.  It was anticipated that EQ-
5D-3L items of mobility, self-care and usual 
activities would be associated with ICECAP-O 
scores. 
Quality of care transition 
Those with higher quality of care transitions, 
measured by the CTM-3 would report higher 
ICECAP-O scores. 
Medical care received 
It was expected that those receiving outpatient 
rehabilitation would report higher ICECAP 
scores than inpatients.  
Health 
ICECAP-O tariff scores were correlated with 
EQ-5D-3L index scores (0.437).  Control, but not 
Enjoyment and Role, were associated with EQ-
5D-3L scores.  Mobility, self-care, usual 
activities and anxiety and depression were 
associated with EQ-5D-3L index scores. 
Quality of care transition 
CTM-3 scores were significantly correlated with 
ICECAP-O tariff scores 
 
Medical care received 
Results not found 
 
 
Socio-demographic 
Age was not associated with any item of the 
ICECAP-O.  Whether the participant had an 
informal carer was associated with the Role item. 
 
Relationships between ICECAP scores and self-
reported health and quality of care transitions 
suggest that these may influence some, but not 
all aspects of a person’s capability.  These factors 
are more influential than socio-demographic 
factors on capability scores. 
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Couzner 
(2013) 
Patient vs general public 
It was anticipated that the patient sample would 
report lower ICECAP-O scores than the general 
population sample.  The magnitude of the sample 
differences on the EQ-5D-3L and ICECAP-O 
would likely differ due to different theoretical 
underpinnings of the measures. 
 
Patient vs general public 
The general population reported higher ICECAP-
O scores that the patient population.  This 
difference was more pronounced for younger 
patients.  Larger, more pronounced, differences 
were found between patients in EQ-5D-3L scores 
than in ICECAP scores. 
No conclusion referring directly to the validity of 
the ICECAP-O was given, however, author 
emphasised the importance of the finding that the 
difference between patients and general 
population in EQ-5D-3L scores are more 
pronounced than the difference in ICECAP 
scores. 
Davis 
(2012) 
EQ-5D-3L 
Usual activities would show association with the 
Role item of the ICECAP-O.  Self-care would 
demonstrate agreement with Control. 
EQ-5D-3L 
The correlation between the ICECAP-O and the 
EQ-5D-3L was 0.47.  Significant differences 
between the self-care and Control and Role and 
usual activities were seen.  A factor analysis 
indicated that a two factor solution was the best 
fitting model, with the majority of ICECAP-O 
items in one factor and the majority of EQ-5D-
3L items in another.   
 
Results indicate that the ICECAP-O and the EQ-
5D-3L provide “largely unique and 
complementary information”.   
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Davis 
(2012) 
No-hypotheses were provided. EQ-5D-3L 
The ICECAP-O and the EQ-5D-3L was 
significantly correlated at 0.47. 
Instrumental activities of daily living 
Role, Enjoyment and Control were significantly 
correlated with IADL. 
Short Physical Performance Battery 
Role and Control were significantly correlated 
with the SPPB 
Physiological Profile Assessment 
Control was significantly correlated with PPA. 
Mini-Mental State Exam 
Security was significantly correlated with mini 
mental state exam (MMSE). 
 
In an older adult population both measures (EQ-
5D-3L and IECCAP-O) provide valuable and 
unique information. 
Flynn 
(2011) 
Relationships were anticipated with: health, 
cohabitation, age, qualifications and receipt of 
benefits. 
Socio-demographic 
No difference in ICECAP-O tariff scores was 
found by gender or ethnic group.  Younger, 
qualified, co-habiting or those not receiving 
benefits reported higher ICECAP scores than 
older, non-qualified, those living alone or those 
receiving benefits. 
Health 
Significant differences in ICECAP-O scores were 
seen between those reporting good, fairly good 
and not good general health. 
 
Results provided support for the validity of the 
ICECAP-O tariff scores.  Health is not the only 
factor explaining ICECAP-O scores, but it is 
clearly an important one. 
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Horwood 
(2013) 
Qualitative work – no hypotheses provided Comprehension problems 
5 informants were identified as having problems 
completing one or more items of the measure, 9 
informants struggled with one or more item but 
answered appropriately, 6 participants had no 
problem.  Of the 100 item responses analysed 7% 
of them showed problems, with comprehension 
problems being the most common. 
Item-by-item 
Informants queried whether the Attachment item 
was relevant to their disease.  Informants 
questioned both the time-frame and the focus of 
the Security item. 
 
The ICECAP-O measure performed well in this 
clinical population, with only a small number 
(7%) of responses showing struggle when 
completing items.  Results indicate that the 
measure may benefit from an introductory 
statement explaining that general quality of life is 
being assessed, and individual items may benefit 
from a short statement clarifying what the 
measure is trying to assess. 
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Makai 
(2012) 
Restrained vs non-restrained patients 
Differences in ICECAP-O scores between 
psycho-geriatric patients who are restrained and 
those who are not. 
Overall life satisfaction and QoL 
Overall measures of life satisfaction and QoL 
would be associated with ICECAP-O scores. 
Restrained vs non-restrained patients 
Significant differences between the two groups 
of patients in all ICECAP items apart from 
Security. 
Overall life satisfaction and QoL 
ICECAP-O scores significantly correlated with 
Cantril’s ladder and overall life satisfaction 
question. 
Health and EQ-5D-3L 
The EQ-5D-3L index and EQ-5D-3L VAS score 
was significantly correlated with ICECAP-O.  
The strength of the correlation was between 0.43 
and 0.57 depending on the version of the EQ-5D-
3L (family or nursing). 
 
Study showed reasonable convergent and 
divergent validity evidence for the ICECAP-O 
measure.  The measure seems a “promising” 
instrument for use.  Moderate strength of the 
correlation between the EQ-5D-3L and the 
ICECAP should be considered in light of the 
broader evaluative space of the ICECAP 
measure. 
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Makai 
(2013) 
Overall well-being and QoL 
ICECAP-O was anticipated to correlate more 
strongly with Cantril’s ladder and SPF-IL than 
measures of health. 
Health 
The ICECAP-O was expected to correlate with 
the EQ-5D-3L, IADL, GDS and SF-20, but the 
correlation will not be as strong as with measure 
of well-being. 
Overall well-being and QoL 
ICECAP-O tariff scores were strongly correlated 
with Cantril’s ladder and moderately correlated 
with SPF-IL. 
Health 
The EQ-5D-3L index score was moderately 
correlated with the ICECAP-O tariff score.  
Correlations with other health measures were 
moderate to weak.  ICECAP-O was able to 
discriminate between multi-morbid and single-
morbid patients, between depressed and non-
depressed and between IADL dependent and 
non-dependent people. 
Socio-demographic 
The ICECAP-O was able to discriminate 
between “young-old” and “old-old” patients. 
The ICECAP-O measure showed good 
convergent validity with measures of health and 
well-being.  The correlations with health were 
unexpectedly similar to those of well-being.  The 
ICECAP-O seems to be a promising instrument 
for use.  
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Ratcliffe 
(2011) 
Health 
It was anticipated that there would be strong 
relationships between ICECAP-O tariff scores 
and EQ-5D-3L index scores.  Mobility, self-care 
and usual activities were expected to be strongly 
associated with ICECAP scores.  Control, Role 
and Enjoyment were hypothesised to be more 
likely to associate with EQ-5D-3L scores than 
Security and Attachment.  ICECAP-O scores 
would be inversely related to scores of the 
Modified Rankin Scale. 
Hope 
Higher scores on the Herth Hope Index would be 
associated with higher ICECAP-O scores. 
 
Quality of care transition 
It was anticipated that there might be an 
association between the CTM-S and the 
ICECAP-O tariff scores. 
 
Health 
A correlation of 0.418 was seen between the 
ICECAP-O and the EQ-5D-3L.  EQ-5D-3L index 
scores were associated with all ICECAP items 
apart from Role.  The EQ-5D-3L item of usual 
activities was associated with Role, Enjoyment 
and Control at the 5% level.  A negative 
correlation of -0.286 was seen with the Modified 
Rankin Scale. 
 
 
Hope 
The Herth Hope Index showed a 0.402 
correlation with the ICECAP-O tariff score and 
was associated with Security at the 5% level. 
Quality of care transition 
A correlation of 0.259 was seen between the 
CTM-3 and ICECAP-O tariff score. 
The strong empirical relationships between the 
comparator measures in this study and the 
ICECAP-O support the construct validity of the 
measure in a clinical rehabilitation study. 
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures 
Ratcliffe 
(2013) 
No hypotheses were provided. Socio-demographic  
Carers and non-carers had similar ICECAP-O 
tariff scores, with a small indication that carers 
may have higher scores.  Carers were more likely 
than non-carers to report the highest capability of 
Role and Control.  Younger, native Australian 
and higher income earners reported higher 
ICECAP-O tariff scores than their counterparts. 
No conclusion referring directly to the validity of 
the ICECAP-O was provided by authors. 
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2.5.4.4. ICECAP-O measure and health 
The majority of the articles assessed the relationship between ICECAP-O measures and health 
through the use of patient-reported outcome measures, such as the EQ-5D-3L.  These results 
are summarised below.   
2.5.4.4.1. Objective measures of health 
Couzner et al [178] used an objective comparison between post-acute care patients and the 
general public.  ICECAP-O scores in the general public were higher than in the patient 
population (0.795 against 0.753).  This difference appears to be less pronounced than the 
difference in EQ-5D-3L scores between the two groups (0.789 against 0.595).  Effect sizes 
which would increase the certainty of this comparison were not provided by authors.   
2.5.4.4.2. EQ-5D-3L 
The most frequently administered health measure in these studies was the EQ-5D-3L.  Studies 
that provided hypotheses all expected moderate correlations or associations between the two 
measures.  Studies found moderate, positive and statistically significant correlations between 
the EQ-5D-3L index score and the ICECAP-O tariff score [172,173,175,176,180], shown in 
Table 3. 
Table 3: Correlations between EQ-5D-3L and ICECAP-O in research articles included 
in review 
 Davis, 2012 Makai, 
2012 
Couzner, 
2012 
Ratcliffe, 
2011 
Makai, 
2013 
Correlation 
between ICECAP-
O tariff score and 
EQ-5D-3L index. 
0.47 0.43 
(family) 
0.57 
(nursing) 
0.44 0.42 0.40 
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Analyses showed that higher EQ-5D-3L index values were recorded in participants 
categorising themselves as having higher levels of capability on individual ICECAP items 
[117,175].  Enjoyment and Control items were strongly associated with the EQ-5D-3L index, 
while the Attachment item was not associated [117,176,180].  A factor analysis of the EQ-5D-
3L and the ICECAP-O completed by Davis et al [173] showed a two factor solution to be the 
best fitting solution: one factor, termed by the authors “physical functioning”, including 
predominantly EQ-5D-3L items and one factor “psychosocial well-being”, including all the 
ICECAP-O items and the anxiety and depression question from the EQ-5D-3L. 
2.5.4.4.3. Measures of general health 
Two studies included brief, general assessments of health.  These assessments used single 
question measures.  Flynn et al [177] found self-reported general health to be significantly 
associated with ICECAP-O scores, with those reporting better health also reporting higher 
ICECAP-O scores.  Coast et al [117] found general health to be significantly associated with 
the items of Role, Enjoyment and Control at the 1% significance level. 
2.5.4.4.4. Measures of physical ability and disability 
Studies that provided hypotheses anticipated that measures of disability would be inversely 
associated with ICECAP-O scores (higher disability, lower ICECAP scores).  Fours studies 
compared ICECAP-O scores with measures of physical ability or disability 
[117,172,174,176].  Two studies used the Instrumental Activities of Daily Living scale as a 
comparator.  Makai et al [172] showed a significant moderate correlation of 0.51 with the 
ICECAP tariff scores, while Davis et al [174] did not find the measures to be significantly 
correlated.  These differences should be viewed in light of further results from Davis et al 
85 | P a g e  
 
[174] which showed the Physiological Profile Assessment (PPA) and Short Physical 
Performance Battery (two measures of physical ability) not to be significantly correlated with 
the ICECAP-O measure.  Ratcliffe et al [176] showed a weak correlation between the 
Modified Rankin Scale and the ICECAP-O measure.  Studies found Role and Control were 
strongly associated with measures of disability [117,172,174,176]  and Coast et al [117] also 
found Enjoyment to be associated. 
2.5.4.4.5. Measure of psychological health 
Mixed evidence was found from the three studies which used measures of psychological 
health in their studies [172,176,180].  Makai et al [172] showed non-significant associations 
between the HADS and the ICECAP in both nurse and family completed measures.  In a post-
hospitalised population the Geriatric Depression Scale (GDS) was strongly correlated with the 
ICECAP-O measure [180].  The Herth Hope Index (HHI) showed moderate correlations with 
the ICECAP-O measure [176].    
Three studies assessed the associations between the anxiety/depression item of the EQ-5D-3L 
and ICECAP-O items [117,175,176].  Mixed and conflicting results were found.  Coast et al 
found the item to be associated with all items apart from Control.  Couzner et al [175] found 
the item to be associated only with Control, while Ratcliffe et al’s [176] results indicate an 
associate with Security, Role and Enjoyment. 
2.5.4.5. ICECAP measures and well-being 
Strong evidence was found that well-being is significantly associated with ICECAP scores.  
Makai et al [172] found two assessments of well-being, Cantrill’s Ladder and the SPF_IL, to 
be significantly associated with the items of Role, Enjoyment and Attachment and to have 
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moderate to strong correlations with the overall ICECAP tariff scores.  Makai et al [180] 
found Cantril’s ladder and an overall life satisfaction measure to be associated with ICECAP-
O scores.  Using a simple, one question assessment of well-being Coast et al [117] found all 
ICECAP items to be associated with well-being. 
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2.5.5. ICECAP-A 
2.5.5.1. ICECAP-A completion rates 
The study by Al-Janabi et al [116] reported a high completion rate of 99%.  The study was 
administered face to face with participants who had agreed to be interviewed.   
The feasibility of use of the ICECAP-A measure has also been assessed through qualitative 
think aloud methodology [181].  The study showed that informants understood and responded 
to questions in the ICECAP-A with a level of struggle and error comparable to the EQ-5D.  
Evidence also indicated that most people understood the questions were asking about their 
capability, rather than their functioning.  This research provides positive evidence for the 
content and face validity of the ICECAP-A measure.    
2.5.5.2. Response distribution 
The response profiles of the ICECAP-A measure reported by Al-Janabi et al show notable 
difference between items in the percentage of respondents reporting full capability.  Over 
60% of people reported full capability on the Attachment item, while less that 20% reported 
full capability on Achievement (Figure 8).   
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Figure 8: Response distribution of ICECAP-A from Al-Janabi (2012) 
 
2.5.5.3. ICECAP-A measures and socio-demography 
No associations between sex or age and the ICECAP-A items were found by Al-Janabi et al 
[116].  Income and employment status was found to be associated with all ICECAP-A items, 
as was home ownership status.  Financial worries were found to associate with Stability, 
Achievement and Enjoyment (see Table 4). 
2.5.5.3.1. Relationship status and bereavement 
Relationship status and recent breakup was associated with all ICECAP-A items other than 
Autonomy.  Unexpectedly, however, recent bereavement was not associated with any 
ICECAP-A item.   
2.5.5.4. ICECAP-A measure and health. 
2.5.5.4.1. EQ-5D-3L 
The EQ-5D-3L index score was found to be associated with all ICECAP-A items apart from 
Attachment.  All EQ-5D-3L items were associated with all ICECAP-A items, with the 
exception of Mobility and Attachment.  A number of these associations were not expected a 
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priori, and it should therefore be concluded that a closer association between the EQ-5D-3L 
and ICECAP-A than expected was found. 
2.5.5.4.2. Other health variables 
Having a long standing illness or being in receipt of informal care was found to associate with 
lower scores on all items apart from Attachment.  Having an outpatient appointment in the 
last year was found to associate with Achievement and Enjoyment.  No associations were 
found for inpatient admissions. 
2.5.5.5. ICECAP-A and freedom 
Al-Janabi et al [116] assessed the association between the ICECAP-A and three one-question 
assessments of freedom.  As hypothesised, the ICECAP-A tariff score was positively 
correlated with these assessments, and these correlations were stronger than the correlations 
between the freedom variables and the EQ-5D-3L. 
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Table 4: Summary of primary hypotheses, results and conclusions from research articles referring to the ICECAP-A included in 
review 
 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures. 
Al-
Janabi 
(2012) 
Health 
Impairments for physical health were expected to 
reduce capability for Stability, Autonomy, 
Achievement and Enjoyment, while impairments 
to psychological health were expected to reduce 
capability for Attachment. 
Socio-demographic 
Participants who were employed or had a good 
income, were expected to have higher Stability, 
Achievement and Enjoyment.  Those in 
relationships were anticipated to have higher 
levels of Stability, Attachment and Enjoyment, 
but lower levels of Autonomy.  Individuals with 
higher levels of education would also have 
higher levels of Autonomy and Achievement.  
Participants who had suffered a recent major 
negative life event (bereavement, break-up, 
financial problems, ill-health) were anticipated to 
report lower levels of Stability, Attachment, 
Achievement and Enjoyment. 
Freedom 
It was anticipated that correlations between 
freedom variables (opportunities, Control over 
what happens, can do things I want) and the 
ICECAP-A would be stronger than correlations 
Health 
EQ-5D-3L physical health attributes were 
associated with capability on the Stability, 
Autonomy, Achievement and Enjoyment items.  
The anxiety/depression question on the EQ-5D-
3L was associated with Attachment. 
Socio-demographic 
Employment status and income was associated 
with all ICECAP-A items.  Relationship status 
was associated with all items apart from 
Autonomy.  Education was associated with all 
items apart from Attachment.  Associations were 
found between individuals who had suffered a 
recent break-up and all items apart from 
Autonomy, while financial worries were 
associated with Stability, Achievement and 
Enjoyment.  Happiness was associated with all 
ICECAP-A items. 
 
 
Freedom 
Freedom variable showed stronger correlations 
with the ICECAP-A score than the EQ-5D-3L 
score. 
The findings, which indicate that ICECAP-A 
capability scores are associated with freedom, 
socio-demographic and health variables, provide 
encouraging evidence of the validity of the 
measure in the general population.  Evidence of 
some anticipated associations not being seen and 
some unanticipated associations being found 
tempered the positive conclusions of the authors. 
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 Author hypotheses Results A summary of author conclusions referring to 
the validity of the ICECAP measures. 
between freedom variables and the EQ-5D-3L. 
 
Al-
Janabi 
(2013) 
Qualitative work – no hypotheses provided. A low number of “errors” (comprehension, 
retrieval, judgement, response) or “struggle” was 
seen.  A number of informants demonstrated that 
the questions were asking what they could do, 
rather than what they did do.  Some confusion 
was demonstrated over the use of the word “can” 
in the Attachment item. 
With some degree of struggle and error 
individuals can respond to and answer questions 
about their capability.  Distinctions can be made 
between their capability and functioning. 
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2.5.6. Discussion of methodological review findings 
This review provides an initial indication that the ICECAP-O measure is feasible for use in 
patient and general population samples and that it measures what it purports to measure.  The 
limited number of studies which provide evidence on the validity and feasibility of the 
ICECAP-A, means that there is less evidence on which to form a firm conclusion.   
The ICECAP measures were designed to capture a broader conceptualisation of well-being, 
which frequently used health functioning or health-related quality of life measures do not 
capture.  The assertion that the ICECAP-O offers a broader evaluative space appears to be 
supported by the initial research comparing the measure to health status and health-related 
quality of life measures.  Studies identified by this review consistently reported moderate 
correlations with measures of physical health and disability.  Furthermore, it was evident that 
some items of the ICECAP-O measure may not be associated at all with health measures.  
This suggests that while health is a factor that explains ICECAP-O scores, it is not the only 
or, possibly, even the predominant factor.   
This tentative conclusion is supported by the results from studies which compared the 
ICECAP-O with socio-demographic variables and measure of general well-being.  The results 
from socio-demographic variables showed that relationships and living with a partner had an 
influence upon ICECAP-O results.  Limited evidence was also found which indicated that 
whether a person provided or received informal care had an influence on the ICECAP-O 
scores.  These results, in conjunction with results that show measures of general well-being, 
life satisfaction and happiness to be strongly correlated with ICECAP-O scores, provide 
additional evidence that the measure offers a broader evaluative space. 
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Two sets of evidence suggest that the measure is feasible for use.  The majority of response 
rates, in both patient and general population samples were in the high 90
th
 percentile.  
Response rate is an important practical consideration for researchers considering using a 
measure.  Secondly, the response profiles provided by a number of studies indicate that, with 
the possible exception of Attachment, the ICECAP-O measure items do not suffer from 
ceiling or floor effects, where responses cluster at one extreme of the score range.  The 
Attachment item had the highest percentage of responses in the top level at 60%.  To draw a 
firm conclusion about the absence of a ceiling effect a comparison between two measures of 
the same construct would be needed, but this was not possible. 
2.5.6.1. Strengths and weaknesses of the review 
This review used systematic search criteria to identify research pertaining to the psychometric 
properties of the ICECAP-A and ICECAP-O measures.  Part of this strategy was the direct 
contact of a large number of researchers who have registered to use the ICECAP-A and 
ICECAP-O measures.  This, in conjunction with a keyword/MeSH term search and 
forward/backward citation search, provides a high degree of certainty that the overwhelming 
majority of existing research was identified.  While a comprehensive search was completed, 
and not a weakness of this review per se, the size of the existing pool of research on this topic 
is small.  This results in some uncertainty and the need to draw tentative conclusions. 
Due to the variety of outcome measures used, and differences in the reporting of results in the 
studies, a narrative reporting of findings was the most appropriate way to present results.  It 
has allowed this review to draw out differences and highlight weaknesses in the research.  As 
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the evidence base grows and a more uniform set of outcomes are reported, it may be possible 
to apply quantitative assessments to review findings. 
The focus of this review was to identify and synthesise all existing evidence on the 
psychometric properties of the measure.  This review has not made any attempt to assess the 
quality of research, or exclude research based on quality.  Therefore, it is likely that studies of 
differing qualities are included in this review.  When the evidence base is larger, future 
reviews may choose to apply quality criteria  prior to synthesising the evidence.   
2.5.6.2. Gaps in the literature 
Research into the validity of the ICECAP measures is at an early stage.  A smaller amount of 
research exists for the ICECAP-A measure than for the ICECAP-O, which is presumably due 
to the recent development of this measure.  A distinction should be made between areas where 
the current evidence base does not allow firm conclusions to be drawn and areas where a clear 
gap (absence of research) exists.  In general, further research should provide greater certainty 
for the tentative conclusions drawn in this review.  Specifically, further research should shed 
greater light on the inconsistent results as to the effect of age (and other socio-demographic 
variables) and psychological health upon ICECAP scores.  It should also further the evidence 
around the link between happiness and well-being and ICECAP scores.   
Three primary gaps in the literature exist.  First, all the studies identified by this review are 
cross-sectional studies, using data from one time point.  As discussed in Chapter 3, for a 
measure to be considered valid, it must also be valid over time.  Therefore, assessment of the 
sensitivity to change or responsiveness of these measures is an important future area for 
research.  Second, while the ICECAP-O measure has been used with patient populations, to 
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assess differences between care pathways and differences between patients with differing 
severity of illness, neither of the measures have been tested in the setting of interventional 
research, specifically a randomised controlled trial.  A measure, which is considered suitable 
for economic evaluation, must be found to be valid in such a setting.  Third, the amount of 
qualitative literature on the content validity and feasibility for use of the measure is limited. 
Research using researchers and experts in the field would allow triangulation with the existing 
research using the general public. 
2.6 Chapter conclusion 
This chapter has identified the traditional methods for measuring quality of life in health 
research and randomised controlled trials.  Efforts to put the capability approach into practice 
have been summarised, with particular focus on the ICECAP measures.  The development of 
the ICECAP measures has been reported and the current literature pertaining to the validity of 
these measures has been reviewed.  Three primary gaps in the literature have been identified.  
The research reported in Chapters 4 and 5 is designed to address the lack of qualitative 
research, while Chapters 6, 7 and 8 of this thesis were designed to provide evidence from 
longitudinal research and research within an interventional setting. 
Before continuing to the empirical work, Chapter 3 reports the methodology by which validity 
and responsiveness should be assessed.  The field of psychometric methodology is complex 
and has been under constant change since early assessments of validity.  Debate still exists as 
to how best to assess the validity and responsiveness of measures.  A summary of this debate 
is presented and the methodological norms which have been established in this area are 
reported. 
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CHAPTER 3. THE THEORY OF PSYCHOMETRIC 
TESTING 
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3.1. Introduction 
This chapter will describe and discuss the psychometric properties of a measure: reliability, 
validity and responsiveness.  The theoretical issues currently under debate in the research 
field of psychometric testing, and the practical considerations when assessing each property, 
will be covered.  The properties of validity, and to a lesser extent responsiveness, have 
undergone considerable interpretation and re-interpretation, and are still in flux.  A brief 
history of the evolution of theory is presented alongside current debates. 
A discussion of the methodology normally used to assess reliability, construct validity, 
content validity and responsiveness is provided.  This methodology is taken from leading 
works in the fields of quality of life research [138], measurement scale development [184] and 
psychometric measurement [185].  These methods are used in the majority of psychometric 
studies published in leading journals such as Quality of Life Research, Value in Health and 
Health and Quality of Life Outcomes.  It is therefore representative of best and standard 
practice in the field and is the methodology which is used in this thesis to assess the 
psychometric properties of the ICECAP measures.  The chapter concludes by looking at the 
challenges of assessing the validity of a capability measure in a health research setting; an 
area where there is little precedent in the literature.  
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3.2. Measurement 
‘The act of measurement is an essential component of scientific research’(p.1) [186].  Its 
importance has been long accepted in the health and medical sciences and more recently 
measurement has been seen as an important aspect of social science disciplines, including 
quality of life research.   
When measuring quality of life, and other non-tangible concepts in social science, a focus is 
needed on the relationship between underlying (unobservable) concepts and observable 
indicators.  Therefore, definitions of measurement such as ‘the assignment of numbers to 
objects or events according to rules’(p.22)[187], which may be appropriate in the physical 
sciences, are incomplete for use in social science. Here measurement involves both empirical 
considerations, the observable response or behaviours, and theoretical considerations, the 
underlying unobservable concepts [188].  Therefore an appropriate definition of measurement 
for work with quality of life is [188]: 
 ‘the process of linking abstract concepts to empirical indicants’(p.10) 
The use of short questionnaires, which elicit the patients’ perspective, can allow rigorous, 
reliable and valid measurement of quality of life and health-related quality of life.  They are 
‘especially significant when symptoms, functioning, and well-being are important outcomes 
or areas of concern’(p.s94)[189].  To have confidence in the measurement a patient reported 
outcome measure provides, information is needed on the reliability, validity, and 
responsiveness of the measure.  
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3.3. Reliability  
Inconsistency is present in all observations and measurements [190].  Subtle variations in the 
measure, the manifestation of the construct of interest and the individual all contribute 
towards inconsistency.  This inconsistency, or error, reduces confidence in a measurement 
and subsequently its usefulness.  In order to have confidence in a measurement we must 
assess the degree to which a measure is compromised by error. 
3.3.1. Classical test theory  
The concept of reliability is closely linked with classical test theory.  Classical test theory 
states that any measure or observation has two components: a true score, obtained in an error 
free observation, and an error associated with the observation [186,188,191]: 
(1) X = t + e  
The term ‘true score’ is a misleading one [186] as true scores are hypothetical, unobservable 
values [188].  A person’s true score is the mean score that would be obtained if the measure 
was given an infinite number of times [186,188]. 
All observations are affected by random error.  Equation 1 states that the observed score will 
not equal true score due to error.  Random error means that a score or observation will be 
higher or lower than the true score.  Importantly, a score is as likely to be higher as it is to be 
lower (if a score is more likely to be either higher or lower, then this is systematic error and 
can affect the validity of the measure). 
Classical test theory makes a series of assumptions about true scores, random error and the 
relationship between them: ‘1) the expected mean error score is zero; 2) the correlation 
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between true and error scores is zero; 3) the correlation between the error score on the 
measurement and the true score on a second is zero; 4) the correlation between errors on 
distinct measurements is zero’(p.30)[184,191].  This can be summated in equation 2, where E 
represents the longitudinal mean [191]: 
(2) E(X) = E(t) 
Equation 2 can then be written so that it refers not to a single observed score, true score and 
random error, but to the variance of these [191]: 
(3) VAR(X) = VAR(t) + VAR(e) 
Based on these assumptions of the behaviour of true scores, random error and observed scores 
the reliability coefficient, which expresses the proportion of total variance which is due to 
‘true’ differences between subjects is calculated in equation 4 [191]: 
(4) Reliability =          Subject Variability          
    Subject Variability + Measurement Error 
Equation 4 shows that subject variability will always be less than subject variability + 
measurement error.  Therefore the reliability will vary between 0, no reliability and 1.0, 
complete reliability.  Reliability is the proportion of true variance to observed variance; the 
greater the proportion, the greater the reliability. 
3.3.2. Definition and description of reliability   
Reliability is the extent to which a measure produces repeatable measurements, with a low 
component of inconsistency, or error [138,184].  This can be over time, between different 
modes of administration and between differing situations in which it is used.  A measure 
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should yield consistent results within a population experiencing no change when assessed at 
different points in time and when assessed through postal questionnaire, online survey or 
face-to-face interviews. 
‘Reliability refers to the results obtained with an evaluation instrument and not to the 
instrument itself’(p.78)[192].  Reliability is population specific as it is an interaction between 
the situation, the measure and the population of subjects [186].  A test or measure cannot be 
reliable per se, as its reliability will vary between different populations of patients.  Therefore 
when reporting reliability one should focus on test scores and report the reliability of the test 
with that population [186,193].  This thesis will use a slightly extended definition of reliability 
from Brazier et al [194]: 
‘Reliability is the ability of a measure to reproduce the same value on two separate 
administrations when there has been no change’(p.66) in the construct of interest 
3.3.2.1. Assessing reliability  
There are two primary methods through which reliability can be assessed. 
3.3.2.1.1. Test-retest method 
The test-retest method, by which a measure is given at two different time points or through 
two different modes of administration, is an intuitively appealing way of assessing reliability 
[191].  Patients or participants whose condition is stable should be chosen and a time gap, 
which is neither too long nor too short, should be used [138].   If the scores are identical 
between test and retest the correlation will be 1, however the instability of measures will 
normally mean correlations across time points are less than perfect [191].   
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The retest method, which is expensive both financially and in terms of research time, has 
limitations.  First, measuring an attribute of interest can induce change in that attribute [191].  
After being asked at the first administration of a measure people can become more aware and 
be prompted to think about the domain on which they were questioned.  Second, a “real” shift 
in the underlying theoretical construct may occur [184].  This can be controlled, to some 
extent, by selecting groups that have not changed (e.g. assessing participant for change using 
some other criterion and using a group that has not changed). 
While these are ways that the test-retest method can underestimate reliability, a ‘more 
common problem is overestimation due to memory’(p.39)[188,191].  When the time interval 
between test and retest is short then subjects will remember their initial responses [189].  It 
appears logical that the shorter and simpler the test, the longer will be required before 
memory is no longer a factor.  Nunnally [195] and others [196] purport that the current best 
practice of repeating the measurement within two-weeks to one-month is likely to bring in a 
strong influence of memory.  It is suggested herein that brief patient-reported outcome 
measures should be tested for reliability using a longer re-test period, as the likelihood of 
memory of response is greater.     
3.3.2.1.2. Internal consistency measures 
Internal consistency is a measure of how interrelated the items of a measure are [138].  It is 
considered a measure of reliability, but its output provides very different information to that 
of a test-retest assessment: it provides information on how homogenous the items of a 
measure are.  The method has the advantage that it does not require repeated tests such as the 
test-retest method [188].  Of this set of methods Cronbach’s alpha [197] is a frequently used 
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option.  Under this method inter-item correlations of a measure are recorded and a mean inter-
item correlation is calculated.  Using this calculation the Cronbach’s alpha can be calculated 
using the equation 5 [191]: 
  (5)  α = Np / [1 + p(N-1)] 
Where p equals the mean inter-item correlation and the number of items is represented by N 
[191].  Cronbach’s alpha is therefore dependent on the mean inter-item correlation and the 
number of items in the measure; as both of these increase, so does the value of alpha.  A 
weakness of the test, which needs to be considered when using Cronbach’s Alpha, is that the 
output is dependent on the inter-item correlation, and also the number of items [138]: if either 
increase so will the score.  The developer of the test recognised the need to control for this in 
commenting that ‘a quart of homogenised milk is no more homogenised than a pint of 
milk’(p.86)[138]. 
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3.4. Validity 
Validity is a fundamental consideration in the development and use of a measure [185].  This 
section will define, describe and discuss validity and the process of assessing validity, 
validation.  First, it will start with a brief history of validity theory.    
3.4.1. A short history of validity theory 
The concept of validity, what we mean by it and how we measure it, has evolved markedly 
over the last century.  At the centre of this evolution is a change from validating the measure 
towards validating the inferences drawn from the results of a measure [198].  This has not 
been a smooth evolution [199], rather periods of gradual change punctuated, and often 
reversed, by “landmark” texts that altered the accepted definition and assessment of validity 
[186].   
Prior to 1954 validity essentially assessed how well a test estimated or predicted the variable 
of interest [200].  A test was considered valid if it measured what it claimed to measure [198].  
The variable of interest ‘was assumed to have a definite value’(p.319)[200] measured by a 
criterion measure.  Validity was measured through the correlation between the test and the 
criterion.  This thinking can be seen in early validity texts [201] where a test was considered a 
valid measure of anything with which it correlated.   
The lack of suitable criterion measures and the ‘infinite regress’ [200] involved in comparison 
to the “current” criterion (discussed later) meant that this early conception of validity 
assessment did not provide an adequate analysis structure.  In his article entitled ‘Stamp 
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Collecting versus Science’ Frank Landy [202] described the pre-1954 period of validity 
testing as chaos consisting of ‘dust-bowl empiricism’(p.1183).   
In a landmark text Cronbach and Meehl [203] presented the findings of the 1954 American 
Psychological Association Committee on Psychological Tests.  In what was later termed the 
“trinitarian point of view” [204], Cronbach and Meehl [203] presented a tripartite model for 
validity assessment.  Alongside criterion validity the authors proposed content validity, an 
expert led examination of the content of the items of a test, and construct validity, a 
framework of hypothesis testing [203].  This “watershed event” [200] resulted in a departure 
from the test-criterion correlation assessment of validity and towards a scientific process of 
test validation [202] in four ways. 
First, Cronbach and Meehl [203] advanced validity research by proposing the use of a 
nomological network (discussed later): a scientific theory which provides a framework for 
testing validity [198].  Using the nomological network the validity of the test is established 
through evidence that confirms the theory proposed.  Scientific testing became integral to 
validity research and a scientifically sound, hypothesis based assessment of validity became 
the norm. 
Second, validity assessment became more concerned with the inferences drawn from a test, 
rather than the test itself.  Validity of a test or measure became a question of the accuracy of, 
and the degree of confidence that can be placed in, the inferences, or conclusions, drawn from 
the measure [184]. 
Third, Kane [200,205] proposed an argument-based approach to validation.  It is now widely 
recognised that a test can never be validated absolutely, rather a reasonable case can be made 
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as to what the test scores mean [206].  This has resulted in validation becoming an extended 
analysis and an ongoing process, which includes the development process of the test and 
subsequent studies.   
Finally, while Cronbach and Meehl [203] stated that the three forms of validity were 
categories within an overarching concept of validity, the notion of construct validity began to 
be seen as a general approach [200,207].  A unified version of validity, based around the 
construct validation methodology, was widely accepted [208].   
These four points outline a modern, scientific, hypothesis based conception of validity which 
will be used in this thesis [200].  However, this concept of validation is not without its critics, 
with a further shift in the last ten years focusing on concern with the use of a nomological 
network [209–211].  The primary practical critique is that nomological networks of the sort 
required for construct validation do not exist [209].  The theoretical concerns focus on the 
overly complicated framework for construct validation and rejection of the interpretation of 
the test scores as a basis for validation [212].  This critique has attempted to bring the validity 
evolution full circle, reverting back to the assumption that ‘a test is valid if it measures what it 
purports to measure’(P.1061)[209].  Despite this debate, however, there are few methods 
associated with these views, and the remainder of the thesis uses established conventions for 
validity assessment.    
3.4.2. Definition and description of validity 
3.4.2.1. Definition of Validity  
This thesis draws on a number of works [185,200,206,213] to define validity as: 
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The extent to which a measure allows us to draw accurate conclusions about the 
presence and degree of the attribute of interest, in an individual, at a given time, in a 
predefined context.  
This definition is now broken down in order to give a fuller explanation.   
First consider the phrase “the extent to which”.  Validity is not a binary phenomenon; it is not 
either present or absent, rather it will be present to varying degrees [199,214,215].  Therefore, 
validity is more accurately described through continuous rather than dichotomous indices 
[214,216].  The extent to which a measure is considered valid will depend on the amount and 
quality of research that has been undertaken, and the findings of this research [205,217].  
Validity should be seen as evolving [199], with each new piece of research and evidence 
increasing or reducing confidence in the validity of a measure.  In the initial stages of validity 
assessment the most that can normally be said is that a measure shows indications of being 
valid to some degree. 
Second, “to draw accurate conclusions” refers to the proposition that we do not validate a 
scale or measure, rather the interpretation of the results it yields [218].  By validating the 
inferences or conclusions that we can make based upon results, modern validation is also 
examining the theoretical basis of the measurement.  Kane [212] highlights the importance of 
this through introducing the “begging-the-question fallacy”(p.50), where conclusions are drawn 
which go beyond the more modest conclusions which were validated.  To illustrate, take the 
example of a school physical education test of whether a student can run one mile
2
.  If this test 
is used to report whether a student can run one mile, then this conclusion could be accepted at 
face value with relatively little validation.  If the test was used as a measure of the construct 
“physical endurance” then a definition of physical endurance and an explanation of why this 
                                                 
2
Example adapted from work by Kane [212]. 
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test will show this, would be required.  If this test was being used to draw conclusions about 
athletic ability and whether the student will compete at future Olympic games, then in the 
absence of considerable supporting evidence, this conclusion could not be considered valid.  
The interpretations or conclusions drawn from the test are important and it is these that need 
to be validated [212].         
Third, the ability of a test to provide information “about the presence and degree” of an 
attribute is vital.  There are few situations where a test that shows simply the presence of an 
attribute of interest would be useful.  Even in conditions where the state is binary, such as 
pregnancy, further information is normally useful.  Clinicians, scientists and social scientists 
generally require measures that show the degree to which a construct is present.   
Fourth, it is important that the scale measures the “attribute of interest”.  A scale may 
accurately measure an attribute which is not of interest [188]: a depression measure needs to 
accurately measure depression, rather than lack of happiness or lethargy.  The content of the 
measure needs to be an adequate reflection of the construct to be measured [219].  Using the 
example of the one-mile run test above, in the first conclusion drawn the test is the whole of 
the construct, while in the second and third conclusions the test is to varying degrees a less 
adequate reflection of the construct being judged.  This is important with respect to to the 
conclusions and inferences that can be drawn.  
Lastly, a measure is only valid “in an individual, at a given time, in a predefined context”.  A 
measure that shows high validity within a select demographic, in a distinct circumstance, 
might not be as valid in a different circumstance or with a different demographic.  This is 
why, for example, there are numerous publications validating the EQ-5D-3L measure in 
109 | P a g e  
 
different age patients, with different illnesses and in different countries with different cultures 
[220–224].   
3.4.2.2. The process of validation 
Validation is an ongoing process by which, incrementally, evidence is brought to bear on the 
validity of a measure [200].  This thesis will use a definition of validation from Lawshe [225]: 
‘Validation is a procedure, process, or strategy whereby we collect or generate data 
to determine or defend the extent, degree or strength of the inferences that can be 
made from a set of test scores’.(p.237) 
This definition recognises validation as a scientific process of extended, hypothesis-based 
investigation through which a sound validity argument is formed to support the interpretations 
of the test scores.  Hypotheses should be stated, along with the reasoning or evidence behind 
them.  They should be subjected to testing and the result should be reported.  Whenever 
possible different types of validation should be referred to and not validity types [225,226].   
The argument-based approach to validation proposed by Kane [205] requires the generation 
and collection of evidence to test the proposed interpretations of the results of the measure. 
Kane [205] noted that validation was a matter of building a validity portfolio, based on the 
proposed use of the test, which could be used to justify the interpretations drawn [205].  
Ambitious interpretations generally require more evidence than narrow interpretations [212].  
Whatever the interpretation, compilation of the validity portfolio normally starts during the 
development of the measure, with specification of the expected uses of the measure.  Once 
developed, a critical arm’s length analysis should occur, with assumptions and inferences 
subjected to testing.   
110 | P a g e  
 
Cronbach and Meehl [203] stated that one finding different to expectations would be enough 
to conclude a measure is not valid.  However, it is considered here that negative evidence 
should be handled in the same way as positive evidence, as incrementally informing the 
investigation.  There are three possible reasons for a negative result [227]: First, the test does 
not accurately measure the attribute of interest.  Second, the theory which generated the 
hypothesis for testing is not correct or incomplete.  Third, the experimental design of the 
validation study failed to test the hypothesis properly, which can include the criterion being 
faulty or inappropriate (discussed later).  It should also be noted that any combination of these 
may also occur.  Understanding the reason for a negative result is important when planning 
follow-up studies.   
3.4.3. Criterion validation 
Criterion validation is an analysis of the degree to which the scores of the new measure that is 
under consideration are a satisfactory reflection of an already accepted measure of the 
attribute of interest, ideally the “gold standard” used within the field of interest [186,219].  
The degree of correspondence between the two measures is indicated by the strength of their 
correlation [188]; this is the only evidence that is relevant.  Criterion validation is further split 
into two types: concurrent validation and predictive validation [227].  If the new measure and 
criterion measure are administered, and the scores determined, at the same time then this is 
concurrent validation [188,227].  Concurrent validation is normally used when examining a 
proposed replacement for an existing measure [227].  Predictive validation occurs when a 
future criterion is compared with the new measure [227].     
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There are a number of methodological issues with the use of criterion validation.  First, if 
there is an existing criterion or “gold standard”, why is another measure or test required?  The 
reason may simply be that the new test is less costly or quicker to administer, or that the old 
test was in some way invasive and an alternative is needed.  If the reason is that the 
developers of the new measure consider the old measure flawed to some degree, then use of 
the old measure as a criterion is then methodologically flawed [138]. 
Secondly, in many areas of study there is no adequate criterion to compare a new measure 
with [200,228].  This is often the case when seeking to validate patient-reported outcome 
measures, or new measures such as capability measure, in health [117,189].  When no 
criterion measure is available criterion validation is clearly not a viable option [191].   
Third, correlation evidence is the only applicable evidence for criterion validation [191].  This 
can lead to some spurious and atheoretical conclusions.  For example, if car ownership 
correlated strongly with university dropout, then this would be the ‘whole story’ from a 
criterion validation aspect [191].  A mistaken assumption of criterion validation is that 
correlation equals causality [209].   
Fourth, criterion validation is highly dependent on the availability, quality and validity of the 
criterion itself [200].  If the criterion is a weak approximation of the underlying attribute of 
interest then a validation study using the criterion has to be judged as unsound.  As Cronbach 
[218] stated ‘all validation reports carry the warning clause, ‘insofar as the criterion is truly 
representative of the outcome we wish to maximise’’(p.488).   
Finally, through the use of criterion validation, there is the problem of an “infinite regress” 
[226].  Take, as an hypothetical example, the measurement of bodily health.  The original 
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measure has a “true” correlation with global, bodily health of 0.9.  Three generations of 
measurement development occur.  Each new measure records a strong correlation of 0.9 with 
the previous.  In doing so it becomes the “gold standard” and hence the test which is used as 
the criterion in future analyses.  After three generations of test development we could be left 
with a measure which has a “true” 0.66 correlation with global health (.9*.9*.9*.9 = 0.6561).       
The weakness of criterion validation has resulted in increasingly limited use.  In an 
investigation by the International Society for Quality of Life Research into minimum 
standards for patient-reported outcome measures only 10 percent of informed participants 
stated that it was important to have criterion validation evidence before using a measure [229].  
Borsboom [209] has described it as an ‘atheoretical, empiricist idea…[which]…was one of the 
most serious mistakes ever made in the theory of psychological measurement’(p.1065).  If used 
at all, criterion validation should be viewed as contributing incomplete and potentially 
compromised evidence to the validity argument.      
3.4.4. Construct validation 
Construct validation was proposed by the APA Committee on Psychological Tests in 1954 as 
an alternative to criterion validity.  Cronbach and Meehl [227] suggested that it should be used 
in cases where the attribute of interest is not “operationally defined” recognising that when a 
non-tangible concept is being measured, the validation of the measurement instrument is 
difficult.  Attributes such as height and weight are readily observable and easily measured.  
Other, non-tangible attributes such as depression, happiness, quality of life and capability are 
not easily observable, and therefore not easily measured.   
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In these circumstances Cronbach and Meehl [203] recommend that a nomological network 
should be used.  A nomological network is an interlocking system of laws and relationships 
used to define the links or associations between constructs [217].  The attribute being 
measured is placed in this network as a construct.   ‘A construct can be thought of as a mini-
theory to explain the relationships among various behaviours’(p.257)[186].  The proposed 
system of laws and relationships within the nomological network is used to generate specific, 
testable hypotheses [203].  A measurement can then be validated based on the laws detailed in 
this nomological network.  For example, if within a nomological network for happiness 
wealth is not a determinant of happiness, the scores from a measurement of happiness should 
not systematically differ between people of different wealth.  Within a well-designed study 
this can be tested.  The aim of construct validation is to embed a measurement of a construct 
within a nomological network and test the relations with other variable within that network 
[230].  In a practical sense construct validation is [231]: 
‘a series of procedures concerned with assessing the extent to which the dimension 
scores of an instrument correlate with other hypothesised measures or indicators of 
the health concept or concepts of interest’.(p.43)  
3.4.4.1. Construct validity as a unifying force 
Construct validation has come to be seen as a general organising concept for the assessment 
of validity [226].  Four central principles of construct validation have emerged as general 
principles of “good practice”.  
First, the construct validation model requires an extended analysis, involving theory 
development, development of evidence-based hypotheses, development of measurement 
procedures and continued testing using the formed hypotheses and procedures [226,227].  
Inherent within these requirements is a criticism of the shorter forms of content and criterion 
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validation methods, which often rely solely on expert opinion or a single validity coefficient.  
Consequently criterion validation is now little used and recent work on content validation, 
which is presented below, is beginning to emphasise the need for the triangulation of data and 
work with different informants [232,233].    
Second, there is a need within construct validation to clearly define the theory and the 
construct under examination.  As Cronbach and Meehl stated ‘a necessary condition for a 
construct to be scientifically admissible is that it occur in a nomological net, at least some of 
whose laws involve observables’(p.290)[203].  Kane has provided forceful justification of this 
requirement by stating ‘validation is difficult at the best, but it is essentially impossible if the 
interpretation to be validated is unclear’(p 329)[226].   
Third, validation should be viewed in as the process of constructing a validity “argument” 
[205,226,227] through a continuous process [207,234] of building a validity portfolio for a 
measure [185].  Finally, it is the interpretations of the test scores which are validated, not the 
tests themselves.  Validity is a property of the interpretations and uses of the test, not of the 
test per se [212].   
‘Taking construct validity as the unifying principle for validity puts validation squarely in the 
long scientific tradition of stating a proposed interpretation clearly and subjecting it to 
empirical and conceptual challenge’(p.325) [226].  This has broken down the 
compartmentalisation of different validity types [207], which caused confusion and resulted in 
the opportunistic use of the different types of validity [235].  Different types of validation 
efforts are needed for different types of interpretative arguments [212,236] and the distinction 
between content, criterion and construct continues to provide a structure through which this 
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can happen.  However, due to the idea of construct validation these now happen under a 
unified banner of “validity” [200]. 
3.4.4.2. Assessing construct validity  
3.4.4.2.1. A five point model for validation 
Drawing heavily on proposals by Kane [200] and Smith [234] and based on the acceptance 
that construct validity provides a model of best practice in validation that can be applied to all 
validation types, a five point model for validation is defined.  
1) Specify the theoretical background as clearly as is allowed by past empirical research 
and theoretical work.  The theoretical construct in question should be carefully 
specified. 
2) Develop and describe the validity argument by stating hypotheses to be tested.  
Evidence based rationale should be presented where possible. 
3) Specify the research design to be used to test the hypotheses.  Where useful validation 
“types” should be referred to. 
4) Examine the stated hypotheses by subjecting them to testing.  If there are parts of the 
validity argument which are considered more problematic, a focus should be 
maintained on these. 
5) Interpret the empirical evidence. 
 Steps 2, 3 and 4 can be cyclical, with the interpretation of the empirical evidence informing a 
continued development and description of the validity argument.   
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Three methods dominate construct validation efforts: known groups analysis, convergent 
analysis and divergent analysis.  Known  groups validation is a simple form of validation 
which should be completed alongside other forms of validation [138,184].  This analysis can 
assess whether a measure is capable of distinguishing between two (or more) distinctly 
different groups, but not of distinguishing between people with subtly varying degrees of an 
attribute [138].  Under this process two groups are selected which are known to have differing 
amounts of the attribute of interest [231] or differing amounts of a theoretically related 
attribute.  For example: when validating a measurement of happiness, known groups 
validation would look for the ability of a measure to discriminate between groups of people 
which are happy or sad.   Or, if marital status was hypothesised to be a determinant of 
happiness, then scores on the happiness measures should be significantly different between 
the two groups.  Validity is indicated by a measure being able to show differences in the 
expected direction and it is the magnitude of this difference, rather than the significance of 
this difference that is important [138].      
A methodological issue exists around the selection of known groups.  In delineating the 
groups a judgement has to be made.  If an existing measurement will be used to select the 
groups, the validity of that measurement is an important consideration.  If a new measure is 
being developed because of some perceived inadequacy with the existing measure, then in 
using the existing measure to select the groups it must be recognised that the selection of 
groups is likely to be in-adequate [186].  If there is no available measure, and the groups have 
to be intuitively defined, then confidence becomes weaker still.  
Convergent and divergent validations are other options in construct validation.  Through 
convergent validation information on validity can be gained by seeing how closely the 
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measure is correlated with other variables of the same construct [186] or variables that are 
hypothesised to relate to the measure.  The direction and strength of the correlation are 
important for understanding the association between the measures.  For example, when 
validating a measure of happiness we might hypothesise that friendship is a determinant of 
happiness and the measure under consideration should therefore correlate with a measure or 
indicator of friendship.  A positive correlation shows that that the more friendship someone 
has the higher the scores on our happiness measure.  We might hypothesise this relationship 
to be a strong one, therefore strong correlations would provide confirmatory results.  
However, a very high or perfect correlation would suggest the measure of happiness is simply 
measuring friendship [138].   
Divergent validation is required to ensure that a measure does not correlate with attributes 
that it is hypothesised to be independent from [138].  If happiness is hypothesised to be 
independent of wealth, then there should only be (at best) very weak correlations between our 
measure of happiness and wealth [186].  It is important to note that if an inverse relationship 
between a measure and attribute is hypothesised, this would be assessed under the banner of 
convergent, not divergent, validation.  In this situation a correlation would be hypothesised, 
whereas for divergent validation little correlation between two measures would be 
hypothesised. 
3.4.5. Content Validation 
A great deal of variation can be seen in the way content validation is defined in the literature.  
A basic definition is ‘the degree to which the content of an…instrument is an adequate 
reflection of the construct to be measured’(p.743)[219].  This definition can be extended to focus 
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on ‘the extent to which a scale or questionnaire represents the most relevant and important 
aspects of a concept’(p.743)[233].  Furthermore, assessment of content validity can provide 
‘evidence that the conceptual framework, content of items and overall measurement approach 
are consistent’(p.1263)[232]. 
These definitions are based on the premise that the items of a measure relate to an underlying 
concept [233].  Implicit is the assumption that a test or measure cannot sample the full domain 
of content that is relevant to a construct, but only specific areas that are centrally relevant.  
When assessing content validity the need to specify the full domain or theory is paramount 
[203].  The investigation then needs to focus on whether relevant aspects have been sampled, 
so that content validation furthers an understanding of the inferences which can be drawn 
from the results of the measure; if a measurement does not fully assess a concept then this 
needs to be understood so that inappropriate inferences are not drawn [184].  This places 
content validity within the rigorous approach to validation described above.         
A subsection of content validation is face validation: the assessment of whether the 
dimensions within the measure are sensible and appropriate [231] and whether the measure 
appears to be valid [237].  While highly subjective, it is desirable for a measure to have a high 
degree of consumer acceptability [237] as selection for use is vital if the test is to prove useful 
to the research community.  If a test does not appear to be valid it is entirely possible that 
clinicians will refuse to use it and, if the measure is used, subjects may pay it little attention as 
they deem it irrelevant.   
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3.4.5.1. Assessing content validity  
Content validation and face validation differ notably from the other forms of validation as 
they are based largely on the judgements of individuals, whether they are patients, public or 
research professionals [184].  The focus of content validation is on the content of the measure, 
normally before scores are collected.  Whereas quantitative methods are used to assess 
criterion and construct validation, ‘the most appropriate way to collect data to support content 
validity is by conducting qualitative research’(p.1263)[232].   
A report from a working group meeting of the Patient Reported Outcomes Measurement 
Information System (PROMIS) initiative noted an inconsistency in the evaluation of content 
validity [233].  This, coupled with the perception amongst some that qualitative methods are 
“a soft science” [238], requires that rigorous methodology is employed to maintain the 
scientific integrity of this analysis [232].  There is currently a continued effort to improve, and 
where possible standardise, content validation [232,233].  The central points of this effort are 
focused around the methodology employed, the populations used and the triangulation of 
data.   
The methodology employed to assess content validity should be meticulously documented 
and transparent.  The research should be grounded in the data, rather than following 
assumptions made at the outset [239].  The analysis should be iterative, thematic and 
constantly comparative [240,241].  Analysis should occur throughout the data collection 
process and findings of the analysis should be used to inform and improve future interviews.  
Different methodology will be used depending on whether the focus of the work is to develop 
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a measure with valid content or to assess the content of an existing measure, however these 
central points should be maintained [232]. 
The population used for qualitative research is central to content validation.  Informant 
selection should be achieved through purposive theoretical sampling [239,242,243], to 
achieve a maximum variety within the sample or to achieve a selection of individuals based 
on some characteristic.  These methods can be used to select both patients or public
3
 and 
expert informants.  Patients can provide an insiders’ – emic – perspective and have first-hand, 
personal experience of both the concept and how it might be affected by different situations 
[233].  For example: a cancer patient would be able to describe how the disease has affected 
their quality of life.  Experts can provide an outsiders’ – etic – perspective [233].  For 
example: an oncologist might have a broad knowledge about the different ways cancer has 
affected their patients.  As with the methodology employed, the use of experts versus patients 
might vary depending on whether a measure is being developed or validated post-
development.  However, to reach a secure judgement on the validity of a measure both 
patients and expert opinions should be elicited [233]. 
The triangulation of data involves ‘the use of different methods and sources to check the 
integrity of, or extend, inferences  drawn from the data’(p.46)[244].  This can improve the 
external validity of findings and strengthen confidence in the conclusions drawn [242].  Data 
and findings from one to one interviews and focus groups should be checked against each 
other, as should data from expert versus patient informants and when and where possible from 
qualitative versus quantitative research.  
                                                 
3
 Patients may be more appropriate for validating a capability measure in a health setting, while the general 
public may be more suitable for capability measures to be used in other contexts. 
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3.4.6. Feasibility 
To draw accurate conclusions from the results of a measure, the measure must be practically 
useable in the relevant context.  Feasibility can be assessed through both quantitative and 
qualitative methodology.  Completion rates and missing values, time taken to complete a 
measure and participant and/or researcher post-completion ratings of difficulty, can all 
provide information on the feasibility of the measure [245].  Qualitative methodology can be 
used to elicit opinions of the measure from both participants and researchers.  This can be 
done through semi-structured  interviews or through the use of methodology such as “think 
aloud” [181].  The triangulation of quantitative and qualitative data can provide a fuller 
assessment of the feasibility of a measure than use of either method on its own.     
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3.5. Responsiveness  
3.5.1. The measurement of change 
In health, as in the fields of psychology and education, change is measured for three main 
reasons [186].  First, to identify the differences between individuals in the amount of change 
that has occurred.  Clinical researchers may want to identify individuals who are responsive to 
a treatment or therapy.  Second, once individual differences in change are measured, one may 
then be interested in the correlates of this change.  The third reason, and the focus of most 
clinical trials, is to infer treatment effects from group differences.  Under this goal the average 
change for a control group and intervention group is usually compared to determine the 
presence of a treatment effect. 
3.5.2. Definition and Description 
The terminology “sensitivity-to-change” and “responsiveness” are often used interchangeably 
[246].  However, the meanings of each differ importantly and describe different properties of 
a measure. 
3.5.2.1. Sensitivity-to-change 
Sensitivity-to-change is the ability of the measure to record a level of change in the construct 
being measured.  The concept of sensitivity to change makes no judgement about whether the 
change is meaningful, either clinically or to the patient.  This thesis will use a slightly 
extended version of Laing’s [246] definition of sensitivity-to-change: 
‘The ability of an instrument to measure change in a state regardless of whether it is 
relevant or meaningful to the decision maker’(p.II-85) or patient. 
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3.5.2.2. Responsiveness 
Responsiveness refers to the ability of an instrument to measure important or meaningful 
change [186] and is a key psychometric property of a measure [194].  Responsiveness is 
therefore an interpretation of change that occurs in the score of a measure; a question of what 
is meaningful.  This change may, for example, allow an individual to achieve an essential task 
of daily living, or live with a manageable level of pain [247].  Therefore, like validity, 
responsiveness is context specific and a matter of the interpretation of change in the score of a 
measure [246].   A description of the brief history of how change is interpreted and 
meaningful change defined is followed by the ways in which it is currently assessed. 
3.5.3. A brief history of the measurement of change 
In 1987 Guyatt et al proposed the minimal clinically important difference as a method through 
which change over time could be interpreted [248].  This was followed two years later by a 
landmark paper from Jaeschke et al [249] who developed the proposition of minimal clinically 
important difference by defining it as ‘the smallest difference which patients perceive as 
beneficial and which would mandate, in the absence of troublesome side effects and excessive 
cost, a change in the patient’s management’(p.408).  In these early interpretations of change the 
patient was placed centrally in a judgement that was taken in a decision making context [250]. 
Guyatt et al [251] then proposed a change in terminology from minimal clinically import 
difference to minimal important difference, which the authors defined as ‘the smallest 
difference in score in the domain of interest that patients perceive as important, either 
beneficial or harmful, and which would lead the clinician to consider a change in the patient’s 
management’(p.172)[250].  The differences between the Jaeschke definition and Guyatt’s are 
124 | P a g e  
 
small.  The “C” for clinically has been dropped, but it is still implied within the definition, 
and importantly it specifies that the change must occur in the domain of interest and not 
unspecified general change [250].   
A further extension to the definition was added in 2005 by Schunemann: ‘the smallest 
difference in score in the outcome of interest that informed patients or informed proxies 
perceive as important, either beneficial or harmful, and would lead the patient or clinician to 
consider a change in the patients’ management’(p.594)[252].  These authors stated the 
importance of patients being informed and that informed proxies could be used when required 
[252].  Therefore, current definitions of minimal important difference, through which change 
over time can be interpreted, normally refer to the following points: it is a measure of the 
minimal difference in the outcome; patients or proxies are the judge of difference; the 
definition is placed firmly in a decision making context; and while clinical is now removed 
from the title, clinical management is an important contextual consideration. 
3.5.4. Responsiveness as longitudinal validity 
Disagreement exists within the literature as to whether responsiveness, along with validity 
and reliability, is the third vital psychometric property [253] or whether it is a part, or a sub-
section, of validity: longitudinal validity [186,215].  This is an important consideration.  If 
responsiveness is taken to be a separate measurement property then a measure can be said to 
be valid, but not responsive.  If responsiveness is taken to be part of validity, then a non-
responsive measure will be considered to have a low level of validity.  Simply put ‘a measure 
valid at one time point should also be valid at another time point’(p.74) [215]. 
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Responsiveness is also context specific as it assesses the minimally important difference to an 
individual or population in the context which they are in.  Therefore, if we say that a measure 
validly measures a construct in the population, then we also have to assume that it is able to 
respond appropriately to minimally important change in the construct in an individual.  ‘To 
maintain otherwise is to claim that an initially valid instrument may somehow lose its validity 
over time’(p.74) [254].   
This reasoning then states that evidence of the responsiveness provides information on the 
validity of the measure.  Borsboom states that ‘a test is valid for measuring an attribute if 
variation in the attribute causes variation in the test scores’(p.1067)[209].  Understanding 
whether and how variations in the attribute produce changes in the measurement outcomes, 
increases our understanding of the validity of the measure.  Hays and Hadorn [215] are correct 
in stating that responsiveness should be considered as part of the validity argument portfolio 
of a measure.  This approach will be adopted in this thesis.  
3.5.5. Floor and Ceiling Effects 
A measure should be responsive throughout its whole range.  Floor and ceiling effects result 
in less sensitivity at the extremes of the top or bottom end of the measure [255].  This will 
normally happen when a large proportion of respondents select the top or bottom level of a 
measure, or item within the measure.  When this occurs the measure has lost the ability to 
detect improvement in a large section of the population (i.e. there is no level which to 
“improve to”).  However it is often hard to quantify a ceiling effect.   
An assessment of the percentage of respondents answering the top level of an item or 
reporting full scores on a measure is often used to indicate the presence of a ceiling effect.  
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McHorney and Tarlov [256] have suggested that if 15% or more of respondents answer the 
top level then a ceiling effect may be present.  However, using a percentage of respondents in 
isolation does not provide a definitive indication of a ceiling effect.  A fuller assessment of 
ceiling effect is to compare the results of one measure with results from a measure of the same 
construct [154].   
For example, in many populations the majority of respondents will answer the top level of the 
EQ-5D-3L items [257,258], with (for example) over 95% of a population registered with a 
general practice saying they are not anxious or depressed.  In this situation it is reasonable to 
presume that not all 95% have perfect psychological health; rather they that didn’t feel that 
the next level down (moderately anxious or depressed) applied to them.  This assumption can 
be assessed through the use of a comparator measure of anxiety and depression.  Through 
getting the same respondents to answer another measure, those reporting no problems on the 
EQ-5D-3L anxiety and depression item can be assessed to see what they report on another 
measure.  This comparator measure should, based on existing evidence, be considered to be 
more sensitive and not suffer from ceiling effects.  If the majority of those scoring the top 
level on the EQ-5D-3L item also score highly on another measure, then this might indicate a 
small ceiling effect; the measure has appropriately categorised people as having no anxiety 
and depression.  If a minority of the respondents scored highly on a comparator measure this 
indicates a large ceiling effect; those stating they had no anxiety or depression have been 
shown to have some degree of problems on another measure. 
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3.5.6. Assessing responsiveness  
When assessing the responsiveness of a preference-weighted measure (e.g. EQ-5D) 
consideration needs to be given to the effect of preference weights themselves.  
Responsiveness analyses are assessments of the descriptive system of a measure as well as the 
overall outcome of the measure.  This is important in preference- based measures as the 
ability of the descriptive system to detect change in a construct is an essential precursor for 
the ability of the measure to reflect preferences [259].  However, the use of preference scores 
in the responsiveness analysis may result in conclusions being drawn about the 
responsiveness of the descriptive system of the measure based on the preference values 
attached [259].  For example, a change of, say, 10% in the descriptive system may be 
considered a sizable change.  However, it might be of little value once preferences are 
attached.  If the analyses was just completed using the preference-weighted scores, the 
conclusion could be made that the measure is not responsive; when in fact the measure is 
responsive, but the change is not valued. To avoid this situation and to provide a full analysis 
of the responsiveness of the measure, preference weighted and non-preference weighted 
scores should be used [259]. 
3.5.6.1. Anchor-based assessments of change 
The taxonomy of methods for assessing responsiveness can be summarised under the 
headings of anchor-based and distribution-based approaches [260].  Anchor-based approaches 
explore the relationship between the change in scores of a measure and the same or similar 
concept measured by an independent anchor [260].  When using the anchor based approach it 
is recommended that multiple anchors are used [261].  Ideally a combination of independent 
128 | P a g e  
 
clinical and patient related anchors across a number of different patient populations should be 
used to assess the responsiveness of a measure.  Potential anchors fall into 3 main categories: 
patient ratings, clinician ratings or objective clinical measures. 
A patient ratings method often uses a global transition question or a global rating of change 
question [250].  Here, patients are asked to rate their overall change in the construct under 
consideration between two time points.  Patients answer on a gradient scale, which normally 
has between 5 and 15 points [260], as to whether they are “better”, “worse” or “about the 
same”.  Informants are then categorised into groups which have improved, deteriorated or 
experienced no change.  Groups that have changed a little, by the one point on the gradient 
scale, can be used to assess the minimally important difference.  These categories indicate the 
threshold at which patients begin to notice differences as those in these groups have 
experienced minimal change [261].  Differences between the groups in the score on a measure 
are then assessed. 
The primary concern with the use of global rating of change is the reliance on patient 
memory, which can be inaccurate and suffers from systematic error in the estimation of past 
and current health state [260].  This error is apparent when, as noted by Walters and Brazier in 
their paper [262], change rating has a strong correlation with the follow-up measurement and a 
very weak correlation with the baseline measurement.  In response to this concern the FDA 
proposed the use of the patient global rating concept [260].  Under this method patients rate 
their current state on the construct at baseline and follow-up, changes in ratings are calculated 
across time points and groups of participants are formed based on this calculation.  For 
example, groups may be those who have improved, those who have not changed and those 
who have worsened in the anchor measure.  When using this method it is important to identify 
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those patients who have experienced minimal change [261].  Clinician ratings can be 
calculated in much the same way as a patient rating described above.   
Objective clinical measures are an important tool for interpreting change in a measure as they 
link change in the construct with change in an external criterion [260,261].  Clinical measures 
need to be relevant to and correlated with the measure under consideration.  For example: 
there would be little point in assessing the responsiveness of an asthma related quality of life 
questionnaire against a clinical measure of joint mobility, however this clinical measure might 
be very relevant for an arthritis related measure of quality of life, or a generic quality of life 
measure.  The change in the measure under consideration can be interpreted against large, 
medium and small changes in the clinical criterion.   As when using patient global rating of 
concept it is important to identify those patients who have experienced minimally important 
clinical change. 
It is strongly recommended, and widely accepted, that multiple anchors are used when 
completing an anchor based responsiveness analysis [251,260,263].  Anchors should be 
selected that have a theoretical or proven association with the measure under investigation.  
Selection of anchors can be informed by using an initial assessment of the correlation of 
change scores to identify measures with an acceptable association with the measure under 
investigation.  An acceptable correlation threshold is taken to be 0.3 [260,261].  Revicki [261] 
states that alternative (lower) correlation thresholds may be acceptable in some situations.  
Other factors taken into account can include: a) cross-sectional correlations at baseline and 
follow-up between the measures, b) theoretical or methodological reasons for using the 
anchor or c) whether analysis using the anchor would increase the understanding of how a 
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measure responds with changes in the anchor, which may be of importance to investigators 
and researchers. 
It should be noted that Revicki’s rule of thumb [261] could produce a cyclical analysis process 
that may increase estimates of responsiveness.  When assessing the relationship between the 
changes of two measures, through an anchor based analysis, only using measures that have 
already been shown to correlate with each other may produce inflated estimates of 
responsiveness.  This has the potential to manufacture estimates which are more positive than 
may otherwise be the case.  Therefore, the consideration of additional factors detailed above 
is important. 
3.5.6.2. Distribution-based assessments of change 
The distribution-based approach is a set of methods for estimating change based on a 
statistical parameter of the population or sample [260].  Normally this statistical parameter is 
the relation between the magnitude of effect and some observed variation or distribution 
within the sample [261,264].  The primary criticism levelled at distribution based approaches 
is that they are “anchor free” and have no external reference point [250].  Some have 
concluded that this makes them “meaning free” [261] and so provides no direct information 
about the MID.  Given this limitation, FDA guidance for patient reported outcome measures 
suggests that distribution based approaches should play a supporting role [260].  There are 
two frequently used distribution based approaches: the the effect size and standard response 
mean, which are discussed at greater length in section 6.4.4.4. Effect sizes and standardised 
response means.   
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3.6. Challenges of assessing the psychometric properties of 
the capability measures in a randomised controlled trial 
Discussed above are the three psychometric properties and methods for assessing these 
properties.  The chapter is based on key texts and literature from the fields of psychology, 
health outcomes or patient reported outcome measures [138,184].  Little, if any literature 
exists on the methodology of validating capability measures.  However, there are a number of 
challenges when validating measures of capability in the health research setting or a 
randomised controlled trial.    
3.6.1. Reliability 
To assess reliability via the test-retest method a stable population and two time points close in 
time at which the measure can be completed are required.  Assessing reliability (of any 
measure) in a health intervention setting, such as a randomised controlled trial, is therefore 
methodologically challenging.  Where those in the population may have some form of health 
condition and the presence of an intervention is looking to bring about change, the population 
is not likely to be stable.  A solution to this problem may be to use measures included in the 
research to identify a stable sub-section of the population.  For example, when assessing the 
reliability of a health measure, using other measures of health to identify a population which 
has not changed may offer a possible solution.  However, as discussed below, indicators of 
capability are not normally included with trial questionnaire packs so there is less scope for 
this solution when dealing with capabilities.   
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The 2-4 week gaps in trial follow-ups required for assessment of reliability are rare within an 
intervention setting where the aim is to look for change rather than stability.   
Internal consistency, which is often considered a form of reliability, makes the assumption 
that a measure contains a number of items that assess a single, clearly delineated construct 
(e.g. physical health or happiness).  As discussed in chapter 1, a strength of the capability 
approach is the number and breadth of functionings that are held to be relevant.  A capability 
measure may assess a number of different constructs under the heading of capability.  
Therefore a relatively heterogeneous sample of questions may form a capability measure.  If 
this is the case, a measurement of internal consistency, such as Cronbach’s Alpha may be 
inappropriate or have little informational value.  
3.6.2. Validity 
There are two main challenges when seeking to validate a capability measure in a health 
research setting.  First, there is the need for a clearly defined nomological network, in the 
form of hypotheses which can be subjected to testing.  A number of hypotheses need to be 
formed about the ICECAP measure’s association with indicators of health.  As discussed 
above, capability is an under-defined theory, which has only relatively recently been applied 
to health research.  In comparison to a construct such as health-related quality of life there is 
little developed theory and only embryonic evidence of how capability may relate to health 
constructs.  Applying construct validity when there is not a well-defined, solid theory is 
challenging [200].  Kane [226] and others warn about the dangers of “weak programme” 
validation, which is construct validation without the specification of hypotheses.  
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A second challenge is that the majority of questionnaires administered in baseline and follow-
up questionnaire packs are measures of health, disability or pain.  These questions allow easy 
construct validation of a measure of health or health-related quality of life, but present a 
challenge when validating measures of capability.  A health-related quality of life measure 
would be expected to have a strong association with other measures of health; however a 
capability measure may be expected to have a weaker association.  Some aspects of capability 
may not be expected to associate at all with measures of health.  For example, being in pain 
may have very little bearing on whether or not someone can have friendship or feelings of 
agency and worth.  This consideration should be reflected in the hypotheses drawn.  
Furthermore, the type of measures in a trial questionnaire pack are unlikely to allow a 
comprehensive validation of a capability measure.  Health is only one of a number of factors 
impacting upon a person’s capability.   
3.6.3. Responsiveness  
A number of methodological challenges exist when seeking to assess the responsiveness of a 
capability measure in a trial setting.   
The majority of responsiveness analyses assess how the scores of a measurement instrument 
change when the construct, that the instrument is designed to measure, changes.  In line with 
this aim anchor-based methods normally use an anchor measuring the same, or a very closely 
related construct.  The absence of alternative measures of capability makes the formation of 
an anchor challenging, and in health research in practice is likely to be limited to anchors 
related to health.   
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This limitation has some important implications for the analysis.  Two requirements have to 
be met when choosing anchors: first, if the anchor is not a measurement of capability it needs 
to have a theoretical relationship with the capability.  This proposed relationship needs to be 
clearly described.  Second, the anchor should have appreciable association with the measure 
under consideration [260].  Therefore, when selecting anchors associations and correlations at 
baseline, and over time, need to be taken into consideration. 
The expectations about how much a capability score will change in response to a change in 
health need to be managed.  Large changes in capability with changes in health and strong 
correlations between capability measures and health measures are unlikely.  A number of 
different factors affect the capability of a person, health being one, and therefore the effect of 
changes in health upon capability will be moderated.  Furthermore, the absence of capability 
measures and dominance of health focused measures in health research will impact upon the 
conclusions that can be drawn from a responsiveness study in such a setting.  Firm 
conclusions may be formed as to how a capability measure responds to changes in health, but 
there will be less certainty in the conclusions as to how the measure changes with changes in 
capability.     
3.7. Chapter summary 
This chapter defines the psychometric properties of reliability, validity and responsiveness 
and summarises the methods through which they can be assessed.  The challenges of 
assessing the psychometric properties of a capability measure in health are discussed.  
Chapters 4 and 6 is a discussion of the steps taken to address the challenges identified.  
Chapter 5 reports the outcome of the qualitative assessment of the content validity of the 
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ICECAP-A measure, while Chapters 7 and 8 report the outcomes of the quantitative 
assessment of the validity and responsiveness of the ICECAP measures.  
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CHAPTER 4. QUALITATIVE STUDY OF THE 
CONTENT VALDIITY OF ICECAP-A: METHODS  
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4.1. Chapter introduction 
This chapter reports the methods used in the assessment of the content validity of the 
ICECAP-A measure.  The chapter begins with a description of the key characteristics of 
qualitative research and the methodological challenges associated with a qualitative 
assessment of the validity of a capability measure.  This thesis used one-to-one interviews of 
informants who were purposively sampled in their professional role as researchers working in 
a health research setting.  The selection of informants, the conduct of the interviews and the 
analysis of the data are described.  The development of the comparative direct approach, a 
useful structure within which a thematic analysis of content validity can be completed, is 
described in detail. 
4.2. Defining and explaining qualitative research  
Counter to the mainly numerical evaluations that currently dominate validity assessment an 
emphasis is placed on qualitative methods as a way of assessing content and face validity 
[232] [265,266].  Rigorous qualitative methods are essential in the accurate assessment of 
content validity [233].   
Qualitative research can be broadly defined as research that does not arrive at conclusions ‘by 
statistical procedures or other means of quantification’(p.17)[267].  Rather it attempts to ‘grasp 
phenomena in some holistic way or to understand a phenomenon within its own 
context’(p.171)[268].  To do this qualitative research often relies on language data, such as 
transcripts or reports, or observations to answer questions about “what?”, “how?” or “why?”; 
rather than numerical data which quantifies “how many?” and “how much?” [269].   
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Qualitative research can be inductive, where patterns and associations are identified within the 
data and theories developed [269,270], or deductive, where theories or hypotheses are tested 
against the data [270].  In practice most qualitative research includes both inductive and 
deductive aspects [269].  It is hard to analyse data without existing theories or opinions 
influencing the results in some way while, equally, existing expectations or hypotheses will 
often not be fully formed and will need to be developed form the data [269].  
The findings of qualitative research will ‘inevitably be influenced by the interaction between 
the researcher and the researched’(p.173)[268].  The researcher is normally placed within the 
research, allowing this interaction [238].  Unlike quantitative research which seeks objectivity, 
qualitative research has largely accepted that the values and opinions of the researcher play a 
role in the research.  Rather than seeking to eliminate this, the role that researcher values play 
is examined and understood through the process of reflection [269], whereby the researcher 
self-consciously monitors their impact.  Through this monitoring the researcher is able to 
assess the impact which their preconceptions, or theoretical assumptions, had upon the 
findings of the research [268].  
Two broad categories of qualitative data can be defined: naturally occurring data, collected 
through participant observation and documentary analysis, and generated data [270].  Focus 
groups and one-to-one interviews are the most frequently used methods through which data 
are generated.  One-to-one interviews can be used to form an in-depth understanding of a 
person’s opinions, or ensure that a subject is covered in great detail [244].  Focus groups are 
normally used to form a broader understanding through examining the interactions between 
participants in a more natural setting than a one-to-one interview [244].    
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Samples for qualitative research should be selected in order to include the relevant 
constituents ‘that can illuminate and inform’(p.82) understanding of a phenomena [271].  
Sample recruitment, for both one-to-one interviews and focus groups can be purposive, where 
informants are recruited based on selected features or characteristics [271].  Purposive 
samples are often based on maximum variation sampling, whereby a sample is recruited based 
on widely varying characteristics, or theoretical sampling [239], where informants are 
recruited based on their ability to contribute to the goal of the research.         
Unlike quantitative analysis of data, which has well-accepted procedures, qualitative data 
analysis has fewer agreed rules [241].  The approach taken to qualitative analysis will often 
vary with the characteristics of the data and the objectives of the research.  While there are 
differences in the type of analysis used most qualitative analyses attempt to reduce 
voluminous and often unwieldy data into a more manageable form [272]. Types of analysis 
include: ethnographic accounts [273], conversation analysis [274], discourse analysis [275], 
analytic induction [276], framework analysis [269], thematic content analysis and grounded 
theory.  It is the last two approaches which hold the most relevance to this thesis. 
Thematic content analysis seeks to categorise recurring themes [269].  To achieve this 
transcripts from interviews or focus groups are read and re-read, and codes are used to 
classify segments of the transcript based, normally, on what the segment is referring to.  The 
codes which are used can be developed through examination of early data to identify the key 
themes [269].  Once codes are assigned to the transcript the researcher can move beyond 
simple categorisation and begin to ask questions about how the themes relate to each other 
and why they may differ.    
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Glaser and Strauss [239,277] recommend that the analysis of qualitative data should use a 
constant comparative approach, whereby findings that emerge from the data are compared 
with previously collected data.  Through a cyclical process of collecting and analysing data, 
and then allowing this analysis to inform future collection and analysis, a fuller account can 
be formed [269].  In grounded theory, like in thematic content analysis, transcribed data is 
analysed through the use of a coding structure.  Glaser and Straus recommend that these codes 
are generated from themes identified in data and where possible take the form of words used 
by the informants themselves [239,240].  In grounded theory the application of the coding 
structure should be more intense than in a thematic analysis, with the goal of opening up or 
pulling apart the transcript for analysis [269].  Data collection should continue until saturation, 
where no new themes are being identified [269].  These key principles allow a thorough, 
inductive analysis of the data.     
4.2.1. Methodological challenge  
When measuring concepts such as quality of life, where a tangible concept is not being 
assessed, the questions of what is relevant and what should be measured are important 
[191,203].  This is a notable challenge for researchers attempting to validate the content of 
any measure.  As described in Chapter 3, this methodological challenge can be addressed 
through the use of a nomological network: a scientific theory that gives a construct meaning 
through its links and associations with other constructs.  However, when conducting 
qualitative research this network may have more limited use than in quantitative research.  
Qualitative research takes greater direction from the informant.  Informants will have their 
own conceptualisations of quality of life (their own nomological networks), their own view of 
what content is relevant and what influences it.  This will likely vary from informant to 
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informant.  In a qualitative analysis that seeks to answer the question “does the measure 
sample the important and relevant dimensions of a construct?” variability, and a lack of clarity 
amongst informants about the important and relevant dimensions, are challenges, particularly 
in relation to concepts such as quality of life, where no universally accepted definition exists.   
This thesis used one-to-one interviews of informants who were purposively sampled in their 
professional role as researchers working in a health research setting.  A thematic analysis of 
the data was completed, which drew upon some aspects of grounded theory, particularly the 
analytic notion of constant comparison.  In response to the methodological challenge 
identified, both interviews, and analysis, were structured in such a way as to allow a full 
understanding of the participant opinions of the ICECAP-A measure. 
4.3. Informant selection and recruitment 
4.3.1. Selection of informants 
Informants were selected using purposive sampling, which allows informants to be selected 
based on certain characteristics [239,271].  Maximum variation sampling, a form of purposive 
sampling, allows a sample, which varies on selected characteristics, to be recruited [242], was 
used.  This form of sampling can be useful in identifying the central themes across a number 
of different situations.  Four groups were selected in order to provide a broad and 
representative range of opinions on quality of life and quality of life measurement from 
research professionals involved in controlled trials.   
Informants were selected from four professional groups: 1) medical doctors involved in 
clinical trials and research; 2) clinical, primary care and public health trial experts, including 
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principal investigators and trial managers (this group will be referred to as “trialists”); 3) 
clinical research nurses or researchers with regular participant or patient contact (this group 
will be referred to as “frontline researchers”); and 4) health economists working within trials.  
Medical doctors and frontline researchers, who have regular patient and participant contact, 
have an outsiders – etic – view of how quality of life is affected by different diseases and 
conditions.  In addition, frontline researchers have a unique perspective from regular 
participant contact while the participant is completing quality of life measures.  It was hoped 
that they would be able to provide insight into how patients receive quality of life 
questionnaires.  Trialists and medical doctors are involved in the planning and oversight of a 
trial.  As part of the steering committee or management team of a trial they will select what 
measures are included within baseline and follow-up questionnaire packs.  Health economists 
working with controlled trials advise on which quality of life measures should be used in the 
economic analysis.  Between them these three groups determine which quality of life 
measures are used in trials.  
In addition to these professional characteristics the participant selection sought to identify 
informants with and without prior experience or knowledge of the ICECAP measures.  
Furthermore, of those with prior experience of using, or knowledge of, the ICECAP 
measures, an effort was made to sample those with both a positive and a negative prior 
opinion.  The recruitment of trials to the quantitative work of this thesis (described in Chapter 
6) occurred before the qualitative research and identified a small number of researchers with 
negative opinions of the ICECAP measures and a number of researchers with positive 
opinions of the measures.  These people were asked to participate in the qualitative work as 
informants and have been identified in Table 5 as having positive or negative opinions. 
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Informants working in both the UK and Australia were selected for interview.  The ICECAP-
A is being used in studies and trials in a number of countries outside the UK, Australia being 
one of these.  The selection of Australian informants was designed to increase the 
generalisability of the research findings and identify any divergent views across the two 
countries. 
Informant identification and selection occurred through a pragmatic process.  Potential 
informants were identified through university and trial centre staff lists, as well as through 
existing researcher knowledge.  The staff lists of the Medical Research Council (MRC) Hub 
Network for Trials Methodology Research, the Experimental Cancer Medicine Centre, 
Birmingham Clinical Trials Unit, and the Primary Care Trials Unit, at the University of 
Birmingham, were accessed online in order to identify suitable informants.  Additionally, 
Prof. Joanna Coast and Dr. Hareth Al-Janabi were able to recommend suitable potential 
informants in the UK.  Associate Prof. Paula Lorgelly and Prof. Stephen Jan recommended 
suitable potential informants in Melbourne and Sydney, Australia, respectively.  The selection 
of Australian informants relied heavily on researcher knowledge, with all informants being 
identified through existing researcher knowledge. 
Snowball sampling was used to identify additional informants.  Snowball sampling involves 
asking informants, once they have been interviewed, to identify additional informants that fit 
the selection criteria [271].  Snowball sampling can be used to identify hard to reach groups.  
It was used here to identify additional frontline researchers, who often do not appear on trial 
organisation staff lists and were not known researchers on this project.  
144 | P a g e  
 
Recruitment of informants was stopped after data saturation, the point at which no new 
themes were being identified in the data [269], was reached on the primary objective of the 
research (the validation of the ICECAP-A measure).  Data saturation on emerging themes, not 
central to this objective, was not targeted.  
4.3.2. Recruitment of informants 
Potential informants were approached through a standardised e-mail (Appendix 5) describing 
the purpose of the research and asking for the cooperation of the potential informant.  An 
information sheet was attached to the email (Appendix 6) and the ethical approval gained for 
the study (Appendix 7) was explained.  A follow-up phone call was scheduled for five to 
eight days after the email was sent, in the event of no reply.  On receipt of a positive reply a 
date, time and place was agreed for the interview.  If the date set was more than two weeks in 
advance then a reminder email was sent 2-5 days before the interview.  All but one of the 
interviews were conducted at the informants place of work (one interview was completed at a 
university café). 
4.4. Interview conduct 
At the start of the interview informants were asked to sign a consent form.  The confidential 
nature of the interview and the fact that the interview was being recorded using a digital voice 
recorder was emphasised to the informant verbally at the start of the interview.   
The interviews were semi-structured and designed to allow breadth and depth of discussion, 
while investigating some areas in greater detail.  A topic guide (Appendix 8) was used as an 
aide memoire to encourage a consistent structure to the interviews and adequate coverage of 
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key topics.  This topic guide was flexible and updated throughout the interview process to 
allow development of emerging themes.  Interviews were broadly partitioned into two areas.   
4.4.1. Interview part one 
The first part of the interview assessed the informant’s understanding of quality of life as a 
concept and their own conceptualisation of quality of life, with particular focus on their 
research areas.  This was done in order to add context and increase understanding of data 
gained in the second part of the interviews.  The focus of this initial part of the interview was 
to encourage breadth and depth of discussion and allow informant to define, as fully as they 
were able, quality of life and its influences.  Informants were also encouraged to give their 
opinions on quality of life measures they had previously used in their research.  This was 
designed to enable some understanding about the informants’ general opinion of quality of 
life measures.   
Content mapping was used.  Content mapping includes the use of ground mapping, questions 
to open up the subject area; dimension mapping, questions to focus the informant on a key 
topic; and perspective widening, questions to widen the informants perspective [278].  Ground 
mapping questions were used to encourage the informant to describe their conceptualisation 
of quality of life.   
 “If I said Quality of Life to you, what would you take that term to mean?” 
In order to ensure that informants provided more than their first thoughts or immediate 
reaction the informant was encouraged to take time to think about their answer.  To facilitate 
this, perspective-widening questions were used. 
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“Now you have described health as a major influence on quality of life.  Are there 
other factors that you think may influence someone’s quality of life?  [pause] Take 
your time.” 
Where participants struggled to provide a full description in the level of depth required, 
content mining questions were used to allow the informant to explore further and explain 
more clearly the concepts they defined. 
“You said contact with family is important.  How would this influence someone’s 
quality of life?” 
Conversations in qualitative interviews are rarely sequential and numerous points of interest 
are often raised in quick succession or out of context, or when they are raised are often poorly 
defined.  Dimension mapping questions and clarifying probes were used to ensure that the 
meaning of the informant had been understood and was not assumed. 
“So can I check I understand, you feel that quality of life is influenced to a large 
degree by health, but other factors such as friendship and independence are also 
major influences.  Is that correct?”  
4.4.2. Interview part two 
In the second part of the interview measures were introduced.  Informants were encouraged to 
discuss at length the ICECAP-A and EQ-5D-5L measures and provide their opinions on the 
measure’s content and  their view of its usefulness to their research area.   Interview 
informants were presented with copies of the ICECAP-A and EQ-5D-5L one after the other. 
The order in which the measures were shown to the informants was random except in the 
situation when it was beneficial to the flow of the interview to consider one first. For 
example: if towards the end of the first part of the interview the informant was discussing 
concerns with the sensitivity of the EQ-5D-3L, the EQ-5D-5L would be presented to the 
informant first. Informants were encouraged to discuss the measures at length.  
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The appropriateness and usefulness of the measures for use in the informant’s research area 
were discussed. Content mining questions were used to understand decisions about use of 
measures.   
“So thinking about the research area you work in and the patients you work with, do 
you think that this measure is suitable for use?” 
When an informant found making a comparison between the two measures useful in 
describing their opinions of each measure, this comparison was encouraged.  However, such 
comparisons were not prompted by the facilitator.  
The content validity of the EQ-5D-5L was examined in this work.  The results of this analysis 
are not presented in the main body of this thesis, but can be seen in Appendix 10   
4.5. The comparative direct approach 
The comparative direct approach was developed based on researcher experience from early 
interviews and through using data and experiences from the first batch of data analysis (the 
first 4 interviews). This approach attempts to address the methodological challenge of content 
validation identified in section 4.2.1. Methodological challenge, by providing a useful 
structure with in which a thematic analysis, grounded in the data, could be completed.  The 
process of development and the final approach used is described below. 
4.5.1. The development of a method 
A two-part interview was used from the outset.  This two-part partitioning of the interview 
provided an opportunity for the development of an innovative two stage approach to assessing 
content validity.  The analysis of the first batch of interviews highlighted the possibility of 
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identifying similarities between the informants’ description of quality of life and its 
determinants, and the descriptive system of the measures under consideration.  The researcher 
was able to identify when the informant was discussing the importance of a dimension which 
was assessed by the measures.  As an example take the three brief passages from the same 
informant below.  In these examples the informant describes issues relating to three of the 
dimensions of the EQ-5D-5L descriptive system as influences on quality of life: A) Pain, B) 
Mobility, C) Usual Activities. 
A) “…well obviously there is a pain thing, so the higher the pain the lower your 
quality of life” 
B) “…I mean you could have someone with a bilateral amputation below the knee 
who’s in a wheel chair and their quality of life is zero” 
C) “Work...that’s a BIG thing really” 
Early analysis also showed potential to identify dimensions that informants felt were 
important, but were not included in the descriptive systems of the measures under 
consideration.  In the example below the same informant, talks about the important of 
communication and sensory ability, which is not directly assessed in the EQ-5D-5L. 
Being able to see and hear.  Also, speak to people.  Interaction with the world is all 
about this.   
The discussion in the first part of the interview normally had a broad scope, which was 
notably reduced in the second part of the interviews, when the measure was considered 
directly.  During the first batch of interviews it quickly became apparent that this initial 
discussion was not only useful as a reference point to understanding the later opinions of the 
informant, but also in assessing the content of the measure in itself.   
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In the second part of the interviews informants were encouraged to directly give their 
opinions of the measures under consideration.  Content validity was examined through 
discussion of whether informants felt the content of the measure covered the important and 
relevant dimensions of quality of life.  Face validity was assessed through discussion points 
such as whether the length was appropriate, whether it was understandable and if it would be 
of use in the research area in which they worked.   
In the early interviews, when discussing the content of the measure, informants frequently 
referred back to their earlier description of quality of life, and discussed whether the measure 
did or did not offer coverage of their definition.  It was noted early in the analysis that 
informants gave full and expansive discussion of the measures when making this comparison.  
This was identified as a rich data source.  The topic guide was altered for later interviews to 
include questions and prompts that directly encouraged the informant to refer back to the 
earlier discussion. The informant was encouraged to think about their previous description of 
quality of life and its determinants.  They were asked to discuss whether the measure under 
consideration covered what they felt quality of life to be.  The informant was also encouraged 
to consider each items each measure individually and comment on relevance and 
completeness. 
“So thinking back to how you described quality of life, and what influenced it, do you 
think this measure covers that?”  
“Now if we could go through the measure and consider the content of each item 
individually” 
4.5.2. The comparative direct approach 
These experiences from the early interviews led to the development of an approach that 
allowed a fuller assessment of the content validity of the EQ-5D-5L and ICECAP A measures 
150 | P a g e  
 
than would have been possible at the start of the interview process: the comparative direct 
approach.  This is an effort to respond to calls by Magasi and colleagues [233], Brod and 
colleagues [232] and others for rigorous and transparent qualitative methodology in the 
assessment of content validity or patient reported outcome measures.  
Figure 9: Graphical presentation of the Comparative Direct approach. 
 
The first stage of the analysis, the comparative stage, used data from the initial part of the 
interview, where the informant defined their understanding of quality of life as a concept.  
This description of quality of life is compared by the researcher with the content of the 
measure under consideration. This part of the interview has the advantage that the informant 
has not been influenced by seeing the measure.  This provides a reference point for the 
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analysis for the informant; they have described what they define quality of life to be and what 
influences it. 
The second stage, the direct stage, uses data from the second part of the interview where the 
informant has the measures in front of them. The informant discussed the relevance of the 
measure and the overall content coverage of the measure as a whole and each item in turn.  In 
this part of the interview the informant was asked to think back to what they defined quality 
of life to be in the initial part of the interview, and assess whether they felt the measure covers 
their conceptualisation of quality of life. Using the reference point established earlier in the 
interview is important. It addresses the methodological issue of there being no widely 
accepted definition of quality of life, by allowing understanding of the informants 
conceptualisation, and allows a better understanding of the informants’ opinions on the 
coverage of the measure. 
4.6. Data handling  
Interviews were transcribed verbatim using Olympus transcription software.  All names and 
references to locations that would have indicated the informant’s identity were removed.  
Each informant was assigned a code.  An electronic index of the codes and the corresponding 
informant was kept in a password protected document.  All electronic transcripts were stored 
on a password protected computer in a locked room.  Hard copies of transcripts were kept in a 
locked cabinet in a locked room. 
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4.7. Data analysis 
Interview transcripts were coded using the Atlas-Ti computer-assisted qualitative data 
analysis software. A hierarchical coding structure was formed during the analysis of the first 
batch of interviews and was grounded in the data and researcher experience of the early 
interviews.  Where appropriate the participants’ phrases and language was used to form codes.  
The coding structure was updated and refined throughout the subsequent batches of analysis 
in an iterative manner, to allow the identification and development of themes.  The final 
version of this is placed in Appendix 9.  The process of updating and refining the coding 
structure is presented in  Figure 10.   
An iterative, constant comparative, thematic analysis of the transcripts was completed.  
Transcripts were analysed in four successive batches.  This analysis allowed descriptive 
accounts to be formed.  These accounts were formed for each batch of the analysis and sought 
to synthesise the data, highlight key trends and map the diversity of opinion amongst the 
informants [241]. The iterative nature of the analysis allowed themes which were identified in 
earlier batches to be analysed and developed in later batches of the analysis.  Emerging 
themes were initially identified and then discussed with doctoral supervisors, before being 
assessed in greater detail both through refinement of the interview topic guide and greater 
focus during analysis through the use of the flexible coding structure (above).   
At the conclusion of the work an explanatory account was formed, which through assessing 
patterns within the data and drawing comparisons between informants, sought to move 
beyond descriptive analysis to explanatory analysis [241].  A focus was maintained both on 
participant opinions of the ICECAP-A measure, but also on understanding the reasons for the 
153 | P a g e  
 
opinions held.  This explanatory account formed the basis from which the following chapter 
was written.   
 Figure 10: A representation of the iterative nature of the thematic qualitative analysis 
 
 
 
 
 
 
 
 
 
 
Solid fill lines indicate the refinement of the topic guide and coding structure based on interview experience and emergent themes.  
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CHAPTER 5. QUALITATIVE STUDY OF THE 
CONTENT VALIDITY OF ICECAP-A: RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
Note on chapter: The qualitative results presented in this chapter have been published.  A 
copy of this publication is contained in Appendix 10.  The reference for this publication is:  
Keeley T, Al-Janabi H, Lorgelly P, Coast J (2013) A qualitative assessment of the content 
validity of the ICECAP-A and EQ-5D-5L and their appropriateness for use in health research. 
PlosOne. 8;12.  
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5.1. Introduction 
This chapter reports an assessment of the content and face validity of the ICECAP-A measure 
using rigorous qualitative methodology described in Chapters 3 and the methods described in 
Chapter 4.  The development of the two stage comparative direct approach provided a useful 
structure in which this analysis could be completed.  The reporting of results in this chapter 
reflects this structure.  First, the informants’ conceptualisation of quality of life, which was 
discussed in the first part of the interview, is reported.  The chapter then continues to discuss 
the informants’ perception of the ICECAP-A measure.  Within this section data referring to 
informants’ overall perceptions of the measure is presented first before an item by item 
breakdown of the data is completed.  In the item by item analysis comments before and after 
viewing the measure are presented and compared.  
An emergent theme of how quality of life measures are chosen for use in randomised 
controlled trials is reported.  A conceptual model is offered based on this data.  Discussion of 
these findings in the context of the ICECAP measures is provided.   
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5.2. Interview recruitment and informant characteristics 
Seven male (IS03, IS10, IS11, IS12, IS13, IS16, IS19) and 10 female research professionals 
were interviewed between January and September 2012.  Eight interviews were conducted in 
various locations in Australia; nine interviews were conducted in various locations in the UK.   
Informants were selected from four broad professional roles and different clinical areas, 
shown in Table 5.  Four informants were classified as “frontline” researchers.  Two frontline 
researchers were trained as nurses (IS01, IS05), one as a physiotherapist (IS09) and IS17 had 
no clinical training.  Seven informants were classified as trialists.  The group included 
principal investigators (IS16, IS06) and senior research fellows (IS04, IS07); all those in the 
“trialist” category were experienced investigators in terms of length of time in research and 
number of projects worked upon.  Two “trialists” were clinically trained (IS04, IS16), but 
were not working within a trial as doctors; two had some knowledge of health economics in 
clinical trials (IS16, IS10).  Three informants were classified as research doctors, meaning 
their primary role in a trial was a clinical one.  They have therefore been classified under the 
“trialist” category.  Three health economists were interviewed.   
All but two (IS04, IS11) informants had experience of using the EQ-5D-3L (see Table 5).  
Five informants had experience of using or had previously seen one or both of the ICECAP 
measures, with three (IS01, IS16, IS17) informants holding an a priori positive view and two 
(IS02, IS12) informants holding a negative view of the measure.  None of these changed their 
views after considering the ICECAP-A measure in the interview suggesting the views they 
held on the ICECAP-A measure were already well established.  A number of other measures 
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had been used by the informants, the most common being SF-36 and the EORTC (see Table 
5). 
Informants worked in a number of clinical areas (see Table 5) across primary (IS06, IS07, 
IS09, IS10, IS12, IS16, IS17, IS18, IS19) and secondary (IS01, IS02, IS03, IS04, IS05, IS08, 
IS11, IS13) care settings.   
Data saturation identified as having occurred by interview 14.  This was judged as the point at 
which no new themes were being identified in the data on the primary objective of the 
research (the content and face validation of the ICECAP-A measure).  Data saturation was not 
reached on the emerging theme of how measures are selected for use.  Three additional 
interviews were conducted to check saturation had occurred and to ensure adequate numbers 
were sampled from each professional role.   
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Table 5: Professional characteristics of informants included in qualitative research 
Informant Location Primary clinical 
area  
Role ICECAP-A 
prior opinion 
QoL 
measures 
used 
IS01 UK Cancer Frontline Positive EQ-5D 
EORTC 
ICECAP-O 
IS02 UK Cancer Trialist Negative EQ-5D 
EORTC 
IS03 UK Cancer Trialist None EQ-5D 
QLQ-30 
PEDS-QOL 
IS04 AUS Arthritis Doctor None SF-36 
SF-12 
IS05* UK Cancer Frontline None EQ-5D 
SF-36 
IS06 AUS Physiotherapy Trialist None EQ-5D 
SF-12 
SF-6D 
IS07 AUS Injury Prevention Trialist None EQ-5D 
IS08 AUS Cancer Health 
Economist 
None EQ-5D 
EORTC 
IS09* AUS Physiotherapy Frontline None EQ-5D 
SF-12 
IS10 AUS Multiple areas Trialist None EQ-5D 
SF-36 
AQoL 
IS11 AUS HIV Doctor None AQoL 
HIV spec 
IS12 UK Primary Care Trialist Negative EQ-5D 
SF-36 
IS13 AUS Blood pressure Doctor None EQ-5D 
SF-36 
IS16 UK Public Health Trialist Positive EQ-5D 
SF-12 
SF-36 
AQoL 
ICECAP 
IS17* UK Stroke Frontline Positive EQ-5D 
ICECAP 
SF-36 
IS18 UK Primary Care Health 
Economist 
None EQ-5D 
SF-36 
SF-12 
IS19 UK Pharmacology Health 
Economist 
None EQ-5D 
* Informants who were recruited through snowball sampling.  Please note: due to a coding error the codes IS14 
and IS15 were not assigned to informants.  
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5.3. Content and face validation  
This section presents evidence of a thematic analysis of the content and face validity of the 
ICECAP-A measure.  The informants’ conceptualisation of quality of life and its determinants 
are described.   The direct comments made by informants upon the content of the measure and 
an item-by-item content analysis of the ICECAP-A using the comparative direct approach 
follows.  The relevance and appropriateness for use of the measure in the informants’ research 
area are detailed. 
5.3.1. Quality of life beliefs 
5.3.1.1. Quality of life as a broad concept 
A strong theme running through the interviews was that informants perceived quality of life to 
be a broad concept.  A common initial response to some variation of the probe “what do you 
hold quality of life to be?”, was for informants to state that they thought it was a broad 
construct.  Quality of life was frequently referred to as “big picture”, “multi-dimensional” or 
“broad”. 
IS16 So it has got to be all things to all people. 
IS06 So I guess I view it as a broad construct which is influenced by all of the other 
aspects. 
IS12 it is obviously multi-dimensional 
IS16 I think it is a sort of “how are you” question.   
IS09 and I think...it has to be sort of big picture 
Informants discussion of what determined and influenced this broad construct of quality of 
life could be categorised under three main themes, with each theme having a number of sub-
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themes: physical health and impairment, which included ill health, pain, functioning, mobility 
and treatment side effects; psychological state, which included psychological health and 
outlook on life; and social, life and living, which included family and friends, work and 
ability to lead a normal life. 
5.3.1.2. Physical health and quality of life 
Physical health was recognised as being an important determinant of an individual’s quality 
of life.  A high level of agreement existed amongst informants that poor physical health or 
physical disability reduced quality of life. 
IS09 I still see health as important in that [quality of life].  I think when someone has 
got ill health...it is quite a big determinant. 
Informants were able to give a number of examples of how specific illnesses or conditions can 
reduce quality of life.  Informants used examples from their area of research as well as 
personal example or examples of extreme health states, which emphasised their point. 
IS05 ...you could have somebody, bilateral amputation below, knee who’s in a wheel 
chair and their quality of life is zero. 
IS13 To be incontinent, of either urine or faeces, you know, by God your quality of life 
goes down.  So there are all sorts of terrifying things which can happen. 
Pain was a category of health that informants frequently identified and placed particular 
emphasis upon.  Pain was discussed at greater length by informants who had regular contact 
with patients or trial participants (frontline researchers and research doctors), who noted the 
pervasive influence it can have on quality of life. 
IS18 So you could have chronic back pain and…that would certainly, I mean yeah 
poor health impact on quality of life, there is no doubt about it. 
 IS13 Nothing worse for quality of life in many ways than chronic discomfort and pain.   
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For informants who worked in cancer research, the physical side-effects of treatment were 
identified as having a notable influence on quality of life.  There was a consistency amongst 
these informants in the way side-effects were described as affecting patients, mainly through 
fatigue.  No informants from any other clinical area discussed side-effects. 
IS08 Treatment is probably a predictor of the quality of life.  So the chemotherapy is 
of course and radiotherapy both have a high impact on fatigue. 
IS05 They could be perfectly well and asymptomatic of their disease and then us give 
them lovely cytotoxic chemotherapy and a bit of radioactive isotopic one off injection 
which reduces their quality of life completely. 
IS01 Some of the new wonder drugs that have come through, [we] now realise have 
huge cardio-toxicities attached to them…which is very life limiting and well-being 
limiting. 
Mobility and physical functioning was viewed as allowing a person to complete their daily 
routine and maintain independence.  Mobility and the ability to physically function was 
valued not just for itself, but for what it allowed a person to do.  This is closely linked to the 
normal activities section below.  Informants who worked in physical therapy and falls 
prevention frequently discussed this point. 
 IS02 ...well anything that would impair your ability to live a normal life.  So it could 
be physical in that you can’t walk or paralysis or something extreme like that.  Or it 
could be pain that could make it difficult to function. 
IS03  Yeah, well there is physical functioning...can you live a normal as it were life?  
Can you deal with day-to-day things? 
IS04 …they can’t get down to the shops to do their shopping.  Or, they want to do 
something and they can’t do it.  It is too hard, they have got to think about is it 
feasible to do something that they want to do based on how mobile they are.  It limits 
your options. 
IS06 …physically it might be catching a bus to see their daughter or going down to the 
shops or gardening or something like that. 
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Health was considered a major influence on quality of life.  However, informants indicated 
that they did not feel that it was an overriding influence and were of the opinion that those in 
poor health states were still able to have a good quality of life.  When discussing this point a 
number of informants used personal examples of friends and relatives who were living with, 
or who had lived with, illness or disability. 
IS16 All you see is ill health and states that you don’t want to get into, but there are 
people that get into those states and have a fantastic time. 
IS01 But no he certainly has good quality of life, but he’s got chronic pain and 
breathlessness and fatigue; from the outside point of view it’s harsh, but by no means 
depressed or fed up.  Still the life of the party.  Just not for as long and not with as 
much red wine.  He has shortened some of the things but there is still quality there. 
IS09 ...some people seem to be able to cope with a remarkable amount and yet still be 
able to...access the social contact or be involved in the things they want to do. 
Much of the discussion about people in poor health being able to maintain their quality of life, 
was focused around the ability to cope with and adjust to their health state.  This process of 
adjusting or adapting was discussed from both a shift in perspective of the individual and 
practical adaptation of learning to live with the condition.   
IS16 So then they are not limited and they see it as their lot [in life], and they get on 
with life. 
IS06 So basically they will learn to walk with a prosthesis or learn to be independent 
using a wheel chair.  ...so then their mobility will obviously be affected to some extent, 
but they can still still you know get back to doing things that they enjoy doing. 
5.3.1.3. Psychological health and quality of life 
Informants thought psychological health was an important determinant of quality of life.  The 
majority of informants interviewed discussed the effect of depression or emotional problems, 
and all those who discussed if felt that it was an important influence on someone’s quality of 
life.   
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 IS18 it is so pervasive into everyday life, probably almost more than anything else.  
 IS18 yeah, well I think mental health would impact very strongly. 
Informants discussed mental health as a distinct, separate category from physical health. 
IS12 I can I am sure there are people that are fantastically physically fit but have a 
terrible quality of life because they just are at odds with the world. 
While this distinction was made between physical and psychological health, a link between 
the two was evident.  Informants were of the opinion that psychological ill health, such as 
depression, could be a result of physical ill health.   
IS13 if your illness is causing you more and more trouble you could end up getting 
perfectly understandable amount of depression.  Depression is a frequent co-
morbidity of severe physical illness.   
An informant discussed how the internalised perception of being a “patient”, even in the 
absence of physical symptoms, may affect a person’s quality of life.  
IS16 They aren’t feeling as well as they could be because they recently diagnosed as 
hypertensive and they are not unwell with that, but they are not they no longer 
consider themselves as well, because they are now having to take a drug every 
morning.  And remembering that.  And that is the difficulty that quality of life faces as 
a term. 
A second theme under the overarching psychological topic was psychological outlook or 
outlook on life.  This was distinct from psychological health discussed above, as it was not 
viewed as an illness or condition.  Informants discussed psychological outlook as a mental 
attitude to life or a psychological frame, which might determine an individual’s response to 
situations.  
IS09 I think that some people seem to have been very resilient and get through things 
and other people get bogged down. 
IS13 It depends a lot on, it depends a lot on mental attitude.  So you can have people 
that are seeming to have all the rotten luck in the world and think their lot in life isn’t 
bad.  While you have other bastards that have everything on a silver spoon and think 
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their lot in life is shit. 
Psychological outlook was perceived as having an interaction with physical health, which 
resulted in different people reacting differently to illness and disability.  Those with a positive 
outlook on life were thought to be able to deal with personal ill health better than others. 
IS16 I think health affects people in very different ways depending on what the 
condition is, but also their own psychological frame and their own ability and the 
resources around them to support them through that so, plenty of people in the world, 
who inevitably think the worst of anything that is diagnosed, and that inevitably leads 
to a certain sort of mindset and action. 
5.3.1.4. Social, life and living 
When discussing the topic of social, life and living a greater use of scoping and content 
mining probes were required.  A number of informants raised this theme, but in comparison to 
the ease which all informants discussed physical and psychological health (above), informants 
showed a greater level of struggle when discussing this topic.  While informants struggled to 
discuss this theme, it did not appear that this struggle was linked to the importance they 
attached to it.  Rather it appears that informants had greater trouble verbalising their thoughts. 
The use of appropriate probes, which brought greater structure to this section of the interview, 
allowed informants to discuss social, life and living in depth. Taken as a whole the data 
suggest these informants felt there is a broad spectrum of social influences on a person’s 
quality of life. 
IS13 things that can impact on a person’s life other than being in your trial.  Life is 
going on, having children, they are getting married, they are dying, they are living, 
having operations, they’re going broke, they are making a fortune, and whatever else 
is happening. 
Family and friends were identified as an important determinant of quality of life.  Informants 
felt that as well as the enjoyment that people get from spending time with them, family and 
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friends provide support and assistance which can increase the quality of someone’s life.  
Examples were given of people who were in poor health, finding enjoyment from family and 
friends. 
IS04 the computer keeps his world open enough that people five years later still come 
to visit every day.  People who are not necessarily family, people who were friends, 
people he didn’t really know before...who started coming and then keep coming.  It is 
pretty impressive. 
IS01 Thinking of a family member who has considerable impact on his health from 
lung cancer, but when he is around his family, doing the things he enjoys. 
The situation where someone loses a loved one was frequently used to highlight the 
importance of friends and family. 
IS06 … any major life events, particularly with older people, if their spouse has died, 
or their daughter’s not helping them, or something like that, probably has an influence 
A family support structure was noted as important for those in ill health.  The majority of 
discussion on this topic was focused on the situation where a support structure is absent and 
the negative impact this can have on an individual.  
IS05 “gosh this poor family”…his wife couldn’t deal with it, he couldn’t deal with it, 
they weren’t working together, they weren’t thinking about the other person.  They 
had the daughter there who was just a mess and his wife actually turned around to me 
and said “how to I support him”….  And, his quality of life it wasn’t just wasn’t the 
cancer, it was the fact his family support structure, because it wasn’t there. 
Work and financial security was mentioned by a number of different informants.  Work was 
viewed as positive and a negative perspective influence on quality of life.  Informants 
discussed how work can be an enhancing factor in someone’s life, and the example of 
Stephen Hawking was used by several informants. 
IS08 I think my quality of life in Australia for example, living here, and it includes the 
weather and it includes what type of job I have and how healthy I am at the same time. 
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IS02 you could think about Stephen Hawking, mentioned a lot at the moment.  But he 
is physically very very seriously impaired and yet is he 70 now?  With a very, what 
must be a very, satisfying rewarding job you would think. 
A small number of informants noted that the stress and pressure associated with work can 
limit life; however this was in contrast to the predominant view of work and ability to work 
being a positive influence on quality of life. 
IS01 work as well, being able to get the time away from work without feeling the 
pressure of the place.  
The ability of people to lead their normal life was a strong theme.  This topic was often 
discussed with reference to how loss or reduction of health affected quality of life.  This 
section was closely linked to health and mobility (above), and indicated that these things were 
not just valued for themselves, but rather what they allowed. 
This discussion focused on the ability to do things that they normally do, or lead a normal life.  
When pressed on the meaning of a normal life, informants were quick to explain that they 
didn’t mean a generic or standardised life, rather the life that the person had or wanted to live. 
IS06 So it could be in terms of their participation, that they are not able to do the 
things  that they normally do.  So whether it is looking after grandchildren or cooking 
meals or something like that.  So that aspect of their life can be affected. That they 
perform social roles that they would normally perform I guess. 
IS09 I suppose I would think [quality of life] that someone is doing what they want to 
be able to do. 
Within this discussion was the need for individuals to achieve things of value.  The examples 
given by informants were not of big, one off achievements (such as running marathons or 
climbing mountains), rather everyday day actions that defined the individuals or filled their 
day-to-day life. 
IS12 …he was in and out of hospital, he was in a lot of pain, he couldn’t do all of the 
things prior to that which had great meaning and value to him.  He used to keep pigs 
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and chickens, you know small holding, a really huge part of his life he had to give it 
all up he couldn’t do it. Too ill. 
5.3.2. Informant opinions of the ICECAP-A measure 
Informants viewed the ICECAP-A measure as a broad assessment of quality of life, generally 
appropriate for use in the research fields in which they worked.  The measure was viewed as a 
short, uncomplicated measure, suitable for use with participants in a busy research 
environment: 
IS01 It is a lovely length...because they haven’t, you don’t have the time to spend with 
a long questionnaire.  
IS18 I think that is very clear and it is obviously quite straight forward in that sense to 
actually physically fill it in.  Yeah. 
Informants noted that it was different to existing health-related quality of life measures, 
focusing on the emotional determinants of quality of life.   
 IS06 Yeah I guess this one is more general...and focuses mostly on the emotional.  
 IS07 Its very much the emotional aspects of things. 
When asked to think back to how they defined quality of life in the first part of the interview 
and comment on whether the ICECAP measure captured that definition, the majority of 
informants felt that it did.   
IS06 And, to me this is more about psychological aspects.  Yeh which I think probably 
is actually measuring overall quality of life. 
IS18 So would that capture my quality of life [long pause]?  Errrr [long pause] 
yyyeessss pretty much, pretty much. 
The primary concern that existed was that the ICECAP-A did not directly assess health, 
which informants had identified as an important influence on quality of life in the early part of 
the interview.  A number of informants noted that this.  Some felt this was an important 
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dimension that the measure did not assess, which reduced the relevance of the measure to 
their clinical area. 
IS19 It is just how far away from health it gets I suppose...I think it is just the distance 
from health [which is a concern].  
IS18 a lot of them are health-related quality of life…this clearly isn’t.   
IS04 Yeah, no, that [ICECAP-A] captures Dad’s quality of life and this is the one 
[EQ-5D-5L] we use in studies. 
Several informants made comparison between the EQ-5D-5L and the ICECAP-A measure.  
While different informants had preferences for different measures, these comparisons 
suggested that informants tended to view the measures as measuring two different things.  
The EQ-5D-5L was generally viewed as measuring health; whereas the ICECAP-A was 
viewed as capturing a more general definition of quality of life. 
IS13 when you look at them...this one strikes me again as quality of life, making a 
judgement that emotional things are more important, because that is more 
emotional...wellbeing and this [EQ-5D-5L] is more total health. 
IS18 So this [EQ-5D-5L] is really about THE person and their little box situation, 
whereas this [ICECAP-A] is much broader about their life in general.   
A tension was present in the data between informants who viewed the measure as assessing 
dimensions that matter to patients and a small minority who felt the subject matter were too 
sensitive and not appropriate to ask patients.  The perception of inappropriateness was 
motivated by a concern over the questions being upsetting for people who had low levels of 
the dimensions being assessed, rather than being inappropriate per se.  Informants who felt 
the measure was patient-focused were more likely to be frontline researchers or research 
doctors, while those who held concerns over the measure were more likely to be trialists. 
IS01 I think they would be [happy to answer], because it sums up the kind of 
conversations you have with patients and I think they would be quite comforted with it.  
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IS18 I don’t think they would object.  I don’t think anybody could object to filling that 
is.   
IS02 I find them [the questions] less appropriate... If you were stuck in a dead end job 
might be cheesed off by asking if you can achieve and progress because you spend 
most of your working days doing something that is soul destroyingly dull. 
The majority view of informants was that the measure was appropriate for use in the research 
area in which they worked, with only a small number providing a contrasting opinion.   
IS11 I like it.  I love it.  That is my initial feeling.  I love it. 
IS09 No I quite like that.  I think it covers a lot of issues very simply.   
TK And do you think it would be of use in the research areas that you work in? 
IS09 Yeah I do.  I think this is a good basis for knowing where someone is at. 
A small number of informants commented that it might be of greater use for research with the 
general population.  These informants noted that for a population of very sick people it may 
be a bit too broad for use. 
IS10 But it depends, if you are doing a broad research setting, not every research has 
to be done in people who are really sick.  It could be a very broad intervention...that 
could be very applicable.  But if it’s you know if it’s an oncology and people are really 
sick and people are going to die, that’s probably a bit too broad. 
There was a consensus that the measure would be best used in addition to, rather than as a 
replacement for, existing health-related quality of life measures.  Informants felt that 
something that provided more information about the source of the problems and maintained a 
focus on health-related quality of life was also required.  This was motivated by a perception 
that the ICECAP-A measure was not measuring health-related quality of life. 
IS18 I think it would definitely [be of use]...I probably wouldn’t replace the EQ-5D 
but I would think quite seriously about using it in addition.  
IS19 So it would complement, I wouldn’t see it as a replacement for an EQ-5D, but it 
would certainly complement an EQ-5D type instrument. 
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A number of informants discussed the capability wording of the ICECAP-A measure.  Some 
informants showed a level of cognitive struggle in understanding the focus of the question and 
a level of concern existed about whether the wording would be understandable for participants 
in the studies.   
IS06 Yeah I guess the “can” and….the difference between can and do maybe might be 
confusing to some people…it might be clearer to leave out the can. 
However, in the majority of the discussions about the capability wording informants reached 
an understanding that would be broadly in line with the capability theory (i.e. they understood 
the question correctly). 
IS03 I don’t like the “I am able” or “I can”, you know I don’t know, it feels as if in 
some way you are the person with the control , so I CAN have a lot if I want to I can 
have a lot of love and friendship.  
5.3.2.1. Item by item analysis 
Below is an item by item analysis of the ICECAP-A measure whereby the comments before 
and after viewing the measure are presented and compared.  A description of what the item is 
designed to measure is taken from Al-Janabi et al [115] and is provided at the start of each 
item.  Many of the comments provided after viewing the measure were elicited through asking 
the informant to think back to how they had previously described quality of life.   
5.3.2.1.1 Stability  
The Stability item was designed to assess an individual’s ability to live a life of continuity, 
without feeling concern or uncertainty [115].  Prior to viewing the measure, informants 
identified stability as an important dimension of quality of life.  Living with fear and 
uncertainty due to a physical condition or illness and the concern that unemployment due to 
illness can cause, was identified by a number of informants as a pertinent issue.   
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IS13 You get frightened of taking your medicine.  You get frightened of going to sleep, 
in case you don’t wake up.  
IS08  ...getting back to work.  The worries of losing a job, not getting back, not being 
able to get jobs back.   
Upon considering the measure, there was a broad acceptance that the Stability item was 
relevant to the assessment of quality of life.  Informants indicated that the item would 
resonate with participants of different ages, and would be influenced by both health and non-
health factors.  A number of informants recognised that the item was assessing a construct 
that they had identified as important in the earlier part of the interview. 
IS01 ...it makes sense because...the phase one patients I see are very palliative and 
they don’t have a lot of time.  But you can still be settled and secure with months to 
live.  
5.3.2.1.2. Attachment 
The Attachment item is designed to assess the importance of support, social contact and 
relationships [115].  Prior to considering the measure, informants identified the ability to 
function in a social context as an important consideration.  Relationships were identified as 
important both for the enjoyment and support they provide.  A loved one dying was often 
given as an example of the importance that relationships can have on quality of life.  The 
importance of people suffering from illnesses to achieve social contact and the limiting effect 
that illnesses can have upon one’s ability to achieve social contact was discussed at length. 
IS12 And in the last year of his life, he died by the cancer, he said...this has been the 
best year of my life, because until this moment I never realised how loved I’ve been.  
 IS13 ...people who are incontinent tend to become completely reclusive, they don’t 
want to mix, they are terrified.  They don’t want to go out there and pee in front of 
everyone.  
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Upon considering the measure informants recognised Attachment as a relevant item to ask.  It 
was also noted that it is an area that is not often assessed. 
IS11 Well things like love, friendship and support.  It is all that thing around social 
connectiveness and support and intimacy.  We as a research group are very interested 
in that in people with HIV.  
A level of concern was expressed by a number of informants, over two particular points.  
Firstly, there was a concern that the item was assessing a number of different concepts (love, 
friendship and support) within one question.  The possibility that a person may have one, but 
not all of the concepts being assessed was a concern. 
IS03 ...I could just imagine, particularly with love friendship and support, I could 
imagine someone saying they have got one but not the other things.  Might be difficult. 
A second point of concern was the sense a few informants had, that this was a sensitive 
subject.  These informants were trialists, without regular patient contact.  This concern 
focused on the prospect of asking the question to an individual who had recently lost a loved 
one or in the process of a relationship breakup.  Some informants who had identified 
Attachment as important before viewing the measure had this concern. 
IS02 I don’t think number two is very appropriate.  There is a person here, they may, 
they haven’t got any love or friendship.  That is something that is completely outside 
their control. 
5.3.2.1.3. Autonomy 
The Autonomy item is designed to assess the ability to be independent, both in the practical 
sense of being able to look after oneself and in being able to make decisions [115].  A small 
number of informants discussed independence as a dimension of quality of life prior to seeing 
the measure.  The term “independence” was not used, rather discussion by these informants 
focused on the ability of an individual to do day-to-day things, such as shopping, which was 
often closely linked by informants with a person’s mobility. 
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IS06 ...they can’t get down to the shops to do their shopping.  Or, they want to do 
something and they can’t do it.  It is hard, they have got to think about is it feasible to 
do something that they want to, based on how mobile they are. 
In comparison to the limited discussion prior to viewing the measure, the majority of 
informants identified the Autonomy item as being of central importance to the assessment of 
quality of life.  There was a consistent opinion that the item was more important to older 
people.  
IS17...especially with older people that independence is hugely important to them, and 
that’s one of the depressing things for them when they lose that independence I think.  
5.3.2.1.4. Achievement 
The Achievement item is a measurement of the degree to which an individual can attain their 
goals and move forward in life [115].  The influence upon quality of life of being able to 
achieve and attain personal goals was not discussed by many informants prior to viewing the 
measure.  Gaining a sense of achievement through work was discussed briefly by a small 
number of informants.  The importance of being able to look back with a sense of 
achievement was noted as important. 
IS01 ...I think he [young cancer sufferer] has kind of condensed it all to “Yeah, I am 
25 and I have achieved everything I want”...and he is perfectly sane in what he is 
saying, be he has just reflected back and gone, “Yeah, I have achieved”.  
Informants provided greater discussion after seeing the measure.  The item was considered to 
be relevant, although disagreement existed as to whether it was relevant for older people.  The 
item was considered by a number of informants as being too broad and for some this raised 
the question about whether the top level was really achievable. 
IS03 I mean I don’t think that I can achieve and progress in all aspects of my life, I 
would love to be able to.  BUT. 
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The use of the word “progress” was questioned as for some informants in meant something 
other than what the question was assessing.  For some it focused on the area of paid 
employment (e.g. progress of work), while some of those who worked in cancer noted that 
patients could misunderstand the question as assessing their illness (e.g. has the cancer 
progressed). 
IS01 I think some of them [patients] might think progress as in is the treatment 
working.  Or maybe that is my cancer background.  Is there any progress, has the 
cancer progressed?  
5.3.2.1.5. Enjoyment 
The Enjoyment item assesses the enjoyment gained from fun and exciting things, as well as 
the simple pleasures in life [115].  Enjoyment was discussed by a few informants from the 
perspective of people with illnesses or disabilities enjoying life in spite of their condition.  It 
was normally identified through providing examples, rather than stating explicitly that 
enjoyment was a construct of quality of life. 
IS04 You have people that have an enormously great quality of life who can’t walk 
anywhere...because they have this great social structure and play cards all day.  
On considering the item, informants were split between those who felt the attribute was 
important and relevant, and those who did not.  For those who felt the item was not relevant, a 
motivating factor appeared to be that it was too broad to be relevant.  Field notes taken by the 
interviewer noted a level of surprise by some informants upon seeing the Enjoyment item.   
IS18 What do you mean by enjoyment and pleasure?  I suppose not vague, but 
possibly ambiguous.  
IS01 I think it is very important to have certain feelings...like enjoyment and pleasure.  
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5.4. Summary of content and face validity results 
Informants viewed quality of life as a broad construct, influenced by physical health, 
psychological health and a number of social factors. Informants made direct statements about 
the breadth of the construct, which they thought to be broader than health, and described a 
high and diverse number of influences.  The comparison of the informants’ conceptualisation 
of quality of life prior to viewing the measure with the descriptive system of the ICECAP-A 
indicates that during the discussion, in the first part of the interview, informants discussed all 
of the items included in the ICECAP-A descriptive system, as influences upon quality of life.  
However, it should be noted that there was a considerable amount of discussion about the 
importance of physical and psychological health and the affect that it can have on quality of 
life.  Despite the breadth of the measure, physical and psychological health are not directly 
assessed by the ICECAP-A.  Determinants which informants held as having a notable impact 
on quality of life, such as pain and side-effects, are not directly assessed by the measure.  
The results indicate that on viewing the ICECAP-A informants felt that it was a useful, broad 
measure of quality of life, which captured many aspects of quality of life that were discussed 
in the first part of the interview.  Informants’ perceptions of the ICECAP-A were that it 
measured the broad construct that they had previously defined.  A number of informants 
highlighted that it did not directly assess the health of the individual, which informants had 
previously defined as an important aspect of quality of life.  Item-by-item analysis of the 
discussion in the second part of the interview showed informants emphasised the importance 
of the Stability, Autonomy and Attachment items; while questioning the relevance of the 
Enjoyment item, and to a lesser extent the Achievement item.   
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5.5. Selection of quality of life measures for use in 
randomised controlled trial. 
A theme which emerged through the interviews and analysis was around the decision making 
process about which quality of life measures are selected for use in a trial research 
environment.  Exploration of this issue was not an aim of the interviews at the outset.  The 
original topic guide had no prompts or probes pertaining to this topic, but in discussing the 
pros and cons of existing measures in the early part of the interview, and when discussing the 
ICECAP-A and EQ-5D-5L, it was natural that informants would explain why measures were 
chosen.  In the early interviews informants made reference to both how and by whom a 
measure was selected and what the primary considerations during this selection process were.  
This emerging theme was identified as potentially important to furthering understanding of 
the use of quality of life measures in a trial setting.  The topic guide and the analysis codes 
were refined in order to identify data relating to this theme.  In subsequent interviews this 
theme then continued to be discussed through the use of scoping and mining probes.  While 
much of the data referring to this theme was not discussed by informants when referring 
directly to the ICECAP-A measure, the theme is important for understanding the potential 
barriers to use of the ICECAP-A measure.   
Data collection was stopped once saturation had been reached on the primary focus of the 
research and data saturation was not reached on this emerging theme.  The data collected 
provide an initial indication of a) the factors taken into account by those deciding on quality 
of life measures b) who decides which quality of life measures were used in trials and what 
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the decision process is and c) what the most likely decision is.  Data have allowed the 
tentative proposal of a conceptual model for the decision process of selecting a quality of life 
measure, which could be tested and refined through further work.     
5.5.1. Factors taken into account when choosing a measure for use  
Five factors were identified as important when choosing a quality of life measure for use in a 
research trial setting: precedent of use, evidence of validity, evidence of sensitivity to change, 
perceived relevance of content and practical considerations (e.g. respondent burden).  An 
indication of the relative importance of each was assessed by the consistency with which each 
consideration was identified and the terms in which informants discussed it.  Precedent of use 
and evidence of sensitivity to change were identified as potentially two of the most important 
considerations. 
5.5.1.1. Precedent of use 
Precedent of use appears to be an important factor in choosing a measure for use in a trial.  
Whether the measure had been previously used and was widely accepted amongst research 
colleagues, or had been recommended by an authoritative body, appeared to be a key 
motivator when deciding on the appropriate measure.  This appeared to be motivated in part 
by a desire to be able to compare across studies and interventions.   
 IS04 You know, I haven’t thought about it...is it good is it bad... no....it is what is 
accepted, expected.  It is what is there. It is not a major focus. 
IS08 And then it is just being used because you want to say something about your 
results in light of other results.  So it if you can’t compare it to anything then that 
makes it hard 
IS19 But you know at the end of the day it is the best tool that we have, or it is the tool 
that is most often used, and there is a case consistent from one setting to another. 
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For informants who had knowledge of economic analysis alongside clinical trials, the 
importance of precedence in the decision process had been reinforced by NICE guidance.  
NICE guidance was identified as the reason that the EQ-5D had gained such dominance in 
health economic analysis alongside clinical trials.   
  IS18 Because NICE recommends it and it is not too onerous.   
IS16 it is kind of a bit of a mantra I guess.  It would be a fairly assertive person 
[health economist] not to have EQ-5D in. 
There was also a tendency for informants to defer their opinion to that of experts.  A number 
of examples were found of informants assuming the measure was suitable for use in the trial 
because the measure had been designed and validated by quality of life “experts”. 
IS08 There’s a good team behind the EORTC, the EORTC is a great organisation I 
think …my first thought is the EORTC...  
TK Do you think they capture quality of life adequately? 
[pause] 
IS13 Who am I to say?  Experts have designed these to try and capture domains which 
cover various, must come close to covering [quality of life].   
5.5.1.2. Evidence of validity 
A number of informants who were involved in the selection of measures stated that they 
would want to see evidence of validation or know that a measure had been validated before 
use.  
IS10 But, if someone talks about a questionnaire I have never heard about I would 
want some reassurance that it has been validated and the properties are well 
established. 
IS02 I would want to know a questionnaire was appropriately validated.   
This shows a tension with the theme of precedent of use.  Here informants want to see validity 
evidence rather than deferring opinion either to previous precedent of use or to experts.  It 
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may be that through precedent of use validity evidence is gained, or precedent use is how 
informants judge a measure as valid.  Data cannot confirm this. 
5.5.1.3. Evidence of sensitivity to change 
Sensitivity to change was identified as a major concern for informants.  It was the most 
important of the psychometric properties (validity, reliability and sensitivity to change) 
discussed. 
 TK and that sensitivity to change is a big concern? 
IS16 YES [laughs] Yes huge.  
A concern existed amongst the majority of informants that quality of life measures were not 
sensitive to change and this made them cautious about using them in their trials. 
IS16 I have never used a quality of life measure as a primary outcome…I have shied 
away from using it basically because I haven’t seen any evidence beforehand that I 
would be able to demonstrate a change in quality of life. 
This concern was particularly evident when discussing EQ-5D-3L.  Despite its frequent use 
by informants, the majority felt the measure was not adequately sensitive to change.  This 
may indicate that precedent for use rather than sensitivity to change has a primacy in 
considerations when selecting a measure.  
IS06 I guess in terms of the measurement [EQ-5D-3L] …it is a bit unclear whether 
you can actually detect affect from our intervention, so the jury is still out on that. 
5.5.1.4. Perceived relevance of content  
Perceived relevance to the trial population of the content of the measure was seen as being 
important.  Informants recognised that there are differences both in the descriptive systems of 
quality of life measures and in those aspects of quality of life that are relevant to different trial 
populations.  This point was often raised when discussing the measures under consideration in 
these interviews.  Informants identified measures as being particularly suitable and relevant, 
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or not, to different research populations with which they work.  For example: informants often 
noted that the EQ-5D-5L descriptive system would suffer from a ceiling effect in healthy 
research populations; while the ICECAP-A may lack a health focus in severely sick 
populations.   
IS07  Well its quite targeted to the population so it’s not, you know you haven’t got 
most of the people just saying there is not a problem on all these things, it has to be 
appropriate, the questions have to be appropriate to the target population.   
IS10 I still feel this would be better in general population 
5.5.1.5. Respondent burden  
Practical considerations focused primarily on the length of the questionnaire and the time it 
would take to complete the measure.   Informants identified a need for concise questionnaires, 
while at the same time recognising there was a trade-off between questionnaire length and 
completeness of coverage.   
IS01  because they haven’t got the time to spend with the long questionnaire and 
you’re not going to get attention for long, because they’ll be looking to see are they 
going to get called in to get there bloods done, are they waiting for the doctor.  So it 
has to be quite quick, quite easy 
5.5.2. Decision process when choosing a measure for use 
Informants described a collaborative process through which quality of life measures were 
chosen for use in a trial.  Informants reported that the steering group, led by the chief 
investigator, generally decides on the inclusion and exclusion of measures.  Research 
clinicians and health economists may be involved in the trial management group, but are often 
less involved in the running of the trial.  Those involved in the decision process are referred to 
as agents.   
IS18 So yeah every trial has a different group people around it the table.  There is 
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usually a lot of horse trading.  Usually everything is bunged in and then they say this 
is going to take two hours 
 [laughs] 
 TK A hundred page baseline questionnaire 
 [laughs] 
IS18 yeah quite...it is negotiated overall, the whole package of outcome measures is 
negotiated.   
IS13 A combination of the steering committee, the chief investigators...and experts 
they will bring in to run the study.   
Non-health economist informants, including statisticians and clinicians, identified health 
economists as “experts” on quality of life measures.  Health economists described how they 
were in charge of selecting the health economics outcome measures, including preference 
based quality of life measures.   
 IS19 The things feeding into the economic analysis I would have control of.   
The health economists did not however feel they were responsible for, or capable of, making 
decisions for all quality of life measures.  Health economists did not view themselves as 
experts on all quality of life measures and  identified research doctors as being more 
appropriate judges of the broader spectrum of quality of life measures, including disease 
specific measures. 
IS19 Other quality of life instruments which are nothing to do with the health 
economics, I wouldn’t have that, because I wouldn’t be in a position of being 
knowledgeable in those questionnaires.  It is normally the clinicians who will be up to 
speed on the literature surrounding that particular intervention who would know that 
other studies report measure X Y and Z. 
On the role of research doctors a degree of agreement may be present in the data.  The 
informants who normally discussed the relevance of the content of the measure for their 
populations were research doctors.  They brought a level of analysis and perspective that was 
not present from trialists or health economists.   
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IS10 if it’s an oncology population and people are really sick and people are going to 
die, that’s probably a bit too broad...it’s going to miss the point. 
However, all three research doctors noted in the early stages of the interview that quality of 
life was not their field of expertise and were cautious about commenting on it. 
One informant described a role for an industry agent in determining what quality of life 
measure was to be used in industry sponsored trials.  A research doctor described how 
industry agents wanted a measure that would show a difference for their product.  It was also 
indicated that this decision would be made outside of a collaborative environment and might 
be “imposed” upon the trial.   
5.5.3. Likely decisions and dominant considerations 
There was some indication in the data about what the most likely decision of each of the 
agents in the decision process would be.  Health economists seem likely to choose an 
accepted preference based quality of life measure, acceptable for use in health economic 
evaluation.  Precedent of use seems to be the dominant consideration for health economists.  
All health economists identified concerns and perceived failings with the EQ-5D-3L (which 
focused around sensitivity and relevance), but equally all health economist informants said 
that they used the measure. 
IS18 But I always say “the EQ-5D we have got to have it in there”…even if you don’t 
think much of it, it has got to be in there. 
A collaborative decision taken, by the trial steering or management group, informed by 
doctors, health economists and statisticians, will likely choose a measure that is 
comprehensive, appropriate to the population and sensitive to change.  Precedent of use may 
be considered directly or used to judge these qualities and the practical decisions of length and 
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time of completion would exert some influence.  The collaborative decision would likely 
select a non-preference based measure such as the SF-36 or a disease specific measure like the 
EORTC QLQ C-30.   
The very limited amount of data collected on the decisions of industry indicated that a 
measure that would show a positive outcome would likely be selected.  The primary 
motivation here was a measure that was sensitive to change and would provide a “selling 
point” for their product. 
5.5.4. A conceptual model of quality of life selection 
A conceptual model is proposed based on the exploratory data collected from these interviews 
(Figure 11).  This model proposed possible considerations, how these considerations may 
influence the different agents involved in the selection of quality of life measures and what 
the likely decisions of these agents may be.  This model is a tentative suggestion of the 
process by which a measure may be selected.  The model is based on exploratory data, which 
(for reasons stated above) did not reach data saturation during the interviews conducted.  
Dotted lines indicate that the evidence collected was limited and no firm conclusion could be 
made. 
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Figure 11: A conceptual model of quality of life measure selection for use in randomised controlled trials
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Explanation of Figure 11. 
A - Precedent of use for the health economist is focused largely around what their colleagues have used in the field and the reference case of a funding or rationing 
body. 
B – Precedent of use for the steering and management group appears to be motivated more by the deferring of opinion to precedent.  An assumption made that because 
it has been used by colleagues then it “must” be appropriate. 
C – The consideration of validity evidence was mentioned by a small number of informants.  It appears that depending on the experience and knowledge of individuals 
in the steering group that there will be differing levels of consideration the state of the validity literature on the measure. 
D – The practical considerations were described as “horse trading” focused on a trade off between completeness and brevity of the questionnaire pack.  Data indicates 
that this is done collaboratively with the PI having the final say.  
E – Those who commented as relevance of content being a consideration were largely medically trained, and all but one were research doctors.  Research doctors do 
not appear to make quality of life instruments decisions outside of the collaborative setting of the steering group; however it appears that they may bring consideration 
of relevance to this discussion.  It is not possible to say with certainty that research doctors provide this consideration. 
F – Sensitivity to change is a major consideration of the steering group, possibly to the extent that it has a primacy among the considerations. 
G – Only one informant commented on this pathway.  He was very clear that the consideration of an industry agent would be focused primarily/exclusively on the 
ability of the measure to show change. 
H – Health economists and research doctors work in a collaborative fashion with the steering and management group to select quality of life measures.  This 
collaborative decision will likely lead to a comprehensive, population appropriate and sensitive measure, with a low patient burden being selected.  These measures 
may be disease specific, such as the EORTC QLQ C-30 in cancer or of greater length (than health economic measures) like the SF-36 or the HUI. 
J – Health economists have the determining say on health economic outcome measures and will likely select an accepted, generic, preference based measure such as 
the EQ-5D.  This may be decided at through the collaborative nature of the steering group; however the locus of responsibility for the decision is firmly with the health 
economist.  This is the perspective of both health economists and other members of a steering group. 
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5.6. Summary of measure selection results 
This emergent theme indicates that there are a number of factors considered when choosing a 
quality of life measure for use in a randomised controlled trial.  For new quality of life 
measures these factors may be considered barriers for use.  New measures will not have 
precedent of use and, potentially, only early indications of validity from the development 
process.  The process of assessing the psychometric properties of the ICECAP measures is 
underway and both measures have started to be used in a research setting.  However, in 
comparison to other quality of life measures, both the precedent of use and the weight of 
evidence are small.  Therefore, this emergent theme highlights the importance of the 
assessment of validity and responsiveness in allowing trials to include the ICECAP measures 
and the potential that there may be resistance to using these measures until a clear precedent 
of use exists.     
  
187 | P a g e  
 
CHAPTER 6. QUANTITATIVE STUDY OF THE 
VALIDITY AND RESPONSIVENESS OF THE ICECAP 
MEASURES: METHODS 
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6.1. Chapter introduction 
This chapter reports the quantitative methods used to assess the psychometric properties of the 
ICECAP capability measures in a randomised controlled trial setting.  Two broad lines of 
investigation were conducted: 1) an investigation of construct validity and 2) an investigation 
of the responsiveness of the measure to change over time.  The reliability of the ICECAP 
measures will not be assessed in this thesis as a) the conditions do not exist for a test re-test 
analysis and b) measures of internal consistency are not suitable for the ICECAP measure 
(both points are discussed in greater depth in section 3.6.1. Reliability).  The data for this 
research was collected from the BEEP trial at Keele University, in which the ICECAP-A 
measure was included, and the PastBP trial at the University of Birmingham, in which the 
ICECAP-O was included in.  A description of these trials is given, and the process by which 
they were recruited to this research is described.  The process of evidence-based hypotheses 
formation, the hypotheses which were formed, and the statistical methods used to test these 
hypotheses are described.  The analyses used to assess the validity and the responsiveness of 
the measures are provided.  The results of the construct validity analysis can be found in 
Chapter 7 and the results of the responsiveness to change analysis in Chapter 8.    
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6.2. Trial recruitment and data 
Two medium sized multi-centre randomised controlled trials were used to assess the validity 
and responsiveness of the ICECAP-A and ICECAP-O measures.  The ICECAP measures 
were included in the baseline and follow-up questionnaire packs which were completed by 
patients.  Access to the data was granted by the trial teams for the purpose of assessing the 
psychometric properties of the ICECAP measures.   
6.2.1. Recruitment of trials to quantitative research 
The involvement and cooperation of research groups external to the PhD supervisory team 
was required to test the psychometric properties of the ICECAP measures in a randomised 
controlled trial setting.  In November, 2009 the process of “recruiting” trials to include an 
ICECAP measure began.    The objective at the start of the process was to recruit between two 
and four trials, in different clinical areas.  The trial researchers had to be willing to allow 
external analysis of data for the purpose of validating the ICECAP measures.  The primary 
challenge faced was to identify trials that were soon to start and would yield data within the 
time-span of the PhD (i.e. before summer 2013).  A two-step recruitment process was 
completed: step one focused on formally approaching trial units directly; step two sought to 
use contacts with the Health Economics Unit and the MRC Hub for Trials Methodology 
Research at the University of Birmingham, who were working with trial groups
4
. 
In the first step three trial groups were approached: Cancer Research UK Trials Unit, 
Birmingham; Birmingham Clinical Trials Unit, Birmingham and Primary Care Trials Unit, 
                                                 
4
 Unlike the qualitative research, trials were only recruited from UK institutions.  At the time of recruitment of 
trials the professional links which led to the qualitative research in Australia had not been formed.   
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Birmingham.  Trials units were approached through an email requesting assistance (Appendix 
11).  If a positive response was received then a meeting with the appropriate staff members 
was scheduled.  Positive responses were received from all units and meetings were held 
during December, 2009. 
Productive meetings were held with all three trials units.  Initially three potential trials or pilot 
studies were identified from these meetings.  A pilot study into the effects of diet modification 
on bowel cancer risk in those at risk of bowel cancer was identified.  Contact was kept with 
the trial until late 2010 when the Principal Investigator on the trial withdrew co-operation for 
using the ICECAP-A citing concerns that the content of the questions may prove upsetting or 
disturbing for participants in his trial.  A second surgical trial was discussed which looked at 
the effectiveness of a wound guard in preventing post-operative infections.  Contact was 
maintained with this trial until the surgeons on the investigative team withdrew support in 
early 2011 citing concerns about whether the ICECAP-A measure would be responsive to the 
changes that their intervention would bring about.  A third trial, the PastBP trial (described in 
detail below), was recruited to the research and provided data for this analysis.  
The second step of the recruitment was completed through the Health Economics Unit and the 
MRC Hub for Trials Methodology Research.  The Health Economics Unit completes the 
economic evaluation alongside a number of trials.  The MRC Midlands Hub for Trial 
Methodology Research conducts research into trial methodology and holds an advisory role 
with trials units.  Therefore, both groups have a number of links with trials units that were of 
potential use to this research.   Two studies were identified as potentially appropriate for 
inclusion of the ICECAP-A measure.  The first trial, assessing the efficacy of a treatment for 
non-operable liver tumours, was identified in 2009.  In the initial meeting researchers from 
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the trial voiced concern about the content of the measure, which they felt could be upsetting 
for people suffering from cancer.  Contact was kept with this trial until they declined to 
include the ICECAP-A measure in early 2010.  A second trial, the BEEP trial (described in 
detail below), was recruited to the research and provided data for this analysis.   
6.2.2. Trials agreeing to participate in quantitative research 
The characteristics of the two randomised controlled trials that agreed to participate are 
described below. 
6.2.2.1. The PastBP trial 
The PastBP study (ISRCTN 20962286) was a multicentre, randomised controlled trial, run by 
the Primary Care Trials Unit, the University of Birmingham.  The full title was ‘A 
randomised controlled trial of different blood pressure targets for people with a history of 
stroke or transient ischaemic attach (TIA) in primary care’ [279].  The primary aim of the 
PastBP trial was to determine whether ‘a more intensive target blood pressure for people with 
stroke or TIA in a pragmatic primary care setting will lead to a lower blood pressure’(p.6)[279].  
A secondary aim was to assess the impact of intensive blood pressure monitoring on quality 
of life. 
GP practices were recruited by the trial through the Primary Care Research Networks and the 
Midlands Research Practices Consortium.  Participants were identified through general 
practices, using the TIA/Stroke register.  Patients with a validated history of Stroke or TIA, a 
systolic blood pressure over 125mmHg and who were not taking three or more anti-
hypertensives were eligible for inclusion.  The intervention arm consisted of a target systolic 
blood pressure of 130 mmHg, or a 10 mmHg reduction in systolic blood pressure (BP) if the 
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subjects BP is below 140 at baseline.  The control arm had a target of 140 mmHg systolic 
blood pressure.  The intervention lasted for 12 months. 
The primary outcome of this trial was change in systolic blood pressure between baseline and 
12 month follow up.  Secondary outcomes included quality of life and adverse events.  
Follow-up was at 6 and 12 months, with intermediate follow-ups at monthly intervals between 
1 and 3 months.  The ICECAP-O measure was completed at baseline, 6 and 12 month follow-
ups.  The 12 month follow-up data were used for the analysis of responsiveness in this thesis.   
A target of 610 patients (305 in each arm) gave the trial a 90% power at a 5% confidence 
level to detect a 5mmHg difference in systolic blood pressure.  1167 patients attended 
baseline.  529 were randomised.  The low randomisation rate was due to people not meeting 
the randomisation criteria.  Specifically, the number of people who had lower than the 
required blood pressure was higher than expected.  Further details of the PastBP trial 
participants are provided at the start of both quantitative results chapters.   
The PastBP trial had a number of advantages for assessing the psychometric properties of the 
ICECAP-O measure.  First, due to the inclusion/exclusion criteria, the older people recruited 
by the trial were suitable for completing the ICECAP-O.  Second, this population also had a 
history of stroke or TIA, which indicated that they would be a less healthy sample in 
comparison to the general population.  The development of the ICECAP-O was completed 
with samples of the general population.  Therefore, the use of a clinical population offers the 
potential to establish validity in other contexts and for the triangulation of data.  The third 
advantage was that this trial had a short follow-up period and was very likely to provide data 
with the time-frame of this doctoral research.  Finally, a large number of health and health-
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related quality of life measures were completed by participants, providing ample opportunity 
to assess validity and responsiveness. 
6.2.2.2. The BEEP trial 
The BEEP trial (ISRCTN 93634563) was a multi-centre, randomised, pragmatic controlled 
trial to assess the clinical and cost-effectiveness of, and adherence to, individually tailored, 
physiotherapy led exercise interventions compared to normal physiotherapy care [280].  The 
full title of the trial was ‘Improving the effectiveness of exercise for knee pain in older adults 
in primary care: Benefits of Effective Exercise for knee Pain (BEEP)’ [280].  The trial was 
part of a collaborative link between Keele University and the University of Birmingham.  
Potential participants were identified through either a general practice record search, a survey 
of older adults registered with participating practices, or from a list of patients currently being 
referred to physiotherapy for knee pain.    
Participants were randomised to one of three groups: a control group of standard 
physiotherapy care which lasted 12 weeks; an intervention group of individually tailored 
exercise that lasted 12 weeks, including more contact sessions than standard care; and a target 
exercise adherence arm, which lasted up to 6 months [280].  Follow-up was via self-complete 
postal questionnaires completed at 3, 6, 9, 18, 36 months.  The trial randomised 526 
participants at baseline.  The 6 month follow-up data were used in the analysis of 
responsiveness.  This was the only follow-up data available within the time-frame of the 
thesis. 
Due to an administrative error, an early version of the ICECAP-A was mistakenly included in 
the baseline questionnaire packs for 70 participants.  The remaining 456 questionnaire packs 
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included the finalised version of the ICECAP-A.  The study ID’s of the 70 participants were 
identified through a manual check of paper questionnaire packs by TK.  All follow-up 
questionnaire packs received the finalised version of the ICECAP-A.  The difference between 
the early version and the final version was slight, with the word “only” being included in one 
response option for each item in the early version.  Despite descriptive analyses and simple 
statistical checks finding little or no difference between the response patterns for the two 
groups, the patients receiving the early version of the ICECAP-A were excluded from the 
analysis.  This cautious approach was followed based on the reasoning that when assessing 
the psychometric properties of a test, use of the final version is an important pre-requisite. 
The primary outcome measure for the BEEP trial was self-reported pain and functioning on 
the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire 
[281].  A number of secondary outcome measures were used including measures of pain, 
functioning, depression , anxiety and quality of life. 
This study has a number of advantages for assessing the psychometric properties of the 
ICECAP-A measure.  First, the BEEP trial population includes adults across the age spectrum 
and is therefore suitable for the ICECAP-A measure.  Second, the majority of the participants 
in BEEP have a joint problem, often due to arthritis; this is a different disease pathology to 
Stroke and TIA seen in the PastBP trial.  Third, a large number of health and health-related 
quality of life measures were completed by informants, including assessments of psychical 
and psychological health.    
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6.2.2.3. Measures included in trials 
A number of self-report measures were included in the BEEP and PastBP trials, the data from 
which were provided for this validity and responsiveness analysis.  The measures are 
summarised in Table 6. 
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Table 6: Self-report outcome measures included in BEEP and PastBP trials and used in quantitative analyses 
Construct Measure Description Trial containing 
measure 
General health EQ-5D-3L The EQ-5D-3L is a generic preference based outcome measure, which measures health-related 
quality of life [142,143,282,283] (Appendix 12).  The descriptive system comprises: mobility, 
self-care, usual activities, pain and discomfort, and anxiety and depression [284], with three 
response options in each dimension.  It is scored via a preference weighted algorithm, which for 
UK values produces a score between -0.59 and 1.  The EQ-5D-3L has been extensively validated 
in numerous clinical settings [285–287].   
BEEP 
PastBP 
General health SF-36 The SF-36 is a survey of patient health status consisting of eight sub-scales [144] (Appendix 13). 
The sub-scales are: physical functioning, physical role, bodily pain, general health, vitality, 
social functioning, emotional role and mental health.  Each scale is calculated from a number of 
questions within the questionnaire which are given equal weight during the transformation of the 
scale onto a 0 to 100 scale.  These 0 to 100 scales can be transformed into a T-scores, in line with 
normal practice for scoring of the SF-36 [288].  A T-score has the advantage of standardising 
scores against a population norm which is fixed at 50.  This allows easier interpretation of scale 
scores (e.g. below 50 on any scale is a worse health state than the population norm) and has the 
advantage that published minimally important differences can be used.  The disadvantage of 
using T-scores is that US population norms have to be used [289].  The measure has been 
extensively validated in a number of different clinical and administrative settings [286,290].  It is 
possible to calculate SF-6D from this measure.  Although this wasn’t done here as it would have 
resulted in a loss of information provided by the sub-scales 
PastBP 
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Symptoms/ 
side-effects and 
co-morbidities 
Non-
validated 
measures 
used 
Symptoms and side-effects  or co-morbidity data was collected by both trials. The BEEP trial 
asked a total of 10 questions on co-morbidities (Appendix 14).  In the PastBP trial a total of 24 
questions were asked about symptoms and side effects (Appendix 15).  Differences other than 
the number of questions asked existed between the two questionnaires.  The Past BP asked it the 
participant had experienced symptoms, while the BEEP trial asked if the participant had ever 
been told they had any of the following.  The PastBP trial included minor side-effects such as 
sore throat, while the BEEP trial focused on serious comorbidities such as heart attack, diabetes 
and depression. 
BEEP 
PastBP 
Mobility and 
physical 
functioning 
WOMAC The WOMAC is a widely used set of standardised questions suitable for evaluating the condition 
of patients with osteoarthritis of the knee and hip (Appendix 16) [281,291].  The measure has 3 
sub-scales: pain, assessed by 5 questions; stiffness, assessed by 2 questions; and physical 
functioning assessed by 17 questions.  The range of values for each sub-scale is: pain 0 to 20, 
stiffness 0 to 8, functioning 0 to 62.  All questions carry equal weight in the calculation of sub-
scale values.  The measure has been validated against other measures of health and for use in 
different clinical and administrative settings [281,291–293]. 
BEEP 
Illness 
perception 
Brief IPQ The Brief Illness Perception Questionnaire (IPQ) assesses patients’ ideas and perceptions of their 
illnesses or conditions [294].  The questionnaire is designed so it can be adapted so as to ask 
about the ideas and perception of a specific illness or condition, in this case knee pain, through a 
simple re-wording of the questionnaire (Appendix 17).  For example, the question “How much 
does your knee pain effect your life, could be tailored to ask about cancer simply by replacing 
“knee pain” with “cancer” at the appropriate point.  There is some, limited, evidence of validity 
and reliability for the Brief IPQ [294].    
BEEP 
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Psychological 
health 
GAD-7 
PHQ-8 
The Generalised Anxiety Disorder Assessment (GAD-7) and the Patient Health Questionnaire 
depression scale (PHQ-8) (Appendix 18) are two short questionnaires that assess anxiety [295] 
and depression [296] respectively, which have validity portfolios [296,297].  They are frequently 
used in clinical practice.  The value range is from 0 to 21 for the GAD-7 and 0 to 24 for the 
PHQ-8.  Both measures have clinically meaningful cut-offs of 8 for the GAD7 indicating 
possible anxiety disorder and 10 for the PHQ-8 indicating possible depression.   
BEEP 
Disability Modified 
Rankin 
Scale 
The Modified Rankin Scale is a scale for measuring disability or dependence in the activities of 
daily living in people that have suffered neurological impairment [298].  The scales ask the 
participant to rank themselves on a 0 to 5 scale describing the physical situation.  The 
psychometric properties of the measure have been assessed [299]. 
PastBP 
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6.3. Assessing the construct validity of the ICECAP 
measures  
Validation is an on-going process of building the “validity portfolio” of a measure through the 
use of rigorous and scientifically sound methodology [200].  Current best practice states that 
this should be completed through developing evidence-based hypotheses and subjecting these 
to extended testing and analysis [205,212].  
6.3.1. Hypothesis formation 
A rigorous method of evidence-based hypothesis formation was followed.  Data from the 
review of development and validation studies of the ICECAP-A and ICECAP-O reported in 
Chapter 2 were used to assist hypothesis formation.  These data consisted mainly of 
quantitative evidence, which related both directly and indirectly to the comparator measures 
in the BEEP and PastBP studies.  For example: previous studies have used the EQ-5D-3L as a 
comparator in validation studies, and the EQ-5D-3L measure was included in both the BEEP 
and PastBP trial.  In this situation data could be used directly to inform hypothesis formation.  
Previous studies have also used measures, such as the Short Physical Performance Battery.  
This measure was not included in either the BEEP trial or the PastBP trial, but is closely 
related to measures, such as the Modified Rankin Scale.  In this situation data could be used 
indirectly to inform hypothesis formation.  
The collated information from the review was compiled by TK and presented to three 
investigators (TK,JC,HAJ), along with a list of the comparators in each of the trials being 
used in the research.  Investigators independently formed hypotheses of the associations 
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between a comparator measure (i.e. the EQ-5D-3L, SF-36 etc), as well as sub-sections or 
items of the comparator, and the ICECAP-A or ICECAP-O tariff score, as well as individual 
item scores of the ICECAP measures.  Each indicated a) whether they thought an association 
would be found, b) the direction of the association or correlation and c) for the EQ-5D-3L 
measure, which associations and relationships would be the strongest.  For example: all 
ICECAP-A items may be expected to associate with the mobility item on the EQ-5D-3L, but 
the association with the ICECAP-A item of Autonomy with the mobility item might be 
expected to be the strongest. 
The individual hypotheses were then collated through a predefined process (see Figure 12).  
When all three investigators agreed that an association between the ICECAP tariff or item and 
the comparator measure was expected, this hypothesis was confirmed for testing.  If any 
investigator did not expect an association, the hypothesis was not confirmed for testing.  In 
the situation where investigators expected associations in different directions, this was 
discussed collaboratively (it was normally due to a misunderstanding of the direction of the 
scoring of the comparator measures). 
The three people who participated in the hypothesis formation had an in depth knowledge of 
the capability approach, development of the ICECAP measures and validation efforts to date.  
The hypotheses presented below were therefore formed based both on the theoretical 
knowledge of the investigators and the results from the methodological review. 
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Figure 12: The process of hypothesis formation 
  
Methodological review (Chapter 2) synthesises existing 
evidence of ICECAP measure validity. 
TK and supervisors (JC and HAJ) consider evidence and 
independently form hypotheses about how ICECAP scores 
and items would associate with comparator measures. 
TK compiles the independently 
formed hypotheses, to allow 
confirmation of hypotheses for 
testing. 
One or more investigators 
did not expect an 
association. 
All investigators expected 
an association. 
Hypothesis was not 
confirmed for 
investigation. 
Hypothesis was confirmed 
for investigation. 
Collaborative 
meeting to confirm 
direction of 
hypotheses 
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6.3.1.1. Results of the hypothesis formation 
There was a high level of agreement amongst the three investigators forming hypotheses.  For 
the ICECAP-A analysis, using BEEP trial data, investigators formed 8 hypotheses on how the 
ICECAP-A value tariff would associate with other measures and 70 item-by-item hypotheses.  
Full agreement was found between the three investigators on the 8 ICECAP-A value tariff 
scores.  For the item-by-item hypotheses 10 disagreements were found and these hypotheses 
were not confirmed for testing.  Therefore the overall agreement rate was 87%.  For the 
ICECAP-O analysis, using PastBP trial data, researchers formed 12 hypotheses about how the 
ICECAP-O value tariff would associate with other measures and 101 item-by-item 
hypotheses.    Full agreement was found on the ICECAP-O tariff values scores.  18 
disagreements were found for the item-by-item analysis and these hypotheses were not 
confirmed for testing.  Therefore the overall agreement rate was 84%. 
6.3.2. Hypotheses 
The a priori hypotheses for each trial are reported below.  Hypotheses for the overall 
ICECAP score and individual items of the ICECAP measure are described.   Appendix 19 and 
Appendix 20 show the detailed breakdown of these hypothesised associations including the 
expected direction of the association (taking account of the coding of the items and tariffs) 
and, for the EQ-5D-3L measure in both studies, which item would show the strongest 
association with each item of the ICECAP-A measure. 
6.3.2.1. BEEP trial 
Table 7 shows the hypothesised associations between the ICECAP-A value tariff and items 
and the physical, psychological and socio-demographic comparator measures.  For each 
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ICECAP-A item, the phrasing of the highest response option of the item and a brief summary 
of the theoretical framework that surrounds this item, taken from Al-Janabi et al [115], is 
presented.  The hypothesised associations between both the overall ICECAP-A score and the 
individual items of the ICECAP-A measure and measures of physical health, psychological 
health and socio-demographic variables are given.
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Table 7: Hypothesised associations between ICECAP-A value tariff and item scores and comparator measures 
ICECAP-A attribute and description 
from Al-Janabi et al (2012) 
Physical comparators Psychological comparators Socio-demographic comparators 
Overall ICECAP-A tariff It was hypothesised that the overall 
ICECAP-A tariff score would be 
associated with measures of physical 
health.  Higher levels of pain (EQ-5D-
3L and WOMAC) were expected to 
associate with lower tariff scores.  High 
levels of mobility (EQ-5D-3L) and 
physical functioning (WOMAC) were 
anticipated to be linked with higher 
ICECAP-A tariff scores.  General 
health (EQ-5D-3L overall score) was 
expected to be positively associated 
with the tariff score.  The ability to care 
for oneself and perform ones usual 
activities (EQ-5D-3L) was expected to 
associate with the tariff score. 
It was expected that the overall 
ICECAP-A tariff score would be 
associated with measures of 
psychological health.  High levels of 
anxiety and depression (EQ-5D-3L), 
anxiety (GAD-7) and depression 
(PHQ-8) were anticipated to be 
associated with low levels of overall 
capability. 
 
It was expected that the overall 
ICECAP-A score would be associated 
with increasing age.  Elderly 
individuals were anticipated to have 
lower levels of capability.  No 
association was expected between 
gender and the ICECAP-A tariff score.    
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ICECAP-A attribute and description 
from Al-Janabi et al (2012) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Stability attribute, phrased “I am 
able to feel settled and secure in all 
areas of my life”, refers to the ability to 
live without stress, feeling threatened 
or dramatic changes in one’s life and 
the ability to have continuity and attach 
meaning to life.  This capability 
attribute was thought to be affected by 
health, unemployment, consistent 
relations with friends and family and 
secure work and finances [115]. 
It was hypothesised that measures of 
physical health would be associated 
with the Stability item.  Poor physical 
health was expected to make people 
feel less secure and stable due the 
worry and concern that it causes.  This 
may occur through making people less 
able to work and maintain a regular and 
secure wage.  It was anticipated that 
having greater mobility and ability to 
self-care for oneself (EQ-5D-3L) and 
higher levels of physical functioning 
(WOMAC) would be associated with 
higher levels of Stability.  High levels 
of pain (EQ-5D-3L and WOMAC), 
stiffness and functioning (WOMAC) 
were anticipated to associate with 
lower levels of Stability. 
It was predicted that measures of 
psychological health would be 
associated with the Stability item.  
Feelings of anxiety, worry and 
depression were thought to reduce a 
person’s ability to feel settled and 
secure.  It was expected that higher 
levels of anxiety and depression (EQ-
5D-3L), anxiety (GAD-7) and 
depression (PHQ-8) would be 
associated with lower levels of 
Stability. 
Stability was not expected to be 
associated with gender or age. 
206 | P a g e  
 
ICECAP-A attribute and description 
from Al-Janabi et al (2012) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Attachment attribute, phrased as 
“I can have a lot of love, friendship and 
support”, refers to the capability to be 
close to people, experience affection 
and have a sense of belonging.  Sources 
of these feelings include ability to 
interact with friends, family and 
partners, as well as the quality of these 
interactions.  It is therefore closely 
linked to the presence of family, friends 
and partners and events that bring 
family closer together [115]. 
It was not hypothesised that measures 
of physical health would be associated 
with the Attachment item.  Evidence 
from the ICECAP developmental work 
indicated that poor physical health of 
an individual might strengthen 
relationships and draw people closer 
together, while the initial validation 
work showed mixed results under the 
Attachment item.   
It was not hypothesised that 
Attachment would associate with 
measures of psychological health.  
There was considerable lack of 
agreement in the hypotheses 
researchers formed.  This disagreement 
was likely due conflicting findings in 
the previous literature highlighted by 
the review and presented to 
researchers. 
Attachment was not expected to be 
associated with gender or age. 
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ICECAP-A attribute and description 
from Al-Janabi et al (2012) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Autonomy attribute, phrased “I 
am able to be completely independent”, 
refers to the ability to be independent, 
look after oneself and not feel a 
liability to others.  It is closely linked to 
poor health which might impact a 
person’s ability to complete basic 
activities and corrode their sense of 
identity [115]. 
It was hypothesised that Autonomy 
would be closely associated with 
measures of physical health.  Good 
physical health is an important pre-
requisite and determinant of 
independence.  It was anticipated that 
greater mobility and self-care (EQ-5D-
3L) and physical functioning 
(WOMAC) would be associated with 
higher levels of Autonomy.  It was 
expected that these measures of 
physical health and functioning would 
show a stronger association with 
Autonomy than other ICECAP-A 
items.  High levels of pain (EQ-5D-3L 
and WOMAC) and stiffness 
(WOMAC) were expected to associate 
with lower levels of Autonomy. 
The ability of a person to complete 
their usual activities, a measure of 
independence in the activities of daily 
living, was thought to assess a similar 
domain of quality of life to the 
Autonomy item.  Therefore, greater 
ability to complete usual activities (EQ-
5D-3L) was expected to associate 
strongly with Autonomy. 
It was hypothesised that measures of 
psychological health would be 
associated with Autonomy.  Poor 
psychological health may reduce an 
individual’s ability to look after 
themselves and make decisions.  High 
levels of anxiety and depression (EQ-
5D-3L, GAD-7 and PHQ-8) were 
expected to associate with lower levels 
of Autonomy. 
It was hypothesised that increased age 
would be associated with 
independence.  Therefore the socio-
demographic variable of age was 
expected to associate with Autonomy. 
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ICECAP-A attribute and description 
from Al-Janabi et al (2012) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Achievement attribute, phrased “I 
can achieve and progress in all aspects 
of my life”, refers to the ability of 
people to move forward in order to 
achieve goals in their lives, as well as 
to look back with a sense of satisfaction 
on their achievements.  It is closely 
linked to opportunities that exist at 
work and participation in voluntary 
activities and sport [115].   
It was expected that the Achievement 
item would be associated with 
measures of physical health.  Poor 
physical health was expected to reduce 
the activities that a person is able to 
participate in (i.e. work, voluntary 
roles, child care).  Higher levels of 
mobility and self-care (EQ-5D-3L) and 
physical functioning (WOMAC) were 
anticipated to be associated with higher 
levels of Achievement capability.  
Lower levels of Achievement 
capability were anticipated to associate 
with higher levels of pain (EQ-5D-3L 
and WOMAC) and stiffness 
(WOMAC). 
The ability of a person to complete 
their usual activities (EQ-5D-3L), a 
measure of independence in the 
activities of daily living, was expected 
to associate strongly with 
Achievement. 
It was hypothesised that measures of 
psychological health would be 
associated with Achievement.  Poor 
psychological health, such as feelings 
of anxiety and depression, may reduce 
a person’s ability to achieve and 
progress in their life.  High levels of 
anxiety and depression (EQ-5D-3L) 
were expected to associate with lower 
levels of Achievement
5
. 
Achievement was not expected to be 
associated with age or gender. 
                                                 
5
 Due to what appeared to be inconsistency in a researchers hypothesis formation, GAD-7 and PHQ-8 was not confirmed for testing due to disagreement, whereas the 
EQ-5D-3L item of anxiety and depression was confirmed for testing. 
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ICECAP-A attribute and description 
from Al-Janabi et al (2012) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Enjoyment attribute, phrased “I 
can have a lot of enjoyment and 
pleasure”, refers to the ability of people 
to enjoy pleasurable and fun activities 
and live free of depression and pain.  
The capability for enjoyment was 
dependent upon a range of influences 
from friends and family to financial 
activities and poor health [115]. 
It was hypothesised that the Enjoyment 
item would be associated with 
measures of physical health.  Good 
health may increase enjoyment through 
the enabling of enjoyable activities and 
increasing the quality of those 
activities.  Higher levels of mobility 
and self-care (EQ-5D-3L) and physical 
functioning were predicted to associate 
with higher levels of Enjoyment 
capability.  High levels of pain (EQ-
5D-3L and WOMAC) and stiffness 
(WOMAC) were expected to associate 
with lower levels of Enjoyment and 
this association was expected to be 
stronger than for other ICECAP-A 
items. The activities and action of life 
should be a source of enjoyment.  
Therefore, the ability of a person to 
complete their usual activities (EQ-5D-
3L), a measure of independence in the 
activities of daily living, was expected 
to associate with Enjoyment. 
It was hypothesised that measures of 
psychological health would be 
associated with Enjoyment.  Anxiety 
and depression was expected to reduce 
the enjoyment someone finds in their 
life.  High levels of anxiety and 
depression (EQ-5D-3L, GAD-7 and 
PHQ-8) were anticipated to be 
associated with low levels of 
Enjoyment.  It was anticipated that this 
association of psychological health 
with Enjoyment would be stronger than 
for other ICECAP-A items. 
Enjoyment was not expected to be 
associated with age or gender. 
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6.3.2.2. PastBP trial 
Table 8 shows the hypothesised associations between the ICECAP-O value tariff and items 
and the comparator measures.  For each ICECAP-O item, the phrasing of the highest response 
option of the item and a brief summary of the theoretical framework that surrounds this item, 
taken from Grewal et al [109], is presented.  The hypothesised associations between both the 
overall ICECAP-O score and the individual items of the ICECAP-O measure and measures of 
physical health, psychological health and socio-demographic variables are given.
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Table 8: Hypothesised associations between ICECAP-O value tariff and item scores and comparator measures 
ICECAP-A attribute and description 
from Grewal et al (2006) 
Physical comparators Psychological comparators Socio-demographic comparators 
Overall ICECAP-O tariff It was hypothesised that the ICECAP-O 
tariff score would be associated with 
measures of physical health.  Higher 
levels of pain (EQ-5D-3L and SF-36) 
were expected to associate with lower 
capability scores.  High levels of 
mobility (EQ-5D-3L) and physical 
functioning (SF-36) were anticipated to 
be linked with higher levels of overall 
capability.  High levels of disability 
(MRS) were expected to associate with 
low ICECAP-O scores.  General health 
(EQ-5D-3L overall score and SF-36) 
was expected to be positively 
associated with overall capability.  The 
ability to care for oneself and perform 
ones usual activities (EQ-5D-3L) was 
expected to associate with the overall 
capability score. 
It was expected that the overall 
ICECAP-O score would be associated 
with measure of psychological health.  
High levels of anxiety and depression 
(EQ-5D-3L) was anticipated to be 
associated with low levels of overall 
capability.  Higher levels of mental 
health, emotional functioning and 
vitality (SF-36) were expected to be 
associated with higher ICECAP-O 
tariff scores.   
 
It was anticipated that the overall 
ICECAP-O score would be associated 
with the socio-demographic variable of 
age, but not gender. 
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ICECAP-A attribute and description 
from Grewal et al (2006) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Attachment attribute, phrased “I 
can have all the love and friendship that 
I want”, refers to the ability of people 
to experience of love, friendship and 
affection and have a sense of 
companionship.  The sources of this are 
thought to be partners, family, friends 
and in some cases, owning pets [109]. 
 
It was not hypothesised that the 
Attachment item would be associated 
with measures of physical health.  
Feelings of love and affection were not 
thought to be dependent upon health.  
Evidence from the Attachment item in 
the ICECAP-A offers limited evidence 
that poor health may pull a family and 
friends closer together. 
It was not hypothesised that measures 
of psychological health would associate 
with the Attachment item.  There was 
notable disagreement between 
investigators during the hypothesis 
formation in this area, possibly 
generated by inconsistencies in 
previous data, with some studies 
showing associations and other not.  
However social function and emotional 
role, which are scales in the 
psychological summary section of the 
SF-36, were expected to associate with 
Attachment. 
Attachment was not expected to be 
associated with age or gender. 
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ICECAP-A attribute and description 
from Grewal et al (2006) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Security attribute, phrased “I can 
think about the future without any 
concern”, refers to the ability to feel 
safe and secure, living without worry 
and not having feelings of 
vulnerability.  It is thought to be 
affected by having sufficient finances, 
practical and emotional support and 
good health [109]. 
It was hypothesised that measures of 
physical health would associate with 
the Security item.  Physical health 
problems are likely to cause greater 
worry and concern and reduce the 
feelings of security that a person is able 
to experience.  It was anticipated that 
high levels of self-care (EQ-5D-3L), 
physical functioning, physical role and 
general health (SF-36) would be 
associated with higher levels of 
Security.  Being in physical pain (EQ-
5D-3L and SF-36) or reporting high 
levels of disability (MRS) was 
expected decrease feelings of security. 
It was anticipated that measures of 
psychological health would associate 
with the Security item.  Feelings of 
anxiety, worry and depression were 
expected to reduce a person’s ability to 
think about the future without concern.  
High levels of anxiety and depression 
(EQ-5D-3L) and low levels of mental 
health (SF-36) were expected to 
associate with lower levels of Security. 
 
Security was not expected to be 
associated with age or gender. 
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ICECAP-A attribute and description 
from Grewal et al (2006) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Role attribute, phrased “I am able 
to do all the things that make me feel 
valued”, refers to the ability an 
individual to feel valued by others, as 
well as themselves.  This attribute is 
closely linked to having a purpose or 
doing something worthwhile [109]. 
It was hypothesised that measures of 
physical health would associate with 
the Role item.  Poor physical health can 
restrict the ability of people to fulfil 
roles or achieve activities which make 
them feel valued.  Lower levels of 
mobility, self-care (EQ-5D-3L), 
physical functioning, role physical and 
general health (SF-36) were expected 
to associate with lower scores on the 
Role attribute.  High levels of pain 
(EQ-5D-3L and SF-36)  or high levels 
of disability (MRS) were expected to 
associate with lower scores on the Role 
item. 
The usual activities item (EQ-5D-3L) is 
an assessment of the ability to complete 
everyday activities, including work and 
family activities.  It was expected that 
this item would associate strongly with 
the ability to do things that make you 
feel valued.  Therefore, high scores on 
the usual activities item were 
hypothesised to associate strongly with 
high scores on the Role item.  
It was hypothesised that measures of 
psychological health would be 
associated with the Role item.  Low 
levels of anxiety and depression (EQ-
5D-3L) and high levels of vitality, 
social functioning, role emotional and 
mental health (SF-36) we expected to 
associate with high levels of Role.   
Role was not expected to be associated 
with age or gender. 
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ICECAP-A attribute and description 
from Grewal et al (2006) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Enjoyment attribute, phrased “I 
can have all of the enjoyment and 
pleasure that I want”, refers to the 
ability to experience pleasure and joy 
and a sense of satisfaction.  The 
sources of these feelings are expected 
to be both personal and communal 
activities [109]. 
It was anticipated that measures of 
physical health would associate with 
the Enjoyment item.  Good health may 
increase enjoyment through the 
enabling of enjoyable activities and 
increasing the quality of those 
activities.  While side effects of poor 
health, such as pain and fatigue, may 
reduce the enjoyment a person has in 
their life.  High levels of mobility, self-
care (EQ-5D-3L), physical functioning, 
role physical and general health (SF-
36) were expected to associate with 
high levels of Enjoyment.  High levels 
of pain (EQ-5D-3L and SF-36) were 
anticipated to associate with low levels 
of Enjoyment and this association was 
expected to be stronger than for other 
ICECAP-A items.   
 
It was hypothesised that measures of 
psychological health would associate 
with Enjoyment.  Feelings of anxiety 
and depression would likely reduce the 
level of enjoyment in an individual’s 
life.  High levels of anxiety and 
depression (EQ-5D-3L) were expected 
to associate with low levels of 
Enjoyment, while high levels of 
vitality, social functioning, role 
emotional and mental health (SF-36) 
were expected to associate with high 
levels of Enjoyment.  These 
associations with Enjoyment were 
expected to be stronger than for other 
ICECAP-O items. 
Enjoyment was not expected to be 
associated with age or gender 
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ICECAP-A attribute and description 
from Grewal et al (2006) 
Physical comparators Psychological comparators Socio-demographic comparators 
The Control attribute, phrased “I am 
able to be completely independent”, 
refers to the ability of a person to be 
independent and make their own 
decisions.  Influences upon this 
attribute are thought to be 
psychological and physical health, as 
well as having sufficient means and 
finances so as not to rely on others 
[109]. 
It was anticipated that measures of 
physical health would associate with 
the Control item.  Poor physical health 
may increase the need for people to 
rely on others and reduce their ability 
to complete tasks independently.  High 
levels of mobility, self-care (EQ-5D-
3L), physical functioning, role physical 
and general health (SF-36) were 
expected to associated with high levels 
of Control.  High levels of pain (EQ-
5D-3L and SF-36) and high levels of 
disability (MRS) were anticipated to 
associate with low levels of Control.  It 
was hypothesised that measures of 
physical functioning would show a 
stronger association with control than 
with other items in the ICECAP-O. 
The ability to complete the normal 
actions of everyday living is a large 
part of independence.  The usual 
activities (EQ-5D-3L) item was 
expected to associate strongly with 
Control. 
It was hypothesised that measures of 
psychological health would be 
associated with control.  Feelings of 
anxiety, depression or emotional 
instability would like reduce the control 
an individual feels that they can 
exercise upon their life.  High levels of 
anxiety and depression (EQ-5D-3L) 
and low levels of vitality, social 
functioning, role emotional and mental 
health (SF-36) were expected to 
associate with low levels of Control.  
It was hypothesised that older 
individuals would have lower levels of 
independence.  Therefore, increasing 
age was expected to associate 
negatively with levels of Control 
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6.3.3. Statistical analyses used in validity analysis 
6.3.3.1. Descriptive statistics 
The mean values of the measures included in the baseline questionnaire pack were used to 
describe the characteristics of the sample used in the analysis.  The feasibility of the measure 
for use was assessed using the completion rates of measures and the item-by-item missing 
values.  An assessment of potential ceiling effects was completed using the distributions of 
responses (the response profile) across each of the levels of the ICECAP-A.  These were 
considered alongside values from the general population for comparison.  The full assessment 
of the ceiling effect, described in Section 3.5.5. Floor and Ceiling Effect, was not possible due 
to the lack of other capability measures in these trials that could act as comparators. 
6.3.3.2. Correlation coefficient 
Correlation coefficients can be used to assess the strength of the association between two 
continuous variables.  In this thesis they were used to assess the strength of the association 
between the ICECAP tariff scores and other measures with an outcome as a continuous 
variable.  Pearson’s correlation coefficient was used for data that were normally distributed 
and did not show skew [300].  Spearman’s rank correlation coefficient was used for data that 
showed deviation from normality [301].  Correlation values less than 0.3 were described as 
weak, values from 0.3 to 0.6 were described as moderate and values of 0.6 and above were 
described as strong.  Goodman and Kruskal’s Gamma is a measure of rank correlation [302].  
It provides an indication of the strength and direction of association when both variables are 
ordinal.  It provides values ranging from +1 to -1, with -1 being a perfect negative correlation. 
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6.3.3.3. ANOVA 
One-way analysis of variance (one way ANOVA) can be used to compare the mean of a 
continuous variable across three or more groups [303].  One way ANOVA was used to assess 
the mean tariff scores of the ICECAP measures across groups formed by using the levels of 
items in other measures.  For example, the relationship between the means of the ICECAP-A 
tariff value across the three levels of the mobility item of the EQ-5D-3L.  Where the 
continuous variable was not normally distributed, the Kruskal-Wallis analysis of variance was 
used.  To assess differences in ICECAP-A and ICECAP-O tariff scores between consecutive 
levels of EQ-5D-3L items, Kruskal-Wallis multiple groups comparison was used.  
6.3.3.4. Chi-square 
Chi-square tests allows the assessment of the presence of association between categorical 
variables [303].  In this thesis they were used to assess associations between the ICECAP 
items and the items of another measure.  Where appropriate, and when computationally 
feasible, the Fisher’s exact test was used.   
6.3.3.5. Factor analysis 
Factor analysis is a statistical test based on the premise that a battery of questions can be 
described based on a smaller number of underlying factors [184].  Factor analysis describes 
variability amongst a number of variables or items through the use of a smaller number of 
unobserved variables, known as factors [138].  If a scale is uni-dimensional then one factor 
should explain the variance accurately [138].  Factor analysis can also be used to test the 
assumption that a pool of items assesses different underlying factors.  For example, Davis et 
al [173] used factor analysis to determine whether the five constructs of the EQ-5D-3L and the 
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five constructs of the ICECAP-O measure assessed different underlying factors.  Factor 
analysis was used to further investigate the association between ICECAP items and items on 
the EQ-5D-3L.      
Factor analysis assumes that variables are continuous and follow a normal distribution.  When 
using categorical variables factor analysis can be performed using a polychoric distribution, 
which was used in this thesis.  The number of factors retained was chosen with reference to 
the Kaiser Criterion [304], which advocates retaining factors with Eigen Values greater than 1 
and using the scree plot to assess the suitability of this choice.  An oblique Promax rotation 
[305] was used, which allows for the potential that factors are correlated [138].  Correlations 
between factors equal to or greater than 0.32 is considered the point at which oblique rotations 
are appropriate [306].    
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6.4. Assessing the responsiveness of the ICECAP measures 
6.4.1 A methodological note 
As discussed in greater depth in Section 3.6 a number of methodological challenges exist 
when seeking to assess the responsiveness of a capability measure in a trial setting.  These 
challenges mean that this responsiveness analysis is designed to assess changes in scores of 
the ICECAP measures when a change in health occurs within a randomised controlled trial; 
not how they respond to changes in capability.  While some assumptions can be made that a 
change in health may have resulted in a change in capability, no firm conclusion can be 
drawn.  Efforts were made to assess the change in ICECAP scores when a minimally 
important change in health occurred, but this does not allow assessment of a minimally 
important difference in ICECAP measure scores.  Unlike the validity analysis, which drew 
upon previous cross-sectional studies, there is no precedent of testing the responsiveness of an 
ICECAP measure using longitudinal data.  Due to its novel nature, the analysis is exploratory, 
with a focus on understanding how the ICECAP measures changed with measures of health.  
With this aim, numerous anchors (more than may have been used had previous 
responsiveness data been available to guide and inform the analysis) have been used to 
provide a greater breadth of results, which might inform future analyses.   
6.4.2. Anchor-based analysis 
Baseline and follow-up data from the PastBP trial and BEEP trial were used to explore 
responsiveness.  Participants who had completed both baseline and follow-up assessments 
were included in the analysis.  An anchor based analysis was completed using measures from 
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the trials which were administered at baseline and follow-up.  Appropriate statistical analyses 
were completed (below).  An item by item descriptive analysis of the changes in response 
profile was completed.  
6.4.2.1. Anchor selection 
An anchor based approach uses anchor measures to assign participants to groups reflecting 
some degree of change between baseline and follow-up in the anchor measure [261].  In line 
with recommendations multiple anchors were used to assess the responsiveness of the 
ICECAP measures [251,260,261].  Revicki [260,261] indicates that when choosing anchors, 
as a rule of thumb, change correlations of 0.3 are required between the change scores of the 
anchor and the measure under consideration, although alternative (lower) correlation 
thresholds may be acceptable in some situations.  In line with this advice, anchors were 
chosen using four considerations: a) cross-sectional correlations at baseline and follow-up 
between the measures, b) the change correlation between the measures, c) theoretical or 
methodological reasons for using the anchor and d) expectation that the analysis using the 
anchor might increase the understanding of the ICECAP measures. 
The choice of anchor is an integral part of the responsiveness analysis and is therefore 
reported in detail as part of the responsiveness results.  The analysis has to be started for the 
anchors to be chosen and it is not appropriate to report this in the methods.  Justification and 
explanation for the choice of individual anchors is provided in the results. 
6.4.2.2. Anchor group formation 
For each chosen anchor, groups that have improved or worsened were defined.  Three 
methods were used to define these groups.  First, some measures produce easily defined 
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groups which can be used.  For example, the Modified Rankin Scale is a single item measure 
with 5 response options.  Each response option can be used to provide 5 groups, which have 
changed by varying degrees for analysis.   
Second, published minimally important differences (MID) in the anchor were used to define 
groups that had changed (increased or decreased) by equal to or greater than the minimally 
important difference.  These were groups of people who have experienced change equal to or 
greater than MID (mean change in these groups were greater than the MID and this mean 
change is presented in the analysis).   
Third, when MID values were not available in the literature, and a naturally occurring group 
was not present, the inter-quartile range was used to define groups.  The inter-quartile range is 
the values between which the middle 50% of a distribution lies.  When groups were formed 
using the inter-quartile range, the change groups represented the upper and lower 25% of the 
distribution.  When it was not appropriate to use the inter-quartile range, and a minimally 
important difference value was not available, an arbitrary value was selected.  No assumptions 
should be made about the importance of this change.   
The method by which the anchors groups were formed is reported in the methods.  The value 
used, the academic source which provided this value is reported and the subsequent outcome 
of this group’s formation is reported for each anchor. 
6.4.3. Methods for assessing responsiveness  
Descriptions of BEEP and PastBP participants used are provided at the start of each trial 
analysis.    The sample of participants used in this analysis is taken from the same pool of 
participants that was used to assess cross-sectional validity presented in Chapter 7.  No 
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selection of participants was made and all complete data available was used in this analysis.  
Participant drop out and loss to follow-up meant that sample characteristics may differ from 
the sample used in the validity analysis in Chapter 7 and between baseline and follow-up. 
Participants included in analyses in this chapter had completed the ICECAP measure and 
comparator measures at baseline and follow-up.  Participants who failed to complete a 
measure were excluded from the analysis using that anchor measure, but may have been 
included in analyses using other anchors if they completed those measures.  Differences in the 
rate of measure completion meant that numbers in each individual analysis varied. 
For each anchor included in the analysis of responsiveness, three analyses were completed: an 
item-by-item analysis, an analysis using the non-value weighted scores of the ICECAP 
measures and an analysis using the value weighted ICECAP-O tariff score.   
6.4.3.1. Item-by-item analysis 
It is likely that changes in different aspects of health and physical functioning will have a 
differing effect upon the items of the ICECAP measure.  A response profile was used to 
assess this change.  The response profile is the spread of responses across each level of each 
item.  It is measured and expressed through calculating the percentage of respondents 
answering each level for each item.  This was calculated at baseline and follow-up.  Change in 
response profiles between baseline and follow-up was analysed in groups which had 
improved or worsened in anchor measure scores.  Analysis of the change in response profile 
provided an indication of which items were the “drivers” of change in the overall measure. 
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6.4.3.2. Non-weighted ICECAP score analysis. 
The sum of the item scores for each participant was calculated without applying the 
preference weighting used to transform the item scores into a tariff score.  This provides a 
non-value weighted ICECAP score.  The correlation of this score with the anchor scores and 
change in this score by change groups in the anchor measures was analysed.  Such an analysis 
of the non-weighted scores of a preference measure is an important step as it takes the 
question of whether a change is valued out of the analysis [259].  This non-weighted analysis 
allows the assessment of whether the descriptive system of the measure is responsive.   
6.4.3.3. ICECAP value tariff analysis 
The value weighted ICECAP tariff scores were calculated at baseline and follow-up and 
subsequently change scores were calculated.  The correlation of the score with the anchor 
scores and the change in the score by change groups in the anchor measures was analysed.  
Comparison between the result of this analysis and the results of an analysis using the non-
weighted scores, gives an indication of how adding the value of the scores to the measure 
might change the overall responsiveness. 
6.4.4. Statistical analyses used in responsiveness analysis 
6.4.4.1. Describing change 
In this thesis, when describing the magnitude of change in ICECAP tariff score a standardised 
descriptive structure of “large”, “moderate”, “small” and “minor” changes was used to 
quantify change.  These labels do not imply whether the change is important, meaningful or 
significant, rather they offer a structure to describe and discuss change.  Minor changes are 
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defined as less than 0.01 changes, small changes are defined as change between 0.01 and 
0.03, moderate changes are changes between 0.03 and 0.08 and large change were changes 
over 0.08. 
Alongside actual change on a measure, change is reported as a percentage of possible change 
on the measures.  This has the effect of standardising change and allowing comparison 
between non-weighted scores and tariff scores and between different measures.  For example: 
the range of the tariff score of the ICECAP measure is 0 to 1, for the EQ-5D-3L index 
measure it is -0.59 to 1.  The standardisation of change through the following equation allows 
the size of change to be compared between the two: 
 Change as a percentage of possible change = (change/range measure) * 100  
6.4.4.2. Correlations 
As described above, correlations were used to inform the selection of anchors for the analysis.  
They also provide a useful indication of the association between the anchor and ICECAP 
measure.  Baseline and follow-up cross-sectional correlations and change correlations were 
calculated for all anchors.  Pearson’s correlation coefficient was used for data that were 
normally distributed and did not show skew [300].  Spearman’s rank correlation coefficient 
was used for data that deviate from normality [301].   
6.4.4.3. Paired t-test 
The paired t-test was used to assess change between baseline and follow-up in the groups 
defined by the anchor values.  The paired t-test tests the null-hypothesis that there has been no 
change in the mean response between baseline and follow-up and outputs indicate whether 
any change is statistically significant [307,308].  A weakness of the t-test is that it is highly 
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dependent on the sample size included in the measure.  Therefore the sample size, which has 
little relation to the responsiveness of the measure, has a sizeable effect on the outcome of the 
test.  The Wilcoxon rank test is the non-parametric equivalent of the t-test and was used when 
there was skew in the data.   
6.4.4.4. Effect sizes and standardised response means 
Two effect size statistics are reported: a standard effect size and the standardised response 
mean (SRM).  Effect size statistics quantify the magnitude of change based on variation in the 
scores of the measure; simply put they are the ratio of signal to noise that exists within a 
measure.  The standard effect size is calculated by dividing the change between baseline and 
follow-up by the standard deviation of the baseline scores [260].   
ES = MFollow-up – MBaseline / SDBaseline  
The SRM is calculated by dividing the change between baseline and follow-up with the 
standard deviation of this change [260].   
SRM = MFollow-up – MBaseline / SDChange 
Cohen [309] recommended the cut off values of 0.2, 0.5 and 0.8 are used to define very small, 
small, medium and large effect sizes [260] [264].  While some minor issues have been raised 
over accuracy when applying these values to SRMs [310], these values will be used here when 
categorising effect size and SRM changes. 
6.4.4.5.  Adding context through use of a reference measure 
The EQ-5D-3L was used at a number of points as a reference measure that enabled greater 
context to be placed around the change observed in ICECAP measures scores.  When it was 
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used as a reference measure to the non-weighted ICECAP scores, a non-weighted EQ-5D-3L 
score is used; when it was used as a reference measure with the value weighted ICECAP tariff 
scores, the preference weighted EQ-5D-3L index score was used.  The use of the EQ-5D-3L 
as a comparator was not designed to assess which measure performs “best”, as they are 
measures of two different constructs.  Rather it was designed to increase the understanding of 
the size of changes in ICECAP scores in the context of another value (or preference) based 
measure. 
6.5. Chapter summary 
This chapter has described the process and the outcome of the recruitment of trials which 
provided data for the quantitative analyses in this thesis.  The methods through which 
construct validity and responsiveness to change were assessed are described in detail, along 
with the statistical tests used.  The results of the construct validity assessment are reported in 
Chapter 7 and the responsiveness results are reported in Chapter 8.  The strengths and 
weakness of the methods used are examined in Chapter 9.   
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CHAPTER 7. QUANTITATIVE STUDY OF THE 
VALIDITY AND RESPONSIVENESS OF THE ICECAP 
MEASURES: VALIDITY RESULTS 
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7.1. Introduction 
This chapter reports the results of two separate investigations into the construct validity of the 
ICECAP-A and ICECAP-O capability measures using baseline data taken from the BEEP 
trial and the PastBP trial.  The chapter first reports the results from validation alongside the 
BEEP trial and then continues to report the results from validation alongside the PastBP trial.   
Described in Chapter 6 are a number of a priori hypotheses that were formed.  When an 
analysis was testing an a priori hypothesis, the results of the analysis are presented with 
contextual reference to the hypothesis.  This is done both through discussion in text and the 
use of bold highlighting in tables to indicate that a priori an association was expected.  Where 
a priori hypotheses were not formed, this is noted and the analysis is then considered 
exploratory.  The level of support provided for the hypotheses as a whole is summarised at the 
end of the section for each trial.    
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7.2. BEEP trial  
The characteristics of the BEEP trial participants are presented in Table 9.  Results show the 
cohort to be older on average than the general population, with a roughly equal percentage of 
male and female participants.  The psychological health of the cohort, as indicated by the 
Generalised Anxiety Disorder Assessment (GAD-7) and Patient Health Questionnaire 
depression scale (PHQ-8), was below the level indicating psychological disorders [295,296].  
The average capability of the cohort, as indicated by the ICECAP-A tariff score was higher 
than values previously found in the general population [116].  The range of scores for both 
psychological health and capability, indicate that while the average scores indicate high levels 
of both construct, some participants were in very poor states.  The EQ-5D-3L index score was 
below the national norm for people of this age group, which indicates worse than average 
population health [311].  The WOMAC scales indicated some participants have notable 
physical impairment and ill health.  An item-by-item breakdown of the EQ-5D-3L scores 
(Appendix 21) show that reduced EQ-5D-3L scores were primarily due to increased pain and 
reduced mobility.  This could reasonably be expected for a cohort of patients suffering from 
knee pain. 
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Table 9: Characteristics of BEEP trial participants 
Characteristic Mean values 
(SD) 
Measure range Sample range Sample size 
Socio-demographic 
Age (SD) 63.3 (9.9)  45 to 90 456 
Gender (%male) 50.2%   456 
Health and functioning 
ICECAP-A tariff  0.88 (0.12) 0.0 to 1.0 0.34 to 1.0 452 
EQ-5D-3L index  0.63 (0.24) -0.59 to 1.0 -0.18 to 1.0 442 
WOMAC pain 8.5 (3.5) 0 to 20 0 to 18 449 
WOMAC stiffness 3.8 (1.7) 0 to 8 0 to 8 451 
WOMAC functioning
 
28.7 (12.2)
 
0 to 68 0 to 62 446 
GAD-7
 
3.4 (4.7)
 
0 to 21 0 to 21 439 
PHQ-8
 
4.1 (4.8) 0 to 24 0 to 24 442 
 
526 patients were randomised and completed the baseline questionnaire packs.  As noted in 
the methods, due to an administrative error, some participants were given an early version of 
the ICECAP-A questionnaire in their baseline questionnaire packs.  To ensure rigour those 
participants were removed from this analysis, resulting in the results from 456 participants 
being used in this analysis.  
  
232 | P a g e  
 
7.2.1. ICECAP-A missing values  
The BEEP trial baseline questionnaire packs were completed by participants at home and 
returned via post.  Included within the baseline questionnaire was the consent form for the 
trial.  Only those participants who had completed the consent form in this questionnaire pack 
were included in the analysis of missing values. 
The number of missing values is in part dependent on the setting in which the questionnaire is 
completed and the protocol for ensuring completion.  The EQ-5D-3L missing values allows a 
useful comparison.  The EQ-5D-3L is a questionnaire of comparable patient burden (both are 
short form questionnaires consisting of five items) and it immediately preceded the ICECAP-
A in the baseline questionnaire packs for this study.  ICECAP-A tariff scores could not be 
calculated for four of the 456 participants in the trial, meaning that 452 (99%) of informants 
completed all items on the ICECAP questionnaire.  The index scores of the EQ-5D-3L could 
not be calculated for 14 participants, meaning that 442 (97%) of informants completed all 
items on the EQ-5D-3L. 
An item-by-item analysis (Table 10) shows the distribution of missing values by ICECAP and 
EQ-5D-3L items.  There is no indication from the results of any item on the measure 
producing an unexpectedly high number of missing values, or notably more missing values 
than other items. 
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Table 10: Missing values by ICECAP-A items (EQ-5D-3L used as comparator) in BEEP 
trial. 
Item Values missing (%) 
ICECAP –A  
Stability 4 (0.88%) 
Attachment 2 (0.44%) 
Autonomy 2 (0.44%) 
Achievement 2 (0.44%) 
Enjoyment 2 (0.44%) 
EQ-5D-3L  
Mobility  2 (0.44%) 
Self-care 2 (0.44%) 
Usual activities 6 (1.32%) 
Pain/Discomfort 9 (1.98%) 
Anxiety/Depression 4 (0.88%) 
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7.2.2. ICECAP-A response patterns 
Figure 13 shows the distribution of ICECAP-A tariff scores.  The distribution has a 
significant skew (p<0.01) and kurtosis (p<0.01), with the highest concentration of response in 
scoress over 0.9.   
Figure 13: Frequency distribution of ICECAP-A tariff scores at baseline in BEEP trial 
 
Table 11 and Figure 14 show the distribution of responses by item on the ICECAP-A.  The 
frequency and percentage of participant answers for each level of each item are provided.  
Results show a very low number of respondents answering the bottom level of capability for 
any of the items, with the majority of respondents answering the top two capability levels.  
Over 60% of participants reported full capability (level 4) for Attachment and Autonomy, 
indicating the possibility that these items may suffer from ceiling effects in this population.  
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A breakdown of the ICECAP-A response profile from Al-Janabi et al’s [116] investigation of 
construct validity in the general population is provided to allow for comparison.  The pattern 
of response is similar to that seen in Al-Janabi’s [116] results using the general population.  
The order of most selected to least selected responses for each item were the same for both 
samples (e.g. for the Stability item in both populations, the most frequently selected response 
level was the second, followed (in order) by the top, third and fourth levels), although in 
comparison to Al-Janabi et al’s work [116] there was a notably larger percentage of BEEP 
trial participants who selected the top level of capability on the Autonomy and Achievement 
items.    
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Table 11: Distribution of responses by ICECAP-A item in BEEP trial (with Al-Janabi et 
al [116] values presented for comparison) (n=454)  
Attribute and level Frequency 
(%) 
Al-Janabi 
(2012) 
Stability*   
I am able to feel settled and secure in all areas of my life 141 (31.2%) 29% 
I am able to feel settled and secure in some areas of my life 245 (54.2%) 51% 
I am able to feel settled and secure in a few areas of my life 56 (12.4%) 17% 
I am unable to feel settled and secure in any areas of my life 10 (2.2%) 3% 
   
Attachment    
I can have a lot of love, friendship and support 301 (66.3%) 60% 
I can have quite a lot of love friendship and support 125 (27.5%) 31% 
I can have a little love, friendship and support 28 (6.2%) 7% 
I cannot have any love friendship and support 0 (0.0%) 1% 
   
Autonomy   
I am able to be completely independent  277 (61.0%) 47% 
I am able to independent in many  things 156 (34.4%) 41% 
I am able to be independent in a few things 21 (4.6%) 11% 
I am unable to be independent  0 (0.0%) 1% 
   
Achievement   
I can achieve and progress in all aspects of my life 126 (27.8%) 18% 
I can achieve and progress in many aspects of my life 271 (59.7%) 53% 
I can achieve and progress in a few aspects o my life 55 (12.1%) 26% 
I cannot achieve and progress in any aspects of my life 2 (0.4%) 2% 
   
Enjoyment   
I can have a lot of enjoyment and pleasure 199 (43.8%) 37% 
I can have quite a lot of enjoyment and pleasure 210 (46.3%) 46% 
I can have a little enjoyment and pleasure 45 (9.9%) 15% 
I cannot have any enjoyment and pleasure 0 (0.0%) 2% 
* Stability sums to less than 454 due to missing values 
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Figure 14: Response profile of the ICECAP-A in BEEP trial 
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7.2.3. Socio-demographic variables and the ICECAP-A 
The age and gender of the participants were available for all 456 participants used in this 
analysis.  This section presents the analysis of the ICECAP-A’s association with socio-
demographic variables  
7.2.3.1. Gender 
There was no statistically significant association between the ICECAP-A tariff score and the 
gender of the participant.  An item-by-item analysis (Table 12) showed that there were no 
statistically significant associations between any items of the ICECAP-A measure and the 
gender of the informant.  These results were in agreement with hypotheses of no association 
between participant gender and ICECAP-A tariff score or an of the ICECAP-A items. 
Table 12: Associations between gender and ICECAP-A items (n=452) 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
Gender 
 
0.722 0.799 0.417 0.439 0.843 
* Significant at the 5% level, **Significant at the 1% level. 
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7.2.3.2. Age 
Table 14 shows a negligible, non-significant correlation between the age of the participant 
and the ICECAP-A tariff score.  Table 13 shows significant associations between age and 
Autonomy at the 1% level of significance and between age and Achievement at the 5% 
significance level.  These results provide mixed support for a priori hypotheses.  As 
hypothesised, age was associated with the Autonomy item.  The expected association between 
age and ICECAP-A tariff score was not found.  An unexpected association was seen between 
age and Achievement.    
Table 13: Associations between age and ICECAP-A items (n=452) 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
Age  
 
0.103 0.481 0.005** 0.036* 0.581 
* Significant at the 5% level, **Significant at the 1% level. 
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Table 14: Correlations between measures in BEEP trial at baseline 
* Significant at the 5% level, **Significant at the 1% level. 
Table 14 shows correlations between all measures administered in the baseline questionnaire pack.  The majority of correlations are weak to moderate in strength and 
all of the moderate correlations, and some of the weak correlations, are significant at the 1% level.  Stronger correlations are seen within the WOMAC sub-scores of 
pain, stiffness and functioning.  The correlations of the WOMAC sub-scales with the EQ-5D are stronger, than the correlations with the ICECAP.  The measures of 
anxiety (GAD-7) and depression (PHQ-8) show stronger correlations with the ICECAP-A tariff than with measures of physical health.
 ICECAP-A 
tariff score 
Age EQ-5D-3L 
index score 
WOMAC 
pain score 
WOMAC 
stiffness 
score 
WOMAC 
functioning 
score 
IPQ score GAD-7 
score 
PHQ -8 
score 
No. of co-
morbidities 
ICECAP-A 
tariff score 
1.00          
Age 0.047 1.00         
EQ-5D-3L 
index score 
0.486** 0.094* 1.00        
Womac pain  -0.146** 0.089 -0.455** 1.00       
Womac 
stiffness  
-0.158** 0.136** -0.45** 0.594** 1.00      
Womac 
functioning  
-0.274** 0.166** -0.596** 0.795** 0.674** 1.00     
IPQ score -0.272** -0.06 -0.447** 0.467** 0.37** 0.519** 1.00    
GAD-7 score -0.517** -0.047 -0.367** 0.184** 0.146** 0.192** 0.227** 1.00   
PHQ-8 score -0.517* -0.083 -0.427** 0.224** 0.233** 0.27** 0.271** 0.703** 1.00  
No. of co-
morbidities 
-0.22** 0.124** -0.276** 0.141** 0.175** 0.205** 0.114* 0.204** 0.293** 1.00 
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7.2.4. Physical health and the ICECAP-A 
Four measures assessing physical health were completed by BEEP participants at baseline:  
the EQ-5D-3L, the WOMAC, the IPQ and participant co-morbidities.  This section presents 
the analysis of the ICECAP-A’s association with the EQ-5D-3L, the WOMAC and the patient 
co-morbidities.  The analysis using the IPQ is placed in Appendix 22 and summarised briefly 
here.  Where appropriate, comparisons are drawn with the a priori hypotheses reported in the 
methods chapter. 
7.2.4.1. The EQ-5D-3L 
7.2.4.1.1. ICECAP-A tariff score and the EQ-5D-3L  
Table 14 shows there was a moderate, statistically significant correlation of 0.486 between the 
EQ-5D-3L index score and the ICECAP-A tariff scores.  Figure 15 provides a graphical 
representation of this association. This suggests that as EQ-5D-3L scores increase, so do the 
ICECAP-A scores.  The statistical significance of the correlation suggests this is unlikely to 
be due to chance.  
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Figure 15: Scatter plot of association between EQ-5D-3L index and ICECAP-A tariff  
 
This moderate correlation, which was hypothesised a priori, between the ICECAP-A tariff 
and the EQ-5D-3L index score is suggestive of a non-perfect association between the two 
measures.  Cross-sectional correlations, such as this, are not able to confirm causality.  
However, this moderate correlation indicates that ICECAP-A capability scores are dependent 
(at least in part) on determinants not measured by the EQ-5D-3L descriptive system.   To 
assess whether this correlation held across different levels of health, correlations were 
assessed for those in the top quartile of EQ-5D-3L scores, the middle two quartiles of EQ-5D-
3L scores combined, and the bottom quartile of health.  Table 15 shows that the correlation 
was moderate at the lower levels of health and weak at the higher levels of the EQ-5D-3L 
health state.   
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Table 15: Correlations between ICECAP-A tariff and EQ-5D-3L index at differing 
levels of health (n=442) 
 
EQ-5D-3L  ≥0.76 
EQ-5D-3L <0.76 & 
≥0.62 
EQ-5D-3L <0.62 
ICECAP-A tariff  0.238* 0.392** 0.407** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 16 and Table 17 should be considered together.  Table 16 shows that the ICECAP-A 
tariff score was significantly associated with each EQ-5D-3L item.  Table 17 displays mean 
ICECAP-A tariff scores by EQ-5D-3L item levels.  The results indicate a positive association 
between the two measures, across all EQ-5D-3L items.  Higher scores on each EQ-5D-3L 
item was associated with higher ICECAP-A tariff scores.  This finding is in line with the 
positive correlation between ICECAP-A tariff scores and EQ-5D-3L index presented in Table 
14 and is supportive of the hypothesis of positive associations between ICECAP-A tariff and 
all EQ-5D-3L items. 
Table 16: Associations between ICECAP-A tariff and EQ-5D-3L items (n=442) 
Comparator Mobility Self-care 
Usual 
activities 
Pain and 
discomfort 
Anxiety and 
depression 
ICECAP-A 
tariff 
 <0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.   
In Table 17, with the one exception of pain and discomfort, differences in the mean ICECAP-
A tariff score between the top two levels were statistically significant.  For three items - usual 
activities, pain/discomfort and anxiety and depression - there were significant differences in 
the ICECAP-A scores between the bottom two levels.   The exceptions were mobility, where 
no participant was bedbound, and self-care, where the power of the test suffered from low 
numbers in the bottom group.  These results provide strong evidence that, in a medium sized 
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sample, the ICECAP-A tariff score differs across the levels of the health dimensions included 
in the EQ-5D-3L.   
Table 17: Mean ICECAP-A tariff score by EQ-5D-3L item levels (n=451) 
EQ-5D-3L Attribute  ICECAP-A tariff score 
(95% CI) 
Mobility  
No problems (n=145) 0.91 (0.903, 0.930) 
Some problems (n=306) 0.86 (0.848, 0.878)† 
Bedbound (n=0) - 
Self-care  
No problems (n=411) 0.89 (0.884, 0.904) 
Some problems (n=39) 0.74 (0.681, 0.794)† 
Unable (n=1) 0.76 (n/a) 
Usual activities*   
No problems (n=194) 0.92 (0.909, 0934) 
Some problems (n=246) 0.85 (0.839, 0.871)† 
Unable (n=7) 0.67 (0.491, 0.844)†† 
Pain and discomfort*  
No pain and discomfort (n=11)  0.94 (0.895, 0.977) 
Moderate pain and discomfort (n=380) 0.89 (0.882, 0.903) 
Extreme pain and discomfort (n=54) 0.78 (0.733, 0.829)†† 
Anxiety and depression*  
Not anxious or depressed (n=321) 0.92 (0.912, 0.929) 
Moderately anxious or depressed (n=115) 0.8 (0.775, 0.826)† 
Extremely anxious or depressed (n=13) 0.58 (0.501, 0.662)†† 
Statistically significant differences at the 1% level in the mean ICECAP-A tariff score between †some(moderate)/no(not) 
response options and ††unable(extreme)/some(moderate) levels of the EQ-5D-3L.  *These items sum to less than 451 due to 
missing values. 
7.2.4.1.2. ICECAP-A items and the EQ-5D-3L 
Table 18 shows associations between ICECAP-A items and the EQ-5D-3L index scores.  
Results show that all items were significantly associated with the EQ-5D-3L index score.  As 
can be seen, an unexpected association between the EQ-5D-3L index and the ICECAP-A item 
of Attachment was found. 
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Table 18: Associations between EQ-5D-3L index and ICECAP-A items (n=422) 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
EQ-5D-3L 
index score 
(n=442)
 
<0.001** <0.001** <0.001** <0.001** <0.001** 
 
Table 19 should be considered together with Table 18.  The results show that EQ-5D-3L 
index scores were strongly and positively related to all ICECAP-A attributes.  There were 
statistically significant differences in the EQ-5D-3L index score between the top and the 
second levels and the second and third levels on every ICECAP-A attribute.  No statistically 
significant differences were seen between the scores of the bottom two levels of any attribute, 
which may be due to small numbers resulting in poor statistical power of the Kruskal-Wallis 
multiple group comparisons at these lower levels. 
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Table 19: Mean EQ-5D-3L index scores by ICECAP-A item levels (n=442) 
ICECAP-A Attribute Mean EQ-5D-3L 
score (95% CI) 
Stability*  
I am able to feel settled and secure in all areas of my life (n=137) 0.69 (0.656, 0.718)†† 
I am able to feel settled and secure in many areas of my life (n=238) 0.66 (0.637, 0.684)† 
I am able to feel settled and secure in a few areas of my life (n=55) 0.42 (0.336, 0.512) 
I am unable to feel settled and secure in any areas of my life (n=10) 0.12 (-0.073, 0.317) 
Attachment  
I can have a lot of love, friendship and support (n=292) 0.65 (0.625, 0.676)†† 
I can have quite a lot of love, friendship and support (n=123) 0.60 (0.563, 0.646)† 
I can have a little love, friendship and support (n=27) 0.45 (0.321, 0.579) 
I cannot have any love, friendship and support (n=0) - 
Autonomy  
I am able to be completely independent (n=270) 0.69 (0.671, 0.713)†† 
I am able to be independent in many things (n=152) 0.56 (0.516, 0.599)† 
I am able to be independent in a few things (n=20) 0.24 (0.092, 0.389) 
I am unable to be at all independent (n=0) - 
Achievement  
I can achieve and progress in all aspects of my life (n=122) 0.71 (0.682, 0.738)†† 
I can achieve and progress in many aspects of my life (n=264) 0.64 (0.613, 0.664)† 
I can achieve and progress in a few aspects of my life (n=54) 0.38 (0.294, 0.473) 
I cannot achieve and progress in any aspects of my life (n=2) 0.3 (n/a) 
Enjoyment  
I can have a lot of enjoyment and pleasure (n=193) 0.70 (0.678, 0.726)†† 
I can have quite a lot enjoyment and pleasure (n=205) 0.60 (0.570, 0.636)† 
I can have a little enjoyment and pleasure (n=44) 0.39 (0.294, 0.491) 
I cannot have any enjoyment and pleasure (n=0) - 
Statistically significant differences at the 1% level in the mean EQ-5D-3L index score between †† all (a 
lot)/many (quite a lot) and † many (quite a lot)/few (a little) ICECAP-A response options.  *Stability sums to 
less than 442 due to missing values. 
Table 20 shows the associations between the ICECAP-A items and the EQ-5D-3L items.  The 
associations which were expected a priori are highlighted in bold.  As can be seen, all of the 
19 hypothesised associations were significant at the 5% statistical level, with all but one 
significant at the 1% level.  Four associations were found that were unexpected: Attachment 
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was unexpectedly associated with self-care, usual activities and anxiety, while Stability was 
unexpectedly associated with usual activities. 
Table 20: Associations between ICECAP-A and EQ-5D-3L items (n=442) 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
EQ-5D-3L      
Mobility
 
0.038* 0.089 <0.001** <0.001** <0.001** 
Self-care <0.001** 0.002* <0.001** <0.001** <0.001** 
Usual activities <0.001** 0.022* <0.001** <0.001** <0.001** 
Pain <0.001** 0.264 <0.001** <0.001** <0.001** 
Anxiety <0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level. Hypothesised associations are highlighted in bold 
font 
Evidence of the direction of the relationship between the ICECAP-A items and the EQ-5D-3L 
items is provided in Table 21 using Goodman and Kruskal’s Gamma.  All rank correlations 
were in the anticipated direction. All correlations were negative due to the difference in 
scoring between the ICECAP-A and the EQ-5D-3L (i.e. the top level on ICECAP items is 4, 
whereas the top level for EQ-5D-3L items is 1).  Therefore, the results indicate that high 
scores on the health attribute (e.g. mobility) associates with high scores on the capability 
attribute (e.g. Autonomy).   
The associations that were hypothesised a priori to be particularly strong are highlighted in 
bold.  All these associations were moderate or strong.  There were unexpectedly strong 
correlations seen between 1) Pain/Discomfort and Autonomy and 2) Anxiety and Depression 
and Stability and Achievement.     
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Table 21: Rank correlations between ICECAP-A and EQ-5D-3L items (n=442) 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
EQ-5D-3L      
Mobility -0.178 -0.157 -0.485 -0.396 -0.342 
Self-care -0.563 -0.457 -0.868 -0.779 -0.514 
Usual Activities -0.368 -0.250 -0.641 -0.623 -0.460 
Pain/Discomfort -0.400 -0.226 -0.545 -0.475 -0.497 
Anxiety/Depression -0.836 -0.480 -0.613 -0.773 -0.724 
Highlighted in bold are the associations which were hypothesised to the strongest for each EQ-5D-3L item. 
7.2.4.1.3. Exploratory factor analysis 
The results presented above indicate a closer association between the ICECAP-A measure and 
the EQ-5D-3L than was hypothesised.  There were a number of unexpected associations 
between items (Table 20) and the strength of some of these associations was stronger than 
anticipated (Table 21).  This raises an important question: are the ICECAP-A and EQ-5D-3L 
measuring different constructs, or are they different measures of the same construct?  To 
assess this, an exploratory factor analysis was completed using the 5 items from both 
measures.   
The number of factors retained in the final solution was chosen with reference to the Kaiser 
Criterion: both the scree plot (see Figure 16) and the Eigen Values indicated that maintaining 
2 factors was the optimal solution. 
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Figure 16: Factor analysis eigen values by factor number 
 
The choice of an oblique promax rotation was confirmed as correct through use of the 
STATA “estat common” command (post rotation) which indicated a correlation of -0.5149 
between the factors.  This correlation is stronger than 0.32 which is considered the point at 
which oblique rotations are appropriate. 
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Table 22: Exploratory factor analysis comparing the ICECAP-A and EQ-5D-3L items 
(n=442) 
 Rotated item loading on a 2-
factor solution. 
 Factor 1 Factor 2 
EQ-5D-3L   
Mobility  0.816 
Self-Care  0.790 
Usual Activities  0.693 
Pain  0.667 
Anxiety and Depression -0.741  
ICECAP-A   
Stability 0.859  
Attachment 0.671  
Autonomy 0.398 -0.459 
Achievement 0.677 -0.224 
Enjoyment 0.825  
Factor correlations -0.515 
Loadings of <0.2 are dropped to allow easy interpretation of results. 
Table 22 shows a two factor solution indicating that two separate, but correlated attributes are 
assessed by the pooled items of EQ-5D-3L and the ICECAP-A.  The majority of EQ-5D-3L 
items (Mobility, Self-care, Usual Activities and Pain) loaded strongly onto factor two, while 
the majority of ICECAP-A items (Stability, Attachment, Achievement, Enjoyment) and one 
EQ-5D-3L item (Anxiety and Depression) loaded strongly onto factor one.  The loading of 
Autonomy split equally, with moderate loadings onto both factors.  Therefore these results 
strongly indicate that the ICECAP-A and EQ-5D-3L are largely capturing different 
constructs.        
7.2.4.2. WOMAC 
Table 14 shows that, in line with hypothesised associations, all three of the WOMAC scales 
showed weak negative, but statistically significant correlations with the ICECAP-A tariff 
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score.  When levels of pain, stiffness and functioning problems due to knee pain are high in an 
individual; it seems to be reflected to some degree in lower ICECAP-A tariff scores.   
The results in Table 23 indicate that each sub-scale of the WOMAC showed a statistically 
significant association with the four ICECAP-A items of Stability, Autonomy, Achievement 
and Enjoyment at the 1% level of statistical significance.  No statistically significant 
associations were seen between the Attachment item and any of the WOMAC sub-scales. A 
priori expected associations are highlighted in bold and as can be seen it was expected that all 
ICECAP-A items except Attachment would be associated with each of the WOMAC sub-
scales.  All expected associations were significant at the 1% level.  
Table 23: Associations between WOMAC subscales and ICECAP-A items 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
WOMAC pain
 
(n=441) 
0.001** 0.353 <0.001** <0.001** <0.001** 
WOMAC stiff
 
(n=447) 
0.01* 0.789 <0.001** 0.002** 0.008** 
WOMAC func 
(n=389) 
<0.001** 0.07 <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.  
7.2.4.3. The Brief Illness Perception Questionnaire summary 
The results of the IPQ analysis are presented in Appendix 22 and a summary is provided here.  
The IPQ showed a weak statistically significant association with the ICECAP-A tariff.  Four 
items of the questionnaire showed a statistically significant association with the ICECAP-A 
tariff.  These were: affect - an assessment of the affect that knee pain has on life; symptoms - 
an assessment of how many symptoms are experienced; concern - an assessment of the level 
of concern over knee pain; and emotion - an assessment of the emotional effect of knee pain.  
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There were a number of statistically significant associations between IPQ items and ICECAP-
A items. 
7.2.4.4. Co-morbidities  
A ten item questionnaire of co-morbidities was included in the baseline questionnaire pack of 
the BEEP trial.  This questionnaire contained the question “Have you ever been told that you 
have any of the following?” and the options were: high blood pressure, angina, heart failure, 
stroke, depression, osteoporosis, diabetes, asthma, bronchitis and heart attack.  The first part 
of this analysis presents a summed value of “total number co-morbidities” and the second part 
of the analysis looks at the impact of individual co-morbidities on the ICECAP-A tariff 
scores.  This analysis was exploratory. 
Table 14 shows a weak, statistically significant correlation of -0.22 between the ICECAP-A 
scores and the number of co-morbidities reported by participants.  This correlation indicates 
that the more co-morbidities a person has, the lower their ICECAP-A scores tend to be.  To 
analyse this further the total number of co-morbidities was transformed into a categorical 
variable of none, some (1 to 2) and many (2 to 10).  Table 24 shows the mean ICECAP scores 
for participants in each of these groups.  The groups with less co-morbidities had higher 
ICECAP-A scores. 
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Table 24: Mean ICECAP-A tariff scores by prevalence of co-morbidities (n=229) 
 ICECAP-a tariff score (95% 
CI) 
None 
 
0.903 (0.884, 0.921) 
Some 
(1 to 2 co-morbidities) 
0.883 (0.869, 0.897)† 
Many 
(3 or more co-
morbidities) 
0.815 (0.772, 0.858) 
† Statistically significant difference between Some and Many co-morbidities  
Table 25 shows the associations between the categorical co-morbidities variable and each 
ICECAP-A item.  Co-morbidities are associated with each ICECAP-A item apart from 
Attachment.  As stated above, this analysis was exploratory, therefore no a priori hypotheses 
were formed.  However, for other health measures, such as the EQ-5D-3L and WOMAC, 
indicators of health were hypothesised to associate with all ICECAP-A items apart from 
Attachment.  Such a pattern can be seen with the comorbidities question. 
Table 25: Associations between co-morbidities categorical variable and ICECAP-A 
items (n=229) 
 Stability Attachment Autonomy Achievement Enjoyment 
Comorbidities  0.001** 0.062 0.001** 0.001** 0.001** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 26 shows each of the individual co-morbidities assessed in the BEEP trial and the mean 
ICECAP-A tariff score for those who did and did not report that comorbidity.  Significant 
differences were found between the ICECAP-A tariff scores for those with and without 
depression and osteoporosis.  A number of the analyses suffered from low numbers in the 
group reporting the comorbidity.  This limitation applies particularly to angina, heart failure, 
stroke and heart attack. 
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Table 26: Mean ICECAP-A tariff scores by number of self-reported co-morbidities 
 ICECAP-A mean tariff scores 
 Reported comorbidity (95% CI) 
 
Comorbidity not reported (95% 
CI) 
High blood 
pressure 
0.878 (0.862, 0.894) 
(n=211) 
0.883 (0.867, 0.899) 
(n=241) 
Angina 0.847 (0.783, 0.912) 
(n=19) 
0.882 (0.87, 0.893) 
(n=433) 
Heart failure 0.869 (0.741, 0.998) 
(n=8) 
0.881 (0.87, 0.892) 
(n=444) 
Stroke 0.859 (0.815, 0.903) 
(n=15) 
0.881 (0.87, 0.893) 
(n=437) 
Depression** 0.805 (0.773, 0.837) 
(n=99) 
0.902 (0.891, 0.912) 
(n=353) 
Osteoporosis* 0.823 (0.772, 0.875) 
(n=30) 
0.885 (0.873, 0.896) 
(n=422) 
Diabetes 0.863 (0.829, 0.896) 
(n=62) 
0.883 (0.871, 0.895) 
(n=390) 
Asthma 0.851 (0.881, 0.891) 
(n=59) 
0.885 (0.873, 0.896) 
(n=393) 
Bronchitis 0.842 (0.786, 0.898) 
(n=32) 
0.883 (0.872, 0.895) 
(n=420) 
Heart attack 0.902 (0.855, 0.958) 
(n=16) 
0.88 (0.868, 0.891) 
(n=436) 
* Significant at the 5% level, **Significant at the 1% level.   
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7.2.5. Psychological health and the ICECAP-A 
Two measures of psychological health were included in the BEEP trial: the GAD-7 and the 
PHQ-8.  This section presents the ICECAP-A’s association with these measures and 
comments on how the results compare to the a priori hypotheses. 
7.2.5.1. GAD-7 and PHQ-8 
Table 14 shows that the hypothesised negative associations with the ICECAP-A tariff score 
were seen for both the GAD-7 and the PHQ-8.  The moderate associations of -0.517 for both 
measures is the strongest correlation seen between the ICECAP-A tariff score and the scores 
of any measure included in the baseline questionnaire pack of the BEEP trial. 
Table 27 and Table 28 show that the GAD-7 and the PHQ-8 scores are associated with every 
ICECAP-A item.  For both measures associations were found with Attachment and 
Achievement that were not hypothesised.  This suggests that there was a closer association 
between the dimensions of the ICECAP-A measure and measures of anxiety and depression 
than was expected. 
Table 27: Associations between GAD-7 score and ICECAP-A items (n=439) 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
GAD-7
 
<0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.  
Table 28: Associations between PHQ-8 score and ICECAP-A items (n=442) 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
PHQ-8 
 
<0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.   
The GAD-7 and PHQ-8 scores were split into categorical variables based on clinically 
meaningful cut-offs.  For the GAD-7 a score equal to or greater than 8 indicates anxiety 
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disorder [295,297,312], while for the PHQ-8 a score equal to or greater than 10 indicates 
probable depression [296].  Table 29 shows the ICECAP-A tariff scores for those with and 
without anxiety and depression, as indicated by the GAD-7 and the PHQ-8.  A difference of 
0.16 was seen between those with and without probable anxiety disorder and a difference of 
0.18 was seen between those with and without probable depression.  The differences in 
ICECAP-A tariff scores between those with and without probable depression or anxiety 
disorder were significantly different.  No a priori hypotheses were formed as to the 
association of the ICECAP-A with the categorical transformations of the GAD-7 and PHQ-8 
measures.  However, these results are largely in line the hypothesis that the ICECAP-A tariff 
score would be higher in those in good psychological health as judged by the GAD-7 and 
PHQ-8. 
Table 29: Mean ICECAP-A tariff scores by GAD-7 and PHQ-8 levels (based on clinical 
cut-offs) 
Measure of psychological health ICECAP-A tariff score 
(SD) 
GAD-7 (n=439)  
No anxiety disorder 0.91 (0.089)** 
Probable anxiety disorder 0.75 (0.17) 
PHQ-8 (n=442)  
Not depressed 0.91 (0.091)** 
Probable depression 0.73 (0.16) 
** Statistically significant differences at the 1% level in the mean ICECAP-A tariff score between  No(not)/probable 
response options 
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7.2.6. Comparison of results with hypotheses 
A priori hypotheses were formed and have been referred to at a number of points throughout 
the analysis.  Table 30 presents a comparison of hypotheses and results.  Taken as a whole 
these results provide positive, supportive evidence for the validity of the ICECAP-A 
measures.  The majority of hypothesised associations were found; meaning that the measure 
behaved largely as expected.  As can be seen from Table 30, confirmatory evidence pertaining 
to the hypotheses referring to the association of the ICECAP-A tariff with socio-demographic, 
physical health and psychological health variables was found.  
No numerical strength of association or correlation was hypothesised as it was not felt to be 
possible to do this accurately.  However, discussed in Chapter 3 was the expectation that 
strong correlations between the ICECAP-A and measures of physical and psychological 
health would not be found, and that moderate correlations would be expected as there are a 
number of influences upon capability other than health.  As can be seen from the results above 
and Table 30, all correlations are moderate or less; no strong correlations were found. 
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Table 30: A comparison of hypotheses and results from the BEEP trial 
Hypotheses Results 
 Association Direction Strength  Association Direction Strength 
Socio- 
demographic 
Socio- 
demographic 
Age Yes   Age No   
Gender No   Gender No   
Physical health Physical health 
EQ-5D-3L Yes Positive  EQ-5D-3L Yes Positive Moderate 
WOMAC 
Pain 
Yes Negative  
WOMAC 
Pain 
Yes Negative Weak 
WOMAC 
stiffness 
Yes Negative  
WOMAC 
stiffness 
Yes Negative Weak 
WOMAC 
functioning 
Yes Negative  
WOMAC 
functioning 
Yes Negative Weak 
IPQ Exploratory analysis IPQ Yes Negative Weak 
Co-
morbidities 
Exploratory analsyis 
Co-
morbidities 
Yes Negative Weak 
Psychological health Psychological health 
GAD-7 Yes Negative  GAD-7 Yes Negative Moderate 
PHQ-8 Yes Negative  PHQ-8 Yes Negative Moderate 
        
 
No association between gender and the ICECAP-A tariff score was expected; no significant 
association was seen.  The item by item analysis showed mixed support for the hypotheses 
referring to age.  The expected association of the tariff with age was not found.  As expected, 
age showed a significant association with the ICECAP item measuring independence, the 
Autonomy item, and an unexpected association with the Achievement item.   
The associations between measures of physical health in the BEEP trial and the ICECAP-A 
tariff score were as expected.  It was hypothesised that a positive correlation would be found 
between the EQ-5D-3L index score and the ICECAP-A tariff score: a moderate positive 
correlation was found.  It was expected that the scores of the WOMAC subscales of pain, 
stiffness and functioning would negatively associate with the ICECAP-A tariff (e.g.greater 
259 | P a g e  
 
pain, stiffness and functioning problems would be associated with lower capability).  A weak 
negative association between each of the subscales and the tariff score was seen. 
The item-by-item analysis of the ICECAP-A and the measures of physical functioning 
showed some additional non-hypothesised associations.  As expected, statistically significant 
associations were seen between all three WOMAC sub-scales and all ICECAP-A items apart 
from Attachment.  All hypothesised associations between ICECAP-A and EQ-5D-3L items 
were found and an additional four unexpected associations were found.  This discordance 
between the hypotheses and the results indicate a closer than expected association between the 
ICECAP-A items and the EQ-5D-3L items. 
The associations and correlations between measures of psychological health and the ICECAP-
A tariff score were as expected.  A negative correlation was expected a priori; a moderate 
negative correlation was found.  The correlations with the GAD-7 and the PHQ-8 were the 
strongest association of any variable with the ICECAP-A tariff score.  The item-by-item 
analysis showed some additional associations which were not expected a priori, suggesting a 
closer association than expected.  
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7.3. PastBP trial 
The characteristics of the PastBP trial participants are presented in Table 31.  Results show 
this to be an elderly, majority male sample.  The average capability of participants, as 
indicated by an average ICECAP-O score of 0.85, was comparable to values found in the 
general population [118].  The range of ICECAP-O scores indicated that some participants 
had low capability scores.  Participants were on average in reasonable physical health.  The 
mean EQ-5D-3L score for this population was comparable to the average score for this age 
group [311].  The average number of symptoms and side-effects experienced by participants 
was 6 out of the 24 assessed.  The distribution and sample range of both the EQ-5D-3L scores 
and the symptom and side-effects score show a small number of participants to be in very 
poor health states.  The cognitive functioning of the sample was above the MMSE cut-off  of 
25, indicating good cognitive impairment [313].  Scores on the sub-scales of the SF-36 
indicate that physical functioning, limitations to a person’s role due to physical factors and 
vitality were the main impairments to health in this sample.   
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Table 31: Characteristics of PastBP trial participants 
Attribute Mean values 
(SD) 
Measure 
range 
Sample 
range 
Sample size 
Socio-demographic     
Age mean (SD) 71.2 (9.16)  41 to 91 529 
Gender (% male) 59.4%   529 
Health and functioning      
ICECAP-O score  0.85 (0.13) 0 to 1 0.25 to 1.0 456 
EQ-5D-3L  0.72 (0.24) -0.59 to 1 -0.07 to 1.0 476 
EQ-5D-3L VAS 73.3 (18.0) 0 to 100 0 to 100 470 
MMSE 27.9 (2.5) 0 to 30 0 to 30 472 
Number of SSE 6 0 to 24 0 to 20 299 
SF-36 sub-scale scores     
 Physical function 41.0 (12.3) 14.9 to 57.0 14.9 to 57.0 418 
 Physical role 40.1 (17.4) 17.7 to 56.8 17.7 to 56.8 470 
 Emotional role 43.8 (18.1) 9.2 to 55.9 9.2 to 55.9 462 
 Vitality 48.7 (10.7) 20.9 to 70.8 20.9 to 70.8 457 
 Mental health 50.5 (9.9) 14.5 to 64.1 14.5 to 64.1 472 
 Social function 47.3 (11.2) 13.2 to 56.8 13.2 to 56.8 478 
 Pain  47.9 (11.4) 19.8 to 62.1 19.8 to 62.1 474 
 General health 44.9 (9.8) 16.2 to 63.9 16.2 to 63.9 454 
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7.3.1. ICECAP-O missing values 
The majority of baseline questionnaire packs for the PastBP trial were completed in clinic 
under the supervision of a researcher.  The primary role of the researcher was to confirm the 
diagnosis of the patient and facilitate blood pressure measurement and randomisation.   Forms 
were self-completed.  As noted above, the completion rates for a measure are dependent on 
methods of the trial, therefore the EQ-5D-3L is used as a comparator with similar patient 
burden. 
During data entry, all measures were marked electronically as either “completed” or “not-
completed”.  Completed meant that participants had answered one or more items on the 
measure.  Not-completed meant that the measure was included in the baseline questionnaire 
pack administered to participants, but the participant had not answered any items on the 
measure.    Table 32 shows slightly reduced completion rates for ICECAP-O in comparison to 
EQ-5D-3L.  The difference in the total number of questionnaires is due a small number of the 
early baseline questionnaire packs not including ICECAP-O. 
Table 32: Completion rates of ICECAP-O (EQ-5D-3L used as comparator) in PastBP 
trial 
Measure Completed (%) Not-completed (%) Total 
ICECAP-O 460 (92.6) 37 (7.4) 497 
EQ-5D-3L 484 (93.4) 34 (6.6) 518 
 
Missing items were assessed by excluding “not-completed” questionnaires from the analysis 
and assessing the missing items on those questionnaires where at least one item on the 
measure had been completed.  Table 33 shows a very low number of both ICECAP-A and 
EQ-5D-3L items were not completed by the participants who had attempted to complete the 
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measure.  There is no indication of increased non-response on any of the items for either 
measure. 
Table 33: Missing values by ICECAP-O items (EQ-5D-3L used as comparator) in 
PastBP trial  
Item Items missing (%) 
ICECAP –0   
Attachment 2 (0.4) 
Security 1 (0.2) 
Role 3 (0.7) 
Enjoyment 1 (0.2) 
Control 1 (0.2) 
EQ-5D-3L   
Mobility  3 (0.6) 
Self-care 4 (0.8) 
Usual activities 3 (0.6) 
Pain/Discomfort 3 (0.6) 
Anxiety/Depression 3 (0.6) 
Analysis completed using participants who had completed at least one item on measure. 
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7.3.2. ICECAP-O response patterns 
Figure 17 shows the distribution of ICECAP-O tariff scores.  The distribution has a notable 
skew (p<0.01) and kurtosis (P<0.01), with the highest concentration being in values over 0.8. 
Figure 17: Frequency distribution of ICECAP-O tariff scores at baseline in PastBP trial 
 
Table 34 and Figure 18 shows the frequency of responses for each level of each item of the 
ICECAP-O measure.  The percentage of participants answering each level is given, alongside 
percentages from Coast et al’s [117] investigation of the construct validity of the ICECAP-O 
measure in the general population to allow comparison.   
Results show a low number of participants selecting the bottom level of capability.  The item 
with the highest percentageselecting the bottom level was Security with 6.1%.  The majority 
of respondents selected the top two levels of each item, with 60% in the top level for 
Attachment and 51% for Control.  On all items apart from the Control item the order of the 
0
5
0
1
0
0
1
5
0
F
re
q
u
e
n
c
y
.2 .4 .6 .8 1
ICECAP-O tariff scores
Distribution of baseline ICECAP-O tariff scores
265 | P a g e  
 
most selected to least selected levels is the same for both the PastBP and the Coast et al [117] 
general population sample.  Notable increases in the percentage of participants who selected 
the top capability level for Role and Control was seen in comparison to the general population 
sample.  
Table 34: Distribution of responses by ICECAP-O item in PastBP trial (Coast et al [117] 
presented for comparison) (n=459) 
Attribute and Level Frequency 
(%) 
General pop 
percentage 
Attachment*    
I can have all of the love and friendship that I want 275 (60.0%) 57% 
I can have a lot of the love and friendship that I want 131 (28.6%) 30.2% 
I can have a little of the love and friendship that I want 49 (10.7%) 8.9% 
I cannot have any of the love and friendship that I want 3 (0.7%) 3.8% 
Security   
I can think about the future without any concern 115 (25.1%) 18.7% 
I can think about the future with only a little concern 209 (45.5%) 38.7% 
I can only think about the future with some concern 107 (23.3%) 30.2% 
I can only think about the future with a lot of concern 28 (6.1%) 12.4% 
Role*   
I am able to do all of the things that make me feel valued 161 (35.2%) 26.1% 
I am able to do many of the things that make me feel valued 203 (44.4%) 47.4% 
I am able to do a few of the things that make me feel valued 83 (18.2%) 22.9% 
I am unable to do any of the things that make me feel valued 10 (2.2%) 3.5% 
Enjoyment   
I can have all of the enjoyment and pleasure that I want 139 (30.3%) 23.5% 
I can have a lot of the enjoyment and pleasure that I want 222 (48.4%) 51.4% 
I can have a little of the enjoyment and pleasure that I want 90 (19.6%) 21% 
I cannot have any of the enjoyment and pleasure that I want 8 (1.7%) 4.1% 
Control   
I am able to be completely independent 235 (51.2%) 38.7% 
I am able to be independent in many things 176 (38.3%) 41.3% 
I am able to be independent in a few things 43 (9.4%) 17.8% 
I am unable to be at all independent  5 (1.1%) 2.2% 
* Items sum to less than 459 due to missing values. 
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Figure 18: Response profile of ICECAP-O in PastBP trial 
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7.3.3. Socio-demographic variables and the ICECAP-O 
A small amount of socio-demographic information was collected on the participants in the 
PastBP trial.  The age and gender of participants was available for analysis.  This section 
presents the analysis of the association of the ICECAP-O with these variables. 
7.3.3.1. Gender 
There was no statistically significant association between the ICECAP-O tariff score and the 
gender of the participant.  An item-by-item analysis, presented in Table 35, shows there was 
no statistically significant association between any of the ICECAP-O items and gender.  
These results are in agreement with the a priori hypotheses which anticipated no associations. 
Table 35: Associations between gender and ICECAP-O items (n=456) 
Comparator Attachment Security Role Enjoyment Control 
Gender (459)
 
0.954 0.177 0.125 0.735 0.154 
 
7.3.3.2. Age 
Table 37 shows a negligible, non-significant correlation between age and the ICECAP-O 
tariff score.  Table 36 shows that a statistically significant association at the 1% level exists 
between age and the ICECAP-O items of Security and Control.  The association between 
Control and age was expected, while the association between Security and age was 
unexpected.  These results therefore provide mixed support for the a priori hypotheses. 
Table 36: Associations between age and ICECAP-O items (n=456) 
Comparator Attachment Security Role Enjoyment Control 
Age
 
0.608 0.001** 0.969 0.440 <0.001** 
* Significant at the 5% level, **Significant at the 1% level.  
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Table 37: Correlations between measures in PastBP trial at baseline 
 ICECAP-
O tariff  
Age  EQ-5D-
3L index  
EQ-5D-
3L VAS 
Number 
of SSE 
Physical 
function 
Physical 
role 
Emotional 
role 
Vitality Mental 
Health 
Social 
function 
Pain General 
health 
ICECAP-O 
tariff  
1.00             
Age 
 
-0.013 1.00            
EQ-5D-3L 
index score 
0.518** -0.125** 1.00           
EQ-5D-3L 
VAS 
0.533** -0.073 0.536** 1.00          
Number of 
SSE 
-0.477** -0.035 -0.547** -0.499** 1.00         
Physical 
function 
0.467** -0.269** 0.685** 0.541** -0.507** 1.00        
Physical role 0.435** -0.157** 0.557** 0.533** -0.465** 0.592** 1.00       
Emotional 
role 
0.436** -0.051 0.399** 0.389** -0.364** 0.394** 0.559** 1.00      
Vitality 0.599** -0.041 0.604** 0.646** -0.579** 0.572** 0.581** 0.482** 1.00     
Mental 
Health 
0.521** -0.140** 0.382** 0.461** -0.438** 0.301** 0.330** 0.494** 0.585** 1.00    
Social 
function 
0.527** -0.024 0.589** 0.547** -0.453** 0.558** 0.608** 0.561** 0.607** 0.498** 1.00   
Bodily pain 0.328** 0.007 0.696** 0.479** -0.483** 0.508** 0.486** 0.358** 0.480** 0.310** 0.542** 1.00  
General 
Health 
0.609** 0.066 0.506** 0.640** -0.565** 0.513** 0.488** 0.395** 0.678** 0.526** 0.510** 0.429** 1.00 
* Significant at the 5% level, **Significant at the 1% level. The Modified Rankin Scale is not included in this table as it is a 5 point categorical variable and therefore not appropriate for 
correlation analysis. 
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7.3.4. Physical Health and ICECAP-O 
The baseline questionnaire pack administered to participants in the PastBP trial included a 
number of measures of physical health.  These measures were the EQ-5D-3L, the physical 
sub-scales of the SF-36, the Modified Rankin Scale and the symptoms and side-effects 
questionnaire.  This section presents the associations between the ICECAP-O and these 
measures. 
7.3.4.1. The EQ-5D-3L 
7.3.4.1.1. The ICECAP-O tariff and the EQ-5D-3L 
Table 37 shows a moderate, statistically significant correlation of 0.518 between the 
ICECAP-O tariff score and the EQ-5D-3L index score.  Figure 19 provides a graphical 
presentation of this correlation.  This correlation indicates that as the EQ-5D-3L index scores 
increase, so do the ICECAP-o tariff scores.  The statistical significance of this association 
means that it is unlikely to be due to chance.   
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Figure 19: Scatter plot of association between EQ-5D-3L index and ICECAP-O tariff 
 
This result is in line with the correlation hypothesised a priori.  It was expected that 
determinants other than health would also have a significant impact upon the person’s 
capability as measured by the ICECAP-O.  As noted previously, cross-sectional correlations 
are unable to confirm causality, but results indicate that while health is a notable determinant 
of a person’s ICECAP-O scores, other factors may also influence it.    
To assess whether this correlation held at different levels of health, correlations were assessed 
for the top quartile, the middle two quartiles  and the bottom quartiles of EQ-5D-3L scores.  
Table 38 shows weak correlations at the higher EQ-5D-3L scores and negligible correlations 
at the lower levels of EQ-5D-3L scores.   
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Table 38: Correlations between the ICECAP-O tariff and EQ-5D-3L index at differing 
levels of health (n=446) 
 
EQ-5D-3L  ≥0.85 
EQ-5D-3L <0.85 & 
≥0.69 
EQ-5D-3L <0.62 
ICECAP-O tariff 0.219* 0.202** 0.074 
* Significant at the 5% level, **Significant at the 1% level. 
Table 39 and Table 40 should be considered together.  They provide information on the 
association of the ICECAP-O tariff score with the items of the EQ-5D-3L.  In line with a 
priori hypotheses, the ICECAP-O tariff was associated with each of the EQ-5D-3L items at 
the 1% significance level. 
Table 39: Associations between ICECAP-A tariff and EQ-5D-3L items (n=446) 
Comparator Mobility Self-care 
Usual 
activities 
Pain and 
discomfort 
Anxiety and 
depression 
ICECAP-O 
tariff
 <0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.  
Table 40 shows that for each of the EQ-5D-3L items, ICECAP-O tariff scores were higher in 
participants with better levels of health and lower in participants in worse health states.  
There were statistically significant differences between the ICECAP-O tariff scores for the 
top and second level for each EQ-5D-3L item. For Usual Activities and Pain/Discomfort 
there was a statistically significant difference between the bottom two levels.  These 
differences were not seen in the three other EQ-5D-3L items.  However, this could be related 
to the reduced statistical power at the lower levels due to small numbers.  Table 40 provides 
strong evidence that in a medium sized, sample of older people, the ICECAP-O tariff scores 
are different across levels of the health dimensions in the EQ-5D-3L.  
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Table 40: Mean ICECAP-O tariff score by EQ-5D-3L item levels (n=447) 
EQ-5D-3L Attribute ICECAP-0 tariff score 
(95% CI) 
Mobility  
No problems (n=223) 0.90 (089, 0.92)† 
Some problems (n=223) 0.81 (0.79, 0.83) 
Bed bound (n=1) 0.65 
Self-care  
No problems (n=384) 0.88 (0.87, 0.89)† 
Some problems (n=62) 0.74 (0.70, 0.78) 
Unable (n=1) 0.72 
Usual activities*   
No problems (n=260) 0.91 (0.89, 0.92)† 
Some problems (n=168) 0.80 (0.78, 0.82)†† 
Unable (n=18) 0.65 (0.56, 0.74) 
Pain and discomfort*  
No pain and discomfort (n=163)  0.89 (0.87, 0.91)† 
Moderate pain and discomfort (n=254) 0.85 (0.83, 0.86)†† 
Extreme pain and discomfort (n=29) 0.76 (0.69, 0.82) 
Anxiety and depression*  
Not anxious or depressed (n=320) 0.89 (0.87, 0.90)† 
Moderately anxious or depressed (n=123) 0.79 (0.76, 0.81) 
Extremely anxious or depressed (n=3) 0.52  
Statistically significant (P<0.01) differences in the mean EQ-5D-3L index score between †† some problems/extreme 
problems response options and †  no problems/some problems.  * Items sum to less than 447 due to missing values. 
7.3.4.1.2. ICECAP-O items and the EQ-5D-3L 
Table 41 shows the associations between ICECAP-O items and the EQ-5D-3L index score.  
Statistically significant associations were seen between all items and the EQ-5D-3L index 
score.  This provides mixed support for the a priori hypotheses.  Expected associations 
(highlighted in bold) were seen for Security, Role, Enjoyment and Control, while an 
unexpected association between Attachment and the EQ-5D-3L index score was also seen. 
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Table 41: Associations between EQ-5D-3L index and ICECAP-O items (n=446) 
Comparator Attachment Security Role Enjoyment Control 
EQ-5D-3L 
index score 
(n=442)
 
<0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.  Hypothesised associations are highlighted in bold font 
Table 42 can be considered together with Table 41.  These tables indicate that the EQ-5D-3L 
index score was strongly and positively associated with ICECAP-O items.  The possible 
exception to this was Attachment, which while shown to be significantly associated in Table 
41, does not show significant differences between the levels in Table 42.  The EQ-5D-3L 
index scores are greater at the higher capability levels of each ICECAP-O item.  There were 
significant differences between the scores of the top, and second and third levels, of each 
ICECAP-O item apart from Attachment.  There are no statistically significant differences 
between the bottom two levels of any item.  This may be a result of low statistical power at 
these levels due to low numbers. 
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Table 42: Mean EQ-5D-3L index scores by ICECAP-O item levels (n=447) 
Attribute and Level EQ-5D-3L index 
score (95% CI) 
Attachment*   
I can have all of the love and friendship that I want (n=268) 0.75 (0.72, 0.78) 
I can have a lot of the love and friendship that I want (n=129) 0.71 (0.67, 0.75) 
I can have a little of the love and friendship that I want (n=46) 0.67 (0.62, 0.73) 
I cannot have any of the love and friendship that I want (n=3) 0.34  
Security  
I can think about the future without any concern (n=115) 0.81 (0.77, 0.85)†† 
I can think about the future with only a little concern (n=202) 0.76 (0.73, 0.79)† 
I can only think about the future with some concern (n=103) 0.62 (0.57, 0.68) 
I can only think about the future with a lot of concern (n=27) 0.49 (0.39, 0.64) 
Role*  
I am able to do all of the things that make me feel valued (n=158) 0.84 (0.81, 0.87)†† 
I am able to do many of the things that make me feel valued (n=196) 0.73 (0.70, 0.76)† 
I am able to do a few of the things that make me feel valued (n=81) 0.54 (0.48, 0.60) 
I am unable to do any of the things that make me feel valued (n=10) 0.40 (0.21, 0.57) 
Enjoyment  
I can have all of the enjoyment and pleasure that I want (n=137) 0.84 (0.81, 0.87)†† 
I can have a lot of the enjoyment and pleasure that I want (n=216) 0.75 (0.72, 0.78)† 
I can have a little of the enjoyment and pleasure that I want (n=86) 0.53 (0.46, 0.59) 
I cannot have any of the enjoyment and pleasure that I want (n=8) 0.34 (0.13, 0.53) 
Control  
I am able to be completely independent (n=231) 0.82 (0.80, 0.85)†† 
I am able to be independent in many things (n=171) 0.67 (0.63, 0.71)† 
I am able to be independent in a few things (n=41) 0.46 (0.39, 0.54) 
I am unable to be at all independent (n=4)  0.22  
Statistically significant (P<0.01) differences in the mean EQ-5D-3L index score between †† all (any)/a lot (many) response 
options and † a lot (many)/few (a little).  *Items sum to less than 447 due to missing values. 
Table 43 shows the associations between the ICECAP-O items and the EQ-5D-3L items.  A 
number of associations were seen at the 1% level of statistical significance.  Expected 
associations are highlights in bold.  Of the 19 hypothesised associations all were significant at 
the 1% level of significance.  Five unexpected associations were identified, suggesting a 
closer association between the ICECAP-O and the EQ-5D-3L than was expected a priori. 
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Table 43: Associations between the ICECAP-O and EQ-5D-3L items (n=446) 
Comparator Attachment Security Role Enjoyment Control 
EQ-5D-3L      
Mobility
++ 
0.001** <0.001** <0.001** <0.001** <0.001** 
Self-care
++
 0.291 <0.001** <0.001** <0.001** <0.001** 
Usual
++
 <0.001** <0.001** <0.001** <0.001** <0.001** 
Pain
++
 0.203 0.003** <0.001** <0.001** <0.001** 
Anxiety
++
 <0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.   
Evidence of the direction of the relationship between the ICECAP-A items and the EQ-5D-
5L items is provided in Table 44.  Goodman & Kruskal’s gamma (rank correlation) is used.  
All correlations are negative due to the difference in scoring between the ICECAP-A and the 
EQ-5D-3L (i.e. the top level on ICECAP items is 4, whereas the top level for EQ-5D-3L 
items is 1).  Therefore, the results indicate that the better the health attribute score (e.g. 
greater mobility) the higher capability attribute score (e.g. more Control). 
The associations which were expected a priori to be particularly strong are highlighted in 
bold.  As can be seen, all these correlations were over 0.6, with the exception of the 
Enjoyment and pain/discomfort correlation which was unexpectedly low.  Strong correlations 
were also seen between Enjoyment and usual activities and between Role and mobility.  
Table 44: Correlations between ICECAP-O and EQ-5D-3L items (n=446) 
Comparator Attachment Security Role Enjoyment Control 
EQ-5D-3L      
Mobility -0.245 -0.365 -0.599 -0.513 -0.689 
Self-care -0.176 -0.478 -0.588 -0.568 -0.817 
Usual activities -0.325 -0.455 -0.721 -0.664 -0.771 
Pain/discomfort -0.117 -0.260 -0.436 -0.423 -0.444 
Anxiety/depression -0.293 -0.553 -0.573 -0.616 -0.564 
Highlighted in bold are the associations which were expected to be particularly strong. 
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7.3.4.1.3. Exploratory factor analysis 
As with the ICECAP-A results from the BEEP trial, the results from the ICECAP-O in the 
PastBP trial indicate the possibility of a closer relationship with the EQ-5D-3L measure than 
previously anticipated.  As described above, exploratory factor analysis provides a useful tool 
for further investigation of this relationship. 
The number of factors to be retained was again judged on the Kaiser criterion which 
suggested that two factors was the optimal solution (see Figure 20). 
Figure 20: Factor analysis eigen values by factor number 
 
 
To control for the potential that the factors are correlated a Promax rotations was used.  In a 
post-hoc test this was judged as the correct rotation as factors were shown to be correlated (-
0.515) at a levels greater than 0.32, which is the cut off at which a oblique rotation becomes 
appropriate 
Table 45 shows a two factor solution, indicating that the pooled items of the EQ-5D-3L and 
the ICECAP-O measure two different attributes.  Results suggest that the ICECAP-A and 
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EQ-5D-3L measure two different underlying constructs.  With the exception of 
anxiety/depression, all EQ-5D-3L items loaded onto factor one.  Anxiety/depression and all 
ICECAP-O items, apart from control, loaded strongly onto factor 2.  Control was split 
between factor one and two, with a somewhat greater loading onto factor one.  
Table 45: Exploratory factor analysis comparing the ICECAP-A and EQ-5D-3L items 
(n=446) 
 Rotated item loading on a 2-factor 
solution. 
 Factor 1 Factor 2 
EQ-5D-3L   
Mobility 0.862  
Self-Care 0.818  
Usual Activities 0.819  
Pain 0.636  
Anxiety and Depression  -0.576 
ICECAP-A   
Attachment  0.633 
Security  0.678 
Role -0.218 0.703 
Enjoyment  0.778 
Control -0.553 0.312 
Factor correlations -0.531  
Loadings of less than 0.2 are left blank to assist the interpretation of the results.   
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7.3.4.2. The SF-36 
7.3.4.2.1. ICECAP-O tariff score and SF-36 
The correlations between the ICECAP-O tariff score and the SF-36 subscales are presented in 
Table 46 
6
.  All correlations were moderate and statistically significant at the 1% level.  A 
priori expectations were that all SF-36 sub-scales would correlate moderately with the 
ICECAP-O tariff score.  For the purposes of comparison, the correlations between the EQ-
5D-3L and the SF-36 sub-scales are provided.  Correlations between the ICECAP-O and the 
SF-36 sub-scales that were expected to be particularly strong are highlighted in bold.  These 
correlations were all over 0.5.  The mental health sub-scale and ICECAP-O tariff score also 
produced a correlation over 0.5.  A comparison with the EQ-5D-3L shows that for the 
physical subscales there was a trend for stronger correlations with the EQ-5D-3L index score 
than the ICECAP-O tariff score for all subscales apart from general health.  For the 
psychological sub-scales, correlations were similar on all scales except for mental health, 
where the correlation with the ICECAP-O tariff scores was notably stronger than with the 
EQ-5D-3L index. 
                                                 
6
 SF-36 T-scores were used in this analysis.  As described in Table 6 a T-score has the advantage of 
standardising scores against a population norm which is fixed at 50.  This is allows easier interpretation of scale 
scores (e.g. below 50 on any scale is a worse health state than the population norm). 
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Table 46: Correlations between ICECAP-O tariff and SF-36 sub-scales 
SF-36 Correlation with 
ICECAP-O tariff 
Correlation with EQ-
5D-3L index 
Physical    
Physical functioning (n=418) 0.467** 0.685** 
Physical role (n=470) 0.435** 0.557** 
Bodily Pain (n=474) 0.328** 0.696** 
General Health (n=454) 0.609** 0.506** 
Psychological    
Vitality (n=457) 0.599** 0.604** 
Social functioning (n=478) 0.527** 0.589** 
Emotional role (n=462) 0.436** 0.399** 
Mental health (n=472) 0.521** 0.382** 
* Significant at the 5% level, **Significant at the 1% level.  All scales were expected to be associated with the 
ICECAP-O tariff - highlighted in bold are the associations which were expected to be particularly strong.  
7.3.4.2.2. ICECAP-O items and the SF-36 
Table 47 shows the associations between the eight SF-36 sub-scales and the five ICECAP-O 
items.  Of the 40 pairs, 39 showed significant associations at the 5% statistical significance 
level, while 38 of these associations were significant at the 1% level.  Of the 31 hypothesised 
associations all were significant at the 1% level.  Therefore, 8 associations were found that 
were not expected a priori.  These findings provided mixed support for the a priori 
hypotheses: all hypothesised associations were significant, but a number of additional 
unexpected associations between the SF-36 and the ICECAP-O items were identified.  These 
suggest a closer association between the SF-36 and the ICECAP-O than was anticipated. 
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Table 47: Associations between ICECAP-O items and SF-36 sub-scales 
SF-36 scale Attachment Security Role Enjoyment Control 
Physical      
Phys func (n=418)
 
0.009** <0.001** <0.001** <0.001** <0.001** 
Phys role (n=470)
 
0.012* <0.001** <0.001** <0.001** <0.001** 
Pain (n=474)
 
0.400 <0.001** <0.001** <0.001** <0.001** 
Gen health (n=454)
 
<0.001** <0.001** <0.001** <0.001** <0.001** 
Psychological      
Vitality (n=457)
 
<0.001** <0.001** <0.001** <0.001** <0.001** 
Social func (n=478)
 
<0.001** <0.001** <0.001** <0.001** <0.001** 
Emo role (n=462)
 
0.009** <0.001** <0.001** <0.001** <0.001** 
Mental health 
(n=472)
 
<0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.   
The three SF-36 sub-scales demonstrating the strongest correlation with the ICECAP-O 
(General Health, Vitality and Social Functioning) were analysed in greater depth (below).  
Table 47 shows that these three subscales were significantly associated with all ICECAP-O 
items at the 1% significance level.   
Table 48 indicates that SF-36 general health subscale scores are higher at the higher 
capability levels for each ICECAP-O item.  Significant differences were found between the 
scores on the second and third levels for all items.  On four of the items significant 
differences in the SF-36 general health subscale scores were found between the lower two 
levels, while a significant difference between the top two levels was only found on one item. 
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Table 48: Mean SF-36 general health sub-scale score by ICECAP-O item level (n=421) 
Attribute and Level SF-36 General Health 
sub-scale t score (95% 
CI) 
Attachment   
I can have all of the love and friendship that I want (n=249) 46.48 (45.24, 47.73) 
I can have a lot of the love and friendship that I want (n=122) 44.30 (42.73, 45.87)†† 
I can have a little of the love and friendship that I want (n=46) 39.54 (36.86, 42.23) 
I cannot have any of the love and friendship that I want (n=3) 35.29 (-3.52, 74.11) 
Security  
I can think about the future without any concern (n=107) 51.42 (50.06, 52.78)††† 
I can think about the future with only a little concern (n=191) 45.93 (44.74, 47.11)†† 
I can only think about the future with some concern (n=95) 39.26 (37.29, 41.11)† 
I can only think about the future with a lot of concern (n=28) 33.85 (30.46, 37.23) 
Role  
I am able to do all of the things that make me feel valued (n=147) 50.97 (49.68, 52.26) 
I am able to do many of the things that make me feel valued (n=186) 43.97 (42.84, 45, 10)†† 
I am able to do a few of the things that make me feel valued (n=79) 37.77 (35.56, 39.97)† 
I am unable to do any of the things that make me feel valued (n=8) 30.23 (20.86, 39.60) 
Enjoyment  
I can have all of the enjoyment and pleasure that I want (n=127) 51.19 (49.81, 52.56) 
I can have a lot of the enjoyment and pleasure that I want (n=203) 45.13 (44.06, 46.21)†† 
I can have a little of the enjoyment and pleasure that I want (n=85) 36.56 (34.49, 38.62)† 
I cannot have any of the enjoyment and pleasure that I want (n=6) 30.13 (19.01, 41.25) 
Control  
I am able to be completely independent (n=217) 49.01 (47.90, 50.12) 
I am able to be independent in many things (n=160) 42.50 (41.18, 43.83)†† 
I am able to be independent in a few things (n=39) 34.87 (31.55, 38.19)† 
I am unable to be at all independent (n=5)  31.00 (15.01, 46.99) 
Statistically significant differences in the mean SF-36 general health sub-scale score between † unable and a 
little, †† a little and a lot and ††† a lot and all of the things. 
Table 49 shows higher scores on the SF-36 vitality sub-scale were seen at higher capability 
levels on each of the ICECAP-O items.  Pronounced differences in scores between the top 
two levels and the second and third levels on each item were found.  Differences in scores 
between the bottom two capability levels were less pronounced.  
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Table 49: Mean SF-36 vitality sub-scale score by ICECAP-O item level (n=457) 
Attribute and Level SF-36 Vitality sub-scale 
t score (95% CI) 
Attachment   
I can have all of the love and friendship that I want (n=256) 50.23 (48.94, 51.52) 
I can have a lot of the love and friendship that I want (n=120) 48.93 (47.16, 50.69)†† 
I can have a little of the love and friendship that I want (n=44) 41.70 (38.97, 44.44) 
I cannot have any of the love and friendship that I want (n=3) 40.85 (-3.88, 85.59) 
Security  
I can think about the future without any concern (n=111) 55.23 (53.61, 56.85) ††† 
I can think about the future with only a little concern (n=184) 49.77 (48.37, 51.16)†† 
I can only think about the future with some concern (n=101) 43.20 (41.35, 45.06)† 
I can only think about the future with a lot of concern (n=28) 39.07 (35.56, 42.57) 
Role  
I am able to do all of the things that make me feel valued (n=152) 54.98 (53.66, 56.30) ††† 
I am able to do many of the things that make me feel valued (n=185) 48.26 (46.94, 49.59)†† 
I am able to do a few of the things that make me feel valued (n=77) 39.85 (37.62, 42.07) 
I am unable to do any of the things that make me feel valued (n=9) 37.52 (30.87, 44.17) 
Enjoyment  
I can have all of the enjoyment and pleasure that I want (n=131) 54.92 (53.41, 56.43) ††† 
I can have a lot of the enjoyment and pleasure that I want (n=199) 49.55 (48.35, 50.75)†† 
I can have a little of the enjoyment and pleasure that I want (n=87) 39.27 (37.20, 41.35) 
I cannot have any of the enjoyment and pleasure that I want (n=7) 39.07 (32.05, 46.09) 
Control  
I am able to be completely independent (n=221) 52.99 (51.76, 54.22) ††† 
I am able to be independent in many things (n=160) 46.22 (44.77, 47.68)†† 
I am able to be independent in a few things (n=38) 38.68 (35.77, 41.60) 
I am unable to be at all independent (n=5)  33.86 (15.59, 52.13) 
Statistically significant differences in the mean SF-36 vitality sub-scale score between † unable and a little, †† a 
little and a lot and ††† a lot and all of the things. 
Table 50 indicates that on all ICECAP-O items the higher capability levels, the higher the 
scores on the SF-36 social functioning sub-scale.  On the items of Role and Enjoyment, 
which might be considered to be the closest of the ICECAP items to social functioning, 
significant and pronounced differences were seen between the bottom two levels: those who 
could not have any enjoyment or were unable to do any of the things that made them feel 
valued, scored very low on the social functioning sub-scale. 
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Table 50: Mean SF-36 social functioning sub-scale scores by ICECAP-O item level 
(n=478) 
Attribute and Level SF-36 social functioning 
sub-scale t score (95% 
CI) 
Attachment   
I can have all of the love and friendship that I want (n=263) 49.07 (47.79, 50.35) 
I can have a lot of the love and friendship that I want (n=128) 46.88 (44.92, 48.84)†† 
I can have a little of the love and friendship that I want (n=49) 41.71 (38.61, 44.82) 
I cannot have any of the love and friendship that I want (n=3) 35.03 (-13.81, 83.87) 
Security  
I can think about the future without any concern (n=113) 53.33 (52.08, 54.57)††† 
I can think about the future with only a little concern (n=200) 48.59 (47.21, 49.96)†† 
I can only think about the future with some concern (n=103) 42.45 (40.05, 44.84)† 
I can only think about the future with a lot of concern (n=28) 35.62 (30.86, 40.38) 
Role  
I am able to do all of the things that make me feel valued (n=154) 52.78 (51.60, 53.96) 
I am able to do many of the things that make me feel valued (n=196) 48.08 (46.68, 49.48)†† 
I am able to do a few of the things that make me feel valued (n=82) 39.02 (36.44, 41.61)† 
I am unable to do any of the things that make me feel valued (n=10) 29.58 (20.38, 38.77) 
Enjoyment  
I can have all of the enjoyment and pleasure that I want (n=134) 52.49 (51.05, 53.93) 
I can have a lot of the enjoyment and pleasure that I want (n=213) 48.40 (47.09, 49.71)†† 
I can have a little of the enjoyment and pleasure that I want (n=89) 39.94 (37.48, 42.39)† 
I cannot have any of the enjoyment and pleasure that I want (n=8) 26.85 (17.41, 36.29) 
Control  
I am able to be completely independent (n=229) 51.13 (49.96, 52.31) 
I am able to be independent in many things (n=169) 45.20 (43.53, 46.87)†† 
I am able to be independent in a few things (n=41) 38.89 (35.12, 42.67)† 
I am unable to be at all independent (n=5)  33.94 (7.54, 60.34) 
Statistically significant differences in the mean SF-36 social functioning sub-scale score between † unable and a 
little, †† a little and a lot and ††† a lot and all of the things. 
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7.4.3.3. Modified Ranking Scale  
The Modified Rankin Scale scores and the ICECAP-O tariff scores were significantly 
associated at the 1% level, which is in line with a priori hypotheses.  Table 51 shows a trend 
of higher ICECAP-O tariff scores at lower levels of disability.  Differences in ICECAP-O 
tariff scores are more pronounced at the bottom levels of the Modified Rankin Scale, which 
indicate moderate and moderately severe disability. 
Table 51: Mean ICECAP-O tariff score by Modified Rankin Scale score (n=452) 
Modified Ranking 
Scale score 
ICECAP-O tariff score 
Level 0 0.92 (0.9, 0.94) 
Level 1 0.89 (0.88, 0.91)†† 
Level 2 0.84 (0.83, 0.86)† 
Level 3 0.76 (0.72, 0.79) 
Level 4 0.69 (0.60, 0.78) 
Statistically significant differences in the mean SF-36 social functioning sub-scale score between †† no 
significant disability and slight disability and †slight disability and moderate disability.  
An item-by-item analysis, presented in Table 52, shows that the Modified Ranking Scale 
scores were significantly associated with each ICECAP-O item.  Two additional associations 
(with Attachment and Enjoyment) were found that were not hypothesised.  This suggests a 
closer than expected association between the ICECAP-O and the Modified Rankin Scale. 
Table 52: Associations between Modified Rankin Scale and ICECAP-O items (n=452) 
Comparator Attachment Security Role Enjoyment Control 
Modified 
Rankin Scale
 <0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level.   
7.3.4.5. Symptoms and side-effects 
Table 37 shows a moderate, statistically significant correlation of -0.477 between the 
ICECAP-O tariff score and the number of symptoms and side effects a person reports.  This 
correlation indicates that the higher the number of symptoms and side-effects a person 
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reports, the lower the ICECAP-O tariff score will be.  The symptoms and side-effects 
analysis was an exploratory analysis. 
To assess the association further, symptoms and side effects were transformed into a 
categorical variable of: few (3 or less reported symptoms or side-effects), some (more than 3 
and 9 or less) and many (more than 9).  Table 53 shows the ICECAP-O tariff scores by group 
for those who have few, some and many side-effects.  The group with few side effects had 
higher mean ICECAP-O tariff scores than those with some, and those with some had higher 
scores than those with many.  The differences between the groups were statistically 
significant at the 1% level.    
Table 53: Mean ICECAP-O tariff scores by number of symptoms and side-effects 
(n=299) 
 ICECAP-O tariff score (95% 
CI) 
Few 
(Equal to or less than 3) 
0.92 (0.90, 0.94)†† 
Some 
(More than 3 and less 
than or equal to 9) 
0.85 (0.83, 0.87)† 
Many 
(More than 9) 
0.75 (0.71, 0.79) 
Statistically significant difference between †† Few/Some and † Some/Many symptoms and side-effects at P<0.01 level. 
Table 54 shows the associations between the categorical symptoms and side-effects variables 
and each of the ICECAP-O items.  All of the ICECAP-O items were significantly associated 
with the number of symptoms and side-effects at the 1% significance level. 
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Table 54: Associations between number symptoms and side-effects and ICECAP-O 
items (n=299) 
 Attachment Security Role Enjoyment Control  
SSE 0.001** <0.001** <0.001** <0.001** <0.001** 
* Significant at the 5% level, **Significant at the 1% level. 
7.3.5. Comparison of results with hypotheses 
In line with the hypothesis based approach to validity testing, hypotheses were formed a 
priori.  Table 55 presents a comparison of hypotheses and the results of the PastBP trial 
analysis.  These results provide positive, supportive evidence of ICECAP-O validity in the 
PastBP trial patient population.  The overwhelming majority of hypothesised associations 
were confirmed by the results.  Table 55 shows confirmatory evidence of the hypothesised 
associations between the ICECAP-O tariff score and the socio-demographic, physical health 
and psychological health variables.  The strength of the correlations were moderate to weak, 
which was as expected. 
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Table 55: A comparison of hypotheses and results from the PastBP trial 
Hypotheses Results 
 Association Direction Strength  Association Direction Strength 
Socio-demographic Socio-demographic 
Age Yes   Age No   
Gender No   Gender No   
Physical health Physical health 
EQ-5D-3L Yes Positive  EQ-5D-3L Yes Positive Moderate 
EQ-5D-3L 
VAS 
Yes Positive  EQ-5D-3L 
VAS 
Yes  Positive Moderate 
SSE Exploratory analysis SSE Yes Negative Moderate 
Physical 
functioning 
Yes Positive  Physical 
functioning 
Yes Positive Moderate 
Physical 
role 
Yes Positive  Physical 
role 
Yes Positive Moderate 
Bodily 
pain 
Yes Negative  Bodily 
pain 
Yes Negative Weak 
General 
heatlh 
Yes Positive  General 
heatlh 
Yes Positive Moderate 
Psychological health Psychological health 
Vitality Yes Positive  Vitality Yes Positive Moderate 
Social 
functioning 
Yes Positive  Social 
functioning 
Yes Positive Moderate 
Emotional 
role 
Yes Positive  Emotional 
role 
Yes Positive Moderate 
Mental 
health 
Yes Positive  Mental 
health 
Yes Positive Moderate 
 
No significant association between gender and ICECAP-O scores was expected: none was 
seen.  An association between age and the ICECAP-O tariff score was expected but not 
found.  Item by item analysis provided mixed support for the hypotheses: as hypothesised the 
ICECAP-O attribute of Control, was significantly associated with age, and an unexpected 
association was found between age and Security. 
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The associations between the measures of physical and psychological health in the PastBP 
trial and the ICECAP-A tariff score were all as expected.  The EQ-5D-3L index score and the 
EQ-5D-3L VAS score both showed the moderate, positive correlation which was 
hypothesised a priori.  All the subscales of the SF-36 showed the expected direction and 
strength of correlation. 
The item-by-item analysis of the ICECAP-O showed some notable deviations from the a 
priori hypotheses.  Where an association was expected, these associations were found in the 
anticipated direction.  However, for both the EQ-5D-3L and the SF-36 sub-scales there were 
a number of associations found with the ICECAP-O items that were not expected a priori.  
These “extra” associations are suggestive of a closer relationship between the ICECAP-O and 
measures of physical and psychological functioning than anticipated.  The mobility and usual 
activity items showed additional associations with Security, while Attachment showed 
additional associations with the usual activities and anxiety/depression items.  The four 
psychological sub-scales of the SF-36 were unexpectedly correlated with the Security item of 
the ICECAP-O.  The physical sub-scales of the SF-36 were unexpectedly associated with 
Attachment, with 3 unexpected associations between pairs.  
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CHAPTER 8. QUANTITATIVE STUDY OF THE 
VALIDITY AND RESPONSIVENESS OF THE ICECAP 
MEASURES: RESPONSIVENESS RESULTS 
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8.1. Chapter introduction 
This chapter reports the results of two separate anchor based responsiveness analyses for the 
ICECAP-A and ICECAP-O measures using data from the BEEP and PastBP trials 
respectively.  The results from the ICECAP-A analysis are reported first, followed by the 
ICECAP-O analysis. 
A description of the participants included in each analysis is provided at the start of each 
section.  The choice of anchors is then described.  Multiple anchor analyses are then 
presented for each measure.   Each anchor analysis consists of: 1) an item-by-item analysis of 
the change in response profiles of the ICECAP measures; 2) an inspection of the correlation 
between the non-weighted ICECAP scores and the anchor and an analysis of the change in 
non-weighted ICECAP scores in participants whose anchor scores have improved or 
worsened; 3) an inspection of the correlation between the ICECAP tariff scores and the 
anchor and an analysis of the change in ICECAP tariff scores in participants whose anchor 
scores have improved or worsened. 
 As described in Chapter 3, it is recommended that numerous anchors are used in a 
responsiveness analysis [261].  This has the practical implication of making the presentation 
of results repetitive.  To reduce repetition, a number of the analyses have been placed in 
appendices and summaries provided in this chapter.  The analyses retained in full were 
chosen on the basis that, together, they provide a broad and varied selection of anchors 
measuring general health, psychological health, disability and social functioning.  The EQ-
5D-3L has been retained in both ICECAP-A and ICECAP-O analyses due to the frequency 
with which it is currently used in health economic analysis.  The choice of those anchors 
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retained in the chapter was not based on whether the results provide positive or negative 
indications of ICECAP measure responsiveness. 
8.2. BEEP trial 
8.2.1. Participant characteristics 
The characteristics of the BEEP trial participants used in this responsiveness analysis are 
presented in Table 56.  The average age of participants is 64, with a roughly equal proportion 
of male and female participants.  The average ICECAP-A capability tariff scores were higher 
at both baseline and follow-up than values reported in the general population [116].  
Participants reported a mean baseline value of 0.64 for the EQ-5D-3L, which was below the 
UK national average for this age group [311].  The mean GAD-7 and PHQ-8 scores did not 
indicate wide-spread anxiety disorder or depression within the sample [295,296].  The co-
morbidities questionnaire completed at baseline, was not completed at 6 month follow-up; 
therefore change in health could not be assessed using this questionnaire. 
Table 56 shows that the mean value of the ICECAP-A tariff has not changed between 
baseline and follow-up.  Mean change can “hide” individual change and when completing a 
responsiveness analysis the range of change that is present in a sample is an important 
consideration.  Figure 21 shows the distribution of change amongst BEEP participants.  As 
can be seen, the majority of participants either do not change or change by less than 0.1.  
Therefore, this responsiveness analysis was completed in a population that showed small 
changes in capability and had high levels of capability at baseline.
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Table 56: Characteristics BEEP trial participants, including mean scores and median scores 
Attribute Mean baseline 
values  (SD) 
Median 
baseline value 
(IQR) 
Mean follow-up 
value (SD) 
Median follow-
up value (IQR) 
Measure range Sample size 
Socio-demographic       
Age mean  63.9 (9.83)     357 
Gender (% male) 49.3%     357 
Health and functioning       
ICECAP-O tariff  0.89 (0.11) 0.91 (0.85, 0.97) 0.89 (0.12) 0.92 (0.85, 0.97) 0 to 1 355 
EQ-5D-3L index 0.64 (0.23) 0.69 (0.62, 0.76) 0.70 (0.22) 0.73 (0.69, 0.8) -0.59 to 1 351 
WOMAC Pain 8.30 (3.45) 8 (6, 11) 6.25 (3.81) 6 (3, 9) 0 to 18 353 
WOMAC Stiffness 3.66 (1.72) 4 (3,5) 2.98 (1.77) 3 (2, 4) 0 to 8 357 
WOMAC Functioning 27.63 (12.1) 27 (20, 37) 21.55 (13.68) 20 (10, 32) 0 to 62 353 
GAD-7 3.14 (4.41) 1 (0, 4) 2.50 (3.91) 1 (0, 4) 0 to 21 344 
PHQ-8 3.69 (4.44) 2 (1, 5) 2.99 (3.89) 2 (0, 4) 0 to 24 341 
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Figure 21: Frequency distribution of change in ICECAP-A tariff score 
 
8.2.2. Choice of anchors from BEEP trial 
Table 57 shows the correlation of change scores between measures administered at baseline 
and follow-up.  The strongest correlations were seen between the WOMAC subscales, 
between the GAD-7 and PHQ-8 and between the WOMAC subscale of pain and EQ-5D-3L.  
All other correlations were below 0.3, with the majority of correlations with the ICECAP-A 
tariff below 0.2.  The strongest correlations were with the EQ-5D-3L index score, GAD-7 
and PHQ-8. 
The process through which anchors were chosen for the responsiveness analysis is described 
in greater detail in Chapter 3 and Chapter 6.  Based on the strength of correlations between 
ICECAP-A and other measures, and other considerations previously described, the following 
assessments of responsiveness will be completed: 
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 An assessment using the EQ-5D-3L 
 An assessment using the GAD-7 
 An assessment using the PHQ-8 (placed in appendices)
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 Table 57: Correlations between change scores of measures in the BEEP trial
 ICECAP-O 
tariff  
EQ-5D-3L 
index 
WOMAC Pain WOMAC 
Stiffness 
WOMAC 
Functioning 
GAD-7 PHQ-8 
ICECAP-A tariff 1.00       
EQ-5D-3L Index 0.255 1.00      
WOMAC Pain -0.055 -0.402 1.00     
WOMAC Stiffness -0.151 -0.236 0.507 1.00    
WOMAC Functioning -0.103 -0.380 0.737 0.592 1.00   
GAD-7 -0.205 -0.202 0.109 0.040 0.129 1.00  
PHQ-8 -0.190 -0.232 0.057 0.092 0.090 0.511 1.00 
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8.2.3. EQ-5D-3L Index anchor analysis 
8.2.3.1. Anchor group formation 
EQ-5D-3L anchor groups were formed using the minimally important difference values taken 
from Walters and Brazier of 0.074 [262].  Change groups were formed of participants whose 
health status had improved or worsened by equal to or greater than +/-0.074 on the EQ-5D-
3L index.  The mean change in EQ-5D-3L index score in each change group was therefore 
larger than 0.074 (values included in Table 58); therefore these are not groups of minimally 
important change, rather groups of participants who all report at least a minimally important 
change
7
.  EQ-5D-3L change was similar in the improved and worsened groups.  These 
changes are shown in Table 58.  
Table 58: Group numbers and mean EQ-5D-3L index change in the EQ-5D-3Lindex 
anchor groups (n=341) 
Anchor 
group 
Number 
in group 
Mean EQ-5D-
3L change in 
group (95% 
CI) 
Mean EQ-5D 
3L change as 
% of possible 
change 
Improved 97 0.29 (0.254, 
0.326) 
18.2% 
No change 206 0.01 (0.001, 
0.013) 
0.4% 
Worsened 38 -0.31 (-0.373, -
0.241) 
19.3% 
 
                                                 
7
 The mean change in all anchor groups presented in this chapter is greater than the minimally important change 
used to form them.  This can be assessed by the reader through considering the mean anchor change and the 
mean anchor change as a percentage of possible change presented at the start of each section. 
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8.2.3.2. Item by item analysis 
Figure 22 shows the response profiles at baseline and follow-up for the group of respondents 
who reported a reduction in their EQ-5D-3L index scores.  These results are presented in 
numerical form in Appendix 23.  The response profile of these participants changed, with 
reductions in percentage of respondents answering level 4 (full capability) of all items.  The 
largest reductions in the percentage of respondents answering level 4 was for the Enjoyment 
and Autonomy item, where in both cases the reduction was 21 percentage points.  Smaller 
reductions, of between 6 and 11 percentage points was found for the other items.  For all 
items minimal change occurred in the percentage of respondents answering the bottom level 
of capability (level 1). 
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Figure 22: ICECAP-A response profile at baseline and follow-up for participants 
reporting a worsening of their EQ-5D-3L index scores 
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Figure 23 shows changes in the response profiles of the ICECAP-A in participants reporting 
an improvement in their EQ-5D-3L index scores.  These results are presented in numerical 
form in Appendix 24.  The change in the response profile of participants reporting an 
improvement in EQ-5D-3L scores was less pronounced than the change seen for participants 
who reported a worsening.  Increases of 8, 13 and 10 points were seen in the percentage of 
participants reporting full-capability (level 4) on Stability, Autonomy and Achievement 
respectively.  Smaller changes of 4 and 1 points in the percentage of respondents answering 
the top level of Attachment and Enjoyment were found.  There was minimal change in the 
percentage of respondents answering the bottom level on each item. 
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Figure 23: ICECAP-A response profile at baseline and follow-up for participants 
reporting an improvement in their EQ-5D-3L index scores 
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8.2.3.3. Non-weighted ICECAP scores 
Table 59 shows that cross-sectional correlations between the EQ-5D-3L index and the non-
weighted ICECAP-A score at baseline and follow-up were moderate and statistically 
significant at the 1% level.  The correlation of the change in these measures between baseline 
and 6 month follow-up was weak and significant at the 1% level. 
Table 59: Cross-sectional and change correlations between EQ-5D-3L index and non-
weighted ICECAP-A scores (n=341) 
 ICECAP-A 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
EQ-5D-3L index 
score 
0.477** 0.512** 0.191** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 60 shows change in non-weighted ICECAP-A scores by EQ-5D-3L index anchor 
change groups.  In the group of participants reporting an improvement in EQ-5D-3L scores, 
the mean non-weighted ICECAP-A score increased.  In the group reporting a worsening of 
their EQ-5D-3L index scores the mean non-weighted ICECAP-A score decreased.  The 
change in ICECAP-A score was larger in the group that had worsened than in the group that 
had improved.  The mean EQ-5D-3L index score change in these anchor groups was similar; 
therefore the proportion of ICECAP-A change to EQ-5D-3L anchor change was larger for the 
group that had worsened than for the group that had improved.  The effect sizes for the 
improved group were small, while for the group that had worsened they were moderate (or 
approaching moderate). 
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Table 60: Mean change in non-weighted ICECAP-A scores by EQ-5D-3L index anchor 
change groups (n=341) 
Anchor 
group 
Baseline 
ICECA
P-A 
scores 
Follow-up 
ICECAP-
A scores 
Mean ICECAP-
A change 
(95% CI) 
Change as 
a % of 
possible 
change 
ES SRM 
Improved 16.423 16.897 0.474**                  
(-0.123, 0.826) 
3.2% 0.2 0.27 
No change 17.131 17.150 0.019                      
(-0.190, 0.229) 
0.1% 0.01 0.01 
Worsened 16.895 15.842 -1.053**        
(0.496, 1.609) 
7.0% 0.47 0.62 
* Significant at the 5% level, **Significant at the 1% level. 
8.2.3.4. ICECAP-A tariff score 
Table 61 shows the correlations between the ICECAP-A tariff and the EQ-5D-3L index at 
baseline, follow-up and over time.  Baseline and follow-up cross-sectional correlations were 
moderate and significant at the 1% level.  The correlation of the change scores between 
baseline and 6 month follow-up was weak and significant at the 1% level.   
Table 61: Cross-sectional and change correlations between the EQ-5D-3L index and 
ICECAP-A tariff (n=341) 
 ICECAP-A 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
EQ-5D-3L index  0.458** 0.484** 0.255** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 62 and Figure 24 show change in ICECAP-A tariff score by EQ-5D-3L index anchor 
groups.  In the group of participants reporting an improvement in the EQ-5D-3L scores, a 
small mean increase in ICECAP-A tariff scores was observed, which was significant at the 
5% level.    The effect sizes and SRMs for this change were small.  In participants reporting a 
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reduction in the EQ-5D-3L scores, a moderate reduction in ICECAP-A tariff scores was seen, 
which was significant at the 1% level.  The effect sizes and SRMs were moderate.  There are 
differences in the mean change of the ICECAP-A between patients who reported improved or 
reduced EQ-5D-3L scores, with those reporting a worsening reporting a larger reduction.  
Change as a percentage of possible change was smaller for the ICECAP-A tariff score than 
for the non-weighted ICECAP-A scores.   
Table 62: Mean change in ICECAP-A tariff scores by EQ-5D-3L index anchor change 
groups (n=341) 
Anchor 
group 
Baseline 
ICECA
P-A 
scores 
Follow-up 
ICECAP-
A scores 
Mean ICECAP-
A change 
(95% CI) 
Change as 
a % of 
possible 
change 
ES SRM 
Improved 0.863 0.884 0.021*          
(0.001, 0.041) 
2.1% 0.17 0.21 
No change 0.898 0.895 -0.003                   
(-0.128, 0.007) 
0.3% 0.02 0.03 
Worsened 0.890 0.836 -0.054**                 
(-0.084, -0.024) 
5.4% 0.53 0.59 
* Significant at the 5% level, **Significant at the 1% level. 
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Figure 24: Mean change in ICECAP-A tariff scores by EQ-5D-3L index anchor change 
groups (n=341) 
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8.2.4. GAD-7 anchor analysis 
8.2.4.1. Anchor group formation 
Anchor groups from the GAD-7 score were not formed using a minimally important 
difference as no value could be found in the existing literature.  The option of using the inter-
quartile range of change was examined.  The interquartile range values were -1 and 0.  These 
values were not considered a large enough change for this analysis (e.g. using a change value 
of 0 to define an anchor group is not possible).  Therefore, an arbitrary value of change by 2 
points on the GAD-7 was used to define groups.  This value allowed adequate numbers in 
each of the change groups (see Table 63).  No assumption can be made as to whether this 
change was important to participants.   
Table 63: Group numbers and mean GAD-7 change scores in GAD-7 anchor groups 
(n=335) 
Anchor 
group 
Number 
in group 
Mean GAD-7 
change in 
group (95% 
CI) 
Mean GAD-7 
change as % 
of possible 
change 
Improved 83 4.843 (4.043, 
5.642) 
23.1% 
No change 209 0.047 (-0.032, 
0.126) 
0.2% 
Worsened 43 -4.93 (-6.076, -
3.783) 
23.5% 
 
8.2.4.2. Item by item analysis 
Figure 25 shows the response profiles at baseline and follow-up for the group of respondents 
reporting a worsening of their GAD-7 psychological health status (an increase in their GAD-
7 scores).  These results are presented in numerical form in Appendix 25.  Reductions of 14 
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percentage points in respondents answering the level 4 (full capability) of the Attachment and 
Enjoyment were found.  Reductions of 12 and 9 percentage points were found in those 
answering the top level of Stability and Achievement items respectively.  Little change was 
found in the Autonomy item.  There was notable change in the percentage of respondents 
answering the lower capability levels (level 1 and 2) for Stability and Attachment items. 
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Figure 25: ICECAP-A response profile at baseline and follow-up for participants 
reporting a worsening in their GAD-7 health status 
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Figure 26 shows response profiles at baseline and follow up for the group of respondents who 
reported an improvement in their GAD-7 psychological health status (a reduction in GAD-7 
scores). These results are presented in numerical form in Appendix 26.  Changes were 
smaller and less pronounced than changes in the group reporting a worsening of their GAD-7 
psychological health status.  The largest changes in the percentage of respondents answering 
level 4 were found in the Stability and Enjoyment items where there were 9 and 6 percentage 
point increases respectively.  Smaller changes were found in the other items.  In comparison 
to the group of respondents reporting worsening GAD-7 psychological health status, less 
pronounced change in the percentage of respondents answering the bottom two levels was 
found. 
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Figure 26: ICECAP-A response profile at baseline and follow-up for participants 
reporting an improvement in their GAD-7 health status 
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8.2.4.3. Non-weighted ICECAP-A score 
Table 64 shows that cross-sectional correlations between the GAD-7 and the non-weighted 
ICECAP-A at baseline and follow-up were moderate and statistically significant at the 1% 
level.  The correlation of the change in these measures between baseline and follow-up was 
weak and significant at the 1% level. 
Table 64: Cross-sectional and change correlations between the GAD-7 and non-
weighted ICECAP-A scores (n=335) 
 ICECAP-A 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
GAD-7 score -0.522** -0.515** -0.203** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 65 shows change in non-weighted ICECAP-A scores by GAD-7 anchor change groups.  
In the group of participants reporting an improvement in GAD-7 scores, the mean non-
weighted ICECAP-A score increased.  In the group reporting a worsening of their GAD-7 
scores, the mean non-weighted ICECAP-A score decreased.  The change in ICECAP-A score 
was larger in the group that had worsened than in the group that had improved.  Effect sizes 
for the group that improved were small, while for the group that worsened they were 
moderate. 
The use of the non-weighted EQ-5D-3L as a reference measure (Table 66) shows differences 
from the non-weighted ICECAP-A analysis (Table 65).  Change in the EQ-5D-3L scores as a 
percentage of possible change was larger for the group reporting an improvement in GAD-7 
scores than for those reporting a worsening of scores.  This is the reverse of what was found 
in the ICECAP-A analysis.  The size of the change as a percentage of possible change, effect 
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sizes and SRMs, were larger for the ICECAP-A in the worsened group and larger for the EQ-
5D-3L in the improved group.. 
Table 65: Mean change in non-weighted ICECAP-A scores by GAD-7 anchor change 
groups (n=335) 
Anchor 
group 
Baseline 
ICECAP-
A scores 
Follow-up 
ICECAP-
A scores 
Mean 
ICECAP-A 
change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 16.012 16.390 0.378                
(-0.024, 0.780) 
2.5% 0.15 0.21 
No change 17.430 17.569 0.139                
(-0.05, 0.328) 
0.9% 0.07 0.10 
Worsened 16.442 15.279 -1.163**            
(-1.789, 0.537) 
7.7% 0.53 0.57 
* Significant at the 5% level, **Significant at the 1% level. 
Table 66: Mean change in non-weighted EQ-5D-3L scores by GAD-7 anchor change 
groups (n=335) (for comparison) 
Anchor 
group 
Baseline 
EQ-5D-
3L scores 
Follow-up 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 8.16 7.308 -0.852**             
(-1.142, -0.561) 
8.5% 0.56 0.65 
No change 7.421 7.015 -0.406**                 
(-0.56, -0.253) 
4.1% 0.35 0.37 
Worsened 7.878 8.097 0.219                  
(-0.69, 0.251) 
2.2% 0.14 0.14 
* Significant at the 5% level, **Significant at the 1% level. 
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8.2.4.4. ICECAP-A tariff score 
Table 67 shows the cross sectional and change correlations between the GAD-7 and the 
ICECAP-A tariff.  Moderate correlations were found at baseline and follow-up, which were 
statistically significant at the 1% level.  The correlation of GAD-7 and ICECAP-A change 
scores between baseline and follow-up was weak and significant at the 1 % level. 
Table 67: cross-sectional and change correlations between the GAD-7 and the ICECAP-
A tariff (n=335) 
 ICECAP-A 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
GAD-7 score -0.515** -0.509** -0.205** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 68 and Figure 27 show change in ICECAP-A tariff score by GAD-7 anchor change 
groups.  In the group reporting an improvement in their GAD-7 scores, a small mean increase 
in ICECAP-A tariff scores was found.  This change was not significant and the effect size 
and SRM were small.  In the group of participants that reported an improvement in the GAD-
7 scores, the mean ICECAP-A tariff score increased. This change was moderate and 
significant at the 1% level.  Effect size and SRM were moderate.  Comparison with the non-
weighted ICECAP-O analysis shows that change as a percentage of possible change, the 
SRMs and the effects sizes are similar.     
313 | P a g e  
 
Table 68: Mean change in ICECAP-A tariff scores by GAD-7 anchor change groups 
(n=335) 
Anchor 
group 
Baseline 
ICECAP-
A scores 
Follow-up 
ICECAP-
A scores 
Mean 
ICECAP-A 
change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 0.844 0.864 0.02           
(0.002 0.042) 
2% 0.14 0.2 
No change 0.913 0.917 0.004                 
(-0.003, -0.011) 
0.4% 0.04 0.07 
Worsened 0.863 0.792 -0.071**                
(-0.11, -0.032) 
7.1% 0.58 0.55 
* Significant at the 5% level, **Significant at the 1% level. 
Table 69: Mean change in EQ-5D-3L index scores by GAD-7 anchor change groups 
(n=335) (for comparison) 
Anchor 
group 
Baseline 
EQ-5D-
3L scores 
Follow-up 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 0.585 0.686 0.101**   
(0.052, 0.149) 
6.3% 0.39 0.46 
No change 0.667 0.717 0.05**     
(0.022, 0.078) 
3.1% 0.24 0.24 
Worsened 0.614 0.616 0.002                
(-0.079, 0.083) 
0.1% 0.01 0.01 
* Significant at the 5% level, **Significant at the 1% level. 
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Figure 27: Mean change in ICECAP-A tariff scores by GAD-7 anchor change groups 
(n=355) 
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8.2.5. PHQ-8 anchor analysis summary  
The full PHQ-8 anchor analysis is placed in Appendix 27, a summary is provided here. 
In the groups reporting a worsening of PHQ-8 scores, a large reduction of 23 points was 
found in the percentage of respondents reporting full capability (level 4) for the Enjoyment 
item.  Smaller changes of less than 12 percent were found for the other items.  In the group 
reporting an improvement of PHQ-8 scores, smaller changes of less than 14 points were 
found in the percentage of respondents reporting full capability for each item. 
Mean change in the ICECAP-A non-weighted score and the ICECAP-A tariff score was 
larger in the group reporting a worsening of PHQ-8 scores compared to those who reported 
an improvement.  In the group that reported a worsening, the effect sizes and SRMs for the 
ICECAP-A change were small.  The EQ-5D-3L (non-weighted and weighted scores) showed 
a different pattern of change to the ICECAP-A with larger changes in the group that reported 
improved PHQ-8 scores, compared to the group that reported worsened scores. 
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8.3. PastBP trial 
8.3.1. Participant characteristics 
The characteristics of the PastBP trial participants included in this responsiveness analysis are 
presented in Table 70.  The participants from the PastBP trial were a majority male sample, 
with an average age of 71 years.  The mean ICECAP-O scores of participants were slightly 
higher than values found in the general population [177].  Mean participant scores on the EQ-
5D-3L and EQ-5D-3L VAS scores, of 0.75 and 74 respectively, were roughly equal to the 
UK national average for this age group [311].  On average, participants reported roughly 6 
out of the possible 24 symptoms and side-effects assessed at both baseline and follow-up.  
The sub-scales of the SF-36 show that limitations due to physical function and physical role 
were the main impairments in this population.  The cognitive functioning of the sample was 
good, with an MMSE score of 28, which indicates no substantial cognitive functioning 
problems within the sample [313] 
Table 70 shows that the mean score of the ICECAP-O did not change between baseline and 
follow-up.  Figure 28 shows the range of individual change in ICECAP-O scores in the 
sample.  The majority of the PastBP sample reported minimal change in their ICECAP-O 
scores of  less than 0.1.  This responsiveness analysis is therefore being completed with a 
population that reported a low level of change in their ICECAP-O tariff scores and have 
capability levels that are comparable to the general population.
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Table 70: PastBP trial partcipant characteristics, including mean scores and median scores  
Measures Mean baseline 
values  (SD) 
Median baseline 
value (IQR) 
Mean follow-up 
value (SD) 
Median follow-
up value (IQR) 
Measure range Sample size 
Socio-demographic       
Age  71.4 (8.68)     303 
Gender (% male) 62.05%     303 
Health and functioning       
ICECAP-O tariff  0.86 (0.12) 0.89 (0.81,0.93) 0.86 (0.12) 0.89 (0.82,0.93) 0 to 1 301 
EQ-5D-3L index 0.75 (0.23) 0.73 (0.69, 0.85) 0.76 (0.23) 0.76 (0.69,1) -0.59 to 1 293 
EQ-5D-3L VAS 74.3 (17.6) 78 (60,90) 75.4 (17.6) 80 (69,89) 0 to 100 286 
MMSE 28.0 (2.22) 29 (27,30) 27.8 (2.54) 29 (27,30) 0 to 30 249 
No. SSE (range 1 to 24) 5.95 (4.12) 6 (3,9) 5.69 (4.23) 5 (3,8) 0 to 24 164 
SF-36       
 Physical function 42.4 (11.5) 45.4 (33.9,51.8) 40.7 (12.7) 44.4 (31.8,52.8) 14.9 to 57.0 251 
 Physical role 41.1 (17.4) 47.0 (27.5,56.8) 30.9 (7.5) 27.5 (27.5,27.5) 17.7 to 56.8 91* 
 Emotional role 45.6 (17.1) 55.9 (40.3,55.9) 45.6 (17.5) 55.9 (40.3,55.9) 9.2 to 55.9 276 
 Vitality 49.7 (9.9) 50.84 (43.3,58.3) 49.8 (10.6) 50.8 (43.3, 58.3) 20.9 to 70.8 260 
 Mental health 51.6 (9.2) 52.8 (46.1, 59.6) 52.6 (8.9) 53.9 (48.3,59.6) 14.5 to 64.1 264 
 Social function 48.5 (10.40 51.4 (40.5,56.8) 48.3 (10.1) 51.4 (40.5, 56.8) 13.2 to 56.8 284 
 Bodily Pain 48.6 (10.8) 48.0 (38.6,57.4) 48.9 (11.7) 52.7 (38.6,57.4) 19.8 to 62.1 266 
 General health 45.3 (9.1) 47.2 (40.1,52.0) 46.4 (9.2) 47.2 (40.1,52.0) 16.2 to 63.9 268 
* The sample size for the physical role sub-scale of the SF-36 is low.  Manual inspection of the paper copies follow-up questionnaire packs indicates that this is likely due to 
participants missing an item of the scale because the item was placed after an “end of section” sub-heading, which encouraged participants to move onto the next section.  
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Figure 28: Frequency distribution of change in ICECAP-O tariff scores 
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scores were under 0.2 and no correlation exceeded 0.3.  The EQ-5D-3L VAS, the SF-36 
general health sub-scale, the number of symptoms and side-effects, and the EQ-5D-3L index 
showed the strongest correlations with the ICECAP-O.  With the exception of the EQ-5D-3L 
VAS and the SF-36 pain sub-scale, the strength of correlations between the EQ-5D-3L index 
score and other measures was comparable to the strength of correlations between the 
ICECAP-O tariff score and other measures.   
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Correlations of change scores between the ICECAP-O measure and other measures can be 
used to inform the selection of anchors for a responsiveness analysis.  Based on these 
correlations and the considerations discussed in the methods chapter, the following anchors 
were selected for assessment of responsiveness in this chapter: 
 An assessment using the EQ-5D-3L. 
 An assessment using the EQ-5D-3L VAS (placed in appendices) 
 An assessment using the SF-36 subscales of general health, vitality and social 
function (general health and vitality placed in appendices) 
 An assessment using the Modified Rankin Scale. 
 An assessment using the number of symptoms and side-effects that an individual is 
suffering from. 
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 Table 71: Correlations between change scores of measures in the PastBP trial 
 
 
 
 
 
 
 
 
 
 
The Modified Rankin Scale is not included in this analysis as it is a 5 point categorical variable and therefore not appropriate for correlation analysis. 
 ICECAP
-O tariff  
EQ-5D-
3L index 
EQ-5D-
3L VAS 
Number 
of SSE 
Phys 
func 
Phys 
role 
Emo 
role 
Vitality Emotion Soc func Pain Gen 
health 
MMSE 
ICECAP-O 
tariff 
1.00             
EQ-5D-3L 
Index 
0.198 1.00            
EQ-5D-3L 
VAS 
0.277 0.193 1.00           
Number of 
SSE 
-0.235 -0.296 -0.269 1.00          
Physfunc 0.144 0.202 0.218 -0.203 1.00         
Phys role 0.071 0.124 0.134 -0.191 0.215 1.00        
Emo role 0.184 0.118 0.163 -0.048 0.159 0.130 1.00       
Vitality 0.19 0.198 0.353 -0.258 0.147 0.240 0.287 1.00      
Emotion 0.082 0.107 0.138 -0.052 0.130 0.055 0.233 0.286 1.00     
Social func 0.209 0.188 0.266 -0.352 0.258 0.245 0.273 0.357 0.177 1.00    
Pain 0.159 0.348 0.168 -0.362 0.234 0.290 0.162 0.339 0.093 0.510 1.00   
Gen Helath 0.254 0.201 0.284 -0.221 0.341 0.142 0.115 0.314 0.156 0.269 0.242 1.00  
MMSE -0.119 -0.051 -0.212 0.142 -0.147 0.142 -0.082 -0.034 0.028 -0.139 -0.118 0.090 1.00 
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8.3.3. EQ-5D-3L index anchor analysis 
8.3.3.1. Anchor group formation 
Anchor groups were formed based on the same minimally important difference value of 0.074 
taken from Walters and Brazier [262] as used in the BEEP analysis.  Groups comprised of 
participants reporting equal to or greater than the minimally important change in EQ-5D-3L 
scores.  Mean change in the EQ-5D-3L index as a percentage of possible change was roughly 
15% in both change groups. 
Table 72: Group numbers and mean EQ-5D-3L index change scores in the EQ-5D-3L 
index anchor groups (n=279) 
Anchor 
group 
Number 
in group 
Mean EQ-5D-
3L change in 
group (95% 
CI) 
Mean EQ-5D-3L 
change as a % of 
possible change. 
Improved 88 0.243  
(0.210,0.276) 
15.2% 
No change 133 -0.004 
(-0.009,0.001) 
0.2% 
Worsened 58 -0.245  
(-0.288,-0.202) 
15.4% 
 
8.3.3.2. Item-by-item analysis 
Figure 29 shows the response profiles at baseline and follow-up in the group of respondents 
who reported their EQ-5D-3L index scores worsening.  These results are provided in 
numerical form in Appendix 30.  The response profile of these respondents changed.  
Between baseline and follow-up there was a 22 point reduction in the percentage of 
respondents answering level 4 (full capability) for Control and a 9 or 10 point reduction in the 
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percentage in respondents answering level 4 for Security, Role and Enjoyment.  In the 
Control, Role and Security items this change resulted in an increase or respondents answering 
level 3, while for Enjoyment an increase was seen in respondents answering level 2.  The 
response profile for the Attachment item remained largely unchanged.  
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Figure 29: ICECAP-O response profile at baseline and follow-up for participants 
reporting a worsening of their EQ-5D-3L index scores 
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Figure 30 shows the ICECAP-O response profile at baseline and follow-up in the group of 
respondents reporting their EQ-5D-3L index scores improving.  These results are provided in 
numerical form in Appendix 31.  In comparison to the change in profile associated with a 
worsening of EQ-5D-3L scores, there were smaller, less pronounced changes in the ICECAP-
O response profile of this group.  There was a 10 point and 7 point increase between baseline 
and follow-up in the percentage of respondents answering level 4 (full capability) for Role 
and Enjoyment.  There were small increases in the number of participants reporting the top 
level of Security and Control and a small decrease in the percentage of respondents reporting 
the top level of Attachment.   
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Figure 30: ICECAP-O response profile at baseline and follow-up for participants 
reporting an improvement in their EQ-5D-3L index scores 
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8.3.3.3. Non-weighted ICECAP score analysis 
Table 73 shows that cross-sectional correlations between the EQ-5D-3L index and the non-
weighted ICECAP-O scores at baseline and follow-up were moderate and statistically 
significant at the 1% level.  The correlation of the change in scores between baseline and 12-
month follow-up in these measures was weak and significant at the 1% level. 
Table 73: Cross-sectional and change correlations between the EQ-5D-3L index and 
non-weighted ICECAP-O scores (n=279) 
 ICECAP-O 
 Cross sectional  
correlation 
Change 
correlation 
 Baseline Follow-up  
EQ-5D-3L index 
score 
0.548** 0.513** 0.205** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 74 shows change in non-weighted ICECAP-O scores by EQ-5D-3L index anchor 
change groups.  In the group of participants reporting an improvement in EQ-5D-3L index 
score, the mean non-weighted ICECAP-O score increased.  In the group reporting a 
worsening of their EQ-5D-3L index score, the mean non-weighted ICECAP-O score 
decreased.  The change in ICECAP-O score in the group that worsened was larger than in the 
group that improved.  Table 72 shows the mean EQ-5D-3L change in these groups to be 
similar.  Therefore, the proportion of change in ICECAP-O scores to EQ-5D-3L index change 
was larger in the group that worsened than in the group that improved.  The effect size and 
SRM for ICECAP-O score changes were small. 
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Table 74: Mean change in non-weighted ICECAP-O scores by EQ-5D-3L anchor change 
groups (n=279) 
Anchor 
group 
Baseline 
ICECAP-
O scores 
Follow-up 
ICECAP-
O scores 
Mean 
ICECAP-O 
change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 15.761 16.193 0.432                
(-0.028, 0.891) 
2.9% 0.15 0.2 
No change 16.355 16.563 
 
0.207                
(-0.111, 0.526) 
1.4% 0.08 0.11 
Worsened 16.237 15.525 -0.712*             
(-1.284, -0.139) 
4.8% 0.24 0.32 
* Significant at the 5% level, **Significant at the 1% level. 
8.3.3.4. ICECAP tariff analysis 
Table 75 shows that cross-sectional correlations between the EQ-5D-3L index and the 
ICECAP-O tariff at baseline and follow-up were moderate and statistically significant at the 
1% level.  The correlation of change in these measures between baseline and 12 month 
follow-up was weak (approaching moderate) and statistically significant at the 1% level.   
Table 75: Cross-sectional and change correlations between EQ-5D-3L index and 
ICECAP-O tariff (n=279) 
 ICECAP-O 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
EQ-5D-3L index 
score 
0.458** 0.496** 0.179** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 76 and Figure 31 show changes in ICECAP-O tariff score by EQ-5D-3L index anchor 
groups.  In the group of participants reporting an improvement in EQ-5D-3L index scores the 
mean ICECAP-O tariff score increased.   In the group reporting a worsening of their EQ-5D-
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3L index score, the mean ICECAP-O tariff score decreased.  The increase in ICECAP tariff 
scores in the group that improved was small, while the decrease in the group that worsened 
was moderate and statistically significant at the 5% level.  As a proportion of possible change, 
change in the ICECAP-O tariff scores (Table 76), in both the improved and worsened groups, 
was smaller than in non-weighted ICECAP-O scores (Table 74).   The effect sizes and SRMs 
were small to very small.  
Table 76: Mean change in ICECAP-O tariff scores by EQ-5D-3L anchor change groups 
(n=279) 
Anchor 
group 
Baseline 
ICECAP-
O scores 
Follow-up 
ICECAP-O 
scores 
Mean 
ICECAP-O 
change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 0.850 0.866 0.016  
(-0.007,0.039) 
1.6% 0.13 0.15 
No change 0.875 0.877 
 
0.002 
(-0.013,0.017) 
0.2% 0.02 0.02 
Worsened 0.862 0.830 -0.032*  
(-0.063,-0.001) 
3.2% 0.22 0.27 
* Significant at the 5% level, **Significant at the 1% level.  
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Figure 31: Mean change in ICECAP-O tariff scores by EQ-5D-3L anchor change groups 
(n=279) 
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8.3.4. EQ-5D-3L VAS anchor analysis summary 
The full EQ-5D-3L VAS anchor analysis is placed in Appendix 32, a summary is provided 
here. 
In the group that reported a worsening of EQ-5D-3L VAS scores, reductions of between 5 and 
2 points were seen in the percentage of respondents reporting full capability on each item.  In 
the group that reported an improvement, larger increases of between 4 and 10 percentage 
points were found in those reporting full capability for each item. 
Mean change in the non-weighted ICECAP-O score and ICECAP-O tariff score was greater 
for the group that reported an improvement in their EQ-5D-3L VAS scores.  Non-weighted 
ICECAP-O change as a percentage of possible change, effect sizes and SRMs were similar to 
those for the non-weighted EQ-5D-3L reference measure score.  Change as a percentage of 
possible change was smaller for the ICECAP-O tariff than for the non-weighted ICECAP-O 
score.  
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8.3.5. Modified Rankin Scale anchor analysis 
8.3.5.1. Anchor group formation 
The anchor groups for the Modified Rankin Scale were formed using “naturally” occurring 
change groups of those who had improved or worsened by 1 or 2 points on the 5 point scale 
(no informant changed by more than 2 points).  A change of -1 or -2 indicates an 
improvement in a participant’s disability, while a change of +1 or +2 indicates a worsening of 
disability.   
8.3.5.2. Item-by-item analysis 
Figure 32 shows the response profiles at baseline and follow-up for respondents who reported 
an improvement in their Modified Ranking Scale scores (change of -1 or -2).  These results 
are presented in a numerical form in Appendix 35.  Between baseline and follow-up an 
increase of 15 percentage points was seen in participants answering level 4 (full capability) on 
Enjoyment.  Changes in level 4 response of 1 and 7 percentage points were seen for the other 
items.  There was also a notable reduction in the percentage of participants selecting the 
bottom two levels for Role, which resulted in an increase in those selecting the top two levels 
of this attribute. 
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Figure 32: ICECAP-O response profile at baseline and follow-up for participants 
reporting an improvement in their Modified Rankin Scale scores 
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Figure 33 shows ICECAP-O response profiles at baseline and follow-up for those reporting a 
worsening of their Modified Rankin Scale scores (change of +1 or +2).  These results are 
presented in numerical form in Appendix 36.  Reductions in the percentage of respondents 
answering level 4 of 7 points for Security and Role and 9 points for Control were found.  
Smaller reductions of 2 and 5 points are seen in the percentage of respondents answering level 
4 (full capability) of Attachment and Enjoyment.  There is a notable increase of 9 points in the 
percentage of participants answering either of the bottom two levels for the Role item. 
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Figure 33: ICECAP-O response profile at baseline and follow-up for participants 
reporting a worsening of their Modified Rankin Scores  
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8.3.5.3. Non-weighted ICECAP scores analysis 
Table 77 shows change in non-weighted ICECAP-O scores by Modified Rankin Scale anchor 
groups.  In the groups of participants reporting an improvement in their Modified Rankin 
Scale score (decrease in score) the mean non-weighted ICECAP-O scores increased.  The 
increase in ICECAP scores in the group which had changed by 2 points on the Modified 
Rankin Scale was larger than in the group which had changed by 1 point.  In the group of 
participants that reported a worsening of their Modified Rankin Scale score (increase in score) 
the mean non-weighted ICECAP-O score decreased.  The decrease in the group which had 
changed by 1 point was smaller than in the group that had changed by 2 points.  Changes in 
the groups that reported a worsening of their Modified Rankin Scale score were smaller than 
the changes in the group whose Modified Rankin Scale score had improved.  Effect sizes and 
SRMs for the group reporting improvement in Modified Rankin Scale scores of 2 points (2 
point decrease) were moderate, while in the group reporting a worsening by 2 points (2 point 
increase) they were large.  Effect sizes and SRMs for the groups which changed by +/- 1 point 
on the Modified Rankin Scale were small to very small.   
The use of the EQ-5D-3L non-weighted analysis (Table 78) as a reference measure shows 
differences to the non-weighted ICECAP-O score analysis (Table 77).  For those reporting an 
improvement in Modified Ranking Scale scores of 2 points (2 point decrease), the effect size 
and SRM were larger for the non-weighted ICECAP-O scores than the non-weighted EQ-5D-
3L scores.  For those reporting a worsening of Modified Rankin Scale scores (2 point 
increase) the reverse was true.  In the groups that reported an  improvement or worsening by 1 
point change as a percentage of possible change, effect sizes and SRMs were larger for the 
EQ-5D-3L non-weighted scores than for the ICECAP non-weighted scores.  This indicates 
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differences between the measures in sensitivity to change in the Modified Rankin Scale by 1 
point. 
Table 77: Mean change in non-weighted ICECAP-O score by Modified Rankin Scale 
anchor change groups (n=288) 
Anchor 
group 
Number 
in group 
Baseline 
ICECAP-
O scores 
Follow-
up 
ICECAP-
O scores 
Mean 
ICECAP-O 
change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
-2 7 14.571 17.142 2.571**  
(1.075, 4.068) 
17.1% 1.53 1.58 
-1 55 15.982 16.491 0.509*    
(0.074, 0.944) 
3.3% 0.17 0.32 
No 
change 
149 16.127 16.161 0.033              
(-0.798, 0.247) 
0.2% 0.01 0.01 
1 69 16.145 15.870 -0.275             
(-0.798, 0.247) 
1.8% 0.09 0.13 
2 8 17.375 15.75 -1.625             
(-3.670, 0.420) 
10.8% 0.65 0.66 
* Significant at the 5% level, **Significant at the 1% level. 
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Table 78: Mean change in non-weighted EQ-5D-3L score by Modified Rankin Scale 
anchor change groups (n=294) (for comparison) 
Anchor 
group 
Number 
in group 
Baseline  
EQ-5D-
3L scores 
Follow-
up EQ-
5D-3L 
scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
-2 8 8.875 7.125 -1.75*             
(-0.506,-2.994) 
17.5% 0.81 1.18 
-1 61 7.213 6.639 -0.574**         
(-0.201,-0.946) 
5.7% 0.35 0.39 
No 
change 
143 7.049 6.839 -0.21      
(0.001, -0.421) 
2.1% 0.12 0.16 
1 71 6.704 7.098 0.39** 
(0.113,0.676) 
3.9% 0.25 0.33 
2 11 5.545 6.909 1.364** 
(0.611,2.116) 
13.6% 0.99 1.21 
* Significant at the 5% level, **Significant at the 1% level. 
8.3.5.4. ICECAP tariff analysis 
Table 79 and Figure 34 shows change in ICECAP-O tariff score by Modified Rankin Scale 
anchor change groups.  In the group of participants reporting a worsening of Modified Rankin 
Scale scores (increased score), the mean ICECAP-O tariff score decreased.  In those reporting 
an improvement in Modified Rankin Scale scores (a decrease in scores) ICECAP-O tariff 
scores improved.  For changes in both directions, ICECAP-O tariff score change was larger in 
the groups whose Modified Rankin Scale score had changed by 2 points than by 1 point.  
Effect sizes and SRMs were large for groups changing by 2 points and small for the 1 point 
change group. 
In comparison to the non-weighted ICECAP-O score analysis (Table 77), change as a 
percentage of possible change is smaller in the ICECAP-O tariff analysis.  This difference 
was particularly pronounced for the group who reported an improvement by 1 or 2 points on 
338 | P a g e  
 
the Modified Rankin Scale (a decrease of 1 or 2); less of a difference was found for those 
reporting a worsening.  Using the EQ-5D-3L index score analysis as a reference measure 
(Table 80) shows that this trend is not present for the EQ-5D-3L index scores.  Here, change 
as a percentage of possible change is largely unchanged between the non-weighted EQ-5D-3L 
scores and EQ-5D-3L index scores.  Change as a percentage of possible change is larger in 
the EQ-5D-3L index analysis than in the ICECAP-O tariff.  Non-systematic differences 
between the two measures in effect size and SRMs are seen, which may be a result of low 
numbers in the 2 point change groups.   
Table 79: Mean change in ICECAP-O tariff score by change in Modified Rankin Scale 
score (n=288). 
Anchor 
group 
Number Baseline 
ICECAP-
O scores 
Follow-up 
ICECAP-
O scores 
Mean 
ICECAP-O 
change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
-2 7 0.803 0.891 0.088 ** 
(0.037,0.139) 
8.8% 0.9 1.59 
-1 55 0.852 0.877 0.025* 
(0.001,0.049) 
2.5% 0.2 0.27 
No 
change 
149 0.863 0.864 0.001  
(-0.016,0.018) 
0.1% 0.01 0.01 
1 67 0.867 0.847 -0.019 
(-0.048,0.010) 
1.9% 0.17 0.17 
2 8 0.925 0.837 -0.088* 
(-0.169,-0.006) 
8.8% 1.35 0.9 
* Significant at the 5% level, **Significant at the 1% level. 
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Table 80: Mean change in EQ-5D-3L index score by change in Modified Rankin Scale 
score (n=294) (for comparison) 
Anchor 
group 
Number Baseline 
scores 
12 
month 
follow-
up 
scores 
Mean change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
-2 8 0.453 0.735 0.282* 
(0.022,0.542) 
17.7% 0.76 0.91 
-1 61 0.718 0.798 0.08** 
(0.029,0.130) 
5% 0.37 0.41 
No 
change 
143 0.74 0.769 0.029              
(-0.006, 0.065) 
1.8% 0.13 0.13 
1 71 0.776 0.742 -0.034             
(-0.075,0.008) 
2.1% 0.14 0.19 
2 11 0.922 0.687 -0.235*           
(-0.415, -0.055) 
14.7% 2.06 0.88 
* Significant at the 5% level, **Significant at the 1% level. 
Figure 34: Mean change in ICECAP-O tariff score by change in Modified Rankin Scale 
score (n=288) 
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8.3.6. SF-36 subscale anchor analysis  
The three SF-36 subscales of general health, vitality and social functioning were selected for 
use as anchors in the responsiveness analysis.  These anchors showed strong cross-sectional 
correlations with the ICECAP-O tariff at baseline and follow up and showed the strongest 
change score correlations between the ICECAP-O tariff and any of the SF-36 scales.  The 
general health and vitality sub-scales analyses are placed in the appendices.  A summary of 
results is included below.  The anchor groups for the SF-36 scales were taken from the User’s 
Manual for the SF-36v2 Health Survey [288].   
8.3.7. SF-36 general health sub-scale analysis 
The full analysis of the SF-36 general health sub-scale is provided in Appendix 37, a 
summary is provided here. 
In the group of respondents that reported a worsening of their general health, sub-scale score 
reductions of between 17 and 8 points were seen in the percentage of respondents reporting 
full capability on each item, with the largest reductions being in Security and Enjoyment.  In 
the group reporting an improvement in their general health sub-scale scores, increases of 
between 12 and 17 points were found in the percentage reporting full capability on each item, 
apart from control which showed minimal change. 
Mean change in both the non-weighted ICECAP-O scores and the ICECAP-O tariff was 
larger in the group reporting an improvement in their general health sub-scale scores than 
those reporting a worsening of scores (which showed little change).  Effects sizes and SRMs 
were small or moderate for the improved group.  The changes in ICECAP-O scores in the 
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improvement group were larger than the changes in EQ-5D-3L scores, while the reverse was 
true for those reporting a worsening of general health.  
8.3.8. SF-36 vitality sub-scale analysis 
The full analysis of the vitality sub-scale is presented in Appendix 40, a summary is provided 
here. 
In the group reporting a worsening of vitality, response profiles showed a 6 to 9 percentage 
point reduction in respondents answering level 4 (full capability) on each item.  In those 
reporting an improvement in vitality, an increase of greater than 10 percentage points was 
seen for people answering the top level of Attachment, Role and Enjoyment items.    
Mean changes in both the non-weighted ICECAP-O scores and the ICECAP-O tariff were 
larger in the group of respondents who reported improved vitality in comparison to those 
reporting worsened vitality.  In the improved group, effect sizes were small and SRMs were 
moderate.  The non-weighted and index score EQ-5D-3L analyses showed smaller change as 
a percentage of possible change, effect sizes and SRMs than the ICECAP-O for the group of 
respondents whose vitality had improved.  Change was larger in the EQ-5D-3L analyses than 
the ICECAP-O analyses for the group of respondents whose vitality had worsened.  ICECAP-
O change as a percentage of possible change was smaller in the tariff analysis than the non-
weighted analysis. 
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8.3.9. SF-36 social function sub-scale analysis 
8.3.9.1. Anchor group formation 
Anchor groups were formed of participants reporting a change equal to or greater than the 
minimally important change of 6.2 taken from  the SF-36 User’s Manual [288].  The mean 
change each groups was roughly 16% of  the possible change on the measure.  
Table 81: Numbers in group and the mean change in SF-36 social function sub-scale 
scores in anchor groups (n=267) 
Anchor 
group 
Number Mean SF-36 
social function 
change in 
group (95% 
CI) 
Mean SF-36 
social function 
sub-scale 
change as a % 
of possible 
change 
Improved 40 16.48 (14.334, 
18.625) 
16.5% 
No 
change 
180 0.055 (-0.398, 
0.508) 
0.06% 
Worsened 47 -15.622 (-
17.362, -
13.882) 
15.6% 
 
8.3.9.2. Item-by-item analysis 
Figure 35 shows the response profiles at baseline and follow-up for respondent who reported 
a worsening of their EQ-5D-3L scores.  These results are presented in numerical form in 
Appendix 43.  The response profiles changed, with reductions of 5 to 14 points in the 
percentage of respondents reporting full-capability on each item.  The exception was Security, 
which showed little change in the top two levels of the item, but showed notable change in the 
bottom two levels, with an increase of 6 points in the percentage of respondents reporting no 
capability in the measure. 
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Figure 35: ICECAP-O response profiled for participants reporting a worsening in their 
SF-36 social function sub-scale score. 
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Figure 36 shows the response profile at baseline and follow-up for the group of respondents 
reporting an improvement in their SF-36 social function sub-scale scores.  These results are 
reported in numerical form in Appendix 44.  Increases of 10 and 17 points in the percentage 
of respondents reporting full capability were seen for Role and Enjoyment items, while a 
reduction of 6 percentage points was found for Attachment.  There were also noticeable 
changes at lower levels of capability with reductions of 5 to 9 points in the percentage of 
respondents selecting level two on Attachment, Security and Role items.  
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Figure 36: ICECAP-O response profiles for participants reporting an improvement in 
their SF-36 social function sub-scale score. 
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8.3.9.3. Non-weighted ICECAP-O scores analysis 
Table 82 shows that moderate cross-sectional correlations, statistically significant at the 1% 
level, between the ICECAP-A non-weighted scores and the SF-36 social function sub-scale 
scores, were found at baseline and follow-up.  The correlation between change scores on both 
measures was weak and significant at the 1% level. 
Table 82: Cross-sectional and changes correlations between SF-36 social function scale 
and non-weighted ICECAP-O score (n=267). 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
SF-36  
Social Function 
0.49** 0.5** 0.21** 
**Difference significant at p<0.01 
Table 87 shows the changes in non-weighted ICECAP-O scores by SF-36 social functioning 
sub-scale anchor groups.  In the group reporting an improvement in social function scores the 
mean non-weighted ICECAP-O score increased.  In the group reporting a worsening in social 
function scores, the non-weighted ICECAP-O scores decreased.  The increase in non-
weighted ICECAP-O scores was larger than the decrease.  Effect size and SRM for the group 
that improved were small to medium, while for the group that worsened they were very small. 
The non-weighted EQ-5D-3L analysis presented in Table 84 shows small differences in the 
ICECAP-O non-weighted analysis.  Change as a percentage of possible change, effect size 
and SRM in the group that improved were slightly larger for the ICECAP-O than for the EQ-
5D-3L.  The reverse was observed in the group that reported a worsening in social function 
scores.  
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Table 83: Mean change in non-weighted ICECAP-O score by SF-36 social function scale 
change (n=267) 
Anchor group Baseline 
ICECAP-
O scores 
12 month 
ICECAP-O 
follow-up 
scores 
Mean 
ICECAP-O 
change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 14.725 15.85 1.125** 
(0.445, 1.805) 
7.5% 0.41 0.53 
No change 16.527 16.593 0.066              
(-0.209, 0.341) 
0.4% 0.02 0.03 
Worsened 15.851 15.553 -0.298            
(-0.945, 0.350) 
1.9% 0.11 0.13 
** Difference significant at p<0.01 
 
Table 84: Mean change in non-weighted EQ-5D-3L scores by SF36 social-function 
health sub-scale change  (n=281) (for comparison) 
Anchor group Baseline 
EQ-5D-
3L scores 
12 month 
EQ-5D-3L 
scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 7.932 7.25 -0.682**         
(-1.233,-0.13) 
6.8% 0.35 0.37 
No change 6.78 6.599 -0.187            
(-0.361,-0.012) 
1.9% 0.11 0.16 
Worsened 7.127 7.382 0.255               
(-0.128,0.638) 
2.5% 0.14 0.18 
** Difference significant at p<0.01 
 
8.3.9.4. ICECAP-O tariff analysis 
Table 85 shows cross-sectional correlations between the ICECAP-O tariff and SF-36 social 
function sub-scale at baseline and follow-up that were moderate and statistically significant at 
the 1% level.  The cross-sectional correlation between these scores was weak and statistically 
significant at the 1% level. 
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Table 85: Cross-sectional and change correlations between SF-36 social function scale 
and the ICECAP-O tariff (n=267). 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
SF-36  
Social Function 
0.49** 0.5** 0.21** 
**Difference significant at p<0.01 
Table 86 and Figure 37 show the changes in the ICECAP-O tariff score by SF-36 social 
function sub-scale anchor groups.  In the group reporting an improvement in social function 
scores, the mean ICECAP-O tariff scores improved.  This change was statistically significant 
at the 1% level.  In the group that reported a worsening of social function scores, there was 
little change in the ICECAP-O tariff score.  The effects size for the group that improved was 
small, while the SRM was moderate. 
In comparison to the non-weighted ICECAP-O score, change as a percentage of possible 
change was smaller for the ICECAP-O tariff scores.  There are greater differences between 
the ICECAP-O and EQ-5D-3L in the value weighted analysis than the non-weighted analysis 
in change as a percentage of possible, effect size and SRM. 
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Table 86: Mean change in ICECAP-O tariff score by SF-36 social function scale change 
(n=267) 
Anchor group Baseline 
scores 
12 month 
follow-up 
scores 
Mean change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 0.799  0.854  0.055**    
(0.09, 0.02) 
5.5% 0.39 0.55 
No change 0.88 0.875  0.005     
(0.009, 0.019) 
0.5% 0.03 0.04 
Worsened 0.849  0.844  -0.005            
(-0.04, 0.029) 
0.5% 0.04 0.04 
** Difference significant at p<0.01 
 
Table 87: Mean change in EQ-5D-3L index scores by SF36 social-function health sub-
scale change (n=281) (for comparison) 
Anchor group Baseline 
EQ-5D-
3L scores 
12 month 
EQ-5D-3L 
scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 0.637 0.707 0.07                 
(-0.029,0.169) 
4.4% 0.29 0.21 
No change 0.769 0.801 0.032             
(0.005, 0.059) 
2% 0.14 0.18 
Worsened 0.722 0.687 -0.035             
(-0.097, 0.027)  
2.2% 0.14 0.15 
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Figure 37: Mean change in ICECAP-O tariff score by SF-36 social function sub-scale 
change 
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8.3.10. Symptoms and side effects anchor analysis 
8.3.10.1. Anchor group formation 
No psychometric literature exists on the minimally important difference for the 24 item 
symptoms and side effects questionnaire used in the PastBP trial questionnaire pack.  As 
some of the conditions assessed were relatively minor, such as sore eyes, while some were 
more serious, such as impotence, fatigue or nausea, it was thought inappropriate to assume 
that the increase or reduction in one symptom or side effect would represent a minimally 
important difference to participants.  Therefore, groups were formed using the inter-quartile 
range values of +/-2 side effects.  Table 88 includes the mean change in symptoms and side-
effects: the improved group had a mean reduction in side effects of 3.6, while those in the 
worsened group had an increase in side-effects of 4.3.  Change in number of symptoms and 
side-effects as a percentage of possible change, was similar in both groups. 
Table 88: Numbers in groups and mean SSE change scores in SSE anchor change 
groups (n=107) 
Anchor 
group 
Number 
in group 
Mean SSE 
change in group 
(95% CI) 
SSE change as 
a % of possible 
change 
Improved 35 -3.666 (-4.425, -
2.906) 
15.3% 
No change 46 0.113 (-0.094, 
0.320) 
0.4% 
Worsened 26 4.312 (3.038, 
5.585) 
15.4% 
 
The symptoms and side-effects questionnaire is a multi-item questionnaire assessing a broad 
range of symptoms.  To provide indications of the main “drivers” of change in the groups that 
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reported an increase or decrease in symptoms and side effects, the percentage change, 
between baseline and follow-up, in the number of participants reporting each individual side-
effect is reported in Appendix 45.  This shows that pain, breathlessness, fatigue and sleep 
difficulties show reductions of over 30% in respondents in the group reporting an overall 
improvement in their score of two or more.  Pain, breathlessness, fatigue, loss of strength and 
leg and ankle swelling show increases approaching or in excess of 30% of respondents in the 
group reporting an overall worsening of scores of two or more. 
8.3.10.2. Item-by-item analysis 
Figure 38 shows the response profiles at baseline and follow-up for the group of respondents 
who reported a worsening of their symptoms and side-effects (an increase by 2 or more).  
These results are presented in numerical form in Appendix 46.  There are reductions of 15, 19 
and 10 points in the percentage of participants answering level 4 (full capability) of 
Attachment, Role and Enjoyment, respectively.  Smaller reductions of 4 were found points in 
the percentage of people reporting the top levels of Security and Control.   
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Figure 38: ICECAP-O response profile at baseline and follow-up for participants 
reporting a worsening in number of SSE 
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Figure 39 shows the response profile of participants who reported a reduction in symptoms 
and side-effects.  These results are presented in numerical form in  
Appendix 47.  Increases of 15 points and 14 points were found in the percentage of 
participants answering level 4 (full capability) for Role and Enjoyment, respectively.  A 
smaller increase of 8 points was found in the percentage of participants reporting level 4 for 
Security.  A 14 percentage point reduction in the number of participants reporting level 4 for 
Control was seen. A smaller reduction was found in the Attachment item.  Therefore, the 
response profile for an improvement in symptoms and side-effects shows change in different 
directions for different items. 
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Figure 39: ICECAP-O response profile at baseline and follow-up for participants 
reporting an improvement in number of SSE  
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8.3.10.3. Non-weighted ICECAP score analysis 
Table 89 shows the correlations between the non-weighted ICECAP-O scores and symptoms 
and side-effects questionnaire at baseline, follow-up and over time.  The cross-sectional 
correlations at both baseline and follow-up are moderate and significant at the 1% level.  The 
correlation between the change scores of the measures is weak and significant at the 1% level. 
Table 89: Cross-sectional and change correlations SSE and non-weighted ICECAP-O 
scores (n=107) 
 ICECAP-O 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
Symptoms and 
side-effects 
questionnaire 
-0.497** -0.439** -0.299** 
* Significant at the 5% level, **Significant at the 1% level. 
Table 90 shows that the group of participants reporting an improvement in symptoms and side 
effects (a reduction of 2 or more), reported an increase in non-weighted ICECAP-O scores.  
The group of participants reporting a worsening of symptoms and side effects (an increase of 
2 or more), reported a reduction in non-weighted ICECAP-O scores.  The mean change for 
those reporting a worsening of symptoms and side-effects was larger than for those reporting 
an improvement.  Effect sizes and SRM were small. 
Differences between the non-weighted EQ-5D-3L reference analysis (Table 91) and non-
weighted ICECAP-O analysis (Table 90) can be seen.  Change as a percentage of possible 
change on the EQ-5D-3L was larger for the group of participants reporting an improvement of 
symptoms and side-effects, than for the group reporting a worsening.  This is the opposite of 
the response pattern seen in ICECAP-O, where the change for the worsened group was larger 
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than for the improved.  Effect sizes and SRMs for the EQ-5D-3L were larger than for the 
ICECAP-O in the group that improved and similar for the group that worsened..  
Table 90: Mean change in non-weighted ICECAP-O scores by SSE anchor change 
groups (n=107) 
Anchor 
group 
Baseline 
ICECAP-
O scores 
12 month 
follow-up 
ICECAP-
O scores 
Mean change 
in ICECAP-O 
scores 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 15.971 16.514 0.543                
(-0.071, 1.157) 
3.6% 0.19 0.3 
No change 16.26 16.217 -0.043               
(-0.512, 0.425) 
0.2% 0.01 0.02 
Worsened 17 16.222 -0.777                
(-1.797, 0.242) 
5.2% 0.25 0.3 
* Significant at the 5% level, **Significant at the 1% level. 
Table 91: Mean change in non-weighted EQ-5D-3L scores by SSE anchor change groups 
(n=115) (for comparison) 
Anchor 
group 
Baseline 
EQ-5D-
3L scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 7.475 6.775 -0.7**               
(-1.13, -0.27) 
7% 0.39 0.52 
No change 6.614 6.386 -0.227                
(-0.573,0.119) 
2.3% 0.13 0.2 
Worsened 7 7.322 0.322                 
(-0.216,0.861) 
3.2% 0.25 0.22 
* Significant at the 5% level, **Significant at the 1% level. 
8.3.10.4. ICECAP tariff analysis 
Table 92 shows that the baseline and 12 month follow-up cross-sectional correlations between 
the ICECAP-O tariff and the number of symptoms and side-effects were moderate and 
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statistically significant at the 1% level.  The correlation in change scores of these measures 
was weak and statistically significant at the 5% level.  
Table 92: Cross-sectional and change correlations between SSE and ICECAP-O 
measure (n=107) 
 ICECAP-O 
 Cross sectional correlation Change 
correlation 
 Baseline Follow-up  
SSE -0.425** -0.385** -0.235* 
* Significant at the 5% level, **Significant at the 1% level. 
Participants reporting a worsening of symptoms and side-effects had a reduction in ICECAP-
O tariff scores (Table 93 and Figure 40).  Participants reporting an improvement of symptoms 
and side-effects had an increase in ICECAP-O capability scores.  These changes were small 
and neither were statistically significant at the 5% level.  Effect sizes and SRMs were small.  
Changes as a percentage of possible change was smaller in the ICECAP-O tariff analysis than 
in the non-weighted ICECAP-O analysis.  The difference in scores between the weighted and 
non-weighted analysis was also seen in the EQ-5D-3L.  
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Table 93: Mean change in ICECAP-O tariff score by SSE anchor change groups  
(n=107) 
Anchor group Baseline 
ICECAP-
O scores 
12 month 
follow-up 
ICECAP-
O scores 
Mean change 
in ICECAP-O 
scores 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 0.855 0.878 0.023                  
(-0.012, 0.057) 
2.3% 0.16 0.22 
No change 0.864 0.861 -0.003 
(-0.030, 0.023) 
0.3% 0.03 0.04 
Worsened 0.897 0.858 -0.039                
(-0.091, 0.014) 
3.9% 0.44 0.3 
* Significant at the 5% level, **Significant at the 1% level. 
Table 94: Mean change in EQ-5D-3L index scores by SSE anchor change groups 
(n=115) (for comparison) 
Anchor group Baseline 
EQ-5D-
3L scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 0.692 0.777 0.084** 
(0.024,0.145) 
5.3% 0.38 0.45 
No change 0.811 0.835 0.024               
(-0.032, 0.079) 
1.5% 0.11 0.13 
Worsened 0.747 0.714 -0.033            
(-0.12, 0.053) 
2.1% 0.14 0.14 
* Significant at the 5% level, **Significant at the 1% level. 
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Figure 40: Mean change in ICECAP-O tariff score by SSE anchor change groups  
(n=107) 
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8.4. Trends in the responsiveness analysis 
The comparisons made in this chapter between the analyses using the non-weighted ICECAP 
scores and the ICECAP tariff scores, and between the ICECAP measures and the EQ-5D-3L 
have allowed the identification of a number of trends.  These trends are summarised here.  
They are discussed in greater detail in Chapter 9 in the context of the ICECAP measure 
development and evaluation literature. 
8.4.1. Small to moderate changes and effect sizes 
Throughout the chapter, change in the ICECAP tariff, and the effect sizes and SRMs were 
small or moderate.  Change in the ICECAP-A and ICECAP-O tariff scores frequently fell 
between 0.02 and 0.04.  The notable exceptions to this were change in the ICECAP measures 
in response to change in the Modified Rankin Scale (ICECAP-O) and change on the 
psychological health measure of the GAD-7 and PHQ-8 (ICECAP-A).  Small or moderate 
effect sizes and SRMs indicate that the ratio of change to standard deviation (either at baseline 
or overtime) was small: put another way, the signal to noise ratio was small. 
As described in Chapter 3, the potential for ceiling effects could not be fully assessed due to 
the lack of a comparator capability measure.  However, response profiles provide some 
indication that the small changes in ICECAP scores, when respondents report an 
improvement in health, may be due to a ceiling effect in some items.  In both the ICECAP-O 
and the ICECAP-A over 50% of respondents frequently answer the top level (level 4) for the 
Attachment item and the Control or Autonomy item.  In respondents whose health has 
improved, change profiles show small changes on these items between baseline and follow-
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up.  This is an indication that a ceiling effect may be reducing the sensitivity of the measure in 
those who reported a high level of capability at baseline.  
8.4.2. Smaller changes in scores in tariff analyses 
In the majority of anchor analyses presented in this chapter, the ICECAP tariff score showed 
smaller changes over time than the analyses using the non-weighted ICECAP score.  This is 
apparent through considering change as a percentage of possible change on that measure, 
which standardises change to allow this comparison to be made.  In the ICECAP-O analyses 
using  EQ-5D-3L, the EQ-5D-3L VAS, the Modified Rankin Scale, the SF-36 General Health 
sub-scale, the Symptoms and Side-effects as anchors and the ICECAP-A analyses using the 
EQ-5D-3L and PHQ-8 as anchors, change as a percentage of possible change was smaller in 
the tariff analysis than in the non-weighted analysis.  This indicates that, in a population with 
high initial levels of capability, when the general population values were applied to the “raw” 
non-weighted scores, the size of change on the ICECAP measures was suppressed. 
8.4.3. Similar responsiveness of the EQ-5D-3L and ICECAP 
measures 
The use of the EQ-5D-3L as a comparator on anchor measures, allowed the change as a 
percentage of possible change, effect sizes and SRMs of the ICECAP-O to be placed in 
context of scores on another value (or preference) weighted measure.  When change was 
standardised as a percentage of possible change, it was apparent that change in the  non-
weighted analyses of the ICECAP measures was similar to change in the non-weighted 
analyses of the EQ-5D-3L in the analyses using the EQ-5D-3L VAS, Modified Rankin Scale, 
symptoms and side-effects, GAD-7 and PHQ-8.  When the general population value weights 
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were applied to the ICECAP measures and the preference weights were applied to the EQ-5D-
3L measure, the difference between the change scores of the two measures increased.  This 
was due to the value weights supressing change to a greater extent on the ICECAP measures 
than the EQ-5D-3L.  This in turn was likely to be because individuals were concentrated at 
the top end of capability, where relatively little additional value is obtained from a shift 
between ICECAP levels, compared with change at lower levels of capability (discussed in 
greater depth in Chapter 9). 
In the symptom and side-effects, PHQ-8 and GAD-7 anchor analyses, differences were seen 
between the ICECAP measures and EQ-5D-3L.  While the magnitude of change was similar, 
the pattern of change was different.  In these analyses change in the ICECAP measures was 
larger in the group reporting a worsening of health state than in the group reporting an 
improvement.  For the EQ-5D-3L the reverse was true: change was larger in the group 
reporting an improvement than in the group reporting a reduction.  
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CHAPTER 9: DISCUSSION 
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9.1. Chapter introduction 
The discussion contains six sections.  First, the results of the quantitative and qualitative 
research are summarised by drawing out themes running through the research.  Second, the 
methodological strengths and weaknesses of the work are reflected upon.  Third, the findings 
are discussed and placed in the context of existing research.  Fourth, the implications of this 
research for practice and policy are assessed.  Fifth, the key contributions of this research will 
be summarised.  Finally, areas for future research are discussed.  This section will identify 
gaps in the current knowledge base and suggest future research methodologies to provide the 
required evidence.  A conclusion then draws the thesis as a whole to a close. 
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 9.2. Summary of principal findings and research themes 
During the conduct of the research and writing of this thesis it became evident that the results 
centred on a smaller number of broad themes.  The principal findings of the research will be 
described using these themes, which run through the qualitative and quantitative work, 
through the two trials and through the cross-sectional and longitudinal results.   
9.2.1. ICECAP measures are simple and feasible for use 
The question of whether the ICECAP measures are feasible for use in a randomised controlled 
trial, which is designed to improve the physical health of participants, is central to the 
research presented in this thesis.  If a measure does not meet the practical constraints of a trial 
environment then, however valid it is, it is unlikely to be used.  Data from the methodological 
review, the qualitative research, the experience of recruiting trials to the quantitative research 
and the quantitative research itself allow an understanding of practical considerations when 
using a quality of life measure in research and whether the ICECAP measure meets these.   
The qualitative research found that informants viewed the ICECAP-A measure as short, 
straightforward and easy to complete.  This appears to be reflected in the completion rates of 
between 92% and 99% in the studies identified by the methodological review 
[117,172,173,175,177,180] and in the trials used in this research.  These completion rates 
considered in conjunction with the results of the quantitative research indicate that the 
measures are feasible for use in trial-based research.   
The frequency of use of a measure is a good indicator of its feasibility for use.  The number of 
studies which have registered to use the ICECAP measures is increasing year on year.  This 
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suggests that research groups see the benefits of using a broad measure of well-being that 
conceptualises quality of life through the lens of capability.  In contrast, the experience of 
recruiting trials to participate in this research indicated that some researchers hold 
reservations about the measure.   Two research groups declined to include an ICECAP 
measure in their trials due to concerns either with the content of the measure, or concerns over 
whether the measure would be responsive to the intervention being studied.   
Concern about the content of the measure was an unexpected finding, which relates to the 
usability of the measure.  A small number of researchers felt that the content of the ICECAP 
measures was inappropriate and could prove to be upsetting to participants.  The qualitative 
research identified that these perceptions were motivated by the perceived potential for items 
being upsetting to people who had low levels of the dimensions being assessed, rather than 
being inappropriate or upsetting per se (e.g. asking someone about their attachment might be 
upsetting to someone who had little love and friendship in their life, but not to someone who 
had a strong friendship circle).  The qualitative research also suggested that this was a 
minority opinion; the majority of informants found the content of the measure acceptable, 
with some showing notable enthusiasm for its content. 
Taken as a whole the results indicate that the ICECAP measures are feasible for use in a 
randomised controlled trial designed to improve physical health.  Concerns over the relevance 
and sensitivity of the content of the measure, held by some, were not reflected in the majority 
view of the qualitative informants or in the completion rates of the measures.  
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9.2.2. ICECAP measures go beyond health 
Quantitative and qualitative data both indicate that the ICECAP-A and ICECAP-O measure a 
construct that is different from that assessed through health, physical functioning or health-
related quality of life measures.   
Using the comparative direct approach informants’ conceptualisation of quality of life, their 
opinions of the ICECAP-A measure and whether the ICECAP-A captured their 
conceptualisation of quality of life was examined.  In the early part of the qualitative 
interviews informants discussed a construct that was broader than health alone.  A majority 
view was evident that while health was a strong influence on quality of life and well-being, 
other social influences such as family and enjoyment were also important.  When considering 
the ICECAP-A measure, informants frequently observed that it was a broader measure than 
existing health focused measures.  A number of informants, some spontaneously but often 
when prompted, noted that the measure captured the broad definition of quality of life and 
well-being they had previously described. 
The quantitative results provide support for the informants’ perceptions that the ICECAP 
measures reach beyond the measurement of health.  First, moderate correlations were found 
with measures of health and physical functioning, which are suggestive of a non-perfect 
relationship between ICECAP capability scores and the scores of health measures.  If the 
ICECAP measures were capturing solely health status, stronger correlations would be 
expected. These correlations indicate that determinants other than health are affecting scores 
in the ICECAP measures.  Second, the measures were found to associate with the limited 
number of non-physical health measures included in the participant questionnaire packs.  
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Moderate correlations were found with vitality, social function and measures of psychological 
health.  Third, the responsiveness analysis showed, in this population of high capability 
individuals, change in the ICECAP capability scores was smaller than change reported in the 
health anchor.  This suggests that change in the health anchor was not a sole, or possibly even 
a major, determinant of change in ICECAP scores.  Furthermore, the responsiveness analysis 
showed differences in the patterns of change between the ICECAP measures and the EQ-5D-
3L comparator.  For example, the ICECAP-A measure was more responsive to reductions in 
psychological health, whereas the EQ-5D-3L was more response to improvements in this 
construct.     
9.2.3. A complement not a replacement for existing measures 
The qualitative findings and quantitative results indicate that the ICECAP capability measures 
should be used in addition to existing health-related quality of life measures, rather than as a 
replacement.  A strong theme running through the qualitative data was that informants viewed 
the ICECAP-A measure as capturing different information to that captured by existing health-
related quality of life measures.  Informants noted that ICECAP-A and EQ-5D-5L were 
measuring two different concepts: health, versus a more general conceptualisation of well-
being.  The broader assessment of quality of life was viewed as useful in addition to measures 
which maintained a focus on health or health-related quality of life. 
The quantitative results provide support for the opinions of informants.  The two factor 
solution to the factor analyses, found in both trials, indicated that the items of the EQ-5D-3L 
and the ICECAP measures are measuring two different concepts.  EQ-5D-3L items, with the 
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exception of anxiety and depression item, loaded onto a factor; while the ICECAP items 
loaded onto another factor.   
9.2.4. The importance of responsiveness 
Data from both the qualitative and quantitative research indicate that the responsiveness of a 
measure is an important consideration for trialists and an area in need of more research with 
the ICECAP measures.  An emerging theme from the qualitative research was how measures 
are selected for use in a randomised controlled trial.  This emergent theme identified 
responsiveness as a central, if not the primary, consideration for trialists when choosing a 
measure.  Informants discussed how such concerns had stopped them from using quality of 
life measures as an outcome and many were unsure whether it was possible to detect the 
effect of an intervention in existing quality of life measures.  An example of the importance of 
responsiveness was reflected in the decision of one trial to decline inclusion of the ICECAP-A 
measure for the purposes of this research, citing concerns about the responsiveness of the 
measure to their intervention. 
The responsiveness analysis found changes in ICECAP capability scores in response to 
changes in health.  The changes in ICECAP scores were small, but consistently in the same 
direction (e.g. when health improved so did capability).  The inferences that can be drawn 
from these results and the possible reasons for proportionately smaller changes than changes 
in the health anchor are discussed below.  These results, in conjunction with the results 
indicating the importance of responsiveness to trialists and researchers, highlight the need for 
further research, which is discussed later in the chapter. 
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9.2.5. Capability as a new research area 
The development of capability measures for use in health and social care research is in its 
infancy [100,115,159].  A small number of measures have been developed.  Arguably the 
ICECAP measures are most advanced in this process, with a small number of validation 
studies already completed.  The results from the methodological review, the qualitative 
research and the quantitative results reiterate that the development of capability measures is a 
new area of research and the validation of the ICECAP capability measures is in its early 
days.  Results from each section of this thesis suggest the need for further validity research, 
which is discussed further below.  Furthermore, the stage of validation has an implication for 
the conclusions that can be drawn from this thesis.  The argument based approach [205] to 
validation means that validity is inferred as evidence is brought to bear.  The weight of 
evidence informs the certainty of conclusions.  Therefore in this early stage of validation 
cautious conclusions should be drawn. 
9.3. Reflections on the strengths and limitations of the 
work 
The research presented in this thesis has both methodological strengths and limitations which 
need to be considered in order to draw accurate conclusions from the findings.  This is done 
through a reflection on the qualitative research and a discussion of the quantitative strengths 
and weaknesses. 
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9.3.1. Qualitative reflection 
The potential limitations of the qualitative research were: the impact of the researcher upon 
the research; the characteristics of the informants interviewed; and the reaching of saturation 
point.    
9.3.1.1. The influence of the researcher 
A debate exists within the qualitative research community about whether the researcher is an 
objective figure who does not project values or opinions onto the research or whether it is 
impossible for the researcher to be neutral [270].  In this situation it is likely that I, as a 
researcher, had an (largely unquantifiable) effect on the data provided by informants and the 
interpretations drawn during the analysis.  In this situation reflexivity or self-reflexivity is an 
important tool for interpreting work honestly and objectively [270,314].  This involves 
reflection on the ways, as the interviewer, I may have influenced the findings of the research 
and is a fundamental practice in good qualitative research.  Three primary influences may 
have had an effect upon the results: my link with the work on the ICECAP-A measure; my 
relative lack of experience of qualitative research; and my position as a comparatively junior 
researcher to all but one of the informants. 
As a researcher who works within the team that developed the ICECAP-O and ICECAP-A 
measures and whose thesis is focused on assessing the validity of these measures it is likely 
that my position may have influenced the research in two ways.  First, a small number (five) 
of the informants were aware of the research group in which I worked, or had an 
understanding of the subject of my thesis.  This knowledge may have resulted in these 
informants exercising greater caution when critiquing the measure or providing favourable 
373 | P a g e  
 
opinions in order to please.  This was evident during an interview with one informant who 
showed perceptible embarrassment when describing his dislike of the ICECAP-A measure.  
For the other informants who had knowledge of my role, no such hindrance was observed, but 
findings may still have been influenced.   
A second path through which my role may have influenced the results is an underlying bias 
affecting my conduct in the interview or my analysis of the results; in short I may have 
projected my opinion upon the research.  Two steps were taken to reduce this effect.  A topic 
guide was enlisted in conjunction with a cautious approach to ensure non-leading, open-ended 
prompts were used [278].  The transcripts of the early interviews were reviewed by 
supervisors to check that my interview style was suitable for the research and a conscious 
effort was made on my part to ensure that I developed and implemented an appropriate 
interview technique.  Furthermore, a hierarchical coding structure was used in the analysis of 
results.  This allowed the identification of themes within a formal structure. The coding 
structures and the output of the analysis were checked by supervisors at regular intervals.  
This coding structure and supervisor check will likely have reduced the impact of any 
personal bias upon the analysis process; although it is unlikely to have excluded it all 
together.   
My confidence and ability as a qualitative researcher improved throughout the period of 
research.  This was my first piece of qualitative research.  Before starting, I completed a week 
long qualitative research course at the University of Bristol, which had a large practical 
component of interview practice.  This gave me the basic skills required to conduct interviews 
and analyse their content, which were enhanced through the experience of the research 
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interviews
8
.  By the end of the research interviews I had improved in four main areas:  my 
ability to put the informant at ease in the interview (not least because I felt more at ease), my 
ability to identify themes and pertinent points during the interview and use appropriate 
prompts to increase the contextual richness of the data provided; my willingness to provide 
the informant ample time to reply to questions and not jump into every silence; and my ability 
to keep the informant on topic.  The data provided in the early interviews may have been 
constrained due to my ability as a researcher.  Therefore, data from these interviews may add 
less weight to the overall results, than data from the later interviews.   
All except one informant was my senior, often with 20 years or more experience in research.  
This provided an interesting dynamic to the interviews: I adopted the role of a junior 
researcher [269].  In many instances the dynamic of the interview was close to a student and 
teacher relationship, where the teacher (informant) imparts knowledge upon the student 
(interviewer).  This dynamic was logical, in most cases productive, and ensured a good 
working relationship during the interview.  However, it did limit my ability to challenge 
inconsistencies.  To explore inconsistencies in the opinions the informants provided I had to 
step out of the role as “student” and assume a more challenging position.  When doing this the 
dynamic of the interview often quickly changed.  In some cases, this led to a reduction in the 
data provided on that subject.  For example, one informant defined quality of life in very 
broad terms and critiqued the ICECAP-A as being a broad measure.  When challenged on this 
point she became defensive and quickly changed subject. 
                                                 
8
 Furthermore, both of my supervisors, who were experienced in the conduct of qualitative research and the 
analysis of qualitative data, provided ongoing advice and support throughout the work. 
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9.3.1.2. The characteristics of the informants 
Informants were recruited to the research in their position as researchers involved in 
randomised controlled trials.  Their levels of experience varied from senior professors or 
senior research nurses to early career researchers.  A number of researchers had worked on 
numerous trials and some were viewed as leading national or international experts in their 
field.  None of the informants had an expert knowledge of the theory of quality of life 
measurement; however all of them had experience of using quality of life measurement and 
many were experts in the practical issues of trial measurement and analysis of collected data.  
Despite this practical experience and expertise, even the researchers who were most 
experienced were, when asked, very clear about their perceived lack of knowledge or lack of 
professional research interest in the of quality of life measurement.  Therefore, the views 
captured in the qualitative research can be considered as the views of health researchers rather 
than experts in the theory of quality of life.  Effort was made at the start of the interviews to 
establish there were no wrong answers, to ensure that informants felt able to voice their 
opinions and it was emphasised that their opinions were of great value to the research [278].  
Despite these efforts, it was evident that some informants were cautious about voicing their 
opinion and concerned about being “wrong”.  At times this meant that it was difficult to fully 
explore their views. 
Informants were also recruited primarily from clinical areas.  Only a small number of 
informants had experience in social care research or public health research.  The ICECAP-A 
measure may be of particular use in a social care setting or in evaluating the impact of public 
health interventions [99].  While it should not be considered a weakness of a study seeking to 
assess the validity of a capability measure in randomised controlled trials, the results and 
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conclusions of this research may have been different had researchers from a social care setting 
been included in the research.  This is discussed again in the future research section below. 
9.3.1.3. The early achievement of data saturation 
Data saturation [239] was reached quickly on the primary objective of the research: the face 
and content validity of the ICECAP-A measure .  This is likely to be due to the relatively 
homogenous nature of the sample (all informants were involved in health-focused randomised 
controlled trials) and the focus of the research on a clearly defined question.  No new themes 
were identified after the 14
th
 interview.  The relatively low number of informants should not 
be viewed as a weakness of the research.  Data saturation suggests that continued recruitment 
of informants would have provided no additional information on the primary objective of 
research [315,316].  Data saturation was not, however, reached on the emergent theme of how 
measures are selected for use in a randomised controlled trial.  This work provides some 
tentative conclusions on the how a measure is selected for inclusion in a trial and what is 
considered while choosing a measure.  In light of the fact that data saturation was not reached 
these conclusions require further confirmatory research.   
9.3.2. Strengths and weaknesses of the quantitative analysis 
This thesis reports the first assessment of the construct validity of the ICECAP measures in a 
randomised controlled trial and the first analysis of the responsiveness of the measure using 
longitudinal data.  In evaluating the strengths and weaknesses a number of aspects of the work 
are considered, which relate mainly to the randomised controlled trials and methodology used 
in the analysis. 
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9.3.2.1. The randomised controlled trials 
The recruitment of the two randomised controlled trials to this research and the provision of 
data from these trials is a major strength of this research.  The PastBP [279] and BEEP [280] 
trials were trials run by established research units in two different clinical areas.  Bias was 
controlled for and data collection processes were rigorous.  These trials are reflective research 
settings where it is likely that the ICECAP measures will be used in future. 
The provision of data from two medium sized, randomised controlled trials with a sample size 
in both cases of over 500, makes this one of the largest assessments of the construct validity 
of the ICECAP measures to date.  Both trials provided data from the majority of outcome 
measures completed by participants at baseline and follow-up.  This provided a number of 
comparator measures for the baseline validity analysis and a wide choice of anchor measures 
for the longitudinal responsiveness analysis.  Therefore, this research provides a large amount 
of data, substantially adding to the existing validity portfolio, and can be used to inform future 
validity research. 
The provision of this data from two trials (rather than one) in different clinical areas has 
increased the generalisability and applicability of the research.  However, as discussed in 
Chapter 3, the psychometric properties of a measure are context specific [200,205,206].  
Caution should be exercised in applying the results outside of these research settings.  As is 
the case with the majority of randomised controlled trials, the inclusion and exclusion criteria 
of the PastBP and BEEP trials resulted in a specific sub-section of the general population 
being included in the trial.  The PastBP inclusion criteria were those who had suffered a 
stroke or TIA, had a systolic blood pressure over 125mmHg and were not taking three or 
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more anti-hypertensive drugs.  The BEEP trial randomised those who had consulted GP due 
to knee pain in the last 12 months or were being referred to a specialist due to knee pain.  The 
result of such selection criteria is to select a group of participants that is different to the 
general population on a number of key characteristics [119].  Therefore, caution needs to be 
exercised when generalising these results to either the general population or other trial 
populations.  The characteristics of these populations are presented in detail in this thesis, 
which it is hoped will assist researchers when deciding whether it is appropriate to generalise 
the results to other populations. 
Two participant characteristics are of particular note.  Firstly, the EQ-5D-3L index scores of 
0.63 in the BEEP trial and 0.72 in the PastBP trial indicate that while the participants do have 
health problems they are not, on average, in a debilitative health state.  Different values may 
be found in other populations with the same health issues or with populations with different 
health issues.  For example, a late stage cancer patient might be expected to be in worse 
health.  Second, the ICECAP tariff scores of patients in both trials were comparable to or 
higher than the general population.  It is not possible to comment if the capability of these 
participants was unusually high for a trial population or whether trial populations generally 
exhibit high capability levels.  Either way the quantitative results of this thesis need to be 
considered in light of these high capability scores. 
The PastBP trials used a pharmaceutical intervention to reduce a person’s blood pressure, 
while the BEEP trial used a physical intervention to increase a person’s recovery from knee 
pain. To what extent these interventions would change the capability of a person and to what 
extent this affects a psychometric assessment is an important consideration when interpreting 
the results of this research.  It was the hope of the supervisory team at the outset of the 
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research that a trial where patients had considerable disability and had a notable improvement 
in health or physical functioning, such as a hip operation, or a trial of a social care 
intervention, such as the maintenance of independent living, would be recruited to the 
research.  No trials of this type that would provide data within the timespan of the PhD were 
found.   Large changes in the capability of the participants in the recruited trials were not 
expected.  This was reflected in informal conversations amongst the supervisory team, as well 
as with the trial teams during the continuation of the research.  This was particularly so for the 
PastBP, where high blood pressure is largely non-symptomatic until a cardiac event occurs.   
To what extent this matters to a psychometric analysis, especially the analysis of 
responsiveness needs to be understood clearly.  This analysis did not use the randomisation of 
participants in this analysis.  So no analysis of those receiving intervention versus placebo 
was completed.  Rather, the responsiveness analysis used anchors to define groups which had 
changed by some degree on some measure and then ICECAP scores were analysed in these 
groups.  Therefore, the analysis of responsiveness does not rely on the success of the 
intervention; rather a level of change in the population needs to have occurred.  Analyses 
presented in Chapter 8 indicate that the majority of participants reported small changes in the 
EQ-5D-3L and ICECAP scores occurred in these populations.  Therefore, the responsiveness 
analysis was completed in a population showing low levels of health and capability change.   
9.3.2.2. The methods 
The methodology used for this analysis has a number of strengths.  It has utilised best practice 
from established and well reported research techniques in the field of quality of life measure 
validation [185,186].   Firstly it used a scientifically rigorous process of hypothesis formation 
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and testing.  Hypotheses were formed through a pre-planned process [200].  Three researchers 
independently formed hypotheses.  These were then compiled and confirmed for final testing 
when all researchers agreed on the direction of the association.  Where post-hoc or 
exploratory analysis has been completed (which did not involve the use of stated hypotheses) 
this is clearly highlighted in the text and caution has been exercised when interpreting the 
results.  
The methodology and statistical analysis used to test hypotheses is appropriate [138,184] and 
has been used consistently in the testing of the psychometric properties of patient-reported 
outcome measures [116,117,287,317].  Known groups, convergent and divergent validation 
has allowed this research to show what measures the ICECAP O and ICECAP-A associates 
with and what the discriminative ability of these measures are.  Anchor based analyses 
allowed the assessment of change in ICECAP scores when a change in the health anchor 
occurred.  This has the benefit of allowing the results to be easily interpreted in light of past 
and future research.  
This research methodology also has some limitations which should be noted, namely, the 
predominance of health measures alone being available for use as comparators and anchors.  
In this analysis the validity and responsiveness of the ICECAP measures were tested using 
data from measures already included in the randomised controlled trials.  Hypotheses were 
formed and correlations and associations were assessed against these measures.  As is shown 
in the results chapters and discussed here, this provided informative and novel information to 
contribute to the validity and responsiveness portfolio of the ICECAP measures.  However, 
the predominance of health, physical functioning and health-related quality of life measures 
and the lack of measures of social well-being (which are rarely included in trial questionnaire 
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packs), means that the scope of this assessment of validity and responsiveness has its 
limitations. 
The ICECAP measures are an assessment of a broad conceptualisation of well-being, 
capability.  Grewal et al [109] identify health as one of six broad factors that impact a person’s 
capability, including having activities and things to do, home and surroundings, family and 
other relationships, standard of living and wealth and religion or faith; while Al-Janabi et al 
[115] identify five conceptual attributes that determine an individual’s capability, each of 
which is assessed in the ICECAP-A measure via one item.  This forms the empirical basis 
upon which the ICECAP-O and ICECAP-A measures were developed.  In the research for the 
development of both ICECAP measures health is acknowledged as one of a number of 
influences, albeit important, upon the capability of a person.  This was reflected in the 
development of, and ultimately in the final versions of, the ICECAP measures.    The data 
made available by the trials for use as comparators and anchors in this analysis predominantly 
assessed the health of the individual.   
In Chapter 3 the use of a nomological network was defined and discussed. The idea that a 
number of stated hypotheses about how the measure under investigation was expected to 
associate with other measures should be tested is a widely accepted method of construct 
validation [203].  The data available from these trials meant that hypotheses on how the 
measure associated with measures or indicants of health and physical functioning could be 
tested; while associations with the other determinants of capability went under assessed.  For 
example, in both ICECAP measures the ability to achieve and the ability to feel secure or 
stable are important constructs.  Data from measures which assessed such constructs, or 
similar constructs, were not available.  Therefore, no hypotheses could be formed or tested 
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which provided information on the association of the ICECAP measures with measures of 
achievement or security.  Consequently, a complete nomological network could not be tested.  
This challenge also applied to the responsiveness analysis where the change in the measure 
was assessed against change in health and physical functioning measures, but not against 
changes in other influences on capability. 
These limitations in the data mean that this analysis seeks to validate and assess the 
responsiveness of two measures which have theoretical grounding in the capability approach 
by using outcome measures which are largely couched in the health economics extra-welfarist 
school of thought [7].  As discussed in chapter one, the practical exposition of the extra-
welfarist approach has a limited evaluative space of health or health-related quality of life 
[7,318].   While not all of the measures included in the PastBP and BEEP trial were included 
with the aim of informing the economic analysis of the trial, the majority would be suitable 
for use either in a cost-effectiveness analysis or in the case of the EQ-5D-3L and SF-36 (that 
can be transformed into the SF-6D preference based measure [153]), a standard cost-utility 
analysis [88,89,319].     
This predominance of health-focused outcome measures is not exclusive to the trials included 
in this research.  The majority of randomised controlled trials in health research will focus on 
health outcomes.  If the ICECAP measures are to be used in randomised controlled trials, then 
their psychometric properties must be validated in such a setting.  So while the scope of this 
analysis is truncated, this should not be considered a limitation which is exclusive to this 
research or a reason for not continuing validation research into the ICECAP measures in 
randomised controlled trials.  It is a challenge that this research faced and one that future 
evaluations of capability measures in randomised controlled trials will also face: how to 
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validate a capability measure using predominantly health outcome measures.  This point is 
discussed further in the future research section.    
9.4. Discussion of principal findings 
This section will discuss the findings of the qualitative and quantitative research in the context 
of existing research, much of which is presented in the methodological review in Chapter 2. 
9.4.1. Content and face validity  
The need for triangulation of qualitative research that assesses the face and content validity of 
a measure is discussed in Chapter 3 [242,244].  Recently published guidelines for assessing 
content validity highlight the need for comparison between research completed with both 
experts and public or patients in reaching a conclusion on the validity of the content of a 
measure [233].  This allows the integrity of results to be checked and, potentially, inferences 
extended [244].  The qualitative “think-aloud” research by Al-Janabi et al [181] allows for 
triangulation with research using the general public as informants
9
.  Comparison can be made 
on five points: ease of completion, understanding of capability wording, breadth of the 
questions, whether the questions are upsetting and the relevance of the Achievement item. 
The results show expert informants viewed the ICECAP-A as a short, easy to complete 
measure and suitable for use in a trial environment.  Particular emphasis was placed by 
informants upon how well the measure fitted with the time constraints that exist in such 
research.  This confirms the findings from research with the general public, which found the 
measures straightforward, unsurprising and possible to complete with a low level of error 
                                                 
9
 A qualitative “think aloud” study by Horwood was identified through the methodological review. [182].  This 
study used the ICECAP-O and therefore is not used here 
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[181].  Together, these results indicate that the ICECAP-A measure is an easy to complete 
measure (and quantitative results, discussed above further confirm this). 
The use of the phrase “I can” and “I am able” (to indicate capability) was discussed by 
informants in the qualitative research both in this thesis and in the “think aloud” research with 
the general public.  While the majority of expert informants demonstrated an understanding of 
the capability wording that was broadly in line with capability theory, a number of informants 
expressed concern about the phrasing of the questions.  Expert informants felt that the 
wording may be confusing for participants completing the questionnaire.  The “think aloud” 
work [181] showed that some informants interpreted the questions as assessing functioning, or 
they struggled with the use of the phrase “I can”, sometimes interpreting it as a question of 
worthiness.  However, not all general public informants struggled with this phrase and many 
reached an understanding which was correct.  Together these data indicate that participants 
may experience some problems interpreting the capability wording of the questionnaire and 
draws attention to the importance of the phrasing of capability questions in future 
questionnaires.   
A small minority of the expert informants objected to the content of the measure on the basis 
that it may prove upsetting for informants.  Those who did object were considering the 
situation where a respondent had low levels of capability and answering questions about this 
may prove upsetting.  No indication of this was found in the research with the general public 
[181].  This, in conjunction with the majority of expert informants who either felt the measure 
was appropriate or did not comment on this issue, suggests that this issue may not be 
widespread. 
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 Contrasting findings were found between this research and the “think aloud” research on the 
suitability of the breadth of the ICECAP-A items.  Al-Janabi et al [181] found that the breadth 
of the items allowed ‘participants to bring a large range of factors, which influenced their 
well-being into their answers’(p.120).  The findings from the research with experts indicated 
that, with particular reference to the Attachment item, informants had concerns about items 
assessing more than one construct.  The example was given of a person having love, but not 
friendship and support, and the question was raised how someone would then answer the 
Attachment item. 
Informants from both pieces of research raised the question of whether the Achievement item 
was relevant for older people (the ICECAP-A being applicable for all adults).  Some of the 
older general public informants questioned its relevance to people at their (later) stage of life, 
making the point that for many at their stage of life it is about maintaining what they have, 
rather than achieving more [181].  The expert informants went further, firstly by questioning 
whether it would be appropriate for older respondents, but also whether the top level is 
achievable for anybody.  It should be noted here that this concern was not borne out in the 
quantitative results where large percentages of both the older PastBP and younger BEEP trial 
populations reported full capability for the Achievement item.  However, the results of both 
qualitative studies indicate that further consideration of this item of the ICECAP-A measure 
may be required. 
As discussed above, the ICECAP-A measure was viewed as a complement rather than a 
replacement for existing health-related quality of life measures.  Informants discussed the use 
of the ICECAP measures alongside other measures.   Health economist informants discussed 
using it alongside preference or value based measures, namely the EQ-5D-3L.  It is usual for 
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trials to include more than one health-related quality of life measure in their questionnaire 
packs.  It is recognised that inclusion of multiple outcomes for assessment of the clinical 
effectiveness of the trial is acceptable as long as the primary and secondary outcomes are 
specified a priori in the trial protocol [125].  The use of multiple outcomes may increase the 
depth of the information captured.  For the purposes of health economic analysis alongside a 
randomised controlled trial, the norm is that one preference or value weighted measure is 
included in the questionnaire pack and the results of this measure is used to form QALYs 
which inform an economic analysis.  The traditional choice has been for a single measure to 
be used to form a QALY.  Therefore, the potential of use of the ICECAP measures in addition 
to existing measures may be a possibility for researchers assessing the effectiveness of a 
treatment.  However, in light of current and accepted norms for health economic measurement 
alongside randomised controlled trials this may not be an option, in spite of health economist 
informants raising this possibility. 
In summary, a number of similar themes were identified in both the qualitative research from 
this thesis and past research by Al-Janabi et al [181].  Triangulation has allowed results to be 
compared and contrasted under these themes.  Considered as a whole and together, the 
qualitative research into the ICECAP-A measure provides encouraging evidence of content 
and face validity.  
9.4.2. Construct validity  
9.4.2.1. Meaning of results in context of past research 
The results from the validation studies using the PastBP and BEEP trials can be compared 
with findings of the literature included in the methodological review.  The associations of 
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ICECAP measures found in these trials largely confirm the associations found in previous 
studies that were reviewed and the majority of stated hypotheses were confirmed by results.   
The response profile of the ICECAP-O in the PastBP trial was similar to findings by other 
studies with both the general public [117,178] and patient populations [176,180].  Out of the 
five ICECAP-O items the Attachment and Control items received the highest proportion of 
respondents reporting full capability, which is reflective of past research.  The mean ICECAP-
O tariff score was at the top of the range of scores seen in past research 
[116,175,176,178,179] and the ICECAP-A tariff scores was a little higher to the only existing 
value in the general population [116]. 
Moderate correlations with measures of self-reported health were found, which are suggestive 
of a non-perfect relationship between the ICECAP measures and health.  This is similar to 
findings from past research.  The correlation of the ICECAP-O with the EQ-5D-3L was 
slightly higher than previously found [173–176]; while the correlation for the ICECAP-A was 
also moderate.   
The ability of a measure to discriminate between individuals in different health or capability 
states is an important characteristic of valid measures to be used in health research.  The 
known groups analysis using the Modified Rankin Scale, the symptoms and side-effects or 
co-morbidities questionnaires, the GAD-7 and the PHQ-8 provides encouraging indications 
that the ICECAP measures can differentiate participants with different levels of psychological 
and physical health.  This reflects past findings which showed significant differences in 
ICECAP scores between those reporting different levels of general health [177] and 
psychological health [172,180]. 
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The item-by-item analysis showed some additional unexpected associations.  The closer than 
expected association of the ICECAP item of Attachment with measures of health showed 
similarities to results found by Al-Janabi et al [116] and Ratcliffe et al [176].  Using factor 
analysis, Davis et al [173] have previously suggested that the ICECAP-O and EQ-5D-3L are 
measuring two separate, but correlated factors of “physical functioning” and “psychosocial 
well-being”.  The factor analyses in this research using the ICECAP-O confirm this two factor 
solution found by Davis et al.  The first factor analysis using the ICECAP-A, which shows a 
very similar two factor solution, is also presented herein. 
The availability and use of data from the psychological scales of the SF-36 with the ICECAP-
O and the GAD-7 and the PHQ-8 with the ICECAP-A, means that this is the most 
comprehensive assessment of the associations between the ICECAP measures and measures 
of psychological health to date.  Past research using the Hospital Anxiety and Depression 
Scale [172] and the Herth Hope Index [176] provided mixed and incomplete results on the 
associations with psychological health.  Our analysis shows consistent results confirming the 
hypothesised association of the ICECAP measures with measures of psychological health.  
Both ICECAP measures show moderate correlations with measures of psychological health 
and the known group analyses show the both measures are able to discriminate between 
participants in different levels of psychological health. 
9.4.2.2. Conclusions to be drawn 
As discussed at a number of points in this thesis, validity is context specific and this is the 
first assessment of its kind in this context.  The argument based approach to validation, 
proposed by Kane [205], explains that evidence needs to be brought to bear and that the 
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certainty of conclusions increase as more and more evidence is provided.  As the first 
assessment of validity in this setting, the conclusions drawn from this work need to be 
relatively cautious.  Previous research from other settings can assist in the interpretation of the 
results, but do not allow firm conclusions to be drawn.   
The results presented in this thesis provide encouraging initial evidence of the validity of the 
ICECAP measures in a randomised controlled trial setting.  Associations which were 
expected a priori were found for both measures.  The results are suggestive of a measure that 
is capturing a conceptualisation of quality of life that is broader than health or health-based 
assessments of quality of life.  This broad measure appears to be able to discriminate between 
groups in different states of health or physical functioning.  Further research is required to 
confirm this finding, and the potential nature of this research, is discussed below.    
This finding will be of interest to health economists.  This provides an early indication that 
capability may be accurately measured through the use of value weighted, patient reported 
outcome measures in a randomised controlled trial.  As discussed in Chapter 1 the extra-
welfarist approach has been criticised for restricting the scope of its evaluative space.  The 
finding that capability may be accurately measured in a trial environment, alongside which 
the majority of health economic analyses currently take place, should prompt health 
economists to question again the close reliance on measures of health.   
This finding will also be of interest to trialists and health researchers.  The ICECAP measures 
are currently being used in a number of research projects.  These findings will allow trialists 
and researchers to have greater confidence that the measure offers a broader conceptualisation 
of well-being and the inferences that we can draw from it are accurate and sound.  Research 
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which previously showed encouraging evidence of validity in the general public and patients, 
has been extended to a interventional health research setting.  Conclusions of their trial 
participants’ capability can now be measured with more confidence. 
Capability researchers and those interested in the application of the capability approach in 
health will likely be interested in the findings.  The findings indicate that Sugden et al’s [54] 
question over whether the approach could be operationalised has been (largely) answered in 
the area of health, through findings that show strong indications of capability measure 
validity.   It also provides an indication that development of capability measures at the 
methodologically driven research end of Robeyns [111] continuum (rather than at the 
theoretical end) may be the most promising route to operationalizing capability measures in 
health. 
9.4.3. Responsiveness 
This is the first analysis to assess the responsiveness of the ICECAP-A or ICECAP-O 
measures using longitudinal data.  The results from this analysis provide evidence for the 
responsiveness of the ICECAP measures.  Results show small changes in ICECAP-O and 
ICECAP-A tariff scores in response to changes in health.  The majority of SRMs and effect 
sizes for these changes are small to moderate, indicating that the proportion of change to 
standard deviation of baseline score or change score was small.  
Analyses using the non-weighted ICECAP scores, which were calculated by summing the raw 
item scores without applying the tariff values, indicate that the small levels of change in the 
value tariff scores may in part be due to the values of this tariff.  The use of the EQ-5D-3L as 
a comparator measure allows further context to be added to the results.  Comparison of non-
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weighted scores and value weighted ICECAP tariff scores with the non-weighted and 
preference weighted EQ-5D-3L scores allows comment on the change in ICECAP scores in 
the context of another value weighted measure.  As has been stated above, this comparison is 
not designed to assess which measure is “best”, rather to contextualise the results.  
These results were found in two populations which had high capability, reasonable physical 
health and good psychological health at baseline and follow-up.  Furthermore, these results 
were found in trials of two interventions that were attempting to improve specific areas of 
physical health.  The context in which these results were found is an important consideration 
when interpreting the results.  Different interventions will attempt to improve different aspects 
of physical and psychological health, or sometimes aspects that stretch beyond health.  
Changes in different health areas will likely have differing impacts upon capability.  For 
example it is unlikely that the changes in capability that are brought about by, for example, a 
hip replacement, cancer treatment and impotence treatment will be the same.  It seems likely 
that some treatments will have a larger influence on capability than others.   
9.4.3.1. Non-weighted versus value weighted scores 
A comparison between the non-weighted ICECAP change scores and the value weighted 
ICECAP tariff change scores shows that change as a percentage of possible change is smaller 
for the value weighted tariff scores than for the non-value weighted scores.  This trend was 
found in both the ICECAP-O and ICECAP-A measures.  This indicates that when the value 
tariff was applied to the non-weighted scores the magnitude of change was reduced. 
The value tariffs for the ICECAP-O and ICECAP-A were calculated using best-worst scaling 
[118,166].  there are differences in the value attached to change between the different item 
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levels.  Significant value is attached to change between “none” and “a little”, changes 
between “a little” and “a lot” hold moderate value and little value is attached to changes 
between “a lot” and “all”.  This is shown in Figure 41, which presents data taken from Coast 
et al’s [118] work on the valuation of the ICECAP-O.  As can be seen a change between 
“none” and “a little” has greater value, and results in greater change in the overall ICECAP 
tariff score, than a change between “a lot” and “all”.  The exception to this rule was the 
Security item which showed similar differences across all levels.  This is not the case for the 
non-weighted analysis where change between all of the levels held the same weight.  A 
similar pattern is seen for the best-worst scaling of the ICECAP-A measure [166].   
Figure 41: Tariff values of ICECAP-O measure, taken from Coast et al (2008) 
 
 
This responsiveness analysis was completed in a high capability population.  The extensive 
item by item analysis shows that the majority of change in this population occurred by 
respondents switching answers between the top two levels of both measures.  Therefore, the 
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majority of change occurred at the top of the measure.  When applying the value tariff these 
changes are of less value, and contribute less weight to the overall tariff score, than change at 
the bottom of the measure.  Consequently these “top end” changes held less weight in the 
value weighted tariff score than they did in the non-value weighted score.  This accounts for 
the reduction in the size of change in the value tariff in comparison to the non-weighted 
scores.  
This distinction is important.  The results show that the responsiveness of the descriptive 
systems of the ICECAP measures is reduced when the tariff is applied because changes at the 
top end are not strongly valued.  Therefore, in high capability populations not experiencing 
large changes in capability the ICECAP tariff scores could be seen as not very responsive, 
even though the descriptive system of the ICECAP measure has detected change.  In 
populations with low levels of capability this may not be the case.  Here, the value weighted 
ICECAP tariff weightings may better reflect changes at the bottom end of the measures, 
because these changes hold greater value.     
9.4.3.2. EQ-5D-3L reference measure 
The use of the EQ-5D-3L as a reference measure showed that the size of change, the effect 
sizes and standardised response measures were similar for the non-weighted EQ-5D-3L scores 
as they were for the non-weighted ICECAP-O and ICECAP-A scores.  Change as a 
percentage of possible change in the two measures was similar and both measures showed 
small to medium effect sizes and SRMs on the majority of anchor analyses.  While the size of 
change and the signal to noise ratios were similar, the pattern of change was, at times, 
different.  The ICECAP-O showed greater change in those whose symptoms and side effects 
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had worsened than improved.  The ICECAP-A showed greater change in those whose 
psychological health had worsened, than in those in which it had improved.   In both instances 
the reverse is true of the EQ-5D-3L.  
While there were differences between the two measure the results of this research indicate 
that the responsiveness of the non-weighted ICECAP-O and ICECAP-A capability measures 
was similar to the non-weighted EQ-5D-3L health-related quality of life measure.  This means 
that in response to changes in health anchors, the descriptive systems of these two measures, 
which are measuring different constructs, seem to show similar levels of change.   
There were greater differences between the preference weighted EQ-5D-3L index score and 
the value weighted ICECAP tariff scores than there were in the non-weighted analyses.  As is 
discussed in the previous section there were differences between the value weighted and non-
weighted ICECAP scores.  This trend, of the value (or preference) based scoring system 
reducing the magnitude of change, was less evident for the EQ-5D-3L index score.  However, 
these differences were, in most cases, still small and effect sizes and SRMs were small or 
medium in both value weighted measures. 
9.4.3.3. A non-perfect relationship between health and capability 
As with the assessment of cross-sectional validity (where moderate correlations were 
suggestive of a non-perfect relationship) the results of this responsiveness analysis indicate a 
non-perfect relationship between change in health and change in capability.  Correlations 
between the anchor change scores and ICECAP change scores were weak and the change in 
ICECAP value tariffs were smaller than change in the anchors (judged as a percentage of 
possible change).  Considerations of the reasons for this non-perfect relationship is important. 
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A change in health represents a change in one of a number of factors that affect a person’s 
capability.  The descriptive systems of the ICECAP measures are constructed based on the 
broad range of factors identified by Grewal et al [109] for the ICECAP-O and Al-Janabi [115] 
for the ICECAP-A.  Therefore, the impact that a change in health has upon the descriptive 
system of the ICECAP may be small.  The following hypothetical example highlights this 
(Figure 42).  Take three measures: an aspect specific measure of pain, a health-related quality 
of life measure and a capability measure.  For the aspect specific measure, pain is the only 
determinant of scores on that measure.  Scores on the health-related quality of life measure 
are determined by a number of health related factors, with pain being an important 
determinant.  The capability measure scores are determined by a number of health and non-
health related factors.  Therefore, pain may have a considerably smaller impact on capability 
scores than on the scores of the other two measures. 
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Figure 42: An illustrative example of the potential of impact of single aspect of health as 
measure scope broadens 
 
While this description does seem the most convincing justification for a non-perfect 
relationship between change in health and change in ICECAP scores, a number of other 
reasons also need to be considered.  First, people may adapt to changes in health, which 
results in the changes not being reflected in how they rate their capability.  Sen [48,53,320] 
has described at length the potential for adaptation of health and desires, in part as a 
justification for the use capability as a measure.  If people are adapting to their health state so 
that changes are not reflected in self-reported capabilities, then this justification for the use of 
capabilities may not hold in patient-reported outcome health research.   
Second, the changes in capability brought about by changes in health could be time lagged 
and not captured in the timeframe of the trials.  It may be that, for example, only after many 
years or months reduced attachment that reality overtakes memories when an individual 
describes their love and friendship.   
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Third, changes in health may change the basic capabilities of an individual, such as the ability 
to live without disease and the ability to have bodily integrity, while the higher order 
capabilities assessed by the ICECAP measures may not be affected.  Sen [53,76] proposes that 
in some situations the assessment of basic capabilities may be appropriate.  Sen normally 
states this with reference to poverty.  However, if the descriptive system of the ICECAP 
measures, which assess higher order capabilities are not responsive, then this may raise the 
question of whether more basic capabilities are appropriate for assessment in a health research 
setting.   
Two further explanatory factors of the relationship between health and capability scores, 
which are specific to this research are the high ICECAP scores at baseline found in both the 
PastBP and BEEP samples and the possible selection of a sample that is different from the 
general population.  The mean ICECAP capability scores at baseline are higher than any of 
the mean scores found for these measures by the methodological review.  The ICECAP-O 
tariff score of 0.86  is higher than mean values found in the general public of 0.814 [118] and 
0.832 [177] and in patient populations of 0.779 [176] and 0.753 [178].  The ICECAP-A score 
of 0.89  is higher than values found in the general public of 0.832 [116] and these are the first 
values for a patient population.  While the ICECAP scores were above average, the level of 
health in the trial populations (measured by the EQ-5D-3L) was either, in the case of PastBP, 
slightly below the average for the age group (0.75 versus 0.78) or, in the case of BEEP, 
considerably below the average for the age group (0.64 versus 0.8).  Therefore the populations 
used in this analysis have better than average capability, but lower than average health in 
comparison to the general population.  
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Most trials have selective inclusion and exclusion criteria which results in a population with 
different characteristics than the general population [119].  The inclusion criteria for the 
PastBP and BEEP trials have resulted in a population with high capability and below average 
health; in these individuals capability is high despite their reduced health.  This may be 
suggestive of a population in which the factors other than health have a large impact on their 
capability.  Sen [53] draws the distinction between agency and well-being and factors 
identified by Grewal [109] and Al-Janabi [115] find health to be one of a number of factors 
influencing capability.  It is possible to suppose that participants in the PastBP and BEEP 
trials have a level of independence which allows them to participate in a trial, or a support 
structure which does.  These individuals may also be able to participate in activities, such as 
clinical trials, which make them feel valued.  Therefore it may be that this is a population 
where agency, rather than well-being or health, is having a larger influence on capability and 
changes in health which occurred in these trial participants have had a disproportionately 
small impact on their capability.  
A second potential influence of the high ICECAP scores and low health scores upon the 
responsiveness results is a methodological one.  If the ICECAP scores are high at baseline and 
the scores of the health measures are low, when a participant’s state improves there is more 
scope for improvement in the health measures than in the ICECAP scores.  The results from 
the BEEP trial indicates this may be the case: a decrease in health score results in a decrease 
in ICECAP scores, but an increase in health score results in a proportionately much smaller 
increase in ICECAP scores.  This is suggestive of a ceiling effect, where the sensitivity is lost 
at the top of the measure due to a clustering of responses towards the maximum score of the 
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measure.  Ceiling effects can be fully assessed through comparison with another measure of 
the same construct, which is not possible here.    
In summary the longitudinal responsiveness analysis provides an initial indication of the 
responsiveness of the measure.  Interpreting these results has been challenging due to the 
challenges involved in this research.  A number of potential explanations are proposed which 
deserve further research before a conclusion can be made with any form of certainty.  This is 
discussed in the directions of future research section below.      
9.5. Implications of research for practice and policy  
The research presented in this thesis is largely methodological.  It seeks to assess whether the 
ICECAP measures can be used with confidence in a research setting.  Therefore its primary 
contribution is to health and social care research practice.  However, in light of recent 
guidance by NICE and SCIE on the use of broad outcome measures, this methodological 
research also has some important implications for decision making and policy. 
The methodological review and primary research presented in this thesis have provided 
evidence that the ICECAP measures are feasible and valid for use in health research and 
randomised controlled trials.  Early evidence is presented indicating that the ICECAP 
measures respond to changes in health and the magnitude of change is in many cases similar 
to changes seen in the frequently used EQ-5D-3L.  Furthermore, the qualitative and 
quantitative results from this research show that the ICECAP-A and ICECAP-O are 
measuring a construct that is broader than health. 
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These findings should allow health and social care research groups to use the ICECAP 
measures in health and social care research settings with greater confidence than has 
previously been the case, and this may lead to more frequent use.  In doing so research groups 
may be able to fully capture the impact of an intervention on broader well-being, rather than 
constraining their analysis to the effect on health.  This should allow a more accurate 
conceptualisation of effects of interventions that reach beyond health. 
While the evidence of validity and responsiveness is encouraging, research into these 
measures is still at an early stage and has only been assessed in two specific contexts.  
Researchers considering use of these measures are cautioned against the assumption that the 
measures have been validated for use in all areas of health and social care research.  They 
have not.  In many research areas it may be suitable for the researcher to complete a validity 
and/or responsiveness analyses of the ICECAP measures in parallel to their use in an 
effectiveness analysis.  This is particularly the case in research in clinical areas, or with 
populations, which do not show similarities to the PastBP and BEEP trials or the studies 
included in the methodological review.  For example, there is no known example of the 
ICECAP measures being validated in a cancer population.  The first research group to do so 
should complete a validity analysis of the measure alongside their research.   
The results of this thesis have some important policy implications.  If the effects of a 
treatment or intervention reach beyond health, then the use of health focused outcome 
measures currently used will under represent the effects of the treatment.  The use of a 
measure that accurately captures the full range of benefits of a treatment will provide a better 
estimation of the impact and value of an intervention.  Therefore the use of broader measures 
of well-being, such as the ICECAP measures, in a decision making context will likely lead to 
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different decisions being taken, due to what is being measured and valued.  NICE and SCIE 
have highlighted a need for the use broad preference based measures in social care research 
[169,170].  The ICECAP measures have been identified by NICE and SCIE as two measures 
through which this may be achieved.  However, both decision making bodies have cautioned 
that validation efforts are at an early stage and currently recommend the use of these measures 
in tandem with other broad measures such as ASCOT, in order to increase understanding of 
these measures.    
The ICECAP measures appear to fulfil the NICE and SCIE criteria that measures used in 
social care should be broad, preference-based assessments of well-being.  Furthermore, the 
strong indications from this research (which is the largest study of validity and responsiveness 
in a health research setting to date) that the ICECAP measures can validly assess capability 
and are responsive to changes in a health, in a health research setting, should increase 
confidence in the use of ICECAP measure outcomes in a decision making process and go 
some way to allaying concerns, expressed by NICE and SCIE, about the lack of validity 
evidence.      
It should be noted that there is a difference between the areas in which NICE and SCIE have 
recommended the use of broader measures of well-being and the areas in which the ICECAP 
measures have been validated.  The area of social care has been highlighted by NICE and 
SCIE as a suitable place for the ICECAP measures to be used, while the majority of research 
to date has validated these measures in a health setting
10
.  This has two implications.  First, it 
highlights the need for research into the validity and responsiveness in a social care setting.  
                                                 
10
 Please note that NICE and SCIE guidance was provided in 2013 and therefore was not available at the point 
when trials were being recruited to the quantitative research and informants recruited to the qualitative research. 
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However, logically, a degree of confidence should be held that the measures will be valid and 
responsive in a social care setting, where many of the interventions are designed to have 
benefits outside of health.  Second, the ability to accurately measure in a health research 
setting a broader construct than health, may enable NICE and SCIE to consider whether it is 
appropriate to extend social care research outcomes guidance to health interventions.  While a 
broader debate about what outcomes from health care a society should value is needed before 
such a decision could be taken, a research portfolio is starting to emerge which suggests that if 
broader outcomes were to be valued, they could be accurately measured.   
9.6. Contributions of this research 
The qualitative and quantitative research presented in this thesis has made four primary 
contributions.  These are discussed below with reference to the existing research base and 
with comment on how they may inform practice in the future. 
9.6.1. New qualitative methodology for assessing content and face 
validity 
The PROMIS working group recently noted the inconsistency of content validation efforts 
and called for improvements to the methodology used [233].  Meticulously documented and 
transparent analysis, which is grounded in the data, is needed [266].  The comparative direct 
approach was developed in this thesis in response to the challenges faced in validating the 
ICECAP-A measure and may be a method through which requirements outlined by the 
PROMIS working group could be accomplished.  The approach encourages participants first 
to discuss and describe a theoretical concept, and then comment on how the measure under 
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consideration captures their description of the concept.  This approach could prove a useful 
methodological framework for validating the content of patient reported outcome measures 
going forward as many of the strengths of this methodology are generic.  The ability to gain a 
fuller understanding of the informant’s conceptualisation of a non-tangible concept, such as 
quality of life, well-being, happiness or capability, before assessing their views upon a 
measure of that construct, proved extremely useful in this research and could be beneficial to 
other research.   
9.6.2. The first analysis of content validity using research 
professionals 
Triangulation of qualitative research using both research professionals and patients or the 
general public as informants allows a fuller understanding than either on its own [233].  This 
thesis presents the first analysis of the content and face validity of the ICECAP-A measure.  
This allows triangulation with existing research (see below), which extends the inferences 
drawn from both this study and the “think aloud” work by Al-Janabi et al [114].  In addition to 
an assessment of content validity this qualitative work provides the first in depth analysis of 
the acceptability of a capability-based patient reported outcome measure amongst health 
research professionals working in randomised controlled trials.  Interviews with researchers 
with different professional roles allowed investigation of whether the phrasing of the 
questions was thought to be understandable and whether the content of the measure was 
considered by these health professionals to relate to their conceptualisation of quality of life 
and to be appropriate and suitable for use with patients in their trials. 
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9.6.3. The first analysis of construct validity in a randomised 
controlled trial setting 
A growing body of research assessing the validity of the ICECAP measures in patient and 
general public populations exists.  Validity is a context and population specific quality.  
Evidence of validity of a measure in a general population survey, does allow the assumption 
that the measure is valid in a randomised control trial.  This study is the first analysis of the 
validity of the ICECAP measures in the context of randomised controlled trial.  A priori 
hypotheses were formed through a rigorous process of hypothesis formation and tested using 
appropriate measures of association.  This analysis provides early evidence that the ICECAP 
measures are valid for use in an intervention health research setting and in particular the first 
evidence for the validity of the ICECAP-A measure outside of a general population. 
9.6.4. The first analysis of responsiveness 
Responsiveness is an important psychometric property and this qualitative research shows 
that it is an important consideration for research professionals when choosing a measure for 
use.  This research provides the first analysis of the responsiveness of the ICECAP measure 
using longitudinal data.  Results are presented from trial populations that showed reasonable 
levels of health and capability levels similar or higher than values previously recorded in the 
general population.  Results indicate changes in the ICECAP tariff occur in response to 
changes in underlying health.  Comparison between non-value weighted scores and value 
weighted tariff and between the ICECAP scores and EQ-5D-3L scores allowed greater 
interpretation of the data.  
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9.7. Directions of future research 
This is the first research to assess the validity of the ICECAP measures in a randomised 
controlled trial, the first qualitative assessment of the content and face validity of the 
measures and one of the first validation studies per se.  In addition to the 3 areas for future 
research area identified below, there is a general need for greater study into the validity of 
these measures.  Kane proposed the now widely accepted argument approach to validation 
[205], which recognises that no one study can confirm the validity of a measure and each 
validation study has the potential to add to the certainty of the conclusions we can form as to 
the validity of the measure.  Studies using different comparator measures, in different 
populations and in different research settings will add weight to the validity portfolio of the 
ICECAP measures and allow greater understanding of their measurement properties. 
9.7.1. Research with a greater spread of comparators 
Future validity and responsiveness analyses, both within and outside of a randomised 
controlled trial, will benefit from the use of a broader range of comparator and anchors 
measures.  Measures that allow a wider nomological network to be defined and a greater 
breadth of hypotheses to be tested will advance the understanding of the validity and 
responsiveness of the ICECAP measures.  Validation against measures of social 
connectedness, happiness, enjoyment and independence would enable a better understanding 
of the associations of the ICECAP measure and greater certainty in the validity conclusions 
reached. 
This should be coupled with the use of both subjective and objective measurement that would 
also provide increased certainty in the conclusion formed.  The majority of the research to 
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date has used subjective patient reported outcome measures.  Many of the constructs assessed 
by these measures do not have a clear objective assessment option (for example, there is no 
objective assessment of happiness).  However, for those that can be measured objectively, 
such as physical functioning or bodily strength [321], use of such measures would be of value 
to future analyses. 
9.7.2. Responsiveness and causality 
The most urgent area for future research is responsiveness.  As discussed earlier the results of 
this responsiveness analysis provide an indication of how the ICECAP measures respond to 
changes in health, but provide little indication of how it responds to changes in individuals 
underlying capability.  Further research is required to assess both of these points.  Trials with 
similar outcomes to the trials that we have used here would allow further assessment of the 
changes in ICECAP scores with the changes in health.  For this analysis more objective 
measures of health, in addition to patient reported health, would be useful in drawing firm 
conclusions. 
The assessment of responsiveness of the measure to changes in capability is more 
challenging.  As described in Chapter 2 a limited number of capability measures, suitable for 
use in a health context exist.  Furthermore, the responsiveness or validity of these measures is 
either un-researched or under-researched.  Therefore, the potential of assessing the 
responsiveness of the ICECAP measures, by using one of these measures to form anchor 
groups seems unwise.  An option is to assess responsiveness of the measure using a wide 
variety of anchor measures, which include assessments of factors other than health that 
determine capability, identified by Grewal[109] and Al-Janabi [115].  Such an analysis would 
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also include using measures of social-connectedness, physical and financial security, 
independence and happiness in the formation of anchor groups.  If this was to be completed in 
a trials environment it seems likely that trials where health is not the primary outcome would 
need to be recruited, possibly including social care or psychological health trials. 
A final area for future research is in populations with low baseline capability and populations 
who experience changes in capability from a low starting point.  As described above, this 
analysis assessed capability at the upper end of the ICECAP range, where changes in 
capability held less value in the tariff score.  Assessment of the responsiveness of the measure 
in those with low levels of capability would add greater context to these results. 
9.7.3. Selection of measures 
An emerging theme in the qualitative research was how measures are selected for inclusion in 
randomised controlled trials.  This research allowed the identification of the considerations 
undertaken when choosing measures, as well as who the main agents are in making this 
choice.  As has been shown in this discussion this knowledge was useful in understanding and 
contextualising the data pertaining to face validity, but it is also of use independent of a 
validity analysis.  The analysis showed provides future developers of measures with important 
information on the qualities of measures that are important to the potential users of measures.  
Also identified is the possibility of a misunderstanding of who holds expertise in the area of 
quality of life; this may be important for the governance and running of trials. 
The assessment of how measures are selected is thought to be the first analysis of its kind and 
as noted above data saturation was not achieved on this emergent theme.  Further qualitative 
research is required on this topic.  Individual interviews would be well complemented by 
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focus groups where the different agents in the selection process are included. It is likely that 
the spontaneity that arises from the more challenging and dynamic context of a focus group 
[244], where participants respond to each other would allow the process of choice in a clinical 
trial to be better understood.  Furthermore, a study which observes the process of measure 
selection in a trial planning meeting would be of great benefit to understanding the process. 
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9.8. Conclusion 
There is growing interest in the application of Sen’s capability approach in health and health 
economics research [66].  The ICECAP-A [115] and ICECAP-O [100] are two measures that 
have been developed to assess capability in a health research setting [159,163].  This thesis 
reports a qualitative assessment of the content validity of the ICECAP-A and quantitative 
investigations of the validity and responsiveness of both ICECAP measures. 
Qualitative findings indicate that health research professionals view the ICECAP-A as 
measuring content which is relevant to the assessment of capability, or a broader 
conceptualisation of well-being, and feasible for use in health research.  The breadth of the 
measures was frequently noted, along with the observation that the measure would be of use 
in addition to, rather than as a replacement for, existing measures of quality of life.   
The quantitative results largely confirm a priori expectations, providing a strong indication 
that the measures are valid for use in a health research environment.  Moderate correlations 
and item-by-item associations of the ICECAP measures with measures of physical and 
psychological health reflect and extend past findings, by providing data from an interventional 
research setting.  The longitudinal data provides the first analysis of the responsiveness of the 
ICECAP measures.  The results indicate that the measures respond to changes in health and 
highlight the need for further confirmatory research in this area. 
Together, the qualitative and quantitative results provide greater confidence in the conclusions 
that can be drawn from the ICECAP measures and show that changes that occur in an 
interventional health research setting will be detected.  In doing so, this research has made a 
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substantial contribution by filling many of the pre-existing gaps in the literature, as well as 
identifying future directions for research.  
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Appendix 1  
The ICECAP-O measure 
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Appendix 2  
The ICECAP-A measure 
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Appendix 3  
Text of key person search e-mail 
Dear , 
I am a PhD student based at the MRC Midlands Hub for Trials Methodology Research, the 
University of Birmingham, conducting research into the validity of the ICECAP-O and 
ICECAP-A capability measures.  As part of this research I am currently completing a 
systematic review of validation studies of the ICECAP measures.   
As part of the search strategy I am contacting people who may have knowledge of studies that 
have attempted to validate the ICECAP measures.  Prof. Jo Coast and Dr. Hareth Al-Janabi 
suggested that I contact you as someone who has either registered use of the ICECAP 
measure via the University of Birmingham website or attended the ICECAP workshop in 
2011.   
It would be very helpful if you could notify me of a) any studies that you may have undertook 
looking at the validity of the ICECAP measures or b) any studies that you are aware of that 
provide validity evidence on the ICECAP measures (either published or in press).  Validity 
evidence can be both quantitative and qualitative and may be included in a study where the 
primary aim is not the validation of a measure. 
I am extremely grateful for any help you may be able to give. 
Yours sincerely  
 
Tom 
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Appendix 4  
Detailed summary of review studies 
Author 
(Year) 
Country Participants: 
General 
population or 
patients 
Participants: demographic 
and health characteristics 
Participants
: 
Number in 
study 
Study: 
Design 
Study: 
sampling 
strategy 
Study: 
comparators 
used 
Study: 
analyses used 
Study limitations reported 
by authors of study 
Articles providing information on the ICECAP-O 
Coast 
(2008) 
UK General 
population 
Mean age: 74.6 (6.43) 
Female: 56.2% 
Mean ICECAP: not reported 
Mean EQ-5D-3L: 0.76 (0.27) 
n=315 Cross-
sectional 
study. 
Sample 
stratified 
based on 
postcode. 
Socio-
demographic. 
EQ-5D-3L.  
Disability and 
Pain. 
Social support 
and contact with 
others. 
Chi-squared. 
One-way 
ANOVA. 
ICECAP administered a 
couple of months after the 
comparator measures.  Partial 
assessment of construct 
validity due to comparators 
available.  No ability to 
distinguish between cause and 
effect. 
Couzner 
(2012) 
Aus Patients of an 
outpatient day 
rehabilitation 
unit or a 
residential 
transition care 
unit, with 3 
months of 
hospital 
admission. 
Mean age: outpatient rehab 
74.87 (7.17), transition care 
80.69 (6.27) 
Female: outpatient rehab 
45%, transition care 59% 
Mean ICECAP: outpatient 
rehab 0.82 (0.15), transition 
care 0.79 (0.16) 
Mean ICECAP: outpatient 
rehab 0.54 (0.25) 0.49 (0.3), 
transition care 0.79 (0.16) 
n=82 Cross 
sectional 
study. 
Patients 
either visiting 
outpatient or 
residential in 
transition 
care facility 
were invited 
to participate. 
EQ-5D-3L 
Care transition 
measure (CTM-
3). 
 
T-test. 
One way 
ANOVA. 
Chi-squared. 
Small sample size.  UK 
versions of ICECAP-O and 
EQ-5D-3L and algorithms 
were used.  The number of 
comparators in the study 
limited the scope of analysis. 
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Author 
(Year) 
Country Participants: 
General 
population or 
patients 
Participants: demographic 
and health characteristics 
Participants
: 
Number in 
study 
Study: 
Design 
Study: 
sampling 
strategy 
Study: 
comparators 
used 
Study: 
analyses used 
Study limitations reported 
by authors of study 
Couzner 
(2013) 
Aus General 
population and 
post-acute 
hospital patients 
Mean age: not reported 
Female: patients 41%, general 
population ICECAP 62%, 
general population EQ-5D-3L-
3L 49% 
Mean ICECAP: general 
population 0.795 (0.17), 
patients 0.753 (0.18) 
Mean EQ-5D-3L: general 
population 0.789 (0.02), 
patients mean 0.595 (0.2) 
n=1260 Cross-
sectional 
study. 
Patients were 
recruited 
from 
outpatient 
rehabilitation 
centre. 
ICECAP-O 
from Health 
Omnibus 
Survey and 
EQ-5D-3L 
from online 
panel survey. 
EQ-5D-3L T-test 
ANOVA 
Limited socio-demographic 
data available.  Different 
modes of questionnaire 
administration may have 
affected results.  
Davis 
(2012) 
Canada Patients visiting 
falls prevention 
clinic 
Mean age: 79.3 (6.2) 
Female: not reported 
Mean ICECAP: 0.815 
(0.177) 
Mean EQ-5D-3L: 0.701 
(0.291) 
n=215 Cross-
sectional 
study. 
All patients 
visiting clinic 
invited to 
participate. 
EQ-5D-3L. Spearman’s 
correlations. 
Paired 
Wilcoxon 
sign-rank test. 
Exploratory 
factor 
analysis. 
EQ-5D-3L administered first 
to all patients.  Language of 
ICECAP may not be 
appropriate for Canadian 
participants and UK scoring 
algorithms were used.  
Possible influence of 
completing measures in 
controlled clinic environment. 
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Author 
(Year) 
Country Participants: 
General 
population or 
patients 
Participants: demographic 
and health characteristics 
Participants
: 
Number in 
study 
Study: 
Design 
Study: 
sampling 
strategy 
Study: 
comparators 
used 
Study: 
analyses used 
Study limitations reported 
by authors of study 
Davis 
(2012) 
Canada Patients visiting 
falls prevention 
clinic 
Mean age: 79.3 (6.2) 
Female: not reported 
Mean ICECAP: 0.815 
(0.177) 
Mean EQ-5D-3L: 0.701 
(0.291) 
n=215 Cross-
sectional 
study. 
All patients 
visiting clinic 
invited to 
participate 
EQ-5D-3L 
Physiological 
Profile 
Assessment 
(PPA). 
Short Physical 
Performance 
Battery.  
MMSE. 
Instumental 
Activities of 
Daily Living 
(IADL) 
Pearson or 
Spearman 
correlations. 
Stepwise 
linear 
regression 
models. 
Cross-sectional so unable to 
prove causation.  Limited 
sample size (although 
bootstrapping used).  Due to 
specificity of sampling results 
may not generalise. 
Flynn 
(2011) 
UK General 
population  
Mean age: not reported 
Female: not reported 
Mean ICECAP: 0.832 
(0.123) 
Mean EQ-5D-3L: 
N=809 Cross 
sectional 
study 
All 65 year 
olds and over 
returning a 
city wide 
quality of life 
survey. 
Numerous socio-
demographic 
variables, 
including 
whether 
receiving 
benefits or caring 
for a person. 
Univariate 
statistics. 
Multivariable 
regression. 
 
Horwoo
d (2013) 
UK Pre and post-
operative 
patients with 
osteoarthritis of 
hip or knee 
Mean age: 70 
Female: 70% 
Mean ICECAP: pre-op 
patients 0.77; post-op patients 
0.82. 
Mean EQ-5D-3L:  
N=20 Qualitative 
think aloud 
study. 
Purposive 
sampling  
n/a A thematic 
analysis and 
an item-by-
item analysis 
of response 
problems. 
Think aloud methodology is 
dependent on the ability of the 
informants to verbalise their 
thoughts.  The clinical 
population used (although 
complements general 
populations used in 
development. 
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Author 
(Year) 
Country Participants: 
General 
population or 
patients 
Participants: demographic 
and health characteristics 
Participants
: 
Number in 
study 
Study: 
Design 
Study: 
sampling 
strategy 
Study: 
comparators 
used 
Study: 
analyses used 
Study limitations reported 
by authors of study 
Makai 
(2012) 
Holland Psycho-geriatric 
patients 
Mean age: nursing version 82 
(9.1), family version 82 (7.3) 
Female: nursing version 68%, 
family version 67% 
Mean ICECAP: nursing 
version 0.5 (0.2), family 
version 0.43 (0.17) 
Mean EQ-5D-3L: nursing 
version 0.49 (0.21), family 
version 0.46 (0.2) 
n=122  Cross-
sectional 
study. 
Convenience 
sample of 
those in 
restraints and 
a random 
sample of 
non-
restrained 
controls. 
EQ-5D-3L. 
Cantril’s ladder. 
HADS. 
Care dependency 
scale (CDS). 
Overall life 
satisfaction. 
Chi-sqaured. 
Mann-
Whitney U. 
OLS 
regression. 
Small sample size.  Limited 
analysis due to limited 
comparators available.  
Possible methodological 
issues with multiple 
imputation used. 
Makai 
(2013) 
Holland Patients 3 
months post-
admission to 
hospital 
Mean age: 76.21 (6.79) 
Female: 53.8% 
Mean ICECAP: 0.84 (0.14) 
Mean EQ-5D-3L: 0.8 (0.17) 
n-275 Cross 
sectional 
study 
All patients 
admitted to a 
hospital in a 
5 month 
period were 
approached 
to participate 
EQ-5D-3L. 
Cantril’s ladder. 
Geriatric 
depression scale 
(GDS-15). 
SF-20 
Correlation 
analysis. 
T-test. 
One-way 
ANOVA. 
Stepwise 
multi-variate 
regression. 
 
Sample not representative of 
elderly post-admission 
populations (more frail).   
Ratcliffe 
(2013) 
Aus General 
population 
Mean age: not reported 
Female: carers 77%, non-
carers 61% 
Mean ICECAP: carers 0.848 
(0.123), non-carers 0.838 
(0.147) 
Mean EQ-5D-3L:  
n=786 Cross-
sectional 
study 
Health 
Omnibus 
Survey 
Numerous socio-
demographic 
variables 
including 
whether they are 
informal carers. 
Kruskal-
Waliis 
analysis of 
variance. 
Mann-whitney 
U test. 
Study nested with larger study 
and framing influences are 
possible.  No assessment of 
hours per week caring.  Small 
sample size in the carers 
group.  UK version of 
ICECAP and scoring 
algorithm used. 
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Author 
(Year) 
Country Participants: 
General 
population or 
patients 
Participants: demographic 
and health characteristics 
Participants
: 
Number in 
study 
Study: 
Design 
Study: 
sampling 
strategy 
Study: 
comparators 
used 
Study: 
analyses used 
Study limitations reported 
by authors of study 
Ratcliffe 
(2011) 
Aus Patients of an 
outpatient day 
rehabilitation 
unit, inpatient 
medical 
rehabilitation or 
a residential 
transition care 
unit. 
Mean age: 75.8 (IQR 69-84) 
Female: 59.7% 
Mean ICECAP: 0.779 
(0.154) 
Mean EQ-5D-3L: 0.526 
(0.297) 
n=181 Cross 
sectional 
study. 
All eligible 
patients 
attending one 
of the three 
treatment 
centres were 
invites to 
participate. 
EQ-5D-3L. 
CTM-3. 
Herth Hope 
Index. 
Modified Rankin 
Scale. 
Chi-squared. 
Spearman’s 
correlation. 
Small sample size.  A small 
number of participants (n=22) 
were under 65 when the 
ICECAP-O was administered 
to them.  UK versions of 
ICECAP-O and EQ-5D-3L 
and algorithms were used. 
Articles proving information on the ICECAP-A 
Al-
Janabi 
(2012) 
UK General 
population 
Mean age: 51.7 (18.2) 
Female: 62% 
Mean ICECAP: 0.832 
(0.157)* 
Mean EQ-5D-3L: 0.815 
(0.245)* 
n=418 Cross-
sectional 
study 
Sampled 
using a two 
stage 
stratified 
sampling 
procedure. 
Numerous socio-
demographic 
variables, 
including life 
events. 
EQ-5D-3L and 
other health 
variables 
Chi-squared. 
One-way 
ANOVA. 
Slight over sampling of 
female participants.   
Al-
Janabi 
(2013) 
UK General 
population 
Mean age: not reported 
Female: 53% 
Mean ICECAP: not reported 
Mean EQ-5D-3L:  not 
reported 
n=34 Qualitative 
think aloud 
study. 
Purposive 
sampling 
EQ-5D-3L Qualitative 
constant 
comparative 
analysis 
Potential queries around the 
effect of think aloud 
methodology.  Very few 
informants were in bad health 
states.  
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Appendix 5  
Invitation e-mail 
 
Dear <Name> 
I am a PhD student at the University of Birmingham, conducting research on Quality of Life 
patient reported outcome measures. A part of my research I am carrying out a number of short 
interviews with clinical trialists, medical clinicians involved in research, research nurses and 
other “frontline” researchers. 
<Name of individual> recommended you as an excellent person to speak to and I obtained 
your contact details through <insert source>.  I would be very interested in speaking to you as 
<role of potential participant> who has involvement in research.  Your professional 
experience could be very informative to this project. 
From these interviews I am looking to gain a greater understanding of quality of life measures 
in a research setting, how quality of life data is handled and specifically I am looking for 
opinions on a number of quality of life measures currently in use. 
If you agree to take part the interview will last approximately 40 minutes, and no longer than 
an hour and can be conducted at a location most convenient for you (most likely your place of 
work) and a time most convenient for you.  Attached is an information sheet giving you more 
information about the research. 
The research is confidential.  Once the interview is recorded a unique identity code will be 
allocated to the information you have provided, allowing us to keep your details and the 
recording separate.  Furthermore, we secure the information you provide by storing it on a 
secured computer network which only the lead researcher has access to.  Data will be stored 
for 10 years.  Data, in this form, will be analysed in collaboration with colleagues at Monash 
University, Australia see information sheet for more details.   
I have a contact number for you (<number>) and I will call you within the next week to 
discuss this further.  Alternatively, you could contact me on <number>.  If you would rather 
not be contacted please e-mail me at tjk962@bham.ac.uk. 
Yours sincerely  
 
 
Thomas Keeley,  
Doctoral Researcher 
Health Economics Unit / MRC Midlands Hub for Trials Methodology Research 
The University of Birmingham 
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Appendix 6  
Informant information sheet 
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Appendix 7  
Ethical approval for qualitative work 
425 | P a g e  
 
Appendix 8  
Qualitative topic guide 
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Appendix 9  
Qualitative analysis codes 
1) Professional details 
1.1) Current role 
  1.1.1) Research area 
  1.1.2) Role  
 1.2) Background/experience 
1.3) Informant & QoL measurement 
 1.3.1) QoL experience 
  1.3.1.1) Measured used 
  1.3.1.2) Knowledge 
 1.3.2) Involvement in measure selection 
 
2) QoL 
 2.1) Beliefs 
2.1.1) Physical 
   2.1.1.1) Pain 
   2.1.1.2) Functioning 
    2.1.1.2.1) Mobility 
     2.1.1.2.1.1) Mobility independence 
   2.1.1.3) Health 
2.1.1.3.1) Treatment 
     2.1.1.3.1.1) Side-effects 
  2.1.2) Psychological 
   2.1.2.1) Psychological outlook 
   2.1.2.2) Happiness  
  2.1.3) Social 
   2.1.3.1) Freedom 
    2.1.3.1.1) Independence   
   2.1.3.2) Work 
  2.1.4) Family and friends 
  2.1.5) Life 
   2.1.5.1) Normal life 
   2.1.5.2) Role achievement 
   2.1.5.3) Goal attainment 
   2.1.5.4) Life Events 
   2.1.5.5) Financial 
  2.1.6) Broad construct  
  2.1.7) Capability  
  2.1.8) Adaptation 
 2.2) Measurement 
  2.2.1) Assessment 
   2.2.1.1) Other assessment methods 
   2.2.1.2) PROMs 
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    2.2.1.2.1) Who selects 
     2.2.1.2.1.1) Precedent 
    2.2.1.2.2) Measures used 
     2.2.1.2.2.1) Opinions 
    2.2.1.2.3) Patient disruption 
  2.2.2) Subjectivity 
   2.2.2.1) Adaptation 
   2.2.2.2) Interpretation 
   2.2.2.3) Completion  
  2.2.3) Requirement 
2.3) Psychometrics  
  2.3.1) Sensitivity to change 
  2.3.2) Validity 
  2.3.3) Reliability 
  2.3.4) To use 
   2.3.4.1) Precedent  
2.3.5) Subjectivity 
   2.3.5.1) Adaptation 
   2.3.5.2) Interpretation 
 
 
3) Measure assessment 
 3.1) ICECAP-A 
  3.1.1) First reaction 
  3.1.2) Basics 
   3.1.2.1) Length 
   3.1.2.2) Layout 
   3.1.2.3) Understandable 
   3.1.2.4) Patient friendly  
    3.1.2.4.1) Ease of completion 
     3.1.2.4.1.1) missing data 
    3.1.2.4.2) Patient focused 
   3.1.2.4) Of use 
    3.1.2.4.1) Of use colleagues 
   3.1.2.5) Appropriateness 
  3.1.3) Wording 
   3.1.3.1) Wording capability 
  3.1.4) Focus 
   3.1.4.1) Psychological vs Physical 
    3.1.4.1.1) Psychological 
    3.1.4.1.2) Functioning 
   3.1.4.2) Timeframe 
   3.1.4.3) Breadth  
    3.1.4.3.1) Questionnaire breadth  
    3.1.4.3.2) Item breadth 
   3.1.4.4) Relevance 
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   3.1.4.5) Question duality 
   3.1.4.5) Coverage  
  3.1.5) Response options 
   3.1.5.1) Number 
   3.1.5.2) Unachievable 
  3.1.6) Attributes/Constructs 
   3.1.6.1) Stability 
   3.1.6.2) Attachment 
   3.1.6.3) Autonomy 
   3.1.6.4) Achievement 
   3.1.6.5) Enjoyment and pleasure 
 3.2) EQ-5D 
  3.2.1) First reaction 
  3.2.2) Basics 
   3.2.2.1) Length 
   3.2.2.2) Layout 
   3.2.2.3) Understandable 
   3.2.2.4) Patient friendly  
    3.2.2.4.1) Ease of completion 
     3.2.2.4.1.1) missing data 
    3.2.2.4.1) Patient focused 
   3.2.2.4) Of use 
    3.2.2.4.1) Colleagues 
   3.2.2.5) Appropriateness  
  3.2.3) Wording  
  3.2.4) Focus 
   3.2.4.1) Psychological vs Physical  
    3.2.4.1.1) Psychological 
    3.2.4.1.2) Functioning 
   3.2.4.2) Timeframe 
   3.2.4.3) Breadth  
    3.2.4.3.1) Questionnaire breadth  
    3.2.4.3.2) Item breadth 
   3.2.4.4) Relevance 
   3.2.4.5) Question duality 
   3.2.4.6) Coverage 
  3.2.5) Response options 
   3.2.5.1) Number 
   3.2.5.2) Unachievable 
  3.2.6) Attributes/Constructs 
   3.2.6.1) Mobility 
   3.2.6.2) Sefl-Care 
   3.2.6.3) Usual Activities  
   3.2.6.4) Pain/Discomfort 
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Appendix 11  
Trial recruitment letter 
Dear        ,  
My name is Tom Keeley, I am a PhD student in the University’s MRC Trials Methodology 
Hub.  <Name>  has suggested that I contact you to discuss the possibility of incorporating a 
new, short, outcome measure (the ICECAP capabilities index) for use in cost-effectiveness 
analysis into a trial within the <name of trials unit> 
The ICECAP measure may allow for a broader assessment of improvements in quality of life 
following health interventions than is available from using the current EQ-5D.  It has the 
same sort of properties as the QALY approach in that it is possible to utilise the measure 
across interventions that impact on both quality and quantity of life.  The measure has five 
dimensions: Attachment (love and friendship), Security (thinking about the future without 
concern), Enjoyment (enjoyment and pleasure), role (doing things that make you feel valued) 
and control (independence).  It has already been shown to have validity in cross-sectional 
studies and sensitivity to change in the context of total joint replacement.  As a practical 
measure it is comparable in length and simplicity to the EQ-5D – like the EQ-5D, it only 
takes one page of A4 and has only five questions.  There is more information about the 
measure and its development on its website: http://www.icecap.bham.ac.uk/ICECAP-
A/index.shtml. 
My PhD project is part of a continuing research stream within the Health Economics Unit into 
the use of the ICECAP measure, and is particularly concerned with looking at the 
implications for cost-effectiveness of using this different approach to economic evaluation. 
My aim is to compare assessments of cost-effectiveness using the ICECAP measure with 
those obtained using other measures such as QALYs obtained from EQ-5D or SF-6D, so it 
would be especially helpful to be able to put the ICECAP measure alongside EQ-5D or SF-
36/SF-12 in studies where you were already planning to include one or other of these 
measures. 
I would really appreciate it if my supervisors (Jo Coast, Hareth Al-Janabi) and I could meet 
with you in the near future to talk about the possibility of including this measure within a trial 
in your unit, and hope that you won’t mind if I ring in a week or so to try to arrange 
this.  Please feel free to get back to me with any questions about the measure or the work that 
I am doing.   
With best wishes, 
Tom 
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Appendix 12  
EQ-5D-3L 
 
438 | P a g e  
 
439 | P a g e  
 
Appendix 13 
SF-36 
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Appendix 14 
Co-morbidities measurement (BEEP) 
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Appendix 15  
Symptoms and side effects measurement (PastBP) 
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Appendix 16  
WOMAC 
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Appendix 17  
Brief Illness Perception Questionnaire 
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Appendix 18  
GAD-7 and PHQ-8 
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Appendix 19 
Hypotheses for BEEP trial 
Expected association between the ICECAP-A tariff score and the socio-demographic, 
physical health and psychological health variables 
Hypotheses 
 Association Direction  
Socio-demographic 
Age Yes Negative  
Gender No   
Physical health 
EQ-5D-3L Yes Positive  
WOMAC Pain Yes Negative  
WOMAC stiffness Yes Negative  
WOMAC functioning Yes Negative  
IPQ Exploratory analysis 
Co-morbidities Exploratory analysis 
Psychological health 
GAD-7 Yes Negative  
PHQ-8 Yes Negative  
* Strength refers to the strength of a correlations between the variable and the ICECAP- tariff score. 
Expected associations between gender and the ICECAP-A items 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
Gender No No No No No 
 
Expected associations between age and ICECAP-A items 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
Age No No Yes No No 
 
Expected associations between ICECAP-A and EQ-5D-3L items 
Comparator Mobility Self-care Usual 
Activities 
Pain/ 
Discomfort 
Anxiety/ 
depression 
ICECAP-A Yes Yes Yes Yes Yes 
 
Expected associations between EQ-5D-3L tariff score and ICECAP-A items 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
EQ-5D-3L Yes No Yes Yes Yes 
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Expected direction and strength of associations between EQ-5D-3L items and the 
ICECAP-A items 
Comparator 
variables 
 Stability Attachment Autonomy Achievement Enjoyment 
Mobility Association Yes  Yes Yes Yes 
Strength   Strong*   
Self-care Association Yes  Yes Yes Yes 
Strength   Strong*   
Usual 
activities 
Association   Yes Yes Yes 
Strength   Strong*   
Pain/ 
discomfort 
Association Yes  Yes Yes Yes 
Strength     Strong* 
Anxiety/ 
depression 
Association Yes  Yes Yes Yes 
Strength     Strong* 
* Researchers were asked to predict the ICECAP-A item that would show the strongest association with each EQ-5D-3L item.  Therefore 
“strong” is not a numerical prediction of a correlation rather prediction of the strength of the correlation in relation to other ICECAP-A items 
for that EQ-5D-3L item.  
 
Expected associations between WOMAC sub-scales and ICECAP-A items 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
WOMAC   
Pain 
Yes  Yes Yes Yes 
WOMAC 
stiffness 
Yes  Yes Yes Yes 
WOMAC 
functioning 
Yes  Yes Yes Yes 
 
Expected associations between measures of anxiety and depression and ICECAP-A 
items 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
GAD-7 Yes  Yes  Yes 
PHQ-8 Yes  Yes  Yes 
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Appendix 20  
Hypotheses for PastBP trial 
Expected associations between the ICECAP-O tariff score and socio-demographic, 
physical and psychological variables 
Hypotheses 
 Association Direction 
Socio-demographic 
Age Yes Negative 
Gender No  
Physical health 
EQ-5D-3L Yes Positive 
EQ-5D-3L VAS Yes Positive 
SSE Exploratory analysis  
Physical functioning Yes Positive 
Physical role Yes Positive 
Bodily pain Yes Negative 
General heatlh Yes Positive 
Psychological health 
Vitality Yes Positive 
Social functioning Yes Positive 
Emotional role Yes Positive 
Mental health Yes Positive 
 
Expected associations between gender and the ICECAP-0 items 
Comparator Attachment Security Role Enjoyment Control 
Gender No No No No No 
 
Expected associations between age and ICECAP-O items 
Comparator Attachment Security Role Enjoyment Control 
Age No No No No Yes 
 
Expected associations between ICECAP-O and EQ-5D-3L items 
Comparator Mobility Self-care Usual 
Activities 
Pain/ 
Discomfort 
Anxiety/ 
depression 
ICECAP-O Yes Yes Yes Yes Yes 
 
Expected associations between EQ-5D-3L tariff score and ICECAP-O items 
Comparator Attachment Security Role Enjoyment Control 
EQ-5D-3L No Yes Yes Yes Yes 
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Expected strength of associations between EQ-5D-3L items and the ICECAP-O items 
Comparator 
variables 
 Attachment Security Role Enjoyment Control 
Mobility Association   Yes Yes Yes 
Strength     Strong* 
Self-care Association  Yes Yes Yes Yes 
Strength     Strong* 
Usual 
activities 
Association   Yes Yes Yes 
Strength   Strong*  Strong* 
Pain/ 
discomfort 
Association  Yes Yes Yes Yes 
Strength    Strong*  
Anxiety/ 
depression 
Association  Yes Yes Yes Yes 
Strength    Strong*  
* Researchers were asked to predicted the ICECAP-O item that would show the strongest association with each EQ-5D-3L item.  Therefore 
“strong” is not a numerical prediction of a correlation rather prediction of the strength of the correlation in relation to other ICECAP-O items 
for that EQ-5D-3L item.  In the case of usual activities no agreement was reached on which ICECAP-O item would associated strongest, 
therefore both Role and Control were marked as expected a strong association.  
 
Expected strength of associations between SF-36 subscales and ICECAP-O tariff scores 
SF-36  Correlation with 
ICECAP-O tariff 
Physical   
Physical functioning Association Yes 
 Strength  
Physical role Association Yes 
 Strength  
Bodily Pain Association Yes 
 Strength  
General Health Association Yes 
 Strength Strong 
Psychological    
Vitality Association Yes 
 Strength Strong 
Social functioning Association Yes 
 Strength Strong 
Emotional role Association Yes 
 Strength  
Mental health  Association Yes 
 Strength  
* Researchers were asked to predict which SF-36 sub-scales would have the strongest association with the ICECAP-O tariff.  Therefore 
“strong” is not a numerical prediction of a correlation rather prediction of the strength of the correlation in relation to other ICECAP-O /SF-
36 sub-scale correlations. 
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Expected associations between SF-36 sub-scales and ICECAP-O items  
SF-36  Attachment Security Role Enjoyment Control 
Physical      
Phys func
 
 Yes Yes Yes Yes 
Phys role
 
 Yes Yes Yes Yes 
Pain
 
 Yes Yes Yes Yes 
Gen health
 
 Yes Yes Yes Yes 
Psychological      
Vitality
 
  Yes Yes Yes 
Social func
 
Yes  Yes Yes Yes 
Emo role
 
Yes  Yes Yes Yes 
Mental health
 
 Yes Yes Yes Yes 
 
Expected associations between Modified Rankin Scale and ICECAP-O items 
Comparator Attachment Security Role Enjoyment Control 
MRS No Yes Yes No Yes 
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Appendix 21  
Detailed breakdown of baseline EQ-5D-3L scores (BEEP)  
  
0% 20% 40% 60% 80% 100%
Self-care
Anxiety/depression
Usual activities
Mobility
Pain/discomfort
No problems
Some problems
Extreme problems
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Appendix 22  
Brief Illness Perception Questionnaire Analysis 
The analysis of the Brief IPQ was exploratory.  Little information on the development or 
validity of the measure could be found on which to base expectations of the association with 
the ICECAP-A.  Furthermore, no previous studies had assessed the association of the 
ICECAP-A with this measure, or any measure like it.  Therefore, no a priori hypotheses were 
formed.  
As can be seen from Table A the overall Brief IPQ score showed a weak, but statistically 
significant correlation with the ICECAP-A tariff score.  The Brief IPQ is made up of 8 
questions.  Each of the 8 questions has 11 response options (a 0-10 scale).  Therefore each of 
the variables is an 11 level categorical variable.  To avoid low numbers each variable was 
recoded to form a 3 level categorical variable of low (0-3) medium (4-6) and high (7-10).   
Four Variables showed a significant association with the ICECAP tariff score at the 5% 
significance level: Affect, an assessment of the affect that knee pain has on life; symptoms, an 
assessment of how many symptoms are experienced; concerned, an assessment of the level of 
concern over knee pain; and emotion, an assessment of the emotional effect of knee pain. 
Table A: Correlationss between ICECAP-A tariff score and IPQ questions 
 Affect 
Continu
e 
Control 
Treatm
ent 
Sympto
ms 
Concer
ned 
Underst
and 
Emotio
n 
ICECAP 
A tariff  
<0.001
** 
0.233 0.77 0.4 0.023* 0.016* 0.902 
<0.001
** 
 
Table B shows the associations between each item of the Brief IPQ and the ICECAP-A items.  
There are a number of significant associations at the 5% and 1% significance level.  Affect, 
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Symptoms and Emotion were most likely to associate with the Brief IPQ items.  Attachment 
showed association with Emotion at the 5% level of significance.  It can therefore be inferred 
from these results that a person’s perception of the affect knee pain has upon their life, the 
frequency of symptoms experienced and the emotional affect of knee pain is reflected in the 
scores of the ICECAP-A measure.   
Table B: Associations between ICECAP-A items and IPQ questions 
 
 
 
 
 
Comparator Stability Attachment Autonomy Achievement Enjoyment 
Affect
 0.029** 0.222 <0.001** <0.001** <0.001** 
Continue
 0.798 0.960 0.284 0.248 0.223 
Control
 0.985 0.658 0.952 0.634 0.377 
Treatment
 0.990 0.834 0.197 0.171 0.587 
Symptoms
 0.002** 0.103 0.02* <0.001** 0.017* 
Concerned
 0.040* 0.442 0.336 0.145* 0.027** 
Understand
 0.549 0.910 0.711 0.368 0.688 
Emotionally
 <0.001** 0.023* <0.001** <0.001** <0.001** 
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Appendix 23 
ICECAP-A response profile for worsened EQ-5D-3L index scores 
 Baseline profile Follow-up profile Change between baseline and follow-up 
 Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy 
Level 1 0 0 0 0 0 3 0 0 0 0 +3 0 0 0 0 
Level 2 10 5 3 13 8 18 13 5 18 18 +8 +8 +2 +5 +10 
Level 3 58 29 37 63 45 58 29 55 63 55 0 0 +18 0 +10 
Level 4 32 66 60 24 47 21 58 39 18 26 -11 -8 -21 -6 -21 
 
Appendix 24 
ICECAP-A response profiles for improved EQ-5D-3L index scores 
 Baseline profile 12 month follow-up profile Change between baseline and follow-up 
 Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy 
Level 1 4 0 0 0 0 1 1 1 1 1 +1 +1 +1 +1 +1 
Level 2 15 8 3 13 10 9 5 4 10 9 -6 -3 +1 +3 -1 
Level 3 55 33 43 62 52 56 31 28 54 50 +1 -2 -15 -8 -2 
Level 4 26 59 54 25 38 34 63 67 35 39 +8 +4 +13 +10 +1 
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Appendix 25 
ICECAP-A response profile for worsened GAD-7 health status 
 Baseline profile 12 month follow-up profile Change between baseline and follow-up 
 Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy 
Level 1 5 0 0 0 0 7 0 2 5 5 +2 0 +2 +5 +5 
Level 2 11 9 7 12 12 30 21 7 16 16 +19 +12 0 +4 +4 
Level 3 58 30 33 65 53 49 33 30 65 58 -9 +3 -3 0 +5 
Level 4 26 60 60 23 35 14 46 60 14 21 -12 -14 0 -9 -14 
 
Appendix 26 
ICECAP-A response profile for improved GAD-7 health status 
 Baseline profile 12 month follow-up profile Change between baseline and follow-up 
 Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy 
Level 1 4 0 0 0 0 0 1 0 0 1 -4 +1 0 0 +1 
Level 2 19 11 5 17 16 18 8 2 12 12 -1 -3 -3 -5 -4 
Level 3 59 32 38 65 60 55 32 36 69 57 -4 0 -2 +4 -3 
Level 4 18 57 57 18 24 27 58 61 19 30 +9 +1 +4 +1 +6 
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Appendix 27 
PHQ-8 Anchor analysis 
Anchor groups from the PHQ-8 score were not formed using minimally important changes.  
No values could be found in existing literature.  The interquartile range of change was used 
and groups were formed based on a change of 2.  No assumption can be made as to whether a 
change of 2 is important to participants.  The mean change in PHQ-8 scores in these groups 
was significantly larger than 2 and these values are presented in Table A 
Table A: Group numbers and mean PHQ-8 change scores in the PHQ-8 anchor groups 
(n=331) 
Anchor 
group 
Number 
in group 
Mean PHQ-8 
change in 
group (95% 
CI) 
PHQ-8 
change as a % 
of possible 
change 
Improved 92 -4.473 (-5.139, 
-3.807) 
18.6% 
No change 185 -0.08 (-0.176, 
0.016) 
0.3% 
Worsened 54 4.254 (3.455, 
5.053) 
17.7% 
 
Item by Item analysis 
Figure A show the response profiles at baseline and follow-up the group of respondents 
reporting a worsening of their PHQ-8 psychological health status (increase in PHQ-8 scores).  
These results are presented in numerical form in Appendix 28.  The response profile of these 
participants changed between baseline and follow-up.  A reduction of 23 points in the 
percentage of respondents answering the top level (level 4) of Enjoyment was found.   
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Smaller reductions of 8 points for Attachment and Achievement and 12 points for Stability 
were seen in the percentage of people answering level 4.  Little change in the response profile 
of Autonomy was found. 
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Figure A: ICECAP-A response profile at baseline and follow-up for participants 
reporting a worsening of their PHQ-8 health status 
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Figure B show the response profiles at baseline and follow-up the group of respondents 
reporting an improvement in their PQH-8 psychological health status (increase in PHQ-8 
scores).  These results are presented in numerical form in Appendix 29.  Smaller changes in 
response profiles were found than in the group reporting a worsening of their PHQ-8 health 
status.  The largest change was found in the Achievement item, with an increase of 14 
percentage points of people answering level 4 (full capability).  Smaller changes of between 1 
and 7 percentage points were found in other items. 
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Figure B: ICECAP-O response profile at baseline and follow-up for participants 
reporting an improvement in their PHQ-8 health status 
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Non-weighted ICECAP-A score 
Table B shows that cross-sectional correlations between the PHQ-8 scores and the non-
weighted ICECAP-A scores at baseline and follow-up were moderate and statistically 
significant at the 1% level.  The correlation of change in the scores of these measures between 
baseline and follow-up was weak and significant at the 1% level. 
Table B: Cross-sectional and change correlations between the PHQ-8 and non-weighted 
ICECAP-A scores (n=331) 
 ICECAP-A 
 Cross sectional correlation Change 
correlation 
 Baseline 12 month follow-
up 
 
PHQ-8 score -0.46** -0.502** -0.207** 
* Significant at the 5% level, **Significant at the 1% level. 
Table C shows change in non-weighted ICECAP-A scores by PHQ-8 anchor change groups.  
In the group of participants reporting an improvement in PHQ-8 health state the mean non-
weighted ICECAP-A score increased.  In the group reporting a reduction in their PHQ-8 
health state, the mean non-weighted ICECAP-A score decreased.  The change in ICECAP-A 
score was larger in the group that in had worsened than in the group that had improved.  The 
effect sizes were very small for those who reported an improvement in PHQ-8 health status, 
while they were small for the group that worsened.   For the ICECAP-A a larger change in 
scores was in the group that worsened than in the group that improved was found (Table C).  
For the EQ-5D-3L the larger change is in the group that improved rather than the group that 
worsened (Table D).   
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Table C: Mean change in non-weighted ICECAP-A scores by PHQ-8 anchor change 
groups (n=331) 
Anchor 
group 
Baseline 
ICECAP 
scores 
12 month 
ICECAP 
scores 
Mean ICECAP-
O change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 16.217 16.576 0.359                  
(-0.003, 0.720) 
2.3% 0.15 0.2 
No change 17.486 17.616 0.13                    
(-0.077, 0.336) 
0.8% 0.07 0.09 
Worsened 16.629 15.759 -0.87**               
(-1.398, -0.343) 
5.8% 0.37 0.45 
* Significant at the 5% level, **Significant at the 1% level. 
Table D: Mean change in non-weighted EQ-5D-3L scores by GAD-7 anchor change 
groups (n=326) 
Anchor 
group 
Baseline 
EQ-5D-
3L 
scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-3L 
change 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 8.16 7.309 -0.852**                  
(-1.142,-0.561) 
8.5% 0.56 0.64 
No change 7.421 7.015 -0.407**                   
(-0.56,-0.253) 
4.1% 0.35 0.36 
Worsened 7.878 8.097 0.219                        
(-0.251, 0.69) 
2.2% 0.14 0.15 
* Significant at the 5% level, **Significant at the 1% level. 
ICECAP-A tariff score 
Table E shows that cross-sectional correlations between the PHQ-8 score and ICECAP-A 
tariff value at baseline and follow-up were moderate and significant at the 1% level.  The 
correlation of change scores in these measures between baseline and follow-up was weak and 
significant at the 1% level.  
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Table E: Cross-sectional and change correlations between the PHQ-8 and ICECAP-A 
measures (n=331) 
 ICECAP-A 
 Cross sectional correlation Change 
correlation 
 Baseline 12 month follow-
up 
 
PHQ-8 score -0.455** -0.498** 0.190** 
* Significant at the 5% level, **Significant at the 1% level. 
Table F and Figure C show change in ICECAP-A tariff value by PHQ-8 anchor change 
groups.  In the group of participants reporting an improvement in PHQ-8 scores the mean 
ICECAP-A tariff value increased.  This increase was very small, non-significant and effect 
sizes were small.  In participants who reported a decrease in their PHQ-8 scores the mean 
ICECAP-A tariff value decreased.  This decrease was moderate, statistically significant at the 
1% level and with moderate effects sizes.  There are small reductions in the size of change as 
a percentage of possible change in the ICECAP-A tariff analysis in comparison to the non-
weighted analysis. 
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Table F: Mean change in ICECAP-A tariff values by PHQ-8 anchor change groups 
(n=331) 
Anchor 
group 
Baseline 
ICECAP 
scores 
12 month 
ICECAP 
scores 
Mean 
ICECAP-O 
change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 0.852 0.866 0.014               
(-0.005, 0.032) 
1.4% 0.11 0.15 
No change 0.917 0.92 0.003               
(-0.006, 0.011) 
0.3% 0.02 0.03 
Worsened 0.872 0.825 -0.048**          
(-0.078,-0.017) 
4.8% 0.39 0.43 
* Significant at the 5% level, **Significant at the 1% level. 
Table G: Mean change in EQ-5D-3L index scores by GAD-7 anchor change groups 
(n=326) 
Anchor 
group 
Baseline 
EQ-5D-
3L 
scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 0.559 0.659 0.1**            
(0.05, 0.149) 
6.3% 0.37 0.42 
No change 0.689 0.744 0.056** 
(0.029,0.082) 
3% 0.33 0.31 
Worsened 0.653 0.621 -0.031                   
(-0.098,0.036) 
2% 0.13 0.13 
* Significant at the 5% level, **Significant at the 1% level. 
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Figure C: Mean change in ICECAP-O tariff values by PHQ-8 anchor change groups 
(n=331) 
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Appendix 28 
ICECAP-A response profile for worsened PHQ-8 health status 
 Baseline profile 12 month follow-up profile Change between baseline and follow-up 
 Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy 
Level 1 2 0 0 0 0 4 2 0 2 4 +2 +2 0 +2 +4 
Level 2 15 6 4 15 13 22 14 4 13 16 +7 +8 0 -2 +3 
Level 3 53 35 35 59 44 56 33 33 67 60 +3 -2 -2 +8 +6 
Level 4 30 59 61 26 43 18 51 64 18 20 -12 -8 +3 -8 -23 
 
Appendix 29 
ICECAP-A response profile for improved PHQ-8 health status 
 Baseline profile 12 month follow-up profile Change between baseline and follow-up 
 Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy Stab Attach Auto Achieve Enjoy 
Level 1 2 0 0 0 0 2 0 0 1 1 0 0 0 +1 +1 
Level 2 20 12 6 15 14 15 10 5 13 12 -5 -2 -1 -2 -2 
Level 3 51 28 39 70 53 48 31 37 57 48 -3 +3 +2 +13 -5 
Level 4 27 60 55 15 33 34 59 58 29 29 +7 -1 +3 +14 -4 
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Appendix 30 
ICECAP-O response profile for worsened EQ-5D-3L index scores   
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 2 8 3 3 0 2 12 3 5 3 0 +4 0 +2 +3 
Level 2 12 20 15 10 10 12 18 16 18 12 0 -2 +1 +8 +2 
Level 3 20 43 46 55 23 22 52 55 53 40 +2 +9 +9 +2 +17 
Level 4 67 28 36 32 67 65 18 26 23 45 -2 -10 -10 -9 -22 
 
Appendix 31 
ICECAP-O response profile for improved EQ-5D-3L index scores.   
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 1 7 2 2 2 0 2 3 1 1 -1 -5 +1 -1 -1 
Level 2 7 27 22 19 9 8 28 15 19 8 +1 +1 -7 0 -1 
Level 3 33 42 45 52 40 35 43 45 47 39 +2 +1 0 -5 -1 
Level 4 59 25 30 27 48 57 27 37 37 52 -2 +2 +7 +10 +4 
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Appendix 32 
EQ-5D-3L VAS anchor anlaysis 
The anchor groups for the EQ-5D-3L VAS were formed based on minimally important 
difference values taken from Pickard, Neary and Cella[322] of 7 points.  This study was 
completed in cancer patients, so limitations exist in applying this to a responsiveness 
assessment in the PastBP trial.  The value from this study has been used because of the very 
limited number of studies that provided MID estimates for the EQ-5D-3L VAS.  Groups were 
formed of participants who had improved or worsened by equal to or more than 7 points.    
EQ-5D-3L VAS change as a percentage of possible change was roughly 17% in both groups. 
Table A: Group numbers and EQ-5D-3L VAS change scores in the EQ-5D-3L VAS 
anchor groups (n=273) 
Anchor 
group 
Number Mean EQ-5D-
3L VAS change 
in group (95% 
CI) 
EQ-5D-3L VAS 
change as a % of 
possible change 
Improved 94 17.37 (15.37, 
19.36) 
17.3% 
No change 101 0.24 (-0.35, 
0.82) 
0.2% 
Worsened 78 -17.06 (-18.79,-
15.32) 
17.1% 
 
Item by item analysis 
Figure A shows the ICECAP-O response profiles at baseline and follow-up for those who 
reported a worsening of their EQ-5D-3L VAS scores.  The results are provided in numerical 
form in Appendix 33.  Reductions of 8 points for the Attachment item, 5 points for the 
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Security, Role and Enjoyment items and 2 points for the control item were found in the 
percentage of participants answering level 4 (full capability) for these items.  Change in the 
percentage of respondents answering levels 1 and 2 were minimal in all items. 
Figure A: ICECAP-O response profile at baseline and follow-up for participants 
reporting a reduction on their EQ-5D-3L VAS scores 
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Figure B shows the ICECAP-O response profiles at baseline and follow-up for participants 
who reported an improvement in EQ-5D-3L VAS scores.  The results are provided in 
numerical form in Appendix 34.  The percentage of respondents who answered level 4 (full 
capability) for each item increased by 4 to 10 points between baseline and follow-up.  The 
largest changes were in Security and Enjoyment, while the smallest change was in Control.  
There was a reduction in the percentage of participants answering in the bottom two levels for 
Attachment, Security, Role and Enjoyment, this was particularly marked for the Role and 
Security items. 
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Figure B: ICECAP-O response profile at baseline and follow-up for participants 
reporting an improvement on their EQ-5D-3L VAS scores 
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Non-weighted ICECAP score analysis 
The cross-sectional correlations between the EQ-5D-3L VAS and the non-weighted ICECAP-
O scores at baseline and 12 month follow-up were moderate and significant at the 1% level.  
The correlation of the change in scores between baseline and 12 month follow-up in these two 
measures was moderate and significant at the 1% level.  See Table B. 
Table B: Cross-sectional and change correlations between EQ-5D-3L VAS and non-
weighted ICECAP-O scores (n=273) 
 ICECAP-O 
 Cross sectional correlation Change 
correlation 
 Baseline 12 month follow-
up 
 
EQ-5D-3L VAS  0.554** 0.493** 0.301** 
* Significant at the 5% level, **Significant at the 1% level. 
Table C shows change in non-weighted ICECAP-O score by EQ-5D-3L VAS anchor groups.  
In the groups of participants reporting an improvement in their EQ-5D-3L VAS scores the 
mean non-weighted ICECAP-O score value increased.  In the group that reported a worsening 
of their EQ-5D-3L VAS scores the mean non-weighted ICECAP-O score decreased.  The 
change in ICECAP scores in the group that had improved was greater than in the group that 
had worsened.  The change in ICECAP-O scores as a percentage of possible change (Table C) 
was small in comparison to change as a percentage of possible change that occurred in the 
EQ-5D-3L VAS in each group (Table A).  The effects sizes and SRMs for both change groups 
were small.   
The use of non-weighted EQ-5D-3L score change (Table D) as a reference measure, allows a 
better understanding of the changes in the ICECAP -O.  Change as a percentage of possible 
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change in the non-weighted EQ-5D scores and non-weighted ICECAP-O scores were similar: 
roughly 5% in the improved group and roughly 2.8% in the group that worsened.  Effect sizes 
and SRMs for change in the EQ-5D-3L was similar to those for change in the ICECAP-O 
scores. 
Table C: Mean change in non-weighted ICECAP-O scores by EQ-5D-3L VAS anchor 
change groups (n=273) 
Anchor 
group 
Baseline 
ICECAP 
scores 
12 month 
ICECAP 
scores 
Mean change 
in ICECAP 
tariff values 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 15.617  16.362 0.745**          
(0.341, 1.149) 
4.97% 0.3 0.38 
No change 16.564 16.564 0                         
(-0.357, 0.357) 
0% 0.0 0.0 
Worsened 16.063 15.645 -0.418                  
(-0.953, 0.117) 
2.79% 0.14 0.17 
* Significant at the 5% level, **Significant at the 1% level. 
Table D: Mean change in EQ-5D-3L non-weighted scores by EQ-5D-3L VAS anchor 
change groups (n=286) 
Anchor 
group 
Baseline 
EQ-5D-
3L 
scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 6.745 7.245 0.5** 
(0.219,0.781) 
5% 0.31 0.36 
No change 6.619 6.628 0.009                
(-0.224, -0.243) 
0.1% 0.01 0.01 
Worsened 7.494 7.217 0.277                 
(-0.573, 0.019) 
2.8% 0.15 0.2 
* Significant at the 5% level, **Significant at the 1% level. 
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ICECAP tariff analysis 
Table E shows that the cross sectional correlations between the EQ-5D-3L VAS and 
ICECAP-O index scores at baseline and follow-up were moderate and statistically significant 
at the 1% level.  The correlation of the change scores of these measures was weak and 
statistically significant at the 1% level. 
Table E: Cross-sectional and change correlations between EQ-5D-3L VAS and 
ICECAP-O tariff value (n=273) 
 ICECAP-O 
 Cross sectional correlation Change 
correlation 
 Baseline 12 month follow-
up 
 
EQ-5D-3L VAS  0.493** 0.458** 0.267** 
* Significant at the 5% level, **Significant at the 1% level. 
Table F and Figure C show change in ICECAP tariff value by EQ-5D-3L VAS anchor groups.  
In the group of participants reporting an improvement in EQ-5D-3L VAS scores the mean 
ICECAP-O tariff value increased.   In the group reporting a worsening of EQ-5D-3L VAS 
scores the mean ICECAP-O tariff value decreased.  Changes in the ICECAP-O tariff values 
were small and the change in ICECAP-O tariff values in the group reporting an improvement 
in EQ-5D-3L VAS score was statistically significant at the 1% level.  In comparison to the 
non-weighted ICECAP analysis, change as a percentage of possible change was smaller in 
ICECAP-O tariff values than in the non-weighted ICECAP-O scores.  This difference was 
particularly pronounced in the group that had improved; change as a percentage of possible 
change was 4.97% in the non-weighted analysis and 2.9% in the tariff analysis.  Effects sizes 
and SRMs were small.   
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A comparison of the results of the ICECAP tariff analysis with the EQ-5D-3L index analysis 
(Table G) shows similarities.  Effects sizes and SRMs were similar, while change as a 
percentage of possible change was 1 percentage point larger for the improved group in the 
EQ-5D-3L analysis. 
Table F: Mean change in ICECAP-O tariff score by EQ-5D-3L VAS anchor change 
groups (n=273) 
Anchor 
group 
Baseline 
ICECAP 
scores 
12 month 
ICECAP 
scores 
Mean change 
in ICECAP 
tariff scores 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 0.843 0.872 0.029 **      
(0.011, 0.048)  
2.9% 0.22 0.32 
No change 0.882 0.879 0.003                 
(-0.015, 0.022) 
0.3%   
Worsened 0.857 0.837 -0.020                
(-0.008, 0.049)  
2.0% 0.16 0.16 
* Significant at the 5% level, **Significant at the 1% level. 
Table G: Mean change in EQ-5D-3L index scores by EQ-5D-VAS anchor change groups 
(n=286) 
Anchor 
group 
Baseline 
EQ-5D-
3L 
scores 
12 month 
EQ-5D-
3L scores 
Mean change 
in EQ-5D-3L 
index scores 
(95% CI) 
Change 
as % of 
possible 
change 
ES SRM 
Improved 0.717 0.779 0.062** 
(0.019,0.104) 
3.9% 0.26 0.29 
No change 0.781 0.796 0.015 (-0.018, 
0.048) 
0.9% 0.06 0.09 
Worsened 0.718 0.681 -0.037 (-0.094, 
0.02) 
2.3% 0.14 0.14 
* Significant at the 5% level, **Significant at the 1% level. 
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Figure C: Mean change in ICECAP-O scores by EQ-5D-3L VAS anchor change groups 
(n=273) 
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Appendix 33 
ICECAP-O response profile for worsened EQ-5D VAS scores  
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 0 5 3 2 1 0 6 4 2 2 0 +1 +1 0 +1 
Level 2 11 21 20 20 11 14 23 21 23 14 +3 +2 +1 +3 +3 
Level 3 23 44 39 46 38 28 48 42 47 37 +5 +4 +3 +1 -1 
Level 4 66 29 38 32 49 58 23 33 27 47 -8 -5 -5 -5 -2 
 
Appendix 34 
ICECAP-O response profile for improved EQ-5D VAS scores  
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 2 9 1 1 1 2 3 0 1 0 0 -6 -1 0 -1 
Level 2 12 26 20 21 6 8 21 12 15 9 -4 -5 -8 -6 +3 
Level 3 33 47 49 52 39 29 51 52 48 33 -4 +4 +3 -4 -6 
Level 4 54 17 30 26 54 60 25 36 36 58 +6 +8 +6 +10 +4 
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Appendix 35 
ICECAP-O response profile for improved Modified Rankin Scale scores 
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 0 6 2 2 5 0 3 0 0 2 0 -3 -2 -2 -3 
Level 2 13 22 22 16 6 13 22 9 16 5 0 0 -13 0 -1 
Level 3 36 49 43 54 33 31 46 51 40 36 -5 -3 +8 -14 +3 
Level 4 51 22 33 29 56 56 29 40 44 57 +5 +7 +7 +15 +1 
 
Appendix 36 
ICECAP-O response profile for worsened Modified Rankin Scale scores 
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 0 6 0 0 0 0 6 4 1 3 0 0 +4 +1 +3 
Level 2 10 23 14 21 9 15 20 19 17 11 +5 -3 +5 -4 +2 
Level 3 28 42 49 47 33 25 51 47 55 38 -3 +9 +2 +8 +5 
Level 4 62 29 37 32 58 60 22 30 27 49 -2 -7 -7 -5 -9 
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Appendix 37 
SF-36 anchors anlaysis 
This minimally important difference used to defined general health anchor groups was 7 
[288].  Mean change in SF-36 general health sub-scale scores as a percentage of possible 
change was roughly 11% for both groups. 
Table A: Numbers in groups and mean SF-36 general health sub-scale change scores in 
SF-36 general health sub-scale anchor (n=212) 
Anchor 
group 
Number Mean SF-36 
general health 
change in 
group (95% 
CI) 
Mean SF-36 
general health 
change score 
as % of 
possible 
change 
Improved 28 11.151   
(9.832, 12.469) 
11.2% 
No 
change 
146 -0.282 (-0.737, 
0.173) 
0.3% 
Worsened 38 -10.819 (-
12.202, -9.435) 
10.8% 
 
Item-by-item analysis 
Figure A shows the ICECAP-O response profile at baseline and follow-up in respondents 
reporting a worsening of general health sub-scale scores.  This analysis is presented in 
numerical form in Appendix 38.  A reduction of 17 percentage points was seen in respondents 
answering level 4 (full capability) of Enjoyment.  Decreases of between 8 and 13 percentage 
points were seen in respondents answering level 4 of Attachment, Security and Role.  
Minimal change was seen in the response profile of the Control item. 
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Figure A: ICECAP-O response profile at baseline and follow-up for participants 
reporting a worsening of their SF-36 general health sub-scale score. 
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Figure B show the response profiles of the ICECAP-O at baseline and follow-up in the group 
of respondent reporting an improvement in general health sub-scale scores.  This is presented 
in numerical form in Appendix 39.  Minimal change was seen in response profile of the 
Control item.  There was a 12 to 17 point increase between baseline and follow-up in the 
percentage of respondents answering level 4 (top level) of the other items.  This change was 
most pronounced in the Security and Enjoyment items.  There was a notable reduction in the 
percentage of respondents answering the bottom two levels of the Security and Role items. 
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Figure B: ICECAP-O response profile at baseline and follow-up for participants 
reporting an improvement in their SF-36 general health sub-scale score. 
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Non-weighted ICECAP-O score analysis 
Table B shows that the cross-sectional correlations between the SF-36 general health subscale 
and the non-weighted ICECAP-O score were moderate and significant at the 1% level.  The 
correlation of the change in the two measures between baseline and follow-up was weak and 
significant at the 1% level. 
Table B: Correlations between SF-36 general health scale and the ICECAP-O tariff 
value at baseline, 12 month follow-up and over time (n=212). 
 ICECAP-O 
 Cross sectional correlation Change 
correlation 
 Baseline 12 month follow-
up 
 
SF-36 
 General Health 
0.623** 0.526** 0.297** 
* Significant at the 5% level, **Significant at the 1% level. 
Table C shows change in non-weighted ICECAP-O score by SF-36 general health sub-scale 
anchor change groups.  In the group of participants reporting an improvement in their SF-36 
general health sub-scale score the mean non-weighted ICECAP-O score increased.  This 
change was significant at the 1% level and medium (or approaching medium) effect size and 
SRM was found.  Minimal change was seen in non-weighted ICECAP-O scores in 
participants reporting a worsening of their SF-36 sub-scale score.   
A comparison of the changes in the non-weighted ICECAP-O analysis with the non-weighted 
EQ-5D-3L analysis (Table D) shows some differences.  For the group reporting an 
improvement in general health scores, change as a percentage of possible change, effects sizes 
and SRMs were smaller for the EQ-5D-3L than for the IECCAP-O.  In the group of 
respondents reporting a reduction in general health the reverse is true.  
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Table C: Mean change in non-weighted ICECAP-O scores by SF-36 general health sub-
scale anchor change groups (n=212) 
Anchor 
group 
Baseline 
ICECAP 
scores 
12 month 
ICECAP 
scores 
Mean change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 15.511 16.659 1.149** 
(0.513, 1.785) 
7.6% 0.47 0.53 
No change 16.371 16.530 0.158              
(-0.129, 0.447) 
0.1% 0.06 0.09 
Worsened 16.419 16.209 -0.209            
(-0.777, 0.359) 
0.1% 0.08 0.11 
* Significant at the 5% level, **Significant at the 1% level. 
Table D: Mean change in EQ-5D-3L non-weighted scores by SF36 general health sub-
scale anchor change groups (n=251) 
Anchor 
group 
Baseline 
EQ-5D-
3L 
scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 6.979 6.458 -0.521**           
(-0.894,-0.147) 
5.2% 0.34 0.4 
No change 6.924 6.645 -0.278               
(-0.484,-0.073) 
2.8% 0.17` 0.21 
Worsened 7.2 7.578 0.378                 
(-0.003,0.758) 
3.8% 0.26 0.29 
* Significant at the 5% level, **Significant at the 1% level. 
ICECAP-O tariff value analysis 
The SF-36 general health sub-scale showed moderate, statistically significant correlation with 
the ICECAP-O tariff value at baseline and follow-up (Table E).  The correlation in change 
scores between these measures was weak and statistically significant.  
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Table E: Correlations between SF-36 general health scale and the ICECAP-O tariff 
value at baseline, 12 month follow-up and over time (n=212). 
 ICECAP-O 
 Cross sectional correlation Change 
correlation 
 Baseline 12 month follow-
up 
 
SF-36 
 General Health 
0.584** 0.523** 0.235** 
* Significant at the 5% level, **Significant at the 1% level. 
Table F and Figure C show change in ICECAP-O tariff value by SF-36 general health 
subscale anchor change groups.  Participants who reported an increase in their general health 
score had a moderate mean change in their ICECAP-O tariff value of 0.042.  This change in 
ICECAP-O tariff value between baseline and follow-up was significant at the 1% level and 
the effect size and SRM was small.  In the group of participants reporting a decrease in their 
general health scale score minor, non-statistically significant change in ICECAP-O tariff 
values was seen.   
Differences exist between the SF-36 general health sub-scale non-weighted ICECAP-O 
analysis and ICECAP-O tariff analysis.  In the group of respondents who reported an 
improvement in general health a substantial difference in change as a percentage of possible 
change was found between the non-weighted (7.6%) and tariff analysis (4.2%).  The effect 
sizes and SRM for the tariff value was also smaller than for the non-weighted score.  In the 
group of respondents who reported a worsening of general health, change as a percentage of 
possible change was slightly larger in the tariff analysis in comparison to the non-weighted 
analysis.  
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Table F: Mean change in ICECAP-O tariff value by SF-36 general health sub-scale 
anchor change groups (n=212) 
Anchor 
group 
Baseline 
scores 
12 month 
follow-up 
scores 
Mean ICECAP-
O change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 0.842  0.884  0.042**          
(0.013, 0.07) 
4.2% 0.31 0.43 
No 
change 
0.872  0.878  0.006         
(0.019, -0.008) 
0.4% 0.01 0.01 
Worsened 0.871  0.86  -0.008        
(0.024, 0.04) 
0.8% 0.07 0.08 
* Significant at the 5% level, **Significant at the 1% level. 
Table G: Mean change in EQ-5D-3L index scores by SF36 general health sub-scale 
anchor change groups (n=251) 
Anchor 
group 
Baseline 
EQ-5D-
3L 
scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 0.76 0.80 0.049                 
(-0.004,0.102) 
3.1% 0.23 0.27 
No change 0.751 0.799 0.048**    
(0.015, 0.081) 
3% 0.21 0.23 
Worsened 0.736 0.693 -0.043      
(0.096,-0.009) 
2.7% 0.2 0.24 
* Significant at the 5% level, **Significant at the 1% level. 
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Figure C: Mean change in ICECAP-O tariff value by SF-36 general health sub-scale 
anchor change groups (n=212) 
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Appendix 38 
ICECAP-O response profile for worsened SF-36 general health sub-scale scores   
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 0 7 0 0 2 4 6 2 2 0 +4 -1 +2 +2 -2 
Level 2 7 18 27 15 9 10 28 18 16 10 +3 +10 -9 +1 +1 
Level 3 24 44 31 47 31 27 48 46 61 34 +3 +4 +15 +14 +3 
Level 4 69 31 42 38 58 58 18 34 20 56 -11 -13 -8 -18 -2 
 
Appendix 39 
ICECAP-O response profile for improved SF-36 general health sub-scale scores   
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 2 12 2 4 0 4 4 0 2 0 +4 -8 -2 -2 0 
Level 2 12 23 17 17 4 9 17 10 13 4 -3 -6 -7 -4 0 
Level 3 42 44 49 56 42 30 41 46 45 40 -12 -3 -3 -11 -2 
Level 4 44 21 32 23 54 57 38 44 40 57 +13 +17 +12 +17 +3 
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Appendix 40 
SF-36 vitality sub-scale anchor analysis 
The minimally important difference value used to form the vitality anchor groups was 6.7 
[288].  The mean change in SF-36 vitality sub-scale scores was roughly 11 in both the 
improved and worsened groups. 
Table A: Numbers and the mean change in SF-36 sub-scale vitality scores in each 
anchor group. 
Anchor 
group 
Number Mean SF-36 
vitality change 
in group (95% 
CI) 
Improved 41 11.238 (9.757, 
12.719) 
No 
change 
154 -0.157 (-0.662, 
0.348) 
Worsened 38 -10.641 (-
11.846, -9.4360 
 
Figure A shows the response profiles at baseline and follow-up in the group of respondents 
who reported worsening in vitality sub-scale scores.  These are reported in numerical form in 
Appendix 41.  The response profiles changed.  Changes of between 6 and 9 points were seen 
in the percentage of respondents reporting full capability for Security, Role and Enjoyment. 
Minimal change was found in the percentage of people reporting full capability for 
Attachment and Control. 
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Item-by-item analysis 
Figure A: ICECAP-O response profiles (percentages of respondents answering each 
level of each item) at baseline and follow-up for participants reporting a worsening of 
their SF-36 vitality sub-scale score.   
  
  
 
 
 
Figure B shows the response profiles at baseline and follow-up for the group of respondents 
who reported and improvement in their vitality sub-scale scores.  These are reported in 
numerical form in Appendix 42.  Changes of 14 points were seen for Role and Enjoyment, 
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and a change of 11 points for Attachment, in the percentage of respondents reporting full 
capability.  Smaller changes were seen for Security and Control 
Figure B: Baseline and 12 month follow-up response profiles for each item of the 
ICECAP-O for participants reporting a improvement in their SF-36 vitality sub-scale 
score. 
  
  
 
 
 
Non-weighted ICECAP-O score analysis 
Table B shows the cross-sectional correlations between SF-36 vitality sub-scale score and the 
ICECAP-O score at baseline and follow-up were moderate and statistically significant at the 
0
10
20
30
40
50
60
70
Level
1
Level
2
Level
3
Level
4
%
 o
f 
re
sp
o
n
d
e
n
ts
  
Attachment -
Baseline
Attachment -
12 month
0
10
20
30
40
50
60
70
Level
1
Level
2
Level
3
Level
4
%
 o
f 
re
sp
o
n
d
e
n
ts
 
Security -
Baseline
Security - 12
months
0
10
20
30
40
50
60
70
%
 o
f 
re
sp
o
n
d
e
n
ts
 
Role - Baseline
Role - 12
months
0
10
20
30
40
50
60
70
%
 o
f 
re
sp
o
n
d
e
n
ts
 
Enjoyment -
Baseline
Enjoyment - 12
months
0
10
20
30
40
50
60
70
Level
1
Level
2
Level
3
Level
4
%
 o
f 
re
sp
o
n
d
e
n
ts
 
Control -
Baseline
Control - 12
months
497 | P a g e  
 
1% level.  The correlation of change in scores between baseline and follow-up in these 
measures was weak and significant at the 1% level. 
Table B: Correlations between SF-36 vitality scale and the ICECAP-O tariff score at 
baseline, 12 month follow-up and over time (n=233). 
 Cross sectional correlation Change 
correlation 
 Baseline 12 month follow-
up 
Baseline to 12 
month follow up 
SF-36 
 Vitality 
0.56** 0.55** 0.19** 
** Difference significant at p<0.01 
Table C shows change in non-weighted ICECAP-O score by SF-36 vitality sub-scale anchor 
groups.  In the group reporting an improvement in vitality scores the mean non-weighted 
ICECAP-O score increased.  In the group reporting a worsening of vitality scores the mean 
ICECAP-O scores decreased. The change in ICECAP-O scores in the group that improved 
was larger than in the group that had worsened.  The effect sizes and SRM for the improved 
group were small and moderate respectively, while for the worsened group they were very 
small. 
The use of the non-weighted EQ-5D-3L score (Table D) as a comparator, allows a better 
understanding of the changes in the ICECAP-O measure.  In the group that reported improved 
vitality scores change as a percentage of possible change was larger for the ICECAP-O than 
for the EQ-5D-3L.  The reverse is true for the group that worsened.  
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Table C: Mean change in ICECAP-O score by SF-36 vitality sub-scale change (n=233) 
Anchor 
group 
Baseline 
scores 
12 month 
follow-up 
scores 
Mean change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 15.366 16.585 1.219** 
(0.631, 1.807) 
8.1% 0.43 0.65 
No change 16.361 16.348 -0.013            
(-0.339, 0.313) 
0.1% 0.01 0.01 
Worsened 15.718 15.410 -0.308            
(-0.912, 0.297) 
2.0% 0.11 0.16 
** Difference significant at p<0.01 
 
Table D: Mean change in EQ-5D-3L non-weighted scores by SF36 vitality health sub-
scale change (for comparison) 
Anchor 
group 
Baseline 
EQ-5D-
3L 
scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 7.208 6.583 -0.625            
(-1.059, -0.19) 
6.2% 0.36 0.41 
No change 6.894 6.77 -0.124             
(-0.328, 0.08) 
1.2% 0.07 0.09 
Worsened 7.357 7.881 0.524 
(0.121,0.926) 
5.2% 0.28 0.4 
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ICECAP-O tariff score analysis 
Table E shows the cross-sectional correlations between SF-36 vitality sub-scale score and the 
ICECAP-O value tariff at baseline and follow-up were moderate and statistically significant at 
the 1% level.  The correlation of change in scores between baseline and follow-up in these 
measures was weak and significant at the 1% level. 
Table E: Correlations between SF-36 vitality scale and the ICECAP-O tariff score at 
baseline, 12 month follow-up and over time (n=233). 
 Cross sectional correlation Change 
correlation 
 Baseline 12 month follow-
up 
Baseline to 12 
month follow up 
SF-36 
 Vitality 
0.56** 0.55** 0.19** 
** Difference significant at p<0.01 
Table F and Figure C shows change in ICECAP-O value tariff by SF-36 vitality sub-scale 
anchor groups.  In the group reporting an improvement in vitality scores the mean ICECAP-O 
value tariff increased.  In the group reporting a worsening of vitality scores there was minimal 
change in the mean ICECAP-O value tariff.  The effect sizes and SRM for the improved 
group were small and moderate respectively.  In comparison to the non-weighted ICECAP-O 
score the change as a percentage of possible change was smaller in the ICECAP-O value tariff 
analysis. 
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Table F: Mean change in ICECAP-O tariff score by SF-36 vitality sub-scale change 
(n=233) 
Anchor 
group 
Baseline 
scores 
12 month 
follow-up 
scores 
Mean 
ICECAP-O 
change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 0.825  0.873  0.048**           
(0.074, 0.023) 
4.8% 0.32 0.6 
No change 0.874  0.868  -0.006        
(0.011, -0.023)  
0.6%   
Worsened 0.838  0.832  -0.006    
(0.031, -0.043) 
0.6% 0.04 0.07 
** Difference significant at p<0.01 
Table G: Mean change in EQ-5D-3L non-weighted scores by SF36 vitality health sub-
scale change (for comparison) 
Anchor 
group 
Baseline 
EQ-5D-
3L 
scores 
12 month 
EQ-5D-
3L scores 
Mean EQ-5D-
3L change 
(95% CI) 
Change as 
% of 
possible 
change 
ES SRM 
Improved 0.715 0.798 0.084* 
(0.013,0.154) 
5.3% 0.35 0.34 
No change 0.751 0.774 0.022 
(0.009,0.054) 
1.4% 0.09 0.11 
Worsened 0.712 0.642 -0.069            
(-0.146,0.007) 
4.3% 0.35 0.28 
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Figure C: mean change in ICECAP-O tariff score by SF-36 vitality sub-scale change 
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Appendix 41 
ICECAP-O response profile for worsened SF-36 vitality sub-scale scores   
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 2 2 2 2 0 0 7 2 0 0 -2 +5 0 -2 0 
Level 2 17 24 22 12 12 16 27 14 25 18 -1 +3 -8 +13 +6 
Level 3 21 52 42 60 43 25 51 59 55 38 +4 -1 +17 -5 -5 
Level 4 60 21 34 26 45 59 15 25 20 44 -1 -6 -9 -6 -1 
 
Appendix 42 
ICECAP-O response profile for improved SF-36 vitality sub-scale scores   
 Baseline profile 12 month follow-up profile  
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 2 10 2 2 0 2 6 0 2 0 0 -4 -2 0 0 
Level 2 21 31 24 26 7 11 28 17 19 13 -10 -3 -8 -7 +6 
Level 3 29 40 45 43 36 28 43 39 36 30 -1 +3 -6 -7 -6 
Level 4 48 19 29 29 57 59 23 43 43 57 +11 +4 +14 +14 0 
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Appendix 43 
ICECAP-O response profile for worsened SF-36 social function sub-scale scores   
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 2 4 0 0 2 2 10 2 3 2 0 +6 +2 +3 0 
Level 2 8 30 23 23 11 12 24 15 22 12 +4 -6 -8 -1 +1 
Level 3 30 45 43 47 34 32 44 54 56 47 +2 -1 +11 +9 +13 
Level 4 60 21 34 29 53 54 22 29 19 39 -6 +1 -5 -10 -14 
 
Appendix 44 
ICECAP-O response profile for improved SF-36 social function sub-scale scores   
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 0 12 5 5 2 0 4 0 0 0 0 -8 -5 -5 -2 
Level 2 24 29 27 21 10 16 24 18 20 16 -8 -5 -9 -1 +6 
Level 3 26 52 51 55 45 40 51 55 44 40 +14 -1 +4 -11 -5 
Level 4 50 7 17 19 43 44 20 27 36 44 -6 +13 +10 +17 +1 
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Appendix 45 
Change in individual symptoms for improved SSE 
Symptom Percentage at baseline Percentage at follow-up Percentage change 
Pain 76.7% 39.5% 37.2% 
Sore throat 27.9% 4.6% 23.3% 
Nausea 11.6% 9.3% 2.3% 
Breathlessness 48.8% 18.6% 30.2% 
Weight loss 11.6% 11.6% 0% 
Fatigue 69.8% 39.5% 30.3% 
Stiff joints 72.1% 51.1% 21% 
Sore eyes 16.3% 16.3% 0% 
Wheeziness  23.3% 11.6% 11.7% 
Headaches 34.9% 20.9% 14% 
Upset stomach 25.6% 11.6% 14% 
Sleep difficulties 53.5% 20.9% 32.6% 
Dizziness 34.9% 11.6% 23.3% 
Loss of strength 34.9% 25.6% 9.3% 
Los of libido 27.9% 13.9% 14% 
Impotence 25.6% 13.9% 11.7% 
Feeling flushed 18.6% 16.3% 2.3% 
Fast heart rate 34.9% 9.3% 25.6% 
Pins and needles 32.6% 23.6% 9% 
Cough 41.9% 23.3% 18.6% 
Swelling of legs/ankles 25.6% 23.3% 2.3% 
Mood change 18.6% 7% 11.6% 
Rash 9.3% 4.6% 4.7% 
Dry mouth 27.9% 9.3% 18.6% 
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Change in individual symptoms for worsened SSE 
Symptom Percentage at baseline Percentage at follow-up Percentage change 
Pain 37.5% 81.2% 43.7% 
Sore throat 3.1% 25% 21.9% 
Nausea 9.3% 15.6% 6.3% 
Breathlessness 31.2% 59.4% 28.2% 
Weight loss 3.1% 18.7% 15.6% 
Fatigue 31.2% 68.7% 37.5% 
Stiff joints 43.7% 59.4% 15.7% 
Sore eyes 9.4% 28.1% 18.7% 
Wheeziness  15.6% 31.2% 15.6% 
Headaches 9.4% 21.9% 12.5% 
Upset stomach 9.4% 18.7% 9.3% 
Sleep difficulties 31.2% 50% 18.8% 
Dizziness 18.7% 40.6% 21.9% 
Loss of strength 12.5% 40.6% 28.1% 
Los of libido 18.7% 31.2% 12.5% 
Impotence 18.7% 25% 6.3% 
Feeling flushed 12.5% 21.9% 9.4% 
Fast heart rate 15.6% 25% 9.4% 
Pins and needles 31.2% 31.2% 0% 
Cough 31.2% 43.7% 12.5% 
Swelling of legs/ankles 25% 53.1% 28.1% 
Mood change 6.2% 25% 18.8% 
Rash 6.2% 18.7% 12.5% 
Dry mouth 12.5% 40.6% 28.1% 
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Appendix 46 
ICECAP-O response profiles for increase in symptoms and side-effects  
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 0 4 0 0 0 0 4 4 4 4 0 0 +4 +4 +4 
Level 2 7 18 7 15 4 11 26 11 11 4 +4 +8 +4 -4 0 
Level 3 18 48 37 44 37 30 44 48 54 37 +12 -4 +11 +10 0 
Level 4 74 30 56 41 59 59 26 37 31 55 -15 -4 -19 -10 -4 
 
Appendix 47 
ICECAP-O response profiles for reduction in symptoms and side-effects 
 Baseline profile 12 month follow-up profile 
Change between baseline and follow-
up 
 Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont Attach Sec Role Enjoy Cont 
Level 1 0 8 0 0 3 0 5 0 3 3 0 -3 0 +3 0 
Level 2 8 17 26 22 17 3 14 23 11 11 -5 -3 -3 -11 -6 
Level 3 22 44 40 47 28 33 42 26 42 47 +11 -2 -14 -5 +19 
Level 4 69 31 34 31 53 64 39 51 44 39 -5 +8 +15 +13 -14 
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